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Abstract 
The phosphatidylinositol phosphates (PIPns) and inositol phosphates (IPns) are intricately 
involved in cell signalling.  They bind to a vast array of proteins, which results in a host of 
physiological responses.  Therefore it is difficult to determine the precise downstream effects of an 
individual protein-phosphoinositide interaction.  Perturbations of these networks occur in 
pathological conditions such as cancer and diabetes increasing the need to understand these 
systems.  Receptor-Ligand Engineering (RLE) may provide the tools to map these interactions.  
Chemical modification of the small PIPn or IPn ligand and complementary mutation of binding site 
amino acids is used to create a unique protein-ligand binding pair.  Once the modified protein is 
engineered into the cell line, the dose dependent effects of its stimulation with the complementary 
ligand can be studied in isolation from signal pathway cross-talk. 
Phosphatidylinositol 4,5-diphosphate [PtdIns(4,5)P2 / PIP2] and phosphatidylinositol 3,4,5-
triphosphate [PtdIns(3,4,5)P3 / PIP3] analogues with C-alkyl groups replacing the axial inositol C-H 
protons would be suitable ligands for RLE.  To date, no such analogues are known in the literature.  
The key challenges in preparation of such compounds are selective protection and deprotection of 
the myo-inositol hydroxyls, introduction of new inositol C-substituents with retention of myo-
stereochemistry, and phosphorylation of an unnatural tertiary centre.   
4-C-Alkyl IP3 and 4-C-alkyl IP4 analogues were chosen as targets to explore the chemical 
limitations of analogue synthesis.  Orthoesters simultaneously tied up the 1-, 3- and 5-O 
differentiating between the remaining three hydroxyls in a rigid structure.  Oxidation of the isolated 
4-OH to the inos-4-ose and selective reintroduction of the myo-geometry by addition of dimethyl 
sulfoxonium methylide generated the key exo-methylene oxide intermediate.  Lithium alkyl cyano 
cuprates were employed to open the exo-methylene oxide introducing primary, β-secondary, and β-
tertiary alkyl and aryl protrusions. 
4-C-Alkyl triols were prepared by regiocontrolled DIBAL-H reduction of the 
orthobenzoate to a benzyl ether, directed by the 4-C-alkyl protrusion.  The corresponding 4-C-alkyl 
tetrols were obtained by acidic hydrolysis of the orthobenzoate and cleavage of the resultant 
benzoate ester.  All polyols were then phosphorylated and globally deprotected to generate the final 
series of 4-C-alkyl IP3 and IP4 analogues. 
Some initial investigations were also performed to extend this methodology to prepare 4- 
and 5-C-alkyl derivatives from a common precursor. 
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Abbreviations 
ATP  adenosine triphosphate 
Bn  benzyl 
tBu  tert-butyl 
Bz  benzoyl 
COSY  correlation spectroscopy 
DAG  diacyl glycerol 
DIBAL-H diisobutylaluminium hydride 
DMF  dimethylfomamide 
DMP  Dess Martin periodinane 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
EF-Tu  elongation factor Tu 
ENTH  epsin N-terminal homology 
eq.  equivalents 
ER  endoplasmic reticulum 
FYVE  Fab1p, YOTB, Vac1 and EEA1 
GDP  guanosine diphosphate 
GPCR  G-protein coupled receptor 
GTP   guanosine triphosphate 
h  hours 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
ITC  isothermal titration calorimetry 
IPn  inositol polyphosphate 
IR  infra-red 
J  coupling constant 
mCPBA meta-chloroperbenzoic acid 
min  minutes 
MS  mass spectrometry 
NMR  nuclear magnetic resonance 
NOESY  nuclear overhauser enhancement spectroscopy 
PDK-1  3-phosphoinositide dependent protein kinase 1 
PG  protecting group 
PH  plextrin homology 
PI3K  phosphoinositide 3-kinase 
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PIPn  phosphatidyl inositol polyphosphate 
PITP  phosphatidyl inositol transport protein 
PKB  protein kinase B 
PKC  protein kinase C 
PLC  phospholipase C 
Pmb  para-methoxy benzyl 
ppm  parts per million 
PtdIns  phosphatidyl inositol 
PtdOH  phosphatidic acid 
PTEN  phosphatase and tensin homologue deleted on chromosome 10 
PX  PhoX 
Py  pyridine 
Rf  retention factor 
RLE  receptor-ligand engineering 
RMT1  arginine methyl transferase 1 
RNA  ribonucleic acid 
rt  room temperature 
SAH  S-adenosylhomocysteine 
SAM  S-adenosylmethionine 
SHIP   SH2 domain containing inositol-5-phosphatase 
TBAF  tert-butyl ammonium fluoride 
Tbdms  tert-butyldimethylsilyl 
Tbdps  tert-butyldiphenylsilyl 
TFA  trifluoroacetic acid 
TfOH  trifluoromethane sulfonic (triflic) acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
Tms  trimethylsilyl 
TSA  para-toluene sulfonic acid 
UV  ultra violet 
VT  variable temperature 
WT  wild type 
XTP  xanthine triphosphate 
δ  chemical shift 
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Biological Glossary 
 
agonist  a ligand or drug which binds to and activates a receptor 
 
antagonist a ligand or drug which binds to a receptor and blocks receptor activity 
 
eukaryotic a cell with a high degree of internal organisation, including a nucleus which  
  houses the DNA or genes 
 
kinase  an enzyme which transfers a phosphate group to a molecule 
 
KM  the concentration of substrate which permits the enzyme to achieve half Vmax 
 
phosphatase an enzyme which removes a phosphate group 
 
proteome the complete set of proteins expressed by a cell, tissue or organism 
 
Vmax  the rate of reaction when the enzyme is saturated with substrate, and therefore the 
  maximum rate of reaction 
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Preface 
This thesis is divided into seven main chapters.  The first chapter introduces the biological 
background of this project and the long term goals, of which this work forms a key part at the very 
beginning.  The second chapter introduces the chemical background on which this work was based.  
By reviewing the available literature, a synthesis strategy was designed in order to ensure that the 
available time was spent resolving the key transformations rather than in protecting group 
manipulations. 
Chapters three to six contain the results and discussion.  The primary aim of this thesis was 
to prove that the chemistry needed to create the target compounds was feasible, as without it, the 
long term goals of the project are impossible.  Chapter three discusses the introduction of a 4-C-
alkyl group onto the myo-inositol ring, followed by manipulation of the protecting groups to 
generate triols and tetrols in chapter four, which are phosphorylated and deprotected in chapter 
five.  Throughout these chapters, the boundaries and chemical limitations of the synthesis are 
explored, generating valuable information which can be applied to the design of later analogues.   
Chapter six introduces a more general synthetic design, conceived during this project, for 
the introduction of 4-, 5- and 6-C-alkyl groups from a common intermediate.  Based on the results 
of the earlier experimental work and with the longer term goal of generating multiple C-alkyl 
groups at any ring position, this chapter stands alone, and makes an initial foray into demonstrating 
the feasibility of the suggested synthetic strategy. 
Finally chapter seven contains the experimental procedures and spectral analysis for all the 
compounds prepared in chapters three to six. 
Part of the work contained within this thesis is currently in press, having been accepted for 
publication by Organic and Biomolecular Chemistry. J. M. Swarbrick, S. Cooper, G. Bultynck, P. 
R. J. Gaffney; Regioselective deprotection of orthobenzoates for the synthesis of inositol 
phosphates. 
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Introduction 
A relatively small number of interconvertable inositol polyphosphates (IPn) and 
phosphatidylinositol polyphosphates (PIPn) interact with a battery of proteins, leading to 
widespread and, in many cases, interlinked functions and effects.1-5  These interactions are critical 
in essential cell processes such as growth, communication and differentiation.  For example, 
generation of inositol 1,4,5-triphosphate stimulates calcium release which effects muscle 
contraction and vision;5 PIPns are implicated in insulin signal transduction (dysfunction of which 
can lead to diabetes4) and growth factor pathways (where abnormal growth causes cancer6). 
There is still much to learn about these species and their complicated yet specific 
interactions.  Understanding of such signalling cascades would be immensely improved by a 
pharmacological map of exactly how they function.  However, changes in signalling lipids are 
often masked by the large mass of steady-state structural lipids,6 which has made studying the 
dynamics of the IPn and PIPn binding proteins in their native environment difficult.
2  Many studies 
of the roles of phosphoinositides in the cellular environment have relied on indirect or long-term 
methods of manipulating phosphoinositide levels (such as genetic knock-down, or overexpression 
of phosphoinositide metabolizing enzymes).2  The ability of these systems to change over time 
makes the results of these studies difficult to interpret.7  In many cases it has not been possible to 
determine precisely which IPn- or PIPn-protein interaction or sequence of interactions is responsible 
for a downstream effect.  Fast-acting acute chemical inhibitors of phosphoinositide metabolising 
enzymes and agonists for particular phosphoinositide-binding proteins2 are required to help 
elucidate these pathways on the timescale in which they function. 
The synthetic chemistry described in this thesis prepares small molecule tools which could 
be used to study these systems.  Using these ligands it is postulated that, combined with 
engineering of a protein’s binding site, the precise effect of an individual lipid-binding protein 
interaction can be studied.  The implications of being able to stimulate a protein of interest for 
unique activation by a small molecule at our discretion are very wide ranging.  In the short term, it 
would allow us to assign the downstream effects of the protein under study unambiguously and in 
the long term it may suggest targets for the design of therapeutics which may benefit human health. 
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Chapter 1:  The phosphoinositides and inositol phosphates as 
second messengers 
This chapter provides an introduction to the phosphoinositides (IPn and PIPn).  The first 
sections introduce the structure and numbering of these species and give a brief review of the 
historical events which have led to the widespread research interest and the need to understand this 
complex system.  The second half of the chapter introduces receptor-ligand engineering, and its 
proposed application to interrogate the phosphoinositide signalling network. 
In the 1950’s Lowell and Mabel Hokin demonstrated that acetylcholine stimulated the 
turnover of inositol-containing phospholipids in cells.8  This seminal discovery, termed the 
‘phospholipid effect’, spiked a wave of biological research which has begun to uncover the 
complex phosphatidylinositol polyphosphate (PIPn) and inositol polyphosphate (IPn) cellular 
networks.  At the current time, there are 7 known PIPn and over 30 known IPn in eukaryotic cells,
9 
which are interconverted by a battery of kinases and phosphatases.  These species are intricately 
involved in a multitude of cellular processes.2,3,6,10,11 
1.1 Structure and numbering 
The inositol polyphosphates (IPns) and phosphatidylinositol polyphosphates (PIPns) are 
closely related in structure.  To clarify which species is being considered, it is helpful to introduce 
the terminology used for their structure and numbering. 
The IPns are composed of the cyclohexane hexitol myo-inositol, and one or more phosphate 
esters, Figure 1.1.  They are water soluble, polar molecules which are located in the cytosol.13   
OH
OHHO
OH
OHHO
1
2
OH
OHHO
OH
OHO
1
2
P
O
HO
O
4
c) d)
a)
HO
HO
OH
OH
OH
OH
2 1
b)
1
1 2  
Figure 1.1: a) and c) myo-inositol; b) Agranoff’s Turtle12 d) inositol-4-phosphate 
Agranoff’s turtle mnemonic,12 Figure 1.1b, illustrates and resolves much of the confusion 
that has surrounded inositol polyphosphate nomenclature.  It demonstrates the position of the six 
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myo-inositol hydroxyl groups in the most thermodynamically stable chair conformation; the turtle’s 
head represents the axial 2-hydroxyl and the four flippers and tail the five equatorial hydroxyls.  
The ring is conventionally numbered in an anticlockwise direction, when viewed from above, 
starting from the right front flipper, Figure 1.1c.  myo-Inositol has meso-symmetry, with a mirror 
plane running through the axial 2-OH and equatorial 5-OH.  Therefore, addition of a substituent to 
the 1-, 3-, 4- or 6-OH, which are not on the mirror plane, generates a chiral molecule.  Usually only 
one enantiomer of a natural IPn or PIPn is bio-active.  The standard chiral stereospecific numbering 
system is always referred to the D enantiomer (the right handed turtle).  Any one or combination of 
the six ring positions can be reversibly phosphorylated, for example phosphorylation on the 4-OH 
would generate myo-inositol 4-phosphate, Ins(4)P, and its enantiomer myo-inositol 6-phosphate, 
Ins(6)P, Figure 1.1d. 
The PIPns (PtdInsPn, phosphatidylinositol polyphosphate, an inositol lipid) contain an 
additional hydrophobic component, usually phosphatidic acid (PtdOH, diacylglycerol phosphate), 
that is attached to the inositol 1-O via a phosphodiester link,5 Figure 1.2. 
O
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4
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3
R5O
2
1
OH
HO
P
O
O
O
O
O
O
R
2
O
R
1 Ptd Ins,
Ptd Ins(3,5)P2, 3
Ptd Ins(4,5)P2, 4
Ptd Ind(3 ,4,5)P3, 5
R3 = R4 = R5 = H
R4 = H, R3 = R5 =PO3H
-
R3 = H, R4 = R5 =PO3H
-
R3 = R4 = R5 = PO3H
-
R1 and R2 = alkyl / alkenyl  
Figure 1.2: The structure of the phosphatidylinositol polyphosphates (PIPns) 
PtdOH is composed of diacylglycerol (DAG) phosphate with two lipophilic fatty acid ester 
chains which may be saturated or (poly)unsaturated, R1 and R2, Figure 1.2; notably, most 
mammalian PIPns are characteristically polyunsaturated on the sn-2 fatty acid with 3 to 6 double 
bonds in the chain.  Phosphatidylinositol is phosphorylated under physiological conditions at any of 
the 3-, 4- or 5-OH by specific kinases to prepare higher phosphatidylinositol polyphosphates (PIPns 
where n = no. of phosphates) such as phosphatidylinositol 3,5-diphosphate PtdIns(3,5)P2, 
phosphatidylinositol 4,5-diphosphate PtdIns(4,5)P2  and phosphatidylinositol 3,4,5-triphosphate 
PtdIns(3,4,5)P3,
1 Figure 1.2.  PIPns are amphiphilic molecules, located with their fatty alkyl chains 
in the hydrophobic cell membrane and polar inositol head groups in the cytosol.   
1.2 Second messenger signalling  
For a cell to react to an external signal, the signal must first be detected and transmitted 
across the physical boundary of the cell membrane.14  Unlike lipophilic steroids, which can cross 
the fatty plasma membrane by passive diffusion, many chemical signals including growth factors 
and hormones are prevented from entering the cell by its hydrophobic nature.  Instead, these 
primary messengers bind to one of three types of cell surface receptors situated in the membrane; 
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ion channels, tyrosine kinase receptors or G-protein coupled receptors (GPCRs).15  Ion channels in 
the membrane are usually closed and open on receptor activation, allowing ions such as Na+ and K
+ 
to flow into or out of the cell.  Activation of tyrosine kinase receptors causes autophosphorylation 
of one or more tyrosine residues on the cytoplasmic domain of the receptor, which recruits 
regulatory adaptor proteins.  Activation of a transmembrane GPCR causes exchange of GDP for 
GTP in the α-subunit of an associated heterotrimeric G-protein, which allows the G-protein to 
dissociate into the monomeric Gα.GTP subunit and a βγ dimer.  Therefore, the arrival of a primary 
messenger, and binding to one of these cell surface receptors ultimately activates an enzyme, which 
may be either a cytosolic domain of the receptor or may occur indirectly.  This enzyme then acts on 
a second messenger precursor (such as a PIPn) in the vicinity of the receptor.
15  In the case of 
phosphoinositide signalling this activation pathway generates either a water soluble (IPn+1) or a 
membrane bound (PIPn+1) second messenger which exert numerous downstream effects on the cell.  
These, usually very transient and tightly regulated, second messengers go on to activate their 
targets, resulting in a downstream response.14  This mechanism allows second messengers to be 
rapidly generated in response to extracellular stimuli.   
The discovery of the PIPns began with the separation and characterisation of the cellular 
inositol-containing phospholipids, which demonstrated that three individual species were present; 
phosphatidylinositol (PtdIns), phosphatidylinositol 4-phosphate [PtdIns(4)P] and 
phosphatidylinositol 4,5-diphosphate [PtdIns(4,5)P2].
16  PtdIns is formed from PtdOH and myo-
inositol in the endoplasmic reticulum (ER) and transported to the plasma membrane by a specific 
carrier protein (PtdIns Transport Protein, PITP).  All three species are thought to be maintained at a 
steady-state level in the inner leaflet of the plasma membrane by a dynamic equilibrium between 
enzymatic phosphorylation and dephosphorylation,10,11 Figure 1.3. 
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Figure 1.3: The generation of PtdIns(4,5)P2 from PtdOH and myo-inositol. 
In the 1980’s the hormonally induced metabolism of PtdIns(4,5)P2 was demonstrated to 
generate two secondary messengers; diacyl glycerol (DAG) and inositol 1,4,5-triphosphate 
[Ins(1,4,5)P3].
17  Key to this process is phospholipase C (PLC) which is activated upon stimulation 
by an extracellular signal and hydrolyses PtdIns(4,5)P2 into DAG and the Ins(1,4,5)P3 head-group 
which diffuses into the cytosol, Figure 1.4. 
 
Figure 1.4: Upon arival of an external signal, PLC acts on PtdIns(4,5)P2, to generate two second messengers; 
DAG and Ins(1,4,5)P3 
Nishizuka and co-workers18 found that DAG reversibly activates protein kinase C (PKC) in 
the presence of acidic phospholipids and Ca2+.  Meanwhile, Berridge and co-workers17 observed 
that an increase in the cellular concentration of Ins(1,4,5)P3 preceded an increase in the 
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concentration of cytosolic Ca2+, implicating this IP3 as a secondary messenger effecting Ca
2+ 
release.  This second discovery provided the missing link between extracellular activation at the 
plasma membrane and the release of Ca2+ from internal stores.  Binding of Ins(1,4,5)P3 to receptors 
situated in the endoplasmic reticulum (ER), causing Ca2+ to flood from the ER Ca2+ store into the 
cytosol, has since been well characterised.19  The revelation that PtdIns(4,5)P2 was involved in vital 
cell functions, rather than just as a constituent part of the membrane, fueled an expanding research 
field.19 
Rapidly generated second messengers also require efficient removal from the system in 
order to terminate their cellular effect.  Dephosphorylation of Ins(1,4,5)P3 deactivates this second 
messenger, generating first Ins(1,4)P2 then InsP and finally inositol, which is recycled within the 
cell.  It was later discovered that, following stimulation of cells, not only were these expected 
dephosphorylation products of Ins(1,4,5)P3 present, but that other species including Ins(1,3,4)P3 
and Ins(1,3,4,5)P4 emerged rapidly from Ins(1,4,5)P3 metabolism.
13  Over 30 IPn species have since 
been identified with phosphorylation observed on any of the six hydroxyls as well as identification 
of some pyrophosphates, termed IP7 and IP8.
20  In addition to the key role of Ins(1,4,5)P3 in Ca
2+ 
signalling, some other IPns have demonstrated roles in important functions including gene 
transcription, RNA editing, nuclear export and protein phosphorylation.9  The sheer number of IPns, 
the diverse areas of cell biology in which they are implicated, the difficulty in understanding how 
their levels are regulated and poor availability of these species from nature has made them difficult 
targets to study.13 
In the late 1980’s, specific phosphorylation at the PtdIns 3-OH by phosphoinositide 3-
kinase (PI3K) to generate PtdIns(3)P demonstrated that the PIPns were not purely precursors for 
cytosolic IPns.
21  All 7 PIPns resulting from reversible phosphorylation on any combination of the 
3-, 4- and 5-OH were eventually reported,23 Figure 1.5. 
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Figure 1.5: The 7 PIPn which have been identified in biological systems 
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Contradicting the initial in vitro results, it was found that upon growth factor stimulation, 
class 1 PI3Ks act on PtdIns(4,5)P2, phosphorylating the 3-OH to generate PtdIns(3,4,5)P3,
22 Figure 
1.6. 
 
Figure 1.6: Upon stimulation by growth factors, PtdIns(4,5)P2 is phosphorylated by PI3K to generate 
PtdIns(3,4,5)P3.  PtdIns(3,4,5)P3 levels are tightly regulated by kinases and phosphatases. 
Four of the PIPn identified in eukaryotic cells are phosphorylated on the 3-OH; PtdIns(3)P, 
PtdIns(3,4)P2, PtdIns(3,5)P2 and PtdIns(3,4,5)P3.
22  Resting mammalian cells contain significant 
levels of PtdIns(3)P, 6, in internal membranes, but very low levels of the other 3-phosphorylated 
PIPns.
3  The levels of 3-phosphorylated phosphoinositides 3, 5 and 9 are tightly regulated and 
typically rise many fold upon cellular stimulation.14  For example, PtdIns(3,4,5)P3 is present at ~0.1 
% of the level of its precursor PtdIns(4,5)P2 in resting cells.  However, upon stimulation of tyrosine 
kinase receptors or some GPCRs, its concentration can increase by factors of between 2 and 100-
fold.24  This classical response to stimulation is central to the mechanism of action of the 3-
phosphorylated species.  Unlike PtdIns(4,5)P2, the 3-phosphorylated PIPns are not substrates for 
mammalian PLC enzymes, but are modified by specific regulated kinases and phosphatases, as 
illustrated in Figure 1.6.3 
These regulatory proteins act on the inositol ring, reversibly interconverting PIPn species, 
resulting in short term alterations of their protein binding properties and functions.  This ability to 
switch on or off a signal by the generation or removal of a given PIPn make these species highly 
suited as effectors of membrane trafficking and cell signalling.2  Following the generation of 
PtdIns(3,4,5)P3, the inositol lipid phosphatases either counteract or diversify this signal.
3  3-
Phosphatases, including PTEN (phosphatase and tensin homolog deleted on chromosome 10) act 
on PtdIns(3,4,5)P3, to counteract the effect of PI3K by dephosphorylating the 3-O, regenerating 
PtdIns(4,5)P2.
25  The 4- and 5-phosphatases on the other hand, generate the PIP2 species 
PtdIns(3,4)P2 and PtdIns(4,5)P2 which are also involved in signalling.  For example, 
PtdIns(3,4,5)P3 is the substrate for SHIP (SH2 domain containing inositol 5-phosphatase), which 
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dephosphorylates the 5-O to generate PtdIns(3,4)P2.
22  The generation of further PIPn species from 
PtdIns(3,4,5)P3 places this PIP3 at the centre of an increasingly complex signalling network. 
The 3-phosphorylated PIPn species are known to bind directly and selectively to specific 
modular domains expressed in a wide range of proteins and protein families.2,26  A variety of 
structurally different PIPn binding domains have been identified including the PH (pleckstrin 
homology), FYVE (deriving its name from the first four proteins in which it was identified; Fab1p, 
YOTB, Vac1 and EEA1), ENTH (epsin N-terminal homology) and PX (PhoX) domains.1,26  The 
different domains display marked differences in selectivity between the different types of PIPn, 
with some being more discriminating in their binding partners than others.2  For example, all 
FYVE domains characterized to date bind PtdIns(3)P, whereas subsets of PH domains have been 
found to selectively bind PtdIns(3,4)P2 and/or PtdIns(3,4,5)P3 or PtdIns(3)P.
3  Binding to protein 
domains allows PIPns to regulate membrane-bound proteins and recruit cytosolic proteins to the 
membrane.  The interaction of PIPn with lipid binding domains transmits their signal, through 
activation, conformational change or phosphorylation, to the subsequent downstream stages of the 
signalling network.  The 3-phosphoinositides, mainly through PtdIns(3,4,5)P3 and PtdIns(3,4)P2, 
have been shown to influence many different aspects of cell biology, including vesicle trafficking, 
cell growth and proliferation, DNA synthesis, regulation of apoptosis and cytoskeletal 
changes.3,22,24  These widespread roles have led to an intense interest in signalling pathways 
downstream of PI3K as targets for therapeutics in disease control and prevention.24  The 
availability of wortmannin27 and LY294002,28 both cell-permeable, low molecular weight 
inhibitors of the PI3K class of enzymes, has helped to elucidate some of the cellular functions these 
kinases and led to the implication of the PI3K pathway in abnormal cell growth.3  PI3Kα is over-
activated, due to mutation, in several significant colon, gastric and breast cancers.6  Downstream 
from PI3K, PTEN has also been implicated in cancer due to its mutation in many late stage 
tumours.6  Conversely, up-regulation of PTEN has been found to have anti-tumoural effects.  The 
tumour suppressing function of PTEN is believed to be related to its 3-phosphatase activity which 
down-regulates activation of PI3K target proteins by reducing levels of PtdIns(3,4,5)P3.
25  The 
results of these studies have further increased the desire to understand these mutations and their 
effects on disease. 
These potent targets have proved difficult to study.  It has not been possible to assign the 
exact combination of interactions downstream of PI3K or PTEN which lead to the pathological 
results.  While a few PIPn-protein domain interactions appear to be high affinity with dissociation 
constants in the nM range, over 80 % appear somewhat indescriminate in their PIPn binding 
partners and have low binding affinities (in the µM range).29  Binding tends to occur using a 
combination of specific head-group interactions, hydrophobic membrane penetration, electrostatic 
surface interactions and shape complementarity.30  This combination of interactions with one or 
more additional binding sites within the membrane generates stable, high affinity interactions.11,14  
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For example, many small GTPases and GPCRs also bind the PIPn-binding proteins and are located 
in the membrane, providing an additional binding site to generate a highly specific interaction.14  
Some PIPn-binding protein interactions are known to induce a conformational change in the 
recruited protein which then permits the further modification or interaction of the protein at the 
membrane, for example by exposing particular residues, or altering localised membrane 
curvature.2,31  The restriction of the PIPns to the membrane environment due to their fatty acyl tails 
allows them to be compartmentalised, determining their cellular location according to their specific 
function.  This is believed to aid molecular recognition and demonstrates another way in which 
they impart specificity to their downstream targets.3 
The pleckstrin homology (PH) domain is the best known PIPn binding domain, found in 
over 500 diverse cell-regulatory proteins.26,32  While having relatively low sequence homology, 
these domains are expressed as a highly conserved PH superfold, a seven-stranded β sandwich 
structure with a C-terminal α helix.32  Most PH domains bind PIPns and therefore respond directly 
to changes in PIPn levels as regulated by phosphoinositide-kinases and -phosphatases.
26  A subset 
of PH-domains have been shown to bind the 3-phosphorylated products of PI3Ks; PtdIns(3,4,5)P3, 
PtdIns(3,4)P2 and PtdIns(3,5)P2.
32  Many PH-domain baring proteins require membrane association 
to function and studies of these PH domains fused to green flourescent protein have demonstrated 
the ability of PIPn to recruit their binding proteins to the membrane, in a signal dependent manner.
32  
A number of high resolution crystal structures of these domains have been reported, both in the 
absence of a ligand, and bound to an IPn such as Ins(1,3,4,5)P3 which mimics the PtdIns(3,4,5)P3 
headgroup,31 Figure 1.7. 
Figure 1.7: The PKBα-PH domain binding to inositol (1,3,4,5)-tetraphosphate.33 
The high structural homology of the PH domains suggests that less well characterised 
domains may be probed successfully using techniques based on the known crystal structures.  It is 
postulated that this will permit the elucidation of the function of many more PH-domain baring 
proteins once a suitable method has been developed.   
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More than one class of PIPn receptor can be found in a single signalling protein,
26 so there 
is potential for cross-talk between lipid binding events, which has further complicated the 
elucidation of the exact functions of an individual protein.  One particular example, which 
illustrates the need to disentangle these systems in order to understand them, is the activation of 
protein kinase B (PKB, also known as Akt).  PKB has a well characterised N-terminal PH-domain, 
which specifically binds PtdIns(3,4,5)P3 and PtdIns(3,4)P2, and has emerged as a crucial regulator 
of widely divergent cellular processes including apoptosis, cell proliferation, differentiation and 
metabolism.31  Over-activation of PKB has been reported to play a role in cancer initiation and 
progression.  PKB was confirmed as a downstream effector of PI3K signalling by Franke et al.34 
who demonstrated that mutation of the PKB-PH domain prevents the response of PKB to PI3K.  
PKB is activated at the membrane and then appears to detach and translocate to both the cytosol 
and the nucleus.  However the mechanism of activation is complex and not fully understood.23  A 
second protein, phosphoinositide dependent kinase-1 (PDK-1) possesses a C-terminal PH-domain 
and binds to the same two PIPn ligands as PKB.
23,35,36  PDK-1 is known to activate a number of 
different proteins, including PKB, by phosphorylating a Ser or Thr residue in their activation 
loop.36  Therefore, upon generation of PtdIns(3,4,5)P3 by PI3K, both proteins are translocated to the 
membrane, bringing them into close proximity.  On binding to PtdIns(3,4,5)P3, PKB has been 
shown to undergo a conformational change which allows phosphorylation by PDK-1.31  Complete 
activation of PKB is thought to occur via a second phosphorylation by mTOR-rictor, before 
activated PKB diffuses into the cytosol to initiate its downstream effects.  A better understanding of 
its activation and the ensuing cellular effects may point towards therapeutic possibilities.37 
The unique versatility of the PIPns arising from their interconversion by kinases and 
phosphatases, their often transient nature, their spatial distribution and their interaction with a large 
range of effector molecules with specific PIPn-binding domains, is both what permits the 
generation of such a vast range of downstream effects and what makes this system so hard to 
study.24  While there is still plenty to learn about PKB activation and its downstream effects, there 
are many other PIPn-protein interactions which have hardly been characterised.  There is a pressing 
need to understand how these systems work:  How do such similar molecules effect such different 
processes?  How are individual signals converted into a cellular response?  How does one and the 
same phosphoinositide, depending on the physiological context, trigger distinctly different events?  
This need is further compounded by the observation that specific signalling proteins which are 
downstream targets of PIPn and IPns are overexpressed in disease states, such as cancer
6 and 
diabetes,4 making these systems attractive targets for therapeutics.  The elucidation of downstream 
signalling has been complicated by the huge range of different proteins which bind to 
phosphoinositides and cross-talk between signalling networks.  Consequently, a method for 
observing the outcome of a single protein-ligand interaction is required. 
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When chosing targets to probe in this system, the key players PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3 are attractive.  PtdIns(4,5)P2 participates in a vast array of events which occur at, or 
involve, the cell surface.  It plays a major part in the transduction of extracellular signals, either via 
its metabolites, or by fluctuations in its own levels.11  As the substrate for two classes of powerful 
receptor-regulated signal generating enzymes leading to two very different but important signalling 
cascades, PtdIns(4,5)P2 is a focal point in PIPn-dependent signalling.
6  There is also evidence that 
PtdIns(4,5)P2 is a signalling molecule in its own right.  Although its overall levels do not increase 
upon cell stimulation, it is likely that local increases in concentration can occur, for example at its 
sites of biosynthesis.10  It is reported to recruit and bind to an increasing number of effector 
domains, including some ENTH and PH domains (such as the PH domain of PLCδ), to regulate 
actin polymerisation and anchorage, assembly of vesicular coats, endocytic vesicles and regulated 
secretion, among others.24  The ability to selectively stimulate just one of these pathways in 
isolation would help to assign downstream observations to a particular role of this multifunctional 
signalling molecule. 
The sheer number of proteins expressing binding domains which recognise PtdIns(3,4,5)P3, 
the generation of PtdIns(3,4)P2 by specific dephosphorylation and diverse range of downstream 
effects identified as a result of PtdIns(3,4,5)P3-protein interactions make this a second valuable 
target.  Separating out the responses to PIP3 and where they lead in a cellular context would be 
invaluble to biochemical understanding as well as for therapeutic applications. 
Some antagonists of these pathways have been identified:  3-Hydroxymethyl PIPn 
analogues38 and IP5
39 have both been demonstrated to act on the PI3K pathway and therefore to 
suppress the signal from PKB which is thought to inhibit apoptosis in cancer cell growth.38  
However, in order to examine this system in detail, small molecule agonists are required that 
switch on the downstream effects, rather than off.  In order to understand the complexity and 
sensitivity of the system, these observations will have to probe the cellular environment.  The lack 
of this type of probe to date is a reflection of the challenge of generating such molecules.  They 
need to be located at the membrane in order to effect the wild-type protein’s translocation, and they 
need to specifically activate their target proteins as part of a concerted sequence of events. 
1.3 Receptor Ligand Engineering  
It is proposed here that using receptor-ligand engineering (RLE), one individual protein-
ligand interaction can be studied in vivo in isolation from other signalling systems.  This would be a 
powerful method for elucidating the downstream functions of specific interactions such as those 
described in the previous section.  RLE is based on the modification of the specific binding 
arrangement between a protein binding site and its small molecule counterpart, to create a non-
native pair.40  By combining chemical modification of the ligand with complementary mutation of 
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its binding-protein, RLE uniquely pairs one chemical ligand with one protein target.  This allows 
the investigation of their interaction in the context of the whole organism in a time and dose 
dependent manner.41 
For a number of years, classical genetic techniques have allowed us to specifically affect 
the activity of a single protein within an organism and to observe the resulting effects.  However, 
this is a slow technique as protein levels respond slowly to changes at the gene level and 
meaningful results are not guaranteed as the cell tends to compensate for disturbances in key 
signalling pathways by up-regulating other proteins.41  In their genetic studies of mutant kinases, 
Bishop et al.7 found that a signalling pathway of interest typically responded to a deleted kinase by 
increasing the production of closely related kinases.  Therefore, during the 1-2 weeks they required 
for mutant genome expression, the effect of an individual deletion was usually masked.  
Furthermore, for PIPn pathways, a single protein may possess more than one binding site, for 
instance for protein-protein docking, or act as a scaffold for other proteins to assemble around.26  
Consequently knock-out mutants that ablate an entire protein can display phenotypes unrelated to 
their lipid binding functions. 
In response to the difficulties of using classical genetics to study such transient species, 
chemical genetics was developed.42  By employing highly a specific chemical agonist or antagonist 
as a chemical switch, the activity of a target protein within an entire cell can be switched on or 
off.43  The resulting effects can then be observed in a time and dose dependent manner, on addition 
of the small molecule, at diffusion controlled rates within the cell.41  The term chemical genetics 
arose because the phenotype which is observed as a result of a small molecule ligand binding to its 
specific target may be thought of as functionally equivalent to mutating the protein.  However, it is 
difficult to identify small molecules which interact very specifically with a desired target,44 and the 
subsequent syntheses are often time consuming, expensive and may be of limited success.42 
RLE combines the specificity of classical genetics with the versatility of chemical 
genetics.40  A small molecule which interacts with a binding site of interest is modified using 
synthetic chemistry, so eliminating its ability to bind to the natural target.  The small molecule may 
be either a natural ligand or one derived from screening synthetic libraries.  Complementary 
genetic engineering of the protein binding-site then reconstitutes binding to the modified ligand.42  
By directing the protein modification to the binding site, only a small part of the overall structure is 
affected and any other binding sites within the protein should retain their natural functions.  This is 
more precise and less intrusive than common deletion mutants. 
Complementary modifications of small molecule-protein pairs have been carried out using 
two main methods:40  Either a) by altering the shapes of the binding partners, known as steric 
complementation (or bump-hole) RLE; or b) by altering the polar or charged interactions in the 
binding site by manipulating H-bonds or ion pairs. 
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For steric complementation RLE a suitable bump, such as an alkyl or aryl group, is 
introduced on the small molecule ligand increasing the volume the ligand requires in the binding 
pocket and so preventing it from binding to the wild-type (WT) protein.  This is complemented in a 
mutant receptor by the introduction of a void in the binding pocket where a large amino acid side-
chain has been replaced by a small one, as illustrated in Figure 1.8. 
 
Figure 1.8: Schematic demonstrating the preparation of a specific receptor-ligand pair by steric 
complementation RLE 
The specificity arises because the degeneracy of the natural system (where multiple 
proteins interact with the same small molecule ligand) is broken down to a one ligand, one protein 
interaction.  It is a very controlled system because after expression of the unnatural protein in the 
cellular environment, the timescale and dose of introduction of the unnatural small ligand can be 
varied systematically.  The compensatory up-regulation often observed in knock-out mutants is 
prevented as the native components can remain in the system.  The natural ligand may still bind to 
the modified protein, however the modified ligand cannot interact with the WT protein. 
Steric complementation RLE was first described by Schrieber and Belshaw45 who re-
engineered the complex formed by the immunosuppressive drug cyclosporin A and its intracellular 
soluble receptor, cyclophilin.  This complex is a specific inhibitor of the protein phosphatase 
calcineurin and consequently has revealed some of the cellular functions of this protein.45  It is 
thought that the interaction of the cyclosporin A-cyclophilin complex with calcineurin in cells 
outside the immune system is responsible for some of the undesirable side-effects associated with 
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this drug, such as hypertension, central nervous system toxicity and nephrotoxicity.  Cyclophillins 
have been observed in nearly all organisms and tissues, so by generating a modified cyclosporin A-
cyclophillin pair, and expressing the modified cyclophilin in one cell type, they were able to 
observe the tissue specific effects of calcineurin inhibition upon addition of modified cyclosporin 
A.45 
Steric complementation RLE has also been employed to study signal transduction 
pathways (for a review see Bishop et al.7).  Shokat et al.46 combined point mutation of larger amino 
acids to glycine or alanine in the tyrosine kinase v-Src active site with complementary chemical 
modification of the natural ligand/co-substrate, ATP.41  Their aim was to create a mutant kinase 
that would accept a modified ligand, A*TP, which was orthogonal to all other kinases.  The mutant 
kinase required higher catalytic efficiency for A*TP than for natural substrate ATP, so that A*TP 
would preferentially phosphorylate the v-Src substrates.  By studying the binding pocket of the 
native co-substrate ATP in similar kinases two amino acids were identified within a 5Å sphere of 
the ATP-N6 docking point.  Mutation of these amino acid residues to alanine created a pocket in the 
binding site which resulted in these mutants having lower ATP affinity than the WT protein.  They 
then synthesised N6-alkylated derivatives to create A*TP substrates which were orthogonal to the 
WT v-Src domain,47 Figure 1.9. 
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Figure 1.9: Chemical structures of ATP analogues (A*TPs) used to probe the nucleotide binding specificity 
of cellular protein tyrosine kinases.47 
Screening these compounds against the modified kinase, they found that the N6-(benzyl) 
ligand (R= -NHBn, Figure 1.9) bound selectively to the mutant protein even at levels similar to the 
cellular concentrations of native ATP.  By incorporating a radio-active 32P into the terminal γ-P of 
the triphosphate moiety of N6-(benzyl)-A*TP they were able to label and identify the downstream 
substrates phosphorylated by v-Src.47  This work demonstrated that engineering of an active site 
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was possible without affecting kinase activity.  Using this approach, they also designed several 
drug-like nanomolar inhibitors of engineered kinases by applying steric complementation RLE to 
to increase the specificity of non-specific inhibitors.41  These modified inhibitors do not 
significantly inhibit the WT kinases allowing them to be targetted to a kinase of interest.41 
Lin et al.48 used steric complementation RLE to study protein arginine methyltransferases.  
This family of enzymes catalyse the transfer of methyl groups from S-adenosylmethionine (SAM) 
to arginine side chains in their target proteins, thereby regulating transcription, RNA processing 
and receptor-mediated signalling.48  Substitution at the SAM-N6 (similar to ATP-N6) and 
complementary mutation of RMT1 (arginine methyl transferase 1), created a specific orthogonal 
protein-ligand pair.  By incorporating a 14C radio-label they were able to identify the specific 
targets of methyl transfer catalysed by this individual enzyme in vivo.48  Furthermore, similar 
modification of S-adenosylhomocysteine (SAH), which remains after methyl transfer from SAM, 
combined with a complementary RMT1 mutation generated inhibitors which could be used to 
selectively prevent methyl transfer by this protein in vivo.48 
In these examples of steric complementation RLE, the synthetic modification of the ligand 
and protein mutation have been successfully applied to the entire class of ATP-binding and methyl 
transferase proteins, allowing each individual interaction to be probed in turn.  Such a general 
method would be ideal for the step-wise investigation of PIPn signalling networks. 
Small molecule-protein binding is not only shape specific but almost always involves 
complementary charge interactions.40  Manipulation of these key polar binding interactions (such as 
the number and direction of hydrogen bonds or the strength and direction of salt-bridges) offers 
another avenue for modification of the natural interaction to generate specific binding pairs.  This 
second approach reduces the association between the modified protein and the natural ligand which 
is often observed in steric complementation studies,7 making these two approaches somewhat 
complementary. 
One of the first examples of manipulating polar interactions was Hwang and Miller’s49 
examination the role of the protein elongation factor-Tu (EF-Tu) and its natural ligand guanine 
triphosphate (GTP) in protein biosynthesis.  Binding studies revealed that the guanosine base of 
GTP had several hydrogen bonds to amino acids in the EF-Tu binding pocket.  Disruption of one 
key hydrogen bond between aspartic acid-138 (Asp-138) and GTP by replacing the amino acid 
with asparagine (Asn) changed an H-bond acceptor into an H-bond donor.  Replacing GTP by 
xanthine triphosphate (XTP) then provided the new donor with a complementary H-bond acceptor.  
This interaction could then be studied without interference from other signalling events.  The H-
bond reversal successfully permitted the subsequent investigation of other related GTP binding 
proteins.49 
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Exchange of H-bonds in RLE requires the careful design of specific mutants as these 
charged interactions are directional, and the reversal of one H-bond can often cause disruption to 
wider H-bond networks.  The neutralisation, reversal or exchange of ion pairs within the binding 
site has also been used to generate specific receptor-ligand pairs.  Unlike H-bonds, these charged 
interactions are non directional and are therefore easier to manipulate.  However, for the highly 
negatively charged PIPn lipid headgroup, the introduction of a positive charge, or neutralisation of 
an ion pair may significantly reduce the binding affinity of the modified ligand.  Ion pair exchange, 
which could be used to introduce a negatively charged protrusion onto the ligand, would be a 
viable method for RLE of PIPn-protein interactions.  However, the generation of polar exchange 
RLE pairs requires an intricate knowledge of the binding site, such as a known crystal structure.  
While this is possible for some PIPn-protein interactions with published crystal structures, such as 
the PKB-PH domain bound to IP4, it is not possible for the large number of PIPn binding domains 
which have not been co-crystallised with an inositol phosphate ligand. 
1.4 Applying RLE to PIPns 
With the ultimate aim of being able to characterise the downstream consequences of any 
given PIPn-binding protein interaction, it is intended to prepare unique protein-ligand binding pairs 
using steric complementation RLE, as illustrated in Figure 1.10. 
  
Figure 1.10: Applying the bump-hole approach to PIPn-protein binding (a) natural protein-lipid binding; b) 
addition of a steric bump to the lipid; c) accommodation of the bump in the protein binding site; d) the 
natural lipid may still bind the mutant protein.  
It is hoped that once suitable inositol head group-lipid binding domain pairs have been 
established, the full length mutant lipid binding protein can be expressed in vivo and the modified 
lipid added, to study a whole range of PIPn-protein interactions.  In the natural system, a membrane 
bound inositol lipid binds to many related protein binding domains which results in a multitude of 
downstream signalling events (e.g. multiple PH-domains binding to PIP3), Figure 1.10a.  Since the 
lipid can bind to many related proteins, treating a cell with the natural lipid can cause a multitude 
of different downstream effects, making interpretation of the experiment and understanding of the 
system difficult. A small additional substituent (the ‘bump’) is incorporated onto the lipid, which 
prevents it from binding to its WT target proteins, as there is a steric clash in the binding pocket 
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with the bump, Figure 1.10b.  The modified lipid is then said to be orthogonal to the WT protein.  
Next, a single signalling protein of interest is engineered to accept the orthogonal ligand, by 
replacing one or two residues in the binding pocket by amino acids with smaller side chains.  This 
creates an artificial void, which can accommodate the steric addition to the lipid, generating a 
unique binding pair.  The mutation must not interfere with any other aspect of protein function, 
Figure 1.10c.  The mutated protein is engineered into a cell line to investigate the effect on the 
signalling system when the modified ligand is added.  The original shape and size of the binding 
pocket has not been decreased so even if the WT protein is deleted the mutated protein can still 
accept the natural ligand, Figure 1.10d.  Hence there can be no re-routing of the signalling system 
to avoid the mutant protein. 
Using the known crystal structures31,32 of IPn lipid head-groups bound to lipid binding 
domains, it is perhaps possible to propose suitable mutations and chemical manipulations for a 
steric complementation pair.  For example, in the crystal structure of the PKBα-PH domain bound 
to Ins(1,3,4,5)P4, amino acids in the binding site which are electrostatically involved in phosphate 
recognition must be retained to maintain binding affinity, Figure 1.11a.  On the other hand, amino 
acids which are involved in shaping the binding pocket offer possibilities to introduce a void, 
Figure 1.11b. 
Figure 1.11: PKBα-PH domain binding to Ins(1,3,4,5)P4 a) Amino acids with electrostatic binding 
interactions; b) Amino acids with purely steric input at the binding site.33 
By replacing a larger amino acid (e.g. phenylalanine) with a smaller amino acid (such as 
alanine) we create the required void to accommodate a steric protrusion on the ligand.  Glycine, the 
smallest amino acid, could be used, but because it has no alkyl side chain it is more likely to affect 
the protein backbone flexibility which may undesirably distort the native fold of the protein. 
Suitable chemical modifications to the PIPn ligand can be proposed by examination of the 
inositol ring orientation in the known co-crystal structures with binding proteins.  Generally, the 3-, 
4- and 5-positions of the ring will lie deepest in the binding pocket, as these are furthest from the 1-
a) b) 
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O-lipid tail which is anchored in the membrane.  The PH-domain structures suggest that the head 
group binds with one face parallel to the binding pocket of the protein, although the orientation of 
the inositol ring can be reversed depending on the structure of the individual binding pocket,3 
Figure 1.12. 
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Figure 1.12: The orientation of PIPns in the binding pocket 
The phosphate groups on the PIPn are responsible for the electrostatic interactions upon 
binding, so altering these moieties risks reducing the binding affinity.  However, the C-H protons 
around the inositol ring are not involved in electrostatic interactions.  Replacing one of these 
protons with an alkyl group offers an opportunity for introduction of a steric protrusion.  In the 
natural conformation, five of these steric protrusions would be axial (1, 3, 4, 5 and 6) and therefore 
could point directly at the surface of the protein during binding, Figure 1.12.  The 2-position 
contains an axial hydroxyl with the inositol proton occupying an equatorial site, and lies adjacent to 
the 1-O-lipid tail.  Consequently a bump here may not project so directly into the protein-ligand 
interface, making this a less desirable place for introducing a steric protrusion. 
Following the generation of mutated proteins and chemically modified ligands, a method 
for assessing the binding affinity between a given ligand and protein is required so that a successful 
RLE protein ligand pair can be identified.  Classical screening of mutated ligands and proteins to 
find a binding pair has been carried out using affinity chromatography or by immobilising the 
protein or ligand on a solid support,50 which allows large numbers of ligands and proteins to be 
screened at one time.  Rao et al.51 used biotinylated PtdIns(3,4)P2 and PtdIns(3,4,5)P3 bound to 
avadin coated beads to identify proteins which bound 3-phosphorylated PIPns.  Using this 
technique they isolated three proteins from mouse spleen.  Similarly, Hammonds-Odie et al.52 
identifed Ins(1,3,4,5)P4 binding protein Centaurin-α using affinity resin and photoaffinity labeled 
phospholipid analogues of IP4.  That these techniques have only served to identify a small fraction 
of the proteins known to bind PIPn and IPn species, is testamony to the complex nature of the PIPn-
protein binding which is often relatively low affinity,29 with a concerted mechanism of binding to 
other membrane features.  The inability of such screens to recreate these high affinity concerted 
interactions means it is likely that valid mutant protein-bumpy ligand pairs may be missed. 
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Therefore it is planned that screening to identify unique lipid-protein binding pairs will be 
carried out in silico.†  This requires the docking of candidate ligand libraries into potential lipid 
binding protein targets to identify possible mutants which may accommodate the modified ligand.  
The interactions of such highly charged species are difficult to model, and therefore to ensure that 
meaningful results are obtained from in silico studies, it is intended that the model will be validated 
using real binding data.  By generating ion-pair exchange RLE data using mutant proteins already 
available in the group and modified IP4 ligands designed to fit the well known PKB-PH domain, it 
should be possible to collect real binding values for given protein-ligand interactions.  Isothermal 
titration calorimetry (ITC)53 is being used to measure the change in enthalpy which occurs upon 
introduction of a modified IP4 to a mutant PKB.  These values will be compared with the predicted 
values from the in silico model to ensure that it accurately recreates the binding event. 
Once a mutant protein-bumpy phosphoinositide pair has been predicted by the in silico 
model, ITC can be used to confirm and quantify the interaction between the designed ligand and 
mutant protein, to ultimately generate a specific binding pair which can be used within the context 
of the whole cell.  The PIPn ligand must then be synthesised in full in order to ensure it’s location at 
the cell membrane for whole cell studies. 
Following the identification of a specific protein-ligand pair, the protein must be 
engineered into the cell.  It is then hoped that the lipid ligand can be delivered to the cell to observe 
the effects of this one interaction in a time and dose-dependent manner.  This in itself is a complex 
task which will require optimising in order to introduce the modified PIPn to the inner leaflet of the 
plasma membrane.  By comparing the cell content before and after introduction of the bumpy 
ligand using proteomic strategies, it is anticipated that the specific downstream effects from one 
signalling event may be observed. 
Underpinning this strategy to elucidate PIPn signalling, is the requirement to prepare PIPn 
ligand analogues with a steric protrusion, using chemical synthesis.  The preparation of such 
analogues has not been reported in the literature to date, and would provide new tools for the study 
of phosphoinositide systems in a much wider context than the RLE system for which they are 
designed.  The preparation of these analogues represents a considerable challenge in itself, and is 
the focus of the work within this thesis. 
                                                     
† This project is currently being undertaken by an MRes/PhD student, in collaboration with Ian 
Gould at Imperial College.   
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Chapter 2:  Chemistry Introduction 
This chapter reviews the tools available for the synthesis of IPn and PIPns and will explain 
why the 4-C-alkyl IP3 and IP4s were chosen as initial synthetic targets for this work.  By reviewing 
the available literature, a synthetic strategy was designed, which is introduced here in terms of the 
four main requirements for chemical synthesis; protection of a suitably chosen starting material, 
followed by introduction of a steric protrusion suitable for RLE, subsequent rearrangement of 
protecting groups and finally the phosphorylation and deprotection to generate the target 
molecules. 
The preparation of IPn and PIPns has proved challenging due to the requirement for 
regiospecific protection of inositol, phosphorylation of a polyol, removal of phosphate protecting 
groups while avoiding migration, and purification of the final water soluble poly-anions.54  
Combined with the limited availability of these important signalling molecules from Nature, this 
has led to a wealth of synthetic routes.15,54,55  Initial synthetic targets were the natural products 
themselves, although the identification of these molecules in pathways whose perturbation leads to 
disease states rapidly led to the preparation of analogues for biological studies.54  In addition to the 
inherent challenges of IPn and PIPn preparation, the proposed synthesis of C-alkyl PIPns must 
address the stereo- and regiospecific introduction of an alkyl group, replacing an inositol ring C-H. 
In order to address this new challenge an expedient route to a robustly protected inositol 
with a single free hydroxyl was sought.  This intermediate must tolerate, and preferably direct, the 
introduction of a C-alkyl group after oxidation.  Evaluation of protecting group strategies suggested 
that the 4-C could be easily isolated using an orthoester, and that this protecting group could be 
later manipulated to expose the hydroxyls of IP4 analogues for phosphorylation.  It was envisaged 
that 4-C-alkyl introduction would proceed via inos-4-ose, 11, Figure 2.1. 
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Figure 2.1: Introduction of an alkyl group involves oxidation of the 4-OH 
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Stereocontrolled addition of an alkyl equivalent to the inosose would regenerate the 4-OH, 
12.  These derivatives could then be taken on to investigate protecting group manipulations to 
generate a selectively protected triol or tetrol, followed by phosphorylation and deprotection.  In 
order to demonstrate that C-alkyl analogues of PIPns were feasible targets, it was essential that all 
three of these subsequent transformations were possible in the presence of the unnatural tertiary 
centre.  Therefore it was decided to prepare the IPn head group, rather than the full PIPn lipid 
analogue which requires differentiation between the hydroxyls and construction of the 
phosphatidate moiety.  This matter takes up the entirety of this thesis.  Since it is the inositol 
phosphate head group which forms the protein binding site, the IPn analogues should not only 
prove the validity of the chemical transformations, but also provide an adequate model for initial 
binding studies.  Once the chemistry is established and specific targets have been identified for 
RLE, the synthesis of the corresponding PIPn derivatives can be undertaken. 
2.1 Starting Materials 
The reported starting points for the synthesis of inositol phosphates fall into two classes, 
either a) from materials with built-in asymmetry, originating from the chiral-pool, or b) from meso 
myo-inositol or benzene which require a later chemical or enzymatic resolution of enantiomers, 
Figure 2.2. 
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Figure 2.2: Starting materials for inositol phosphate synthesis, numbered according to the position of 
carbons in the subsequent myo-inositol framework 
Simple sugars are attractive starting materials for the preparation of chiral inositols as they 
are available enantiomerically pure at relatively low cost.  Protection of hydroxyl functionalities is 
used to generate a key intermediate such as 13, 14, or 15, which will undergo a rearrangment or 
coupling, transmitting chirality to the newly formed inositol framework.  For example, the Ferrier 
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rearrangement56 of 13 derived from D-glucose was used to prepare Ins(1,4,5)P3
57 and 1-O-
functionalised IP4 affinity probes.
58  Using a similar strategy, chiral 6- and 3,6-deoxy-D-myo-
inositol precursors were prepared from D-galactose derivative 14.59  D-Mannitol,60 L-iditol61 and 
diethyltartrate62 have been used to prepare dialdehydes such as 15 which undergo samarium iodide 
mediated stereoselective reductive couplings to form enantiomerically pure myo-inositol 
frameworks.  Chiral materials other than sugars have also been employed as starting materials:  
Naturally occurring L-quebrachitol [1-L-(-)-2-O-methyl-chiro-inositol] 16 is commercially 
available as a side product of the rubber industry,63 although it is more expensive than alternative 
materials (£48.30 for 250 mg from Sigma-Aldrich).  Protection of some or all of the free hydroxyls, 
inversion of the 3-OH and demethylation of the 1-O (numbering for the myo-inositol product) 
transmits the chirality of the starting material to a myo-inositol derivative.63  One disadvantage of 
such syntheses, is the number of manipulations required prior to the generation of the inositol 
framework, which must often be followed by rearrangement of protecting groups to generate a 
building block suitable for phosphorylation and deprotection to prepare the desired IPn or PIPn. 
In each case, these chiral syntheses only generate one of the two possible enantiomers of 
the final IPn or PIPn and it was for this reason that the meso-cyclohexane hexitol myo-inositol 1 was 
the starting material of choice to prepare C-alkyl IPns.  The need to carry out a resolution of the 
racemic material during synthesis starting from 1 was considered an advantage for the RLE project, 
as both the natural and unnatural enantiomers could ultimately be prepared.  This provides an ideal 
control for biophysical studies as the unnatural enantiomer can be used to assess the effects of 
adding a non-interacting PIPn lipid into the cell.  The pre-installed myo-stereochemistry and 
cyclohexane ring make myo-inositol an attractive choice for rapidly obtaining large quantities of 
material with a suitable protecting group strategy to test the introduction of C-alkyl groups.  
Furthermore, it is available at reasonable cost from chemical suppliers (£11.20 for 50 g from 
Sigma-Aldrich).  For these reasons, myo-inositol has been a popular starting material in the 
preparation of IPns, and the protection and deprotection of the six secondary hydroxyls to permit 
selective functionalisation has been extensively reported.64-66  Benzene 17 has also been used as a 
starting material;67 like myo-inositol, it is cheap and readily available.  The absence of any 
predefined stereochemistry or substituents provides a blank canvas for functionalisation.  Syntheses 
are racemic, starting with oxidation of benzene to introduce hydroxyls.  Related chiral syntheses 
have started from enzymatic dihydroxylation of chlorobenzene to selectively generate one 
enantiomer for further elaboration.  However, the extra steps required to selectively introduce the 
hydroxyls, often involving temporary protecting groups, mean that the route to a fully protected 
intermediate from benzene is not as expedient as with myo-inositol. 
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2.2 The introduction of protecting groups to isolate the 4-C 
With myo-inositol as a starting point for inositol phosphate synthesis it is necessary to 
manipulate, and differentiate between, the six similar secondary hydroxyls.  There are two key 
intermediates which the protecting group strategy must facilitate access to:  The first is the isolation 
of a hydroxyl for manipulation to generate 18a and b.  However, this has to incorporate the second 
requirement, which is that in the later stages of the synthesis, hydroxyls required to undergo 
phosphorylation must be unprotected (the 1,4,5-triol for IP3 and the 1,3,4,5-tetrol for IP4), while 
hydroxyls of the target are protected (the 2,3,6-O for IP3 and the 2,6-O for IP4), 19, as illustrated in 
Figure 2.3 
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Figure 2.3: Protecting group strategy during synthesis of a 4-C-alkyl IP4 analogue 
This strategy requires two types of protecting group; permanent protecting groups which 
remain in position until the final deprotection of the target molecule, and temporary protecting 
groups which can be selectively removed prior to phosphorylation.  After introduction of the C-
alkyl substituent, it is essential that the temporary protecting groups be selectively removed in the 
presence of the permanent protecting groups.  Manipulation of the free hydroxyl of fully protected 
18a and b involves oxidation of a C-H bond to a C-C bond, so both the temporary and permanent 
protecting groups must withstand the conditions required to effect this transformation.  
Furthermore, C-alkyl introduction must be stereospecific so any directing influence which aids 
stereocontrol, for example using steric bulk of protecting groups, would be beneficial. 
Many strategies for the isolation of hydroxyl groups have been developed.64,65  If starting a 
synthesis from myo-inositol, initial protection of two, three or four hydroxyls has typically been 
carried out using either ketals or orthoesters, Figure 2.4. 
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Figure 2.4: Orthoester and ketal groups as initial protecting groups for myo-inositol. 
Both methods have been used to prepare protected inositols in high yields on large scales, 
making them ideal starting points for synthesis.64,65  myo-Inositol mono- and bis-acetals have been 
obtained in good yield, protecting up to four hydroxyls simultaneously.64  Ketalisation of myo-
inositol under forcing conditions results in the formation of a mixture of bis-ketal isomers, which 
are separable by crystallisation.  Orthoesters of myo-inositol have become prominent in the 
literature in recent years, due to their easy isolation in multi-gram quantities68 and the simultaneous 
protection of the 1-, 3-, and 5-O forming a rigid adamantane-like cage.64  myo-Inositol orthoesters 
are prepared by the reaction of myo-inositol with the triethyl or -methyl orthoester of the desired 
carboxylic acid under acid catalysis.68  The reagent exchanges ester bonds with inositol hydroxyls, 
equilibrating between a series of intermediate structures, until the most stable, tricyclic species 
forms.  For myo-inositol, with five equatorial and one axial hydroxyl, there is only one such 
possibility, the 1,3,5-O-triester, Figure 2.5a.  By contrast, the similar transesterification of scyllo-
inositol, 23, which has all six hydroxyls equatorial forms the diorthoester 24,69 Figure 2.5b. 
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Figure 2.5: a) The preparation of orthoesters from myo-inositol, b) The preparation of bis-orthoester from 
scyllo-inositol 
Lee and Kishi70 first fully characterised the orthoformate 22a, Figure 2.5a, in 1985 and it 
has been the most thoroughly investigated of the myo-inositol orthoesters.  Recently, more varied 
orthoesters have been employed in IPn synthesis, including the orthoacetate,
68,71 orthopentanoate72 
and orthobenzoate.73,74  In particular the orthobenzoate, 22d, is reported to be easily recovered by 
recrystallisation from ethyl acetate.73 
When considering which initial protecting group to employ for the preparation of C-alkyl 
inositol phosphates, the simultaneous protection of the 1-, 3- and 5-O offered by an orthoester is 
attractive as either two (for IP3) or all three (for IP4) of these hydroxyls will be phosphorylated at a 
later stage.  Their simple, high yielding preparation should permit large quantities of protected 
material to be carried through to later stages of the synthesis.  It was also anticipated that the 
orthoester would be more stable than the corresponding ketal during oxidation, essential for the 
proposed strategy for introducing a C-alkyl group via oxidation of the 4-OH to the inosose, Figure 
2.1.  On oxidation of an inositol hydroxyl, isomerisation of the resulting inosose to the enolate must 
be avoided in order to prevent elimination of the ring substituents.  The steric constraint of the 
orthoester should prevent tautomerisation, as the adjacent bridgehead carbons prevent the enolate 
double bond from achieving the required co-planarity.  Attempted elaboration of conformationally 
unrestricted inososes under basic conditions has been reported to result in elimination to 
unsaturated products.75 
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After introduction of the orthoester, protecting two of the remaining three hydroxyls will 
isolate a single hydroxyl for manipulation.  Of the 2-, 4- and 6-C, the 4- or 6-position were 
identified as suitable sites for C-alkyl substituents (see Chapter 1.4).  In the protecting group 
strategy proposed in Figure 2.3, the 2- and 6-OH require permanent protecting groups for both IP3 
and IP4 products.  Therefore it was anticipated that introduction of a 4-C-alkyl group by 
manipulation of the 4-OH would require the least number of additional protecting group 
manipulations. 
The orthoester locks the conformation of the cyclohexane ring, so that the remaining 
equatorial 2-OH occupies a very different environment to the axial 4- and 6-OH.  As a result, the 
regioselective protection of the 2-, 4- and 6-O with alkyl, acyl, sulfonyl and silyl protecting groups 
is extensively described in the literature and differentiation of any individual hydroxyl from the 
remaining two has been reported.64-66  The 4- and 6-OH form a strong intramolecular hydrogen 
bond, the result of which is that one of these more hindered hydroxyls may be selectively 
deprotonated before the 2-OH with a strong base, Figure 2.6. 
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Figure 2.6: Stabilisation of 4(6)-O-anion and chelation of metal cation 
The resulting anion 25, is stabilised by intramolecular hydrogen bonding with the 
remaining axial hydroxyl group.  When the base is a metal hydride, the metal ion may be chelated 
in the di-axial 4,6-O pocket, 26, as initially postulated by Billington et al.,76 resulting in selective 
4(6)-O protection with a wide variety of groups.  This selectivity has been exploited to form many 
myo-inositol orthoester alkyl derivatives at the more hindered 4(6)-O with 1 equivalent (eq.) of 
sodium hydride, followed by addition of an alkyl halide, Figure 2.7, 29.  However, alkylation with 
2 eq. sodium hydride results in a mixture of 2,4- and 4,6-O-dialkylated species 28 and 30, due to 
the opposed effects of increased steric hindrance at the remaining axial hydroxyl and chelation of 
the metal in the diaxial pocket.66  Deveraj et al.66 report that 4,6-O-dialkyl derivatives 30 can be 
selectively generated using BuLi to effect the second deprotonation due to improved chelation of 
the small Li-cation in the tight 4,6-O-pocket, Figure 2.7. 
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Figure 2.7: Selective protection of the 2-, 4- and 6-O 
The initial regioselectivity of acylation or sulfonation can be influenced by the choice of 
organic base; use of a weak base such as pyridine preferentially protects the 2-O whereas a stronger 
base such as triethylamine can weakly deprotonate therefore protect the 4(6)-O.77  Thus, in the 
presence of pyridine, 2,4(6)-O-disulfonyl or -diacyl esters are selectively generated by a second 
reaction at the 4(6)-O.78,79  For the sulfonates, this selectivity can be reversed by use of excess 
sodium hydride to prepare the 4,6-O-disulfonates78 with increased selectivity compared to the 
dialkyl species, possibly due to the enhanced chelation of the sodium metal with the initial 4(6)-O-
sulfonate.78  However for the acyl esters, while 1 eq. sodium hydride deprotonates and acylates the 
4-O, addition of 2 eq. sodium hydride in DMF surprisingly generates the 2-O-acyl ester.  Sureshan 
and Shashidhar80 report that addition of sodium hydride to a mixture of 4-O-acetyl orthoformate 
and 4-O-benzoyl orthoacetate in DMF yielded the 2-O-acetyl orthoformate and the 2-O-benzoyl 
orthoacetate resulting from acyl migration.  No cross-products of intermolecular acyl transfer were 
observed.80  Their results suggest that the observed acyl transfer occurs intramolecularly, although 
direct acyl transfer from the 4-O to the 2-O is clearly geometrically impossible.  The reaction is 
dependent on the presence of sodium hydride and DMF; when carried out in THF, 4-O-benzoyl 
migration was observed at a much slower rate, in a non-selective manner, generating a mixture of 
all possible mono-, di- and tribenzoyl products, suggesting that the solvent may act as a shuttle.  
Selective deprotonation with 1 eq. sodium hydride can be extended to bulky groups such as tert-
butyldimethylsilyl (Tbdms) to prepare 4-O-Tbdms derivatives, whereas under mildly basic 
conditions, Tbdms reacts preferentially with the less hindered 2-O, followed by the 4-O, to 
generate the asymmetric 2,4-O-Tbdms2 derivative,
81 Figure 2.7. 
To isolate the 4-C, protecting groups must be introduced on the 2- and 6-O of the myo-
inositol orthoester.  As demonstrated above, this is possible in one step using acyl or sulfonyl 
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groups in the presence of a mild base.  Indeed, the direct preparation of pentaprotected 2,6-O-
dibenzoyl myo-inositol orthoformate is reported in a one-pot proceedure.79  However, in order to 
establish a method for oxidation of the 4-C, robust protecting groups which would be stable to a 
wide range of conditions are required.  Acyl and sulfonyl groups are not stable to the strongly 
basic/nucleophilic conditions which may be needed, for example to effect a Wittig reaction.  As a 
result, the base and largely acid stable benzyl ether was chosen as the permanent 2- and 6-O 
protecting group.  Since dibenzylation of inositol orthoformate reportedly yields a 1:5 mixture of 
2,4- and 4,6-O-diethers favouring diaxially substituted 30,82 a temporary protecting group on the 4-
O would provide the most reliable method for selectively generating the desired 2,6-O-dibenzyl 
isomer.  Gigg et al.83 reported the preparation of a range of allyl and benzyl ethers of myo-inositol, 
using the allyl group as a temporary regiodirecting protecting group, which can be removed once 
the benzyl ethers have been introduced, by isomerisation using tBuOK in DMSO, followed by mild 
acidic hydrolysis.84  Billington et al.76 demonstrated that this difference in stability can be exploited 
to prepare 2,6-O-dibenzyl tetrol from myo-inositol orthoformate, Figure 2.8 
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Figure 2.8: Billington’s use of 4-O-allyl orthoformate to prepare 2,6-O-dibenzyl tetrol76 
It was proposed that this protecting group strategy be used to isolate the 4-OH.  However, 
both Billington and Gigg use acidic conditions to remove the isomerised allyl group which effects 
simultaneous removal of the orthoformate.85  It will therefore be necessary to employ alternative 
conditions in order to selectively cleave the temporary 4-O-allyl ether in the presence of the 2- and 
6-O-benzyl ethers and the 1,3,5-O-orthoester.  For example, the basic removal of a prop-2-enyl 
ether from an acid sensitive carbohydrate derivative is reported using 4 % aq. KMnO4 in 
methanolic NaOH.86 
2.3 Oxidation of the 4-OH and introduction of an alkyl group 
Once the 4-OH has been isolated it must be oxidised to permit introduction of the C-alkyl 
group.  It has been reported that a free inositol orthoester hydroxyl may be oxidised to the inosose, 
using Swern’s method.87,88  Oxidation of either the 2-OH70,82,88,89 or the 4-OH90 are reported.  In 
some cases, upon oxidation of the 2-OH, the observed product is a mixture of the ketone and the 
gem-diol.5,90  However, the ketone can be isolated by azeotropic removal of water in toluene.  This 
ease of hydration may be attributed to the rigid adamantane structure straining the 120 º sp2 
carbonyl carbon bond angle.91  Upon oxidation to the inosose one stereocentre and the myo-
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geometry are lost.  Therefore introduction of the alkyl group must be accompanied by regeneration 
of the myo-geometry at the 4-C.  These two steps can be carried out either simultaneously or 
stepwise, Figure 2.9. 
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Figure 2.9: The simultaneous or stepwise introduction of 4-C-alkyl group 
For 4,6-O-dibenzyl inos-2-ose and 4,6-O-ditosyl inos-2-ose, 39, reduction with NaBH4 is 
reported to proceed entirely stereoselectively from the top face‡ of the inos-2-ose, generating a 
scyllo-geometry product,70,89 40, Figure 2.10a. 
                                                     
‡ Throughout this thesis the inositol 1,3,5-O-orthoesters are consistently drawn in a single 
orientation, with the orthoester situated above the inositol ring, as illustrated in Figure 2.9, 34.  Therefore 
references to reagents which approach from or deliver to the top-face describe those which approach from the 
same face of the inositol ring as the orthoester.  Those described as approaching from or delivering to the 
bottom face approach from the opposite face of the inositol ring to the orthoester protecting group. 
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Figure 2.10: a) 2-OH oxidation to the inos-2-ose and reduction to the scyllo-2-OH70,89; b) 4-OH oxidation to 
the inos-4-ose and methyl delivery to regenerate the myo-4-OH and introduce a 4-C-methyl substituent90 
Both 4,6-O-dibenzyl inos-2-ose and 2,6-O-dibenzyl inos-4-ose have been treated with 
methylmagnesium iodide to prepare the corresponding 2- and 4-C-methyl derivatives.90  In both 
cases methyl addition occurred from the top face of the inosose.  Therefore for inos-4-ose 42 the 
original myo-geometry was regenerated, 43, Figure 2.10b.  The addition of larger alkyl groups to 
inososes has not been reported. 
While these methods simultaneously reintroduce the myo-stereochemistry upon alkyl 
addition, thereby minimising the number of synthetic steps, the stereochemical outcome depends 
on the incoming alkyl group, and must be verified in each case.  Furthermore, introducing alkyl 
groups in this manner attaches them directly to the cyclohexane backbone.  It was postulated that 
this would cause conformational strain in the final products as larger C-alkyl groups were 
introduced.  Both Ins(1,4,5)P3 and Ins(1,3,4,5)P4 are known to occupy chair conformations in 
which a 4-C-alkyl substituent, replacing the 4-H, would occupy an axial position.  It was thought 
that 1,3-diaxial interactions, more so with bulkier alkyl groups, might cause ring flipping or 
skewing to a twist boat to alleviate trans-annular strain (44 → 45).  The natural conformation is 
essential for binding to the protein as it presents the constellation of charged phosphate esters to the 
corresponding positively charged residues in the binding pocket in a precise relative geometry.  
Therefore it was proposed that a methylene spacer be incorporated between the alkyl group and 
inositol ring to place larger secondary, tertiary and aryl groups further away from the cyclohexane 
backbone, allowing them to point out radially 46, Figure 2.11. 
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Figure 2.11: Addition of a methylene spacer preserves the natural configuration in the 4-C-alkyl IPn 
analogue. 
The alternative to the reported90 direct addition is a stepwise approach, in which the 
stereochemistry can be set either prior to, or after alkyl group insertion, Figure 2.9.  In the latter 
case the stereochemistry is again dependent on the incoming alkyl group, and may change for each 
new derivative.  In the former, the stereochemistry is defined prior to alkyl addition and the 
stereochemistry of alkylation therefore does not require verification for each new substituent.  
Epoxides are reactive intermediates with defined stereochemistry, which should undergo 
nucleophilic ring-opening to introduce the alkyl group, simultaneously including a methylene 
spacer.  Insertion of a methylene group to inos-4-ose 48 to generate an epoxide can result in either 
the desired myo-inositol exo-methylene oxide, 49, by methylene insertion to the top face of the 
inosose, or the unwanted epi-inositol exo-methylene oxide, 50, by insertion to the bottom face, 
Figure 2.12. 
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Figure 2.12: Pre-defining the 4-C-stereochemistry by conversion to the exo-methylene oxide can generate 
two geometries, myo or epi. 
The preparation of epoxides is a well developed and highly useful tool for organic 
synthesis.92  Reported methods of epoxidation include direct insertion of methylene into the inosose 
using sulfur ylides,93 chloromethyl lithium92e or diazomethane92c-d,94.  Alternatively conversion of 
the ketone to an olefin using Wittig conditions, followed by oxidation with mCPBA92a or H2O2
92b 
are also reported to generate the corresponding epoxide.  In the latter case, although conversion of 
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the inosose to the olefin is reported in good yield,88 in this laboratory subsequent oxidations 
proceeded without the required stereoselectivity (see section 2.6).  It was therefore hoped to 
generate the epoxide directly from the inos-4-ose, using the readily available sulfur ylides.93 
Corey and Chaykovski first reported dimethyloxosulfonium methylide and 
dimethylsulfonium methylide as methylene transfer reagents, forming epoxides by insertion of 
methylene into a ketone double bond.93  Dimethyloxosulfonium methylide, prepared by the 
reaction of trimethyloxosulfonium chloride or iodide with sodium hydride, was observed to form 
only new equatorial carbon-carbon bonds 52 with cyclohexanone derivatives such as 51, Figure 
2.13. 
tBu
OMe2S-CH2 Me2S
tBu
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535152
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Figure 2.13: Methylene insertion with dimethylsulfoxonium and dimethylsulfonium ylides93 
In contrast, the corresponding ylide prepared by addition of sodium hydride to 
trimethylsulfonium iodide was reported to preferentially generate axial carbon-carbon bonds 53, 
when added to ketones such as 51, (observed ratio 53-52, 83:17)93 Figure 2.13.  The reaction of 5-
substituted adamantan-2-ones, which are structurally similar to the inosose orthoesters, with both 
methylides has also been reported to occur in good yield, generating a mixture of exo-methylene 
oxides with limited stereoselectivity.95  Furthermore, sulfur ylide chemistry has been successfully 
applied to inosose orthoformates by Paquette et al.96 to generate exo-methylene oxides selectively 
at either one, two or all of the 2-, 4- and 6-O for use as lithium ion chelaters.  Using 
dimethylsulfoxonium methylide, they report exclusive delivery to the top (equatorial) face of the 
inosose to form 55.  They also demonstrated, that upon addition of further ylide, the initially 
formed exo-methylene oxide could be expanded to the oxetane 56 by a second methylene insertion, 
Figure 2.14. 
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Figure 2.14: Addition of dimethylsulfoxonium methylide to the inos-4-ose generates the exo-methylene 
oxide.96 
It was hoped that the same face selectivity would be observed for the proposed 2,6-O-
dibenzyl inos-4-ose, to generate the myo-geometry exo-methylene oxide.  Once an exo-methylene 
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oxide has been introduced, this intermediate can be opened with a nucleophile.  There is no 
literature precedent for such reactions on the inositol framework, although this transformation is 
extensively covered elsewhere due to its utility in the synthesis of various natural products.  For 
example, the exo-methylene oxide 57 prepared from adamantanone was quantitatively opened at 
the less hindered carbon using p-methoxyphenylmagnesium bromide to generate 58,97 Figure 2.15. 
57
OH OMeO
58
OMeBr
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Figure 2.15: Nucleophilic opening of an exo-methylene oxide by p-methoxyphenylmagnesium bromide.97 
Further study of the reaction of adamantyleneoxirane 57 with organometallic reagents 
produced varying results.98  While addition of phenyl lithium generated the C-benzyl derivative 59 
in good yield, other reactions were subject to rearrangement or side product formation.  For 
instance the reaction of epoxide 57 with MeMgI and phenylmagnesium bromide generated 
predominantly iodomethyl 60 and carbinol 61, Figure 2.16. 
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Figure 2.16: The reaction of adamantyleneoxirane with alkylating reagents98 
Commercial solutions of both Grignard reagents and alkyl lithiums are readily available, 
and include primary, secondary, tertiary and aryl groups which should allow the introduction of a 
range of substituents.  However, the generation of unwanted side products increases with bulkier 
nucleophiles and more sterically constrained ketones and epoxides.  This has led to modifications 
of these reactions including catalysis by addition of copper iodide.99  The addition of copper(I) to 
phenylmagnesium chloride improved the yield of trans-2-phenyl-cyclohexanol from cyclohexene 
oxide from 3 to 82 %.  However, this improvement is not universal as the same conversion with 
benzylmagnesium chloride did not benefit at all from copper(I) catalysis. 
An alkyl group larger than the methyl reported thus far90 may be needed in order to 
generate a steric clash which prevents binding of a C-alkyl IPn headgroup to the wild-type lipid 
binding proteins.  The development of a reliable route for the introduction of an alkyl or aryl group 
of varying size by nucleophilic substitution of the exo-methylene oxide is therefore a major goal of 
the synthesis.  Therefore it is important to explore the chemistry of appending varying shapes and 
sizes of bump onto the ring, Figure 2.17.   
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Figure 2.17: The proposed target library of 4-C-alkyl compounds 
Since the bumpy lipid head groups will ultimately need to dock with point mutants of lipid 
binding proteins, this implies that the bump should be of comparable size and shape to the lost 
amino acid side chain to produce a specific bump-hole pair, Figure 2.18. 
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+ -OOC NH3
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Figure 2.18: Amino acids and their comparable C-alkyl substituents   
Therefore in addition to alkyl groups, aryl groups such as phenyl, benzyl and 2-naphthyl 
are good target 4-C-alkyl substituents, Figure 2.17.  The limitations for manipulation of the 4-C-
alkyl groups will be explored during the subsequent protecting group manipulations, 
phosphorylation and deprotection steps. For example, larger alkyl and aryl groups may be prone to 
elimination either during orthoester unblocking or after phosphorylation because unconstrained 
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flexing of the ring may allow anti-periplanar relationships of suitable protons and the 4-O-
phosphotriester to arise. 
2.4 Removal of temporary protecting groups to generate both IP3
 
and IP4 
derivatives. 
A major advantage of the orthoester protecting group is the number of different ways in 
which it can be selectively cleaved to expose one, two or all of the underlying hydroxyls, accessing 
a range of products from a single precursor.  Three distinct methods of manipulating the orthoester 
have been explored in the literature:  Reduction with diisobutylaluminium hydride (DIBAL-H), 
methyl insertion into the C-O bond using trimethylaluminium or Grignard reagents, and acidic 
hydrolysis. 
Acidic hydrolysis, followed by removal of the intermediate acyl ester, liberates the 1-, 3- 
and 5-OH.  In the case of the 4-C-alkyl derivatives, 62, this should generate the 1,3,4,5-tetrol 
required for the preparation of 4-C-alkyl IP4.  Acidic hydrolysis of orthoformates has been reported 
using either TFA-H2O (4:1)
78,100 or HCl in MeOH at reflux.56,101  During acidic hydrolysis of the 
orthoformate the presumed intermediate formate ester is spontaneously hydrolysed under the 
reaction conditions to generate the free hydroxyl of triol 64.  In contrast, larger alkyl groups at the 
orthoester bridgehead generate relatively stable acyl esters upon acidic hydrolysis (65), which can 
be removed by nucleophilic attack to liberate the final triol 64, Figure 2.19. 
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Figure 2.19: Acidic hydrolysis of the orthoester 
Potter at al.71 used acidic hydrolysis of the orthoacetate to generate a separable mixture of 
the 1- and 3-O-acetate esters in their preparation of natural Ins(1,4,5)P3.  The same group prepared 
the 1 and 3-O-benzoate esters by acidic hydrolysis of 2,6-O-dibenzyl orthobenzoate with 1.0 M 
HCl in reluxing ethanol (1:2).73  No 5-O-benzoate ester was isolated under these conditions and the 
mixed benzoate esters could be removed to generate the 1,3,4,5-tetrol.  Alternatively, the 1-O-ester 
was used to prepare PtdIns(3,4,5)P3, since it differentiated the 1-O for coupling to phosphatidate 
from the three phospho mono-esters.73  These results suggest that the 2- and 6-O benzyl ether 
permanent protecting groups will be unaffected by complete removal of the orthoester. 
The orthoester employed for the preparation of 4-C-alkyl derivatives is required to 
withstand the conditions needed to introduce the 4-C-alkyl group, but then be selectively removed 
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without destroying this new tertiary centre, in order to permit phosphorylation.  The choice of 
substitution at the orthoester bridgehead can be used to influence the stability of the orthoester.102  
Bouab et al.103 studied rates of hydrolysis of 2,4,10-trioxaadamantanes, 66.  For these compounds, 
very reminiscent of the inositol orthoesters, they report that substitution at the orthoester 
bridgehead reduces the rate of hydrolysis.  This is because the rate determining step requires a ring-
flip of the cyclohexane ring to the boat conformation 70 to allow water to bind to the carboxonium 
ion.  As the carboxonium ion is increasingly stabilised by larger groups the rate of addition of water 
to 70 is reduced as the size of R increases,103 Figure 2.20. 
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Figure 2.20: The rate determining step of orthoester hydrolysis requires a ring-flip to permit the addition of 
water to the carboxonium ion.103 
Bouab et al.103 suggested that the key intermediate in this transformation was 73, in which 
addition of water to the carboxonium ion is simultaneous with ring-flip from the chair to the boat 
conformation.  However, it seems unlikely that such a high energy transient species could undergo 
coordination of water before ring-flip to a more stable intermediate. 
An additional protecting group on the 3-O is required to prepare the desired 2,3,6-O-
protected triols for 4-C-alkyl IP3 analogues.  In contrast to acidic hydrolysis, reduction of the 
orthoester with limited DIBAL-H selectively generates a bridging acetal, 75.  First reported by 
Gilbert and Holmes,104 two equivalents of DIBAL-H are required to effect reduction of the 
orthoformate to the formylidene acetal.  Correspondingly, reduction of the orthobenzoate with 
limited DIBAL-H generates the bridging 1,3-O-benzylidene acetal in good yield.105  Delivery of 
hydride to myo-inositol orthoesters occurs selectively by initial Al coordination to the relatively 
unhindered 5-O.106  Access to the 1 and 3-O is more obstructed, presumably due to the equatorial 2-
OBn.  Upon second hydride delivery the 1,3-O-acetal would presumably be further reduced to a 1- 
or 3-O-benzyl ether 76a and b, Figure 2.21.107 
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Figure 2.21: DIBAL-H insertion into the 5-O-C bond, followed by a second insertion to generate a benzyl 
ether 
Trimethyl aluminium and Grignard reagents are reported to cleave orthoesters 
preferentially at the 1(3)-O-C bond to generate an acetal such as 77, due to chelation of the metal in 
the myo-1,2,3-O-trioxa pocket.104  This regioselectivity complements that of DIBAL-H reduction at 
the 5-O, Figure 2.22. 
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Figure 2.22: Regioselective opening of orthoesters by trimethyl aluminium or Grignard reagents 
This interpretation of the regioselectivity was corroborated by the observation that in the 
absence of an equatorial 2-O, such as for a scyllo-derivative, the orthoester is not cleaved by 
Grignard reagents.108  The proposed mechanisms for the differing sites of cleavage with DIBAL-H 
or MeMgBr and subsequent addition to the oxonium ion are shown in Figure 2.23.106 
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Figure 2.23: Proposed mechanisms of orthoester cleavage with DIBAL-H or MeMgBr.106 
Upon treatment of an orthoester with methyl Grignard, the methyl group was delivered to 
the opposite face of the bridgehead carbon, relative to the site of cleavage.  This face selectivity is 
reported to result from steric hindrance by the pseudo-axial 2-OBn which results from a 
conformational change of intermediate 81 to 82, Figure 2.23b.106 Treatment of the orthoformate 
with larger Grignard reagents, such as phenylmagnesium bromide is also reported, generating a 
1,3-O-benzylidene acetal from an orthoformate.108  The addition of excess Grignard reagent to the 
orthoformate effects a second alkyl delivery, cleaving the remaining 1(3)-O-C bond to generate the 
5-O-protected diol.  The preference for generating 5-O-alkyl derivatives upon attack with Grignard 
reagents make this route less attractive than the alternative DIBAL-H reduction for the direct 
preparation of the 4-C-alkyl IP3 triols. 
As a result of the selective methods reported for deprotection of orthoesters, it was 
postulated that manipulation of one orthoester would allow access to both 4-C-alkyl-IP3 and -IP4 
derivatives.  The orthobenzoate, although less widely used in the literature to date, appears to have 
the potential to generate both groups of compounds.  4-C-Alkyl IP4 derivatives could be accessed 
by acidic hydrolysis of the orthobenzoate and subsequent removal of the benzoate ester.  It was 
hoped that the orthobenzoate would be less labile than the orthoformate during alkyl introduction, 
but that it would still be selectively removed in the presence of the permanent benzyl protecting 
groups, under acidic hydrolysis.  The orthobenzoate also has the advantage that 1-O-benzoate ester 
may be isolated for PIP3 synthesis, allowing this route to be used in the later generation of the 
corresponding 4-C-alkyl phosphatidyl lipids.  4-C-Alkyl IP3 derivatives may be accessed by 
reduction of the orthobenzoate to a benzyl ether using DIBAL-H.  Regioselective total reduction of 
2,6-O-dibenzyl orthobenzoate to generate the 3-O-benzyl ether would generate the necessary triol 
for IP3 analogues.  To favour this isomer over the unwanted 1,2,6-O-tribenzyl ether, it is necessary 
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to influence the regioselectivity of second hydride delivery to the 1,3-O-benzylidene acetal.  This 
would be beneficial both in the synthesis of natural IP3 and the preparation of 4-C-alkyl IP3 
analogues.107  If the respective 4-C-alkyl triols and tetrols can be prepared, these will then be ready 
for phosphorylation and subsequent deprotection. 
2.5 Phosphorylation of polyols and deprotection of the phosphate esters 
and hydroxyls 
Phosphorylation of polyols is extensively reported in relation to IPn and PIPn synthesis.
109-
113  In addition to the usual difficulties of effecting multiple phosphorylations while avoiding 
contamination with cyclic phosphotriester by-products,114 the 4-C-alkyl tertiary hydroxyl must be 
phosphorylated to generate the desired analogues.  Polyphosphorylation during preparation of 
inositol phosphates has been reported either a) directly with P(V) reagents (in which the 
phosphorous atom is already in the correct oxidation state), or b) indirectly using P(III) reagents 
which generate an intermediate phosphite triester that must be subsequently oxidised to the 
required phosphate triester. 
The P(V) reagents are more stable (as are the resultant phosphate triesters), than their P(III) 
counterparts which are more sensitive to attack by nucleophiles such as water.  However, the 
preparation of inositol phosphates usually requires phosphorylation of multiple secondary centres, 
often adjacent to one another, and phosphorylation with the less reactive P(V) reagents has 
sometimes proved difficult.54,115  There are reports of P(III) reagents succeeding in phosphorylating 
vicinal hydroxyls where P(V) reagents have failed.114 
Phosphorylation of vicinal hydroxyls is problematic because general intermediate 84 must 
form transiently with a phosphate or phosphite triester adjacent to a free hydroxyl, Figure 2.24. 
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Figure 2.24: Phosphorylation of vicinal diols can suffer from competing cyclisation reactions 
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From this intermediate there are two possibilities:  Either second phosphorylation or 
phosphitylation of the free hydroxyl, to generate 85; or attack of the free hydroxyl on the adjacent 
phosphate/phosphite triester to form cyclic 86.  These cyclic species are hydrolysed during work up 
to generate 87, reducing the yields of phosphorylation reactions.  Therefore the key to 
polyphosphorylation is to ensure that reaction pathway A happens faster than B.  The P(V) 
phosphates are considerably more stable than the corresponding P(III) phosphites, so the rate of 
transesterification of these intermediates is perhaps 10 times slower.  This means that they are 
slower to form cyclic species.  However the steric bulk means that the rate of phosphorylation of 
the adjacent hydroxyl is also slow.  For the more reactive P(III) phosphites, although more easily 
attacked by the adjacent hydroxyl to generate cyclic products, the corresponding rate of 
phosphitylation of the second hydroxyl is much faster than the P(V) reagents. 
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Figure 2.25: P(V) reagents 
Phosphorous(V)oxychloride 88, Figure 2.25, was first used in 185754 and more recently115 
to effect step-wise phosphorylation of a vicinal 4,5-diol.  Reagent 89, could only mono-
phosphorylate the diol, generating a mixture of products, but this was successfully phosphorylated 
with POCl3.  The most commonly reported P(V) reagent is tetrabenzyl pyrophosphate (TBPP, 90) 
which is commercially available.112,116  In the first reported synthesis of Ins(1,3,4,5)P4, Billington 
and Baker85 use TBPP with sodium hydride in THF to effect tetraphosphorylation of the 1,3,4,5-
tetrol, in 66-70 % yield in the presence of a catalytic quantity of imidazole or 18-crown-6.  
Efficient phosphorylation with TBPP requires conversion of the hydroxyls into alkoxides.117  These 
strongly basic conditions could be problematic with compounds containing sensitive 
functionalities, leading to decomposition. 
Despite their instability towards moisture and oxidation, P(III) reagents are now widely 
used in inositol polyphosphate synthesis, Figure 2.26. 
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Figure 2.26: P(III) reagents 
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For example, di(2-cyanoethyl)phosphorochloridite 91 was used to construct all the 
phosphoryl centres in the Gaffney and Reese synthesis of PIP3.
113  The P(III) phosphoramidites 
have also been used extensively as they are more stable to hydrolysis than the corresponding 
chloridites,109 but are activated by weakly acidic 1-H-tetrazole.  Di(2-cyanoethyl) phosphoramidite 
92 has been frequently employed, including Reese and Ward’s first synthesis of IP3.
118,119  
Alternative phosphoramidites include those protected with benzyl esters; N,N-diethyl- and N,N-
diisopropyldibenzyl phosphoramidite, 93a and b.  The latter was preferred in the preparation of 
both enantiomers of Ins(1,3,4,5)P4
120 due to its easier purification by column chromatography110 
and is now commercially available from Aldrich.  More recently, N,N-diethylamino-5,6-benzo-
1,3,2-dioxaphosphepane 94b has been used in the phosphitylation of multiple hydroxyls.111  This 
less sterically demanding reagent is easily prepared by the reaction of hexaethylphosphorous 
triamide with 1,2-di(hydroxymethyl)benzene.121 
The requirement for the formation of a 1-phosphodiester during phospholipid synthesis, 
and the desire to prepare thio-analogues of phosphate esters for biological studies, led to the 
development of bifunctional phosphitylating reagents, Figure 2.27. 
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Figure 2.27: Bifunctional phosphorylating reagents 
As a result of the differential reactivities of the two chlorines of phosphorodichloridites 95, 
they can be reacted with two different partners to form a protected phosphodiester bridge after 
oxidation, which is useful in both phosphoinositide and oligonucleotide synthesis.  
2-Cyanoethoxy(diisopropylamino)chlorophosphine and the corresponding methoxy derivative 96 
have been used in the preparation of phosphodiester linkages and also phosphorothioate analogues 
of the inositol phospholipids.122,123  Phosphitylation using (benzyloxy)bis(diisopropylamino) 
phosphine 97 with 1-H-tetrazole and subsequent oxidation was used to prepare stable cyclic 
phosphates as conformationally restricted inositol phosphate analogues.124 
Following phosphitylation with a P(III) reagent, the resultant phosphite triester must be 
oxidised to the phosphate triester.  The most effective oxidations employ a one pot procedure 
without isolating the phosphitylated material, reducing the opportunity for hydrolysis.  mCPBA110 
and tBuOOH125 are the most commonly employed oxidising agents.  Yu and Reid110 reported that 
they observed cleaner oxidations of dibenzylphosphite triesters with mCPBA rather than tBuOOH 
in CH2Cl2.  The use of P(III) reagents to prepare initial phosphite triesters has allowed their facile 
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conversion to thioylated inositol analogues.  Cooke et al.126 followed phosphitylation with di(2-
cyanoethyl)phosphorochloridite 91 by oxidation to the phosphorothioates using sulfur in pyridine. 
To the best of our knowledge, the phosphorylation of a tertiary centre as required by the 
proposed 4-C-alkyl targets, has not been reported in the literature.  It would be expected that this 
centre will undergo phosphorylation more slowly than the adjacent secondary centres due to 
increased steric hindrance from the additional alkyl substituent.  This may have undesirable effects 
in terms of side product formation; for example cyclic phosphate formation by attack of the tertiary 
4-OH on the adjacent 3- and 5-phosphites.  Therefore it was expected that a highly reactive P(III) 
phosphorylating reagent would need to be employed, followed by oxidation with mCPBA to 
generate the phosphate triesters. 
Once phosphorylated, to prepare the final inositol phosphates, both the phosphates and 
alcohols need deprotecting.  During deprotection it is essential that the phosphate groups are 
unblocked prior to the alcohols in order to prevent migration of the protected phosphate esters. 
Once the phosphate esters are deprotected, the negative charge suppresses nucleophilic attack by 
neighbouring hydroxyls and hence prevents migration from occurring.  Therefore, as long as the 
pH is maintained between 3 and 10, the alcohols may be unblocked without risk of migration.  If 
possible it is convenient to effect a global one step deprotection, by generating a fully protected 
analogue with only one protecting group.120  This avoids further manipulations of highly charged, 
polar species.  The benzyl protecting group has frequently been chosen for such a deprotection as it 
can be removed under neutral conditions using hydrogenolysis.85  The benzyl phosphate esters are 
considerably more labile (believed to be >1000 fold) than the benzyl ethers on the 2- and 6-
hydroxyls which should ensure that the phosphate esters are deprotected first.127  Considering that 
for the 4-C-alkyl analogues the combination of an electron withdrawing phosphotriester and 4-C-
alkyl substituent on a tertiary centre may make these substrates susceptible to β-elimination, the 
mild conditions of hydrogenation could prove essential to the success of total deprotection.   
It was anticipated that phosphorylation of the 4-C-alkyl triols and tetrols with N,N-
diisopropyldibenzyl phosphoramidite, using the method of Yu and Reid,110 would be sufficient to 
react with the tertiary hydroxyl.  This P(III) species is highly reactive and has performed well in 
published polyphosphorylations.110  It also has the advantage that the phosphate protecting groups 
are benzyl esters, which should permit a one step deprotection to generate the final products.   
2.6 Previous work towards the introduction of a 4-C-alkyl substituent
 
During my MChem project, isolation of the 4-OH and initial attempts to introduce a 4-C-
alkyl group were explored.128  The inos-4-ose was prepared using the following key steps, Figure 
2.28. 
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Figure 2.28: Preparation of the inos-4-ose by oxidation of the isolated 4-OH  
4-O-Allyl orthobenzoate 92 was prepared directly from crude orthobenzoate 22d via 
deprotonation of the 4-OH with sodium hydride, to place a temporary allyl ether on the 4-O,84 
followed by flash chromatography on a large (10 g) scale, avoiding the time-consuming reported 
recrystallisation73 of orthoester 22d.  Protection of the remaining two hydroxyls as benzyl ethers, 
then isomerisation of the allyl group with potassium tert-butoxide, followed by its removal under 
acidic conditions, afforded dibenzyl ether 95 with a single free 4-OH.  This was oxidised to inosose 
96 using Dess Martin periodinane (DMP), which gave cleaner results than the corresponding 
oxidation under Swern conditions. 
From the key intermediate 96 conversion to the exo-methylene oxide using Wittig 
conditions, as previously reported for the inos-2-ose,88 occurred in good yield, Figure 2.29. 
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Figure 2.29: Conversion of the inos-4-ose to an exo-methyelene and generation of both epoxides upon 
addition of mCPBA  
Addition of oxygen to the double bond of exo-methylene 97 using mCPBA92a was not face-
selective, despite the 6-O-benzyl protecting group which might have been expected to obstruct 
access to the bottom face of 97.  A separable mixture of the myo- and epi-inositol exo-methylene 
oxides 98 and 99 were recovered in a ratio of 2:3 myo-epi, as judged by 1H-NMR of the crude 
material.  It was postulated that the lack of selectivity might derive from a balance of opposing 
influences: Greater accessibility along a less hindered equatorial approach, but (despite possible 
obstruction of the axial approach by the 6-O-benzyl ether) delivery to the lower face by the 6-O 
hydrogen bonding to the peracid.  Reduction of both exo-methylene oxides with LiAlH4 to the 4-C-
methyl derivatives permitted identification of the stereochemistry of methylene addition.  The 
desired myo-inositol epoxide was the higher Rf product of the two.  These species were easily 
identified by characteristic double doublets in the 1H-NMR [δH 2.95 (1H, d, J 4), 2.93 (1H, d, J 4) 
ppm and δH 2.89 (1H, d, J 4), 2.82 (1H, d, J 4) ppm]. 
It was hoped that a less hindered, free 6-OH would direct epoxidation preferentially to the 
desired bottom face of the exo-methylene by H-bonded coordination to mCPBA.  Therefore 100 
was prepared in 5 steps from myo-inositol orthobenzoate 22d, Figure 2.30. 
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Figure 2.30: Preparation of 100 with free 6-OH for coordinated mCPBA delivery 
The orthobenzoate 22d was reacted with tert-butyldiphenylsilylchloride (Tbdps-Cl) in the 
presence of triethylamine to selectively afford 6-O-Tbdps, 101 (see section 2.2).  A benzyl ether 
was then introduced onto the less hindered 2-O using mildly acidic conditions, generating 103 in 51 
% yield, with small amounts of the 2,4-O-dibenzyl ether also recovered.  Oxidation of the free 4-
OH of 103 to inos-4-ose 104, followed by conversion to exo-methylene oxide 105 was carried out 
in the same manner as for the 2,6-O-dibenzyl ether 96.  The 6-O-Tbdps was removed using TBAF 
to generate 100 with a free 6-OH for coordinated delivery of mCPBA.  Upon addition of mCPBA, 
oxygen delivery to the lower face of the exo-methyene was favoured, generating the myo-epoxide 
107 preferentially, although the ratio of products was only 3:2 as judged by 1H-NMR of the crude 
mixture.  However the reaction was slow suggesting that neighbouring group delivery was not 
occurring.  The increase in desired myo-epoxide relative to the epoxidation of 97, may therefore 
only be related to the reduced steric hindrance of approach to the bottom face of the exo-methylene 
with the free 6-OH.   
Following the lack of selectivity observed upon oxygen delivery to the exo-methylenes, the 
use of sulfur ylides to insert a methylene group directly into inosose 96 was investigated.  
Treatment of 96 with dimethylsulfonium methylide using the methodology of Corey and 
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Chaykovsky,93 effected only 20 % reaction, with the remainder recovered as unreacted starting 
material, Figure 2.31. 
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Figure 2.31: Insertion of methylene directly to inos-4-ose using sulfur ylides 
In contrast to the observation of Corey, the material recovered from the reaction was the 
result of equatorial addition to the inosose, generating the myo-inositol stereochemistry.  Further 
attempts to generate the exo-methylene oxide with dimethylsulfoxonium methylide generated two 
products, 98 and 108 along with unreacted 96.  exo-Methylene oxide 98 and oxetane 108, resulting 
from a second insertion of the ylide to epoxide 98, were recovered in the ratio 1:3 favouring the 
oxetane, as judged by 1H-NMR of the crude mixture, Figure 2.31.  Although both products were 
the result of the required stereoselective methylene insertion from the top face of the inosose, 
further investigation was required to control the number of methylene insertions and optimise the 
reaction yield.  
2.7 Summary of synthetic strategy for the preparation of 4-C-alkyl IP3 
and IP4 compounds 
The primary objective of the work presented in this thesis was to synthesise C-alkyl 
Ins(1,4,5)P3 and C-alkyl Ins(1,3,4,5)P4 analogues.  The 4-C was chosen as an initial target, as it 
could be easily isolated to permit investigation of alkyl introduction, and the subsequent 
manipulation, phosphorylation and deprotection steps, within the time available, Figure 2.32.   
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Figure 2.32: Summary of synthetic strategy towards 4-C-alkyl IP3 and IP4 derivatives 
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In order to achieve the end targets, four intermediate goals were identified and the latter 
three form the main body of the experimental work described in this thesis. 
a) Protection of myo-inositol and isolation of the 4-OH had been carried out in the 
MChem project128 (see section 2.5).  The inos-4-ose was successfully prepared in 6 steps with an 
overall yield of 71 %.  This provided an ideal starting point for further investigations toward the 
introduction of a C-alkyl group. 
b) Initial attempts to convert the inos-4-ose to an exo-methylene oxide using sulfur 
ylide chemistry were stereoselective, although optimisation of this transformation was still 
required.  Once prepared, a myo-geometry exo-methylene oxide could be opened with a 
nucleophilic carbanion equivalent.  Introduction of an alkyl group directly to the inosose has been 
considered, and although possible, is not the preferred route to the 4-C-alkyl compounds due to the 
likelihood of 1,3-diaxial interactions resulting in distortion of the final products with secondary and 
tertiary alkyl or aryl groups.  These results are discussed in chapter three. 
c) Following the introduction of a 4-C-alkyl substituent, the temporary protecting 
groups need to be removed to selectively generate free hydroxyls for phosphorylation.  For IP4 
derivatives, the 1,3,4,5-tetrol requires full removal of the orthobenzoate, by acidic hydrolysis to the 
benzoate ester, followed by ester exchange to the free hydroxyl.  For IP3 derivatives, the orthoester 
must be cleaved at the 1 and 5-O, to generate the 1,4,5-triol.  Manipulation of the orthoester is 
proposed using DIBAL-H.  These results are discussed in chapter four. 
d) The 4-C-alkyl triols and tetrols must be phosphitylated and oxidised to generate the 
fully protected phosphate esters.  It was hoped that phosphitylation with N,N-diisopropyldibenzyl 
phosphoramidite, followed by oxidation with mCPBA would provide reactive enough 
phosphitylating conditions, followed by a clean oxidation to the phosphate esters.  Subsequent 
global deprotection of the benzyl phosphate esters and benzyl ethers under H2 with Pd catalysis 
should generate the desired 4-C-alkyl IP3 and IP4 products.  These results are discussed in chapter 
five.  
2.8 NMR of the target compounds 
A key feature of this thesis is the assignment of regio- and stereochemistry using 1H-, 13C- 
and 31P-NMR.  The six protons around the myo-inositol cyclohexane ring provide an invaluable 
tool for analysis of these compounds by NMR.  Each carbon bears a secondary hydroxyl, which 
deshields these protons and shifts them into the 3-5 ppm region of the 1H-NMR and 60-80 ppm 
region of the 13C-NMR spectra.  In 1H-NMR, the splitting patterns of these protons provide 
information about the number of neighbouring ring protons and, due to the constrained 
cyclohexane ring, the spatial relationship of these adjacent protons can be interpreted using the 
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coupling constants of the multiplets generated by each proton according to the relationship derived 
by Karplus129.  Spectra which illustrate the key transformations are included for reference in 
Appendix D. 
The protection of the 1-, 3- and 5-OH by an orthoester provides a very rigid, adamantane-
like structure and constrains the cyclohexane ring to a single conformation.  This was clearly 
visible in the 1H-NMR of compounds 22d and 92-95 as 4-bond W-couplings were observed 
between equatorial protons.  meso-Compounds such as 1,3,5-O-orthobenzoate triol 22d generate 
strikingly simple 1H-NMR spectra by symmetry. Once this symmetry is broken, for example by 
introduction of a protecting group on the 4-O, the 6 independent, although often overlapping, 
individual Ins-H resonances can be seen.  The coupling occurring in these derivatives can be 
divided into three types, Figure 2.33. 
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Figure 2.33: Observed couplings in the orthoester derivatives a)  Coupling of two adjacent equatorial protons 
2-4 Hz; b)  Coupling of an adjacent equatorial and an axial proton 1-2 Hz; c) Coupling of two non-adjacent 
equatorial protons through the fixed ring structure (W-coupling) 1-2 Hz. 
Interpretation of these spectra can be complex due to the amount of W-coupling and 
overlapping peaks.  The expected resonance for each of the ring protons is detailed in Table 2.1. 
Table 2.1: Expected splitting patterns of protons in 1H-NMR for an orthoester derivative. 
Proton Orientation 
Splitting by  
adjacent protons 
Long range 
W-couplings 
Observed peak 
1-H Equatorial dd 2 dq 
2-H Axial t 0 t 
3-H Equatorial dd 2 dq 
4-H Equatorial t 1 td 
5-H Equatorial t 2 tt 
6-H Equatorial t 1 td 
The use of benzyl ethers as 2- and 6-O protecting groups also produces distinctive signals 
in the 1H-NMR.  Each benzyl-CH2 resonates as a pair of roofed doublets between 4 and 5 ppm.  
These signals can overlap with the inositol protons, but it is generally possible to resolve the benzyl 
protons due to their striking splitting patterns and large (11-14 Hz) coupling constants. 
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In the 13C-NMR of these derivatives, both the six Ins-H and two benzyl-CH2 peaks fall in 
the 60-80 ppm region.  However the peaks can be distinguished using DEPT-135. 
Each chapter of this thesis describes a new class of compound related to the synthesis of 4-
C-alkyl analogues.  The key transformations are each associated with characteristic changes in the 
NMR spectra, which will be introduced at the start of chapters three, four and five. 
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Chapter 3: Insertion of a 4-C alkyl group 
Following the preparation of the inos-4-ose in my MChem project,128 this chapter discusses 
the introduction of a 4-C-alkyl group with regeneration of the myo-inositol stereochemistry.  In 
order to fully explore the scope of 4-C-alkyl protrusions available for RLE, the addition of primary, 
secondary and tertiary alkyl and aromatic nucleophiles was explored, either directly to, or separated 
from the inositol ring. 
NMR played a key part in identifying the position and geometry of alkyl substitution on 
the inositol ring.  The substitution is evident not only by the absence of one 1H-NMR proton 
resonance, but also in the splitting patterns of adjacent protons, Table 3.1. 
Table 3.1:  Expected 1H-NMR signals of protons in 4-C-alkyl orthobenzoate derivatives. 
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Proton Orientation 
Splitting by  
adjacent protons 
Long range 
W-couplings 
Observed peak 
1-H Equatorial dd 2 dq 
2-H Axial t 0 t 
3-H Equatorial d 2 q 
4-H - - - - 
5-H Equatorial d 2 dt 
6-H Equatorial t 0 t 
On substitution of the 4-H by an alkyl chain both the 3 and 5-H will couple through three 
bonds to only one adjacent proton; the 3-H is expected to resonate as an apparent quartet, and the 
5-H as a double triplet.  This substitution will also remove the W-couplings to the 6-H, which 
would now be expected to resonate as a triplet (J 2-4 Hz) due to its two equatorial neighbours.  
This triplet contrasts with the 2-H which, despite a gauche relationship to the adjacent 1- and 3-H, 
and therefore similar ~60 º dihedral angles to the 6-H and it’s neighbours, displays a much 
narrower triplet (J 1-2 Hz).  The substitution of one Ins-H would also be visible in the 13C-NMR 
where the quaternary C would not be observed in the DEPT-135, leaving 5 C-H peaks in the 60-80 
ppm region.  In addition the peaks for the 4-C-alkyl substituent should be visible in both the 1H and 
13C-NMR spectra. 
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3.1 Addition of alkyl Grignards to the inos-4-ose 
2,6-O-Dibenzyl inos-4-ose 1,3,5-O-orthobenzoate 96 was prepared using the methodology 
described in section 2.5128 (Figure 2.27).  The experimental details for this sequence can be found 
in Appendix A. 
Initial attempts to generate exo-methylene oxides were limited in their success.  Both 
possible geometries of exo-methylene oxide were generated from oxidation of the exo-methylene 
using mCPBA, and low conversions were obtained on addition of sulfur ylides to the inosose, see 
section 2.5.  Therefore it was chosen to confirm and hopefully extend the observations reported by 
Potter et al.130 by direct addition of Grignard reagents to the inos-4-ose.  Upon treatment of inos-4-
ose 96 with methylmagnesium bromide at -78 °C selective equatorial addition of the methyl group 
was observed to afford 4-C-methyl orthobenzoate 115 with simultaneous regeneration of the myo-
geometry 4-OH,130 Figure 3.1. 
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Figure 3.1: Addition of methyl Grignard to the inos-4-ose 
The 4-C stereochemistry was confirmed in later steps by NOESY after unblocking of the 
orthoester (see section 4.1).  Notably, addition of methylmagnesium bromide to inos-4-ose 96 at rt 
generates two distinct products; desired 115 in lower yield than at -78 °C, and the reduction 
product 95 (15 %) which was identical by 1H-NMR to the isolated 4-OH prior to oxidation.  It is 
peculiar that methylmagnesium bromide acts as a hydride donor.  Although β-hydride delivery is 
well documented as a competing reaction for larger alkyl Grignard reagents with hindered 
ketones,131-4 the absence of a β-proton in methylmagnesium bromide should prevent this reaction 
pathway.  Despite this unusual outcome, both 115 and 95 are the result of equatorial delivery, of 
either methyl or hydride, to inos-4-ose 96.  This selectivity of addition may be attributed to a 
combination of steric hindrance of the bottom face of the carbonyl by the 6-O-benzyl ether and 
possible coordination of magnesium to the orthoester 3- and 5-O, Figure 3.2. 
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Figure 3.2: Addition of a methyl Grignard reagent is stereospecific 
It was expected that larger 4-C-alkyl substituents could be introduced by addition of larger 
Grignard reagents to the inos-4-ose.  However, addition of ethylmagnesium bromide to 96 at -78 
°C generated only reduction product 95 in nearly quantitative yield due to β-hydride delivery, and 
none of the desired 4-C-ethyl product 117, Figure 3.3. 
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Figure 3.3: Reaction of ethyl Grignard with inos-4-ose 96; reduction rather than addition. 
The accepted mechanism for Grignard reagent addition to a ketone requires two 
equivalents of the alkyl Grignard.132,133  Initial coordination to the ketone oxygen by the first 
equivalent is followed by alkyl delivery from the second.  Were alkyl delivery to proceed from the 
coordinated Grignard reagent, this would require an unfavourable 4-membered ring intermediate, 
Figure 3.4a.  However, β-Hydride reduction, can occur from the initially coordinated Grignard 
reagent via a 6-membered ring intermediate, Figure 3.4b, leading to increasing preference for the 
latter as the size of the Grignard reagent and steric hindrance of the ketone increase, preventing 
access of the second equivalent for alkyl delivery.131 
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Figure 3.4: The mechanisms for the competing reactions of alkyl Grignards [adapted from ref. 132, 133]; a) 
mechanism of addition; b) mechanism of reduction 
The preference for reduction with Grignard reagents larger than methylmagnesium 
bromide was confirmed by addition of iso-propyl Grignard reagent to inos-4-ose 96, which also 
generated 95 as the only product.  In an attempt to circumvent the generation of β-hydride 
reduction products, benzylmagnesium chloride was prepared.  Upon addition to 96, two products 
were isolated; 4-C benzyl 125 (10 %) and 95 (28 %) Figure 3.5.  Again the presence of the 
reduction product 95 is hard to explain given the absence of β-hydrogens. 
O
O
O
Ph
BnO
OH
BnO
96
125 [10 %]
95 [28 %]
i) BnMgCl (1.1 eq),
ether, -78 °C
ii) H+
 
Figure 3.5: Removal of the β-hydrogens does not prevent elimination with benzyl magnesium chloride 
Addition of Li+, K+ or Na+ salts to dialkyl magnesium species has been reported to increase 
yields of addition in preference to reduction.  However, little improvement in yield is observed for 
branched alkyls such as tert-butyl.134  Similarly, addition of magnesium bromide prior to the alkyl 
Grignard reagent is reported to complex the ketone and, being a stronger Lewis acid than the 
Grignard reagent itself, promote addition reactions.133  However, this method also has reduced 
success as the bulk of the Grignard reagent continues to increase.  The importance of being able to 
introduce larger alkyl groups to create an orthogonal ligand for RLE has already been established.  
Therefore it was concluded that the use of alkyl Grignard reagents may not be the best means to 
achieve this goal.   
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3.2 Insertion of methylene to generate the exo-methylene oxide from the 
inos-4-ose 
Very limited success was achieved with direct introduction of an alkyl group to the 
inosose, as with alkyl substituents larger than methyl, very little or none of the desired 4-C-alkyl 
product was isolated.  However, of the reactions that were observed, delivery of the alkyl or indeed 
hydride, occurred stereospecifically from the top face of the inosose to regenerate the axial 4-OH of 
a myo-inositol orthoester.  Furthermore, a disadvantage of introducing 4-C-alkyl groups using this 
method is that each new 4-C-substituent is required to be delivered in the same manner, and the 
myo-stereochemistry of each product must be verified in turn.  It would be therefore preferable to 
set in place the desired stereochemistry, pre-determining the orientation of the alkyl group.  This 
can be achieved by addition of methylene accross the inosose generating an exo-methylene oxide. 
It has already been postulated (section 2.3) that direct attachment of the 4-C-alkyl to the 
cyclohexane backbone may result in undesirable conformers in the final products.  Conversion to 
the exo-methylene oxide simultaneously introduces the proposed methylene spacer between the 
alkyl group and cyclohexane backbone, and defines the 4-C-stereochemistry.  Direct delivery of 
methylene to the inosose using sulfur ylide chemistry is reported to generate exo-methylene 
oxides.96  It was hoped that, similarly to the Grignard reagents, steric bulk combined with available 
coordination to the orthoester would promote delivery of methylene to the top face of the inosose, 
generating myo-stereochemistry.  From the generation of both exo-methylene oxides on mCPBA 
oxidation of the exo-methylene,128 it was known that desired exo-methylene oxide 98’s protons 
resonate as paired doublets in 1H-NMR at 2.94 and 2.93ppm. 
myo-Inositol exo-methylene oxide 98 was prepared from 96 using dimethylsulfoxonium 
methylide, generated by treatment of trimethyloxosulfonium iodide in DMSO-THF with sodium 
hydride at 0 ºC,135 Figure 3.6. 
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Figure 3.6: Conversion of the inos-4-ose to the exo-methylene oxide 
Initial test reactions had been carried out using the method of Corey and Chaykovski135 in 
DMSO at 50 ºC and produced a mixture of the oxirane 98 and oxetane 108 as a result of a second 
methylene insertion into the oxirane.128  By reducing the temperature to 0 ºC for preparation of the 
ylide, followed by addition of the inos-4-ose as a solution in THF at rt, it was possible to prepare 
the exo-methylene oxide 98 in high yield, with no evidence of the oxetane.  In all cases, including 
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the initial reactions at elevated temperatures, no evidence of axial methylene addition was 
observed. 
exo-Methylene oxide 98 was reduced with excess LiAlH4 in THF to yield the equatorial 4-
C-methyl product 115, Figure 3.7. 
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Figure 3.7: Reduction of the exo-methylene oxide to the 4-C-methyl confirms the 4-C-stereochemistry 
Only the product of nucleophilic attack at the unsubstituted end of the epoxide was 
observed, controlled by steric hindrance.  Comparison to the product from addition of methyl 
Grignard to the inosose verified that the desired myo-inositol stereochemistry exo-methylene oxide 
had been prepared. 
3.3 Addition of alkyl Grignards to the exo-methylene oxide 
It was expected that opening the exo-methylene oxide with an alkyl Grignard reagent 
would generate 4-C-alkyl products including a CH2 spacer, with pre-determined stereochemistry.  
As for the inosose, alkyl anion addition to the exo-methylene oxide will be in competition with β-
hydride reduction. However it was anticipated that this competition would be reduced due to the 
less crowded environment around the unsubstituted carbon of the epoxide. 
Surprisingly, addition of methyl Grignard to 98 generated 4-C-bromomethyl 126, by 
nucleophilic halide attack on the epoxide, Figure 3.8. 
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Figure 3.8: Unexpected halide delivery to open the exo-methylene oxide 
From this unexpected product, an SN2 displacement was attempted to generate the desired 
4-C-alkyl product.  However, addition of excess methyl Grignard to 126 did not effect any further 
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reaction.  It was postulated that removal of the bromine from this reaction would prevent formation 
of 126.  Therefore precipitation of magnesium bromide in dioxane, using the Schlenk equilibrium 
to generate dialkyl magnesium, was attempted.132  However, on addition of the dialkyl magnesium 
to 98, no reaction was observed and only starting material recovered.   
Attempts were made to generate a softer nucleophile by trans-metallation of methyl 
Grignard with copper iodide,136 however addition of this organocuprate to the exo-methylene oxide 
generated a mixture of the 4-C-bromomethyl, 126, and 4-C-iodomethyl, 127, Figure 3.8.  These 
two compounds were identified by the presence of a pair of roofed doublets (δH 3.80, 3.92 and 
3.90, 4.05ppm) in the 1H-NMR spectrum, two quaternary centres (δC 68.9 and 69.8ppm) and two 
methylenes (δC 38.8 and 15.1ppm) in the 
13C-NMR.  The generation of a similar brominated 
compound was observed by Brockway et al.137 during the reaction of an epoxide with 
allylmagnesium bromide under copper catalysis, Figure 3.9. 
O O
Ph
O
O
O O
Ph
O
HO
R
a) or b) or c) a) AllylMgBr, CuI; R = Br [90 %]
b) AllylMgCl; R = Allyl [80-88 %]
c) MgBr2; R = Brether
128 129  
Figure 3.9: Unexpected opening of epoxide with bromide, adapted from ref. 137 
Unlike the mixture of bromo- and iodomethyl compounds observed upon opening of 98, 
they did not observe any iodomethyl derivative.  They suggest a Lewis acid catalysed scission of 
the oxirane ring, having observed formation of the same brominated compound upon addition of 
MgBr2 to their oxirane.
137  The reaction of 128 with allylmagnesium chloride generated their 
desired alkyl product in 80-88 % yield, suggesting that the generation of methylhalide species may 
be specific to bromo Grignard reagents.  The increased reactivity of 98 towards bromide or iodide 
may be a result of increased strain on the epoxide induced by the rigid orthoester inositol 
framework. 
3.4 Addition of alkyl lithiums to the exo-methylene oxide 
One of the main obstacles thus far, had been the lack of successful introduction of any 4-C-
alkyl substituent larger than methyl, which was a key part of the synthetic strategy.  The generation 
of the 4-C-bromomethyl orthobenzoate 126 during treatment of the exo-methylene epoxide 98 with 
alkyl Grignard suggested a halide-free alkylating reagent, such as an alkyl lithium may be more 
successful.  Due to the instability of alkyl lithium solutions during storage, the concentration of 
each alkyl lithium solution was titrated immediately prior to use using salicylaldehyde 
phenylhydrazone as an indicator, prepared according to the method described by Love and Jones.138  
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The titration end point is recognised as a colour change from yellow to red, which indicates the 
start of the second deprotonation, Figure 3.10.  With darker alkyl lithiums such as PhLi, it was 
important that the solution was sufficiently dilute (50-80 mg indicator in 5 mL THF for a 1 M 
solution of Grignard reagent) in order that the end point of the titration could be seen above the 
colour of the reagent. 
OH
N
N
H
Ph RLi
O
N
N
H
Ph
O
N
N
Ph
RLi
Yellow Red130 131 132  
Figure 3.10: Salicylaldehyde phenylhydrazone as an indicator for titration of organometallic reagents 
In order to obviate the possibility of competing β-hydride insertion to the exo-methylene 
oxide, it was decided to first attempt treatment of 98 with phenyl lithium.  Careful addition of 2 eq. 
PhLi slowly converted the starting material to a single spot by TLC.  The desired 4-C-benzyl, 125, 
was recovered following chromatography but despite multiple attempts, yields were very variable 
and the maximum yield achieved was 66%, Figure 3.11. 
O
O
O
Ph
BnO
OH
BnO
98
125 [66 %]
PhLi (2 eq),
THF
-78 °C
 
Figure 3.11: Addition of phenyl lithium to the exo-methylene oxide 
In the hope of expanding the range of 4-C-alkyl substituted products, addition of other 
alkyl lithiums to 98 was attempted.  Treatment of 98 with n-butyl lithium afforded 4-C-pentyl 133 
but only in 18 % yield, Figure 3.12. 
O
O
O
Ph
BnO
OH
BnO
98
133 [18 %]
n-BuLi (2 eq),
THF
-78 °C
t-BuLi (2 eq),
THF
-78 °C
Polymeric
mixture
 
Figure 3.12: Addition of n-butyl lithium and t-butyl lithium to the exo-methylene oxide 
Addition of bulky tert-butyl lithium to 98 generated none of the desired 4-C-alkyl product.  
During these reactions, streaking was observed on the TLC plate, and 1H-NMR of the crude 
Chapter 3: Insertion of a 4-C alkyl group 
 
 
 
- 69 - 
material was broad in the inositol region.  This suggested that the poor recovery of these species, 
without the generation of any other distinct products may be a result of competing polymerisation.  
This could occur due to deprotonation on the phenyl rings of the benzyl ethers or orthobenzoate of 
98, which would then go on to react with further equivalents of 98, generating oligomers.  MS of 
the crude material from the reaction of 98 with tert-butyl lithium suggested that polymerisation had 
occurred as m/z peaks were observed at ≈ [2M+H]+ and [4M+H]
+, corresponding to side reactions 
such as those shown in Figure 3.13. 
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BnO
OH
BnO
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BnO
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BnO
O
O
O
BnO
OH
BnO
Li
[M+H]+975.4,
[M+MeCN+Na+H]+ 1038.4,
C60H62O12 requires 974.4
9898
t-BuLi (2 eq.),
THF
-78 °C
134
135  
Figure 3.13: Polymerisation of 98 on addition of tert-BuLi 
Unlike with the Grignard reagents, no products from β-hydride delivery were observed.  
An increased tendency for polymerisation down the sequence PhLi → n-BuLi → t-BuLi may be 
reflected by the isolated yields of the desired products.  This trend correlates with increasing 
carbanion basicity, leading to an increased degree of polymerisation due to competing 
deprotonation overtaking epoxide opening from nucleophilic attack. 
3.5 Addition of alkyl lithium cuprates to the exo-methylene oxide 
It was hoped that generating a less basic nucleophile would reduce deprotonation of the 
aryl rings and therefore the competing polymerisation.  Higher order mixed cuprates of the form 
R2Cu(CN)Li2, generated by addition of an alkyl lithium to copper cyanide in a 2:1 ratio, are 
reportedly among the mildest and most efficient method for generating C-C bonds.139  They have 
been shown to effect nucleophilic opening of epoxides in high yield.139  It was postulated that the 
alkyl lithium cuprates might be less basic nucleophiles than the corresponding alkyl lithiums.  The 
alkyl lithium cuprates were prepared by drop-wise addition of alkyl lithium to a suspension of 
copper (I) cyanide in dry ether, at -78 ºC.  It was essential that the copper cyanide was dried 
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immediately prior to use by repeated evaporation from dry toluene as the presence of moisture or 
allowing the temperature to exceed -60 ºC quickly destroyed the alkyl lithium cuprate, and could be 
observed by the formation of a black precipitate presumably CuO. 
3.5.1 Addition of primary 4-C-alkyl chains 
The conditions were optimised for the addition of n-butyl lithium cuprate to 98.  Initial 
reactions carried out in THF achieved a maximum yield of 48 % (Table 3.2, A and B).  It is 
suggested that this is the result of the coordination of this solvent to the alkyl lithium causing 
aggregation, which may destabilise the alkyl lithium cuprate complex.140 
Table 3.2: Optimising the conditions for the reaction of 98 with n-butyl lithium cuprate 
Entry 
Reaction 
Time 
(h) 
Reaction 
Temp. 
(ºC) 
Eq. 
CuCN 
Eq. n-
BuLi 
Solvent 
Starting 
Mat., 98 
(%) 
Product, 
133 
(%) 
A 2 -20 1.46 2.67 THF 34 48 
B 2 -78 1.46 2.67 THF 23 35 
C 2 -78 1.46 2.67 Ether 22 67 
D 2 -78 4.00 8.00 Ether 12 68 
E 4 -78 4.00 8.00 Ether 0 70 
It was necessary to use a large excess of alkyl lithium cuprate; typically 8 equivalents alkyl 
lithium and 4 equivalents CuCN per equivalent of exo-methylene oxide (Table 3.2, E) to ensure 
that the reaction went to completion.  It is not known why such a high concentration of reagent was 
required.  However it is possible that the inositol ring oxygens may coordinate to the alkyl lithium 
cuprate complex causing it to partially decompose, in a similar manner to the known coordination 
of solvents such as THF.140 
Addition of primary alkyl lithium cuprates to exo-methylene oxide 98 using the best 
conditions now generated the 4-C-ethyl- and 4-C-pentyl-myo-inositol orthobenzoates in high yields 
(92 and 90 % respectively), Figure 3.14.  
98 133
CuCN (4 eq)
Ether, -78 ºC
[90 %]
n-BuLi (8 eq)
136
CuCN (4 eq)
Ether, -78 ºC
[92 %]
MeLi (8 eq)O
O
O
Ph
BnO
BnO
OH
 
Figure 3.14: Preparation of 4-C-ethyl and 4-C-pentyl substituents by addition of alkyl lithium cuprates to 
exo-methylene oxide 98 
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The increase in yield of 133 (from 18 % with alkyl lithium to 90 % with alkyl lithium 
cuprates) suggested that these reagents were considerably less basic, and that competing 
polymerisation had been suppressed. 
3.5.2 Addition of secondary 4-C-alkyl chains 
Addition of iso-propyl lithium cuprate to the exo-methylene oxide generated two distinct 
products.  Desired 4-C-iso-butyl 137 was isolated in only 26 % yield, Figure 3.15. 
O
O
O
Ph
BnO
BnO
OH
98
137 [26 %]
CuCN (4 eq)
Ether, -78 ºC
i-PrLi (8 eq)
H
OH
OBn
HO
HO
138 [34 %]  
Figure 3.15: Treatment of exo-methylene oxide 98 with iso-propyl lithium cuprate generates two products 
A second compound was crystallised from the crude material with an unexpected 1H-NMR 
resonance at δ 5.74 (1H, d, J 5.4) suggesting elimination had occurred to generate an alkenyl 
proton.  Also present were two sets of iso-propyl methyl doublets (δH 1.12, 1.08, 1.06, 1.02 ppm) 
suggesting a second addition of the iso-propyl nucleophile.  A crystal structure, obtained despite 
twinned crystals, established the identity of this side product as conduritol derivative 138, Figure 
3.16. 
 
Figure 3.16: Structure of unexpected conduritol derivative 138 (Systematic name: 6-benzyloxy-2-isobutyl-5-
isopropyl-cyclohex-4-ene-1,2,3-triol). 
The mechanism of this transformation is not clear.  However this side product was 
recovered in equal or higher yield than the desired 4-C-iso-butyl derivative during each attempt at 
this transformation.  In order to establish whether the reaction was independent of epoxide opening, 
4-C-methyl orthobenzoate 115 was treated with iso-propyl lithium cuprate, in the same manner as 
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exo-methylene oxide 98.  The corresponding product, 139, was generated in 30 % yield (with the 
remainder being recovered as starting material), Figure 3.17.   
115
CuCN (4 eq)
Ether, -78 ºC
i-PrLi (8 eq)
H
OH
OBn
HO
HO
139
[30 %]
 
Figure 3.17: The corresponding conduritol derivative was recovered upon treatment of 115 with iso-propyl 
lihtium cuprate, systematic name: 6-benzyloxy-2-isobutyl-5-methyl-cyclohex-4-ene-1,2,3-triol 
This confirms that the observed cleavage of the orthobenzoate and elimination of the 6-O-
benzyl are independent of epoxide opening.  A mechanism has been proposed by Crandall and 
Lin141 to rationalise side products which they observed during epoxide opening with alkyl lithiums, 
proceeding via a carbene intermediate.  The following mechanism is therefore suggested for 
generation of conduritol derivatives 138 and 139, Figure 3.18. 
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Figure 3.18: Suggested mechanism for the generation of conduritol side products 
Following the isolation of these unusual compounds, the 1H-NMR spectra of all alkylation 
reaction were examined for evidence of allylic protons which would indicate the presence of 
similar species.  However, no such peaks were found, so it would appear that this side product is 
specific to the iso-propyl lithium cuprate. 
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3.5.3 Addition of tertiary lithium cuprates to the exo-methylene oxide 
Upon preparation of tert-butyl lithium cuprate solution, particulate material began to form 
and the solution became brown and discoloured.  However, the exo-methylene oxide was 
completely consumed within the 4 h reaction time.  Two products were recovered; desired 4-C-
neopentyl 144, and the result of β-hydride opening of the exo-methylene, 4-C-methyl 
orthobenzoate 115, Figure 3.19. 
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144 [36 %]
CuCN (4 eq)
Ether, -78 ºC
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Figure 3.19: The addition of tert-butyl lithium cuprate to exo-methylene oxide 98 generates two products 
This was the first observation of β-hydride reduction products during the nucleophilic 
opening of epoxide 98.  In order to try and increase the preference for desired 144 over 115, a 
series of experiments were carried out, Table 3.3. 
Table 3.3: Experiments attempting to improve the ratio of 144:115 
Ratio of Products 
(
1
H-NMR of crude material) Entry 
Reaction 
Time 
(h) 
Reaction 
Temp. 
(ºC) 
Eq. 
CuCN 
Eq. 
t-BuLi 
Eq. 
BF3 
98 144 115 
A 4.0 -78 4 8 - 0.0 2.0 3.0 
B 4.0 -78 4 8 - 0.0 1.0 2.0 
C 1.5 -78 3 6 - 5.0 6.0 5.6 
D 4.0 -78 6 6 - 1.0 2.6 4.0 
E 4.0 -78 3 6 1.0 3.0 7.0 3.6 
F 4.0 -78 → -50 4 8 1.2 1.0 7.0 3.6 
It is apparent that the temperatures and reaction times originally used (-78 ºC, 4 h, Table 
3.3, A and B) are required to allow completion of the reaction.  Shorter reaction times (entry C) 
contained large amounts of unreacted exo-methylene oxide 98, without any evidence of 
improvement in the ratio of products.  It was hoped that different stoichiometries of copper might 
influence the formation of one product over the other, but this also had little impact on the product 
ratio, entry D.  The addition of a Lewis acid such as BF3, is reported to enhance the rate of reaction 
between an epoxide and alkyl lithium cuprate for less reactive epoxides,142 by coordinating to the 
epoxide oxygen, promoting nucleophilic attack on the adjacent carbon centre.  Alexis et al.143 
report a 78 % yield for the opening of cyclohexene oxide with tert-butyl lithium cuprate and 
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BF3.Et2O in ether.  It was hoped that the addition of BF3 would increase the rate of alkyl, rather 
than β-hydride, delivery to 98 (entries E and F).  In both cases, there was still unreacted epoxide, 
perhaps suggesting competing reagent destruction by the Lewis acid.  However, the ratio of 
products obtained was improved, with almost a 2:1 preference for desired 144. 
3.5.4 Addition of aryl lithium cuprates to the exo-methylene oxide 
Addition of phenyl lithium cuprate to exo-methylene oxide 98 afforded 4-C-benzyl, 125 in 
90 % yield (cf. 66 % for phenyl lithium alone, section 3.4), Figure 3.20. 
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BnO
BnO
OH
98125
CuCN (4 eq)
Ether, -78 ºC
[90 %]
PhLi (8 eq)
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n-BuLi (9 eq)
CuCN (4 eq)
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[66 %]
Br
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Figure 3.20: Addition of phenyl lithium cuprate and 2-naphthyl lithium cuprate to exo-methylene oxide 98 
Larger, more diverse aryl lithiums are not available as commercially prepared solutions.  
Lithium-naphthyl and β-lithium-styrene were prepared by lithium halogen exchange from their 
respective bromides using n-butyl lithium.144  The small scale of preparation and thermal instability 
of these compounds meant they could not be easily titrated using the methods described for the 
commercially available solutions.  Therefore, the exact stoichiometry of the aryl lithium in the 
reaction mixture is unknown. 
2-Bromo-naphthalene was treated with n-butyl lithium at rt to prepare 2-lithium-
naphthylene.144 The solution was then cooled to -78 ºC before addition to the ethereal copper 
cyanide suspension at -78 ºC to generate the cuprate.  Addition of lithium naphthyl cuprate to exo-
methylene oxide 98 produced the desired 4-C-(2-naphthyl)methyl product (66 %), with the 
remainder being recovered starting material, Figure 3.20. 
β-Bromo-styrene was treated with n-butyl lithium to generate β-lithium styrene.  
Preparation of the aryl lithium was carried out at -20 ºC to prevent the reaction solution from 
solidifying.  The use of higher temperatures resulted in decomposition of the aryl lithium.  The 
solution was then cooled to -78 ºC before addition to the ethereal copper cyanide solution.  A single 
product was observed on addition of the cuprate to 98 and isolated by chromatography.  Absence of 
the expected alkenyl peaks at δ 5-6 ppm or any splitting of the characteristic 4-C-CH2 doublets at 
4.03 and 3.89 ppm was not encouraging.  Comparison with earlier 1H-NMR spectra from the 
reaction with methyl Grignard and exo-methylene oxide 98 and HRMS confirmed that the single 
product formed was 4-C-bromomethyl, 126, Figure 3.21. 
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(9 eq)
[51 %]  
Figure 3.21: Preparation of β-lithium styrene and addition to exo-methylene oxide 98 
The preparation of 4-C-(β-methyl)styrene was expected to provide a route to 4-C-aryl 
substituents with the phenyl ring at an increased distance from the inositol cyclohexane backbone.  
Upon later removal of the 2,6-O-dibenzyl ethers, the double bond would be reduced to generate a 
4-C-(3-phenylpropyl) substituent.  It was also hoped that this group may provide a simple method 
of generating a wide variety of 4-C substituents.  For example, by dihydroxylation of the double 
bond followed by removal of the benzyl fragment by osmylation would generate a 4-C-
acetaldehyde which could be elaborated to generate further products.  Further oxidation to the 4-C-
ethanoic acid, for example, would generate a ligand which may be suitable for use in ion-pair 
exchange RLE, Figure 3.22. 
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Figure 3.22: Manipulation of 4-C-(3-phenylprop-2-enyl) 146 has the potential to generate ligands suitable 
for ion-pair exchange RLE 
In a parallel project in this laboratory, the related conversion of 2-O-allyl nonabenzyl 
Ins(1,3,4,5)P4 to the corresponding 2-O-acetic acid has already been optimised.  In future it may be 
easier to use acetylide or phenyl acetylide anions to open the epoxide since they can be easily 
generated without the presence of halide salts. 
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3.6 Concluding Remarks 
The scope of alkyl and aryl introduction for steric complementation ligand engineering has 
been broadly investigated.  The addition of alkyl lithium cuprates to the exo-methylene oxide 
proved by far the most reliable and generalisable method for introducing a 4-C-alkyl group.  The 4-
C-methyl (from reduction of the exo-methylene oxide), 4-C-ethyl, 4-C-pentyl, 4-C-iso-butyl, 4-C-
neopentyl, 4-C-benzyl and 4-C-(2-napthyl)methyl have all been successfully prepared, and could 
be synthesised on a large scale.  The low yield for more hindered alkyl nucleophiles (iso-propyl 
lithium and tert-butyl lithium) has been explained by the characterisation of reaction side products.  
In order to access ion-pair exchange derivatives the preparation of β-lithium styrene would require 
modification, for example by removal of the lithium bromide prior to addition to the exo-methylene 
oxide.  There are a number of other routes which could be applied to introduce a similarly 
oxidisable group in this position, thus generating a more diverse library of ligands.  However this 
was beyond the scope of this project. 
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Chapter 4:  Manipulation of the orthoester to generate 4-C-alkyl 
myo-inositol triols and tetrols 
Following the introduction of a 4-C-alkyl group, this chapter explores the removal of 
temporary protecting groups to generate free hydroxyls at the sites of phosphorylation.  It was 
hoped that both the required IP3 and IP4 precursors could be accessed by manipulation of the 
orthobenzoate.  Section 4.1 explores the acidic hydrolysis of 4-C-alkyl-myo-inositol 1,3,5-O-
orthobenzoates to generate Ins(1,3,4,5)P4 precursors, the 4-C-alkyl-2,6-O-dibenzyl-myo-inositol 
tetrols.  Section 4.2 reports the preparation of 4-C-alkyl-myo-inositol orthoformates as an 
alternative strategy for obtaining these precursors.  Section 4.3 addresses 2,4,6-O-tribenzyl-myo-
inositol orthobenzoate as a model system for studying reduction of the orthobenzoate using 
DIBAL-H, followed by a study of the influence of different protecting groups on the 
regioselectivity of this deprotection.  In sections 4.4 and 4.5, these results are applied to the 4-C-
alkyl-myo-inositol 1,3,5-O-orthobenzoates to generate Ins(1,4,5)P3
 precursors, the 4-C-alkyl-2,3,6-
O-tribenzyl-myo-inositol triols.  The side products of DIBAL-H reduction, the 4-C-alkyl 
benzylidene acetals, are employed in section 4.6 as an alternative route for generating 
Ins(1,3,4,5)P4 precursors. 
Once again, NMR spectra of these transformations convey crucial information about the 
enviroment of the inositol ring protons.  Removal of the 1,3,5-O-orthoester will allow the myo-
inostiol ring to adopt its natural chair conformation once more, as the rigidly constrained 
adamantane-like structure is relieved.  As a result, the 1H-NMR of these species will no longer 
display 4-bond W-coupling.  Returning to this configuration with a 4-C-alkyl substituent, there are 
now four axial and one equatorial protons, giving rise to two possible types of coupling, Figure 4.1 
R = alkyl
110 R1 = H
111 R1 = Bn
BnO
R1O
OBn
OH
HO
OH
H
HH
H
H
a
b
R
 
Figure 4.1: Observed couplings after removal of the orthoester; a) Anti-periplanar coupling between adjacent 
axial protons (dihedral angle 180 º) 7-10 Hz; b) Coupling between adjacent axial and equatorial protons 
(dihedral angle 60 º) 1-4 Hz. 
The combination of multiplicity indicating the number of adjacent neighbours and splitting 
patterns indicating oriention of neighbours, alongside COSY spectroscopy, should permit 
identification of the regiochemistry resulting from deprotection of the orthoester.  The 
stereochemistry of alkyl introduction should be confirmed at this stage by NOESY interaction 
between the 4-C-alkyl and 6-H which have a 1,3-diaxial relationship. 
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Table 4.1: Splitting patterns of protons in 1H-NMR for a 4-C-alkyl triols and tetrols. 
Proton Orientation 
Splitting by  
adjacent protons 
1-H Axial dd 
2-H Equatorial t 
3-H Axial d 
4-H - - 
5-H Axial d 
6-H Axial d 
Partial deprotection of the orthoester, for example using DIBAL-H leading to an acetal will 
also demonstrate loss of the highly constrained structure which led to W-coupling in the 1H-NMR 
spectrum.  However in this case the ring will not be free to return to a chair conformation and it 
might be expected that more unusual coupling patterns may be seen, due to formation of boat-like 
structures to ease steric congestion.  The regiochemistry of partial opening of the orthoester can be 
interpreted by the coupling of the protons in 1H-NMR, with the aid of COSY, NOSEY, and D2O 
exchange experiments, to identify the location of the free hydroxyl.  Complete reduction of the 
orthoester with DIBAL-H to generate a benzyl ether for IP3 synthesis can be observed in the 5 ppm 
region of the spectra, where an additional two doublets should appear corresponding to the benzyl-
CH2. 
13C-NMR of the inositol peaks should not change significantly in this step.  However, 
deprotection of the orthoester can be observed by loss of the bridgehead quaternary-C at 100-110 
ppm, and the appearance of an acetal-CH (at 93 ppm), benzyl-CH2 from DIBAL-H reduction (60-
80 ppm) or quaternary benzoate-C=O from acidic hydrolysis (165-170 ppm). 
4.1 Acidic hydrolysis of the orthobenzoate 
The acidic hydrolysis of 2,6-O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoate to a mixture 
of the 1- and 3-O-benzoate esters is already reported.73  It was hoped that the 4-C-alkyl 2,6-O-
dibenzyl-myo-inositol 1,3,5-O-orthobenzoates would generate the corresponding 1-, 3-, and 
possibly 5-O-benzoate esters. 
To accomplish acidic hydrolysis of 4-C-methyl orthobenzoate, 115, required concentrated 
HCl-methanol (1:2 v/v) at reflux, generating a mixture of benzoate esters Figure 4.2. 
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Figure 4.2: Acidic hydrolysis of 4-C-methyl orthobenzoate 
Potter’s conditions73 for the unsubstituted 2,6-O-dibenzyl-myo-inositol orthobenzoate are 
1.0 M HCl-ethanol (1:2) at reflux, for 5 h.  No reaction was observed under these conditions with 
the 4-C-methyl orthobenzoate 115, nor under the reported conditions for acidic hydrolysis of the 
orthoformate, TFA-H2O (4:1, rt, 24 h).
100  Unlike acidic hydrolysis of unsubstituted 
orthobenzoates, which were reported to generate only the 1- and 3-O benzoate esters, hydrolysis of 
4-C-methyl orthobenzoate generated all three benzoate esters. 
The crude mixture of 4-C-methyl benzoate esters could be separated by flash 
chromatography.  The 1-O-benzoate ester 150a was isolated in 29 % yield and fully characterised.  
The 1-O benzoate esters are suitable precursors for PIP3 lipid synthesis, allowing the introduction 
of the phosphatidate phosphodiester at the 1-O as has been demonstrated by Potter et al.145 
For the purposes of 4-C-methyl Ins(1,3,4,5)P4 synthesis, the crude mixture of benzoate 
esters was treated with NaOMe in methanol to generate the desired 2,6-O-dibenzyl tetrol 151a, 
Figure 4.3 
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Figure 4.3: Transesterification of benzoate esters with NaOMe in MeOH generates 4-C-methyl tetrol, 151a 
The stereochemistry of 4-C-methyl addition was confirmed by acetylation of the four free 
hydroxyls and subsequent observation of an NOESY interaction between the 6-H and 4-C-methyl 
protons.  Since the stereochemistry was fixed at the point of epoxide formation by the addition of 
methylene across the inos-4-ose, all other alkyl substituents which are derived from this same 
intermediate must therefore have the same geometry.  For 4-C-alkyl groups larger than methyl, 
refluxing propanol-concentrated HCl (2:1 v/v) for 3 h was required to initiate transesterification.  In 
all cases, a mixture of fluxional compounds was obtained.  The mass was confirmed by HRMS and 
two spots were visible on the TLC plate, with lower Rf than the starting material.  The crude 
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mixtures of benzoate esters were treated with NaOMe in methanol, as for the 4-C-methyl 
derivative, to generate a series of 1,3,4,5-tetrols, Figure 4.4. 
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Figure 4.4: Acidic hydrolysis of 4-C-alkyl orthobenzoates followed by NaOMe in MeOH generates tetrols 
The yields from the two-step orthobenzoate deprotection were noticably lower with larger 
4-C-substituents.  While the mass recovery was consistent for the sequence of reactions, after short 
column chromatography to purify the tetrol, there was a considerable loss of material.  
Identification of the problem was hampered by the fluxional nature of both the mixed benzoate 
esters and the 4-C-alkyl tetrols, making it difficult to observe or identify impurities.  Acetylation of 
the crude 4-C-benzyl tetrol generated a number of products, suggesting that deprotection of the 
orthoester was not proceeding cleanly.  A white solid was often seen to form in chloroform 
solutions after prolonged standing.  Consequently crystallisation of crude 4-C-benzyl tetrol 151f 
from CH2Cl2 was attempted from which a powdery white substance was isolated.  This was 
demonstrated by HRMS to be 4-C-benzyl pentols 153 and 154 [HRMS (ESI+) m/z (%) found 
[M+Na]+ 383.1456, C20H24O6Na requires 383.1471], Figure 4.5.  By contrast MS of the 4-C-benzyl 
tetrol showed none of this peak. 
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Figure 4.5: Acidic hydrolysis of the 4-C-benzyl orthobenzoate generates both the desired tetrol and 
unwanted pentols 
The isolation of the pentol shows that the strongly acidic reaction conditions required to 
effect hydrolysis were resulting in simultaneous cleavage of the 2- and 6-O-benzyl ethers.  This 
explained the loss of mass on purification of the crude tetrols when the much more polar pentol by-
product would remain on the silica pad. 
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The increased resistance to acidic hydrolysis of the 4-C-alkyl orthobenzoates compared to 
their non-alkylated counterparts can be interpreted by the mechanism of 1,3,5-triol orthoester 
hydrolysis established by Bouab et al.,103 as described in chapter 2, Figure 2.20.  In order for the 
addition of water to occur during hydrolysis, the inositol ring of the intermediate must undergo a 
chair-boat inversion.  This provides sufficient space for the addition of water, and prevents 
competing recombination to regenerate the starting material. Bouab et al.103 reported that 
substitutions, such as a phenyl ring, at the bridgehead position result in reduced rates of hydrolysis.  
Additionally, in the 4-C-alkyl orthoester, protonation of any of the 1-, 3- or 5-O followed by chair-
boat interconversion of 156 to 157 introduces a steric clash of adjacent eclipsing pseudo-axial 
substituents, of either the 4-C-alkyl or 6-O-benzyl with the dioxacarbenium moiety.  Furthermore, 
access of water to one face of the carbocation over the inositol ring will be severely hindered by the 
adjacent axial substituent.  Access to the other, less hindered face is also unfavourable, as this will 
increase the clash with the substituent on the other side to generate 158.    All these factors will 
result in a shift of the initial equilibria towards the starting material, Figure 4.6. 
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Figure 4.6: Rate determining step of acidic hydrolysis is likely to be hampered in this system due to steric 
clash 
The 4-C-alkyl tetrols were fluxional presumably due to the now axial alkyl addition, and 
this was evident in their 1H-NMR spectra, which are broad, with reduced coupling constants 
between the 6-H and its anti 1- and 5-H neighbours, indicating a reduced dihedral angle.  For 4-C-
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pentyl tetrol 151c in the chair conformation a coupling constant of 7-10 Hz would be expected for 
this ring proton, due to its two antiperiplanar neighbours.  However, the measured coupling 
constant is 3.4 Hz, and an NOE is observed between both the 3- and 5-H and the pentyl CH2 
suggesting that non-chair conformations, with the 4-C-alkyl group in an equatorial orientation, are 
also partially occupied. 
4.2 Preparation of the orthoformates 
The low yields obtained from acidic hydrolysis of the orthobenzoate led us to consider the 
more widely utilised orthoformate as an alternative 1,3,5-O protecting group.  It is reportedly more 
labile to acidic hydrolysis than the corresponding orthobenzoate.73,100 
Consequently myo-inositol 1,3,5-O-orthoformate was prepared by transesterification of 
myo-inositol with trimethyl orthoformate.  Direct 4-O-allylation of the crude material was carried 
out by addition of 1 eq. sodium hydride followed by allyl bromide,84 to obtain 31 in an unoptimised 
yield of 34 %.  This avoided the more time consuming reported methods involving preparation of 
the tribenzoate68 or chromatography of the crude orthoformate.70  Benzylation of the remaining 2- 
and 6-O with excess sodium hydride and benzyl bromide generated the fully protected intermediate 
32.  Isomerisation of the 4-O-allyl proceeded as reported for the orthobenzoate to prepare the 4-O-
(prop-2-enyl) ether 159.84  As predicted by the results of Billington and Gigg,85 removal of the 4-O-
(prop-2-enyl) ether under acidic conditions generated both desired product 41 and 2,6-O-dibenzyl 
tetrol resulting from acidic hydrolysis of the orthoformate.  However 41 could be regenerated by 
the reaction of 2,6-O-dibenzyl tetrol with trimethyl orthoformate.  The alternative use of basic 
aqueous KMnO4 in methanolic NaOH
86 effected a selective oxidative removal of the prop-2-enyl 
ether without any loss of the orthoformate. 
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Figure 4.7: Preparation of 2,6,-O-dibenzyl inos-4-ose 1,3,5-O-orthoformate from myo-inositol 
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Oxidation of the 4-OH with Dess Martin periodinane (DMP) generated inos-4-ose 42, 
which was converted to the exo-methylene oxide using sulfoxonium ylide.  exo-Methylene oxide 
160 underwent the predicted nucleophilic opening with phenyl lithium cuprate to generate 4-C-
benzyl-2,6-O-dibenzyl-myo-inositol 1,3,5-O-orthoformate 161, which was used to test the acidic 
deprotection of the 4-C-alkyl orthoformates, Figure 4.8. 
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Figure 4.8: Preparation of 4-C-benzyl orthoformate from inos-4-ose 42 and subsequent acidic hydrolysis 
Similarly to the orthobenzoate, the published conditions for orthoformate hydrolysis 
[TFA:H2O (4:1)]
100 did not initiate acidic deprotection of 4-C-benzyl orthoformate 161.  Upon 
treatment of 161 with 2 M HCl-EtOH (1:2) some signs of acidic hydrolysis were observed, but 
after 48 h the conversion was only 50 % complete.  Increasing the concentration of HCl to 4 M, 
increased the rate of reaction.  After purification of crude 151f, the mass recovery was improved 
(63 % product, 10 % starting material recovered) compared to the 4-C-benzyl orthobenzoates and 
no evidence for 2- or 6-O-benzyl ether hydrolysis was observed.  Therefore, during future work 
involving introduction of inositol ring substituents it is advised that the smaller 1,3,5-O-
orthoformate is used in order to reduce steric retardation of acidic hydrolysis.  Unfortunately, 
unlike the benzoate ester generated by acidic hydrolysis of the orthobenzoate, the presumed 
formate ester from initial orthoformate hydrolysis is immediately cleaved under the conditions 
used,78,100 to generate the tetrol.  While this is ideal for the preparation of tetrols for IP4 head 
groups, alternative methods would be required to isolate the 1-O for preparation of PIP3 lipid 
analogues. 
4.3 Selective DIBAL-H reduction to prepare natural Ins(1,4,5)P3 
It was hoped that the reduction of the orthobenzoate using excess DIBAL-H could 
ultimately be used to prepare the 4-C-alkyl-2,3,6-O-tribenzyl inositols required for the synthesis of 
4-C-alkyl IP3 analogues.  Reduction of orthoformates and orthobenzoates with limited DIBAL-H to 
generate the corresponding 1,3-O-acetals by hydride insertion into the 5-O-C bond is known.105  It 
was hoped that a second hydride delivery to the 1-O-C bond would generate the 3-O-benzyl ether.  
Such a reduction was not previously reported and therefore initial test reactions were carried out on 
2,4,6-O-tribenzyl orthobenzoate 162. 
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Symmetrical 2,4,6-O-tribenzyl orthobenzoate 162 was prepared by exhaustive benzylation 
of myo-inositol 1,3,5-O-orthobenzoate.  Use of limited DIBAL-H failed to replicate the yields of 
Maurali et al.105 who report isolation of the bridging 1,3-O-benzylidene acetal in 97% yield from 
2,4,6-O-tribenzyl-myo-inositol 1,3,5-O-orthobenzoate 162.  Despite multiple attempts, addition of 
limited DIBAL-H produced a mixture of the fully reduced 164, the desired bridging benzylidene 
acetal 163 and some remaining starting material, Figure 4.9. 
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Figure 4.9: Partial reduction of the tribenzyl generated a mixture of products 
Only the symmetrical benzylidene acetal was observed, which is consistent with the 
literature precedent that hydride delivery occurs initially to the 5-O-C bond,106 and the subsequent 
generation of only the asymmetric 1,2,4,6-O-tetrabenzyl product. 
Upon treatment of 162 with excess DIBAL-H, total reduction of the orthobenzoate to 
1,2,4,6-O-tetrabenzyl inositol 164 was observed.  For the 2,4,6-O tribenzyl orthobenzoate, the two 
products formed from a second hydride insertion into the 1-O or 3-O bond of the benzylidene 
acetal are identical by symmetry, occurring by definition in a 1:1 ratio.  Since the 5-O-benzyl 
product would be symmetrical, and therefore easily identified, the regiochemistry of reduction to 
the 1(3)-O-benzyl was confirmed by the generation of asymmetrical 164, Figure 4.10. 
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Figure 4.10: Total reduction of 2,4,6-O-tribenzyl orthobenzoate generates one product 
In order to generate the desired IP3 precursors, it was hoped that the second hydride 
insertion could be directed to the 1-O of an orthoester with asymmetric protection.  This would 
preferentially generate the desired 3-O-benzyl ether.  Such regiocontrol would also be of great 
benefit in the preparation of natural Ins(1,4,5)P3.  It was postulated that the 4- and 6-O protecting 
groups could be used to direct the second DIBAL-H delivery. 
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For an asymmetrical material, such as 2,6-O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoate 
95, the second hydride insertion at either the 1- or 3-O is expected to generate two distinct products 
assuming initial attack at the 5-O; 1,2,6-O-tribenzyl-myo-inositol 165 and desired 2,3,6-O-
tribenzyl-myo-inositol 166, Figure 4.11. 
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Figure 4.11: Treatment of 95 with excess DIBAL-H generates two products 
It was postulated that on treatment of 95 with excess DIBAL-H, initial coordination of the 
first equivalent of DIBAL-H to the 4-OH may present a larger steric hindrance to hydride delivery 
at the adjacent 3-O than hindrance of the 1-O by the 6-OBn, thereby directing the reduction of the 
intermediate 1,3-O- benzylidene acetal to give a 3-O benzyl ether.  This would provide an 
expedient method for directing the regioselectivity of reduction, as the bulky 4-O-DIBAL-adduct is 
removed in the work up.  However the ratio of products obtained showed that there was little 
selectivity for the desired 3-OBn (Entry A, Table 4.2).  It was not possible to further influence the 
ratio of products despite variations in the temperature and rate of addition of DIBAL-H. 
Table 4.2: Ratio of crude products in 1H-NMR of 1- and 3-O-benzyl ethers from DIBAL-H reduction 
Ratio of products 
Entry Starting Material 4-O-R 
3-O-Bn  1-O-Bn 
A 95 H 4 : 3 
B 162 Bn 1 : 1 
C 167 Tbdms 4 : 5 
D 168 Tbdps 4 : 5 
Noting that there was a slight preference for desired 166 we hoped to further differentiate 
between the two regioisomers by introducing bulkier temporary protecting groups at the 4-O.  
Unfortunately, upon treatment of 4-O-Tbdms (167) and 4-O-Tbdps (168) with excess DIBAL-H 
both reactions generated two diols, 169 and 170, and 171 and 172 respectively, the result of both 1- 
and 3-O-C hydride insertion, Figure 4.12. 
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Figure 4.12: Treatment of 167 and 168 with excess DIBAL-H 
1H-NMR of the crude material showed a slight preference for the 1-O benzyl products 
(Table 4.2, C and D).  The disappointing lack of selectivity may be due to the repulsion of the 
bulky 4-O-silyl group by the adjacent 5-O-DIBAL adduct in the intermediate benzylidene acetal; 
such bulky groups have been shown to favour the 1,2-diaxial conformation, forcing the 
intermediate back into a chair-like shape,146 Figure 4.13. 
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Figure 4.13: Bulky 4-O-silyl intermediates 173 may be forced back into chair configuration 174 due to 5-O-
DIBAL adduct 
Despite the lack of selectivity observed, an advantage of preparing the 4-O-Tbdms and 
-Tbdps derivatives was that the diols were considerably easier to separate using flash 
chromatography than the corresponding triols from reduction of 2,6-O-dibenzyl orthoester 95.  This 
was reflected in the isolated yields of the two regioisomers in each case (40 and 42 % recovery for 
4-O-Tbdms diols cf. 26 and 13 % for triols).  The identities of 171 and 172 were confirmed by 
removal of the 4-O-Tbdps using TBAF to afford triols 165 and 166, for which the regiochemistry 
had been unambiguously defined by COSY. 
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4.4 Reduction of 4-C-methyl orthobenzoate with DIBAL-H is 
regioselective 
It was demonstrated in section 4.3 that addition of excess DIBAL-H to the 1,3,5-O-
orthobenzoate generates a benzyl ether.  However attempts to direct the regioselectivity of the 
second hydride delivery to the 1,3-O-benzylidene acetal were unsuccessful.  It was hoped that the 
complete reduction of the 4-C-methyl orthobenzoate 115 would show increased regioselectivity 
due to the equatorial 4-C-methyl group. 
Upon addition of excess DIBAL-H to 115 a single product was generated, 175a.  Of the 
three possible regioisomers of the benzyl ether the desired 3-O regioselectivity was confirmed by 
the clear NOESY between the 2-, 3- and 6-H and their benzyl-CH2 signals in the 
1H-NMR, Figure 
4.14. 
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Figure 4.14: Addition of DIBAL-H to 4-C-methyl derivative 115 generates one product 
During the initial hydride reduction at the 5-O on inositol orthoesters lacking a 4-C-alkyl 
group, it is the steric effect of the equatorial 2-O benzyl ether which is assumed to direct the bulky 
DIBAL-H away from the 1- and 3-O.105  The 4-C-methyl derivative 115 has both an equatorial 2-
O-benzyl and the equatorial 4-C-methyl, which should increase the steric hindrance at the 3-O 
substantially.  It would be informative to isolate the intermediate benzylidene acetal as the position 
of initial hydride delivery would indicate which of the two equatorial groups had the greater steric 
influence.  However, despite multiple attempts, it was not possible to isolate any benzylidene acetal 
from the addition of limited DIBAL-H to 115.  Therefore it cannot be determined in which order 
the 1- and 5-O-C bonds undergo hyride insertion. 
4.5 Treatment of larger 4-C-alkyl orthobenzoates with DIBAL-H  
Following the totally selective reduction of 4-C-methyl orthobenzoate 115 to the desired 
2,3,6-O-tribenzyl ether, it was anticipated that larger 4-C-alkyl substituents would produce a 
similar directing effect.  Addition of excess DIBAL-H to 136, 133, 125, 145 and 144 produced two 
products; a single benzylidene acetal isomer and the 2,3,6-O-tribenzyl triol, Figure 4.15 and Table 
4.3. 
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Figure 4.15: Addition of DIBAL-H to the larger 4-C-alkyl derivatives generates two products 
With the exception of 4-C-ethyl orthobenzoate 136 (Table 4.3, entry 2), longer reaction 
times and addition of further DIBAL-H did not force the reaction to completion and both the acetal 
and triol were isolated. 
Table 4.3: Isolated yields from addition of DIBAL-H to 4-C-alkyl orthobenzoates 
Entry Starting Material 4-C Alkyl Derivative 
Yield of Benzylidene 
Acetal, 176 
(%) 
Yield of 
2,3,6-O-Triol, 175 
(%) 
1 115 methyl 0 55 
2 136 ethyl 0(19)* 61(32)* 
3 133 pentyl 13 54 
4 144 neopentyl 58 12 
5 125 benzyl 28 39 
6 145 (2-naphthyl)methyl 42 29 
*Ethyl can be either forced to completion by longer reaction times (48 h), or if both compounds are desired, 
can be stopped earlier (12 h) yields shown in parentheses. 
The fluxional nature of these compounds did not permit clear assignment of regiochemistry 
using 1H-NMR.  Therefore the 1,5-O-diacetyl derivatives 177c and f were prepared from 4-C-
pentyl and 4-C-benzyl triols 175c and 175f.  No acetylation was observed on the more hindered 
tertiary 4-OH, Figure 4.16. 
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Figure 4.16: Acetylation of the 1- and 5-O confirms triol regiochemistry 
Chapter 4:  Manipulation of the orthoester to generate 4-C-alkyl myo-inositol triols and tetrols 
 
 
 
- 90 - 
Locking the compounds into a single chair conformation, the 1H-NMR of diacetates 177c 
and f was sharp, with easily visible splitting patterns and measurable coupling constants.  The 4-C-
benzyl 1- and 5-H resonated at 5.01 (1H, d, J 9.8, Ins 5-H) and 4.95 (1H, bd, J 7.8, Ins 1-H) ppm 
respectively, roughly 1 ppm higher than the unacylated Ins-H shifts of the remaining 2-, 3-, and 6-
H.  The 3-H [for 4-C-benzyl, δ 3.64 (1H, d, J 2.4)] was not acetylated in either case, indicating that 
this was the location of the benzyl ether.  This confirmed the regiochemistry of reduction to the 
desired 2,3,6-O-tribenzyl triol. 
The benzylidene acetals 176b, c, e-f isolated were stable to further DIBAL-H reduction.  
The two products were easily separated using flash chromatography and the less polar acetal was 
found to be a single regioisomer.  Of the three possible benzylidene acetals which could be 
generated from initial hydride delivery only 3,5-O-benzylidene acetals 176 were generated, Figure 
4.17.   
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Figure 4.17: Hydride delivery to the orthobenzoate can occur at one of three positions 
The 1H-NMR for these species have a clear quartet in the inositol region, which exchanges 
to a triplet on addition of D2O [e.g. for 4-C-ethyl benzylidene acetal δ 4.46 (1H, q, J = 7.7 Hz, ex 
→ t)].  Such a resonance could only be generated by 176 where the ring proton with a free 
hydroxyl has two neighbouring protons, to generate a triplet, Figure 4.18. 
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Figure 4.18: 
1H-NMR splitting and NOE confirm identity of benzylidene acetal 
This was corroborated by NOE of the benzylidene acetal bridgehead proton to the 6-H ring 
proton Figure 4.18.  Such an interaction would not be possible in 178b.  This unexpected result 
demonstrates that with the additional 4-C-alkyl group, the mechanism for DIBAL-H reduction may 
now proceed by initial hydride insertion to the 1-O-C bond, rather than the 5-O-C bond.  However, 
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the stability of 176 to a large excess of DIBAL-H and long (24 h) reaction time, as the 4-C-alkyl 
substituent size increases, indicates that the 3-and 5-O of the benzylidene acetals are very 
inaccessible.  Indeed, treatment of 4-C-benzyl benzylidene acetal 176f with excess DIBAL-H at 50 
ºC for 24 h only showed traces of conversion to the desired triol by 1H-NMR, suggesting that this 
acetal is quite stable towards further reduction.  In each case there was DIBAL-H remaining when 
the reaction was quenched, as violent reaction was observed upon dropwise addition of H2O.  It is 
therefore unlikely that the isolated triol derives from 176.  Instead it is postulated that 178a from 5-
O-C reduction is formed transiently, as opposed to 178b which is unlikely to form as the DIBAL-H 
would be required to coordinate between the two equatorial substituents.  Unobserved benzylidene 
178a is then reduced rapidly by a second hydride insertion at the 1-O-C bond.  As the size of the 4-
C-alkyl substituent increased the relative proportion of benzylidene acetal compared to the triol 
also increased, Table 4.3.  This suggests that for smaller 4-C-alkyl groups both 178a and 176 are 
easily reduced by DIBAL-H, but for larger 4-C-alkyl substituents access to the 5-O is much more 
restricted leading to accumulation of 176.  This regiocontrol suggests that larger 4-C alkyl groups 
are more sterically demanding than the 2-O benzyl ether. 
The 1H-NMR of the 3,5-O-benzylidene acetals is characteristic.  No coupling is observed 
between the adjacent Ins 5-H and Ins 6-H indicating that they have a dihedral angle of ca. 90 
degrees to each other,129 rather than the 120 º angle suggested by their axial-equatorial relationship 
in a strictly boat conformation.  Also, in a strictly boat form, the 1-H would couple with a large 
coupling constant (8-10 Hz) to the anti-periplanar 6-H and with a smaller coupling constant (1-4 
Hz) to the gauche 2-H, forming a double doublet.  However the 176f 1-H resonates as an apparent 
triplet [δ 4.46 (1H, t, J = 7.7 Hz].  These unusual dihedral angles suggest that the acetals are twisted 
out of the boat conformation – presumably to relieve steric clashes such as the pseudo-axial 2-O 
benzyl adjacent to the 3,5-O-benzylidene acetal and the 1,4-diaxial interaction of the 1-H and 4-
OH. 
4.6 Removal of 3,5-O-benzylidene acetals: An alternative route to 4-C-
alkyl tetrols  
Initial attempts to record 1H-NMR spectra of the benzylidene acetals using CDCl3 showed 
signs of decomposition after 2 h.  Comparison to the relevant 2,6-O-tetrols confirmed that this was 
a result of acidolysis of the 3,5-O-benzylidene acetal, demonstrating the sensitivity of this group to 
acidic conditions.  The benzylidene acetal generated from the orthobenzoate is much more labile 
than the corresponding formate acetal generated from the orthoformate.147  Treatment of 4-C-alkyl 
benzylidene acetals 176e, f and g with 3 mol% p-TsOH in H2O-EtOH-CH2Cl2 cleanly afforded 4-
C-alkyl tetrols 151e, f and g, which were separated from the resulting benzaldehyde by-product by 
flushing though a pad of flash silica, Figure 4.19. 
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Figure 4.19: Removal of the 3,5-O-benzylidene acetal to generate tetrols 
Reduction of the orthobenzoate with DIBAL-H to selectively generate both the required 
triols and tetrols for larger C-alkyl derivatives is particularly useful in simultaneously preparing 4-
C-alkyl IP3 and IP4 libraries from a common precursor.  Due to the unexpected difficulties of using 
acidic hydrolysis to effect removal of the orthobenzoate (see section 4.1) this route was adopted as 
the major pathway for generating 4-C-alkyl tetrols for use in further steps. 
4.7 Concluding Remarks 
Acidic deprotection of the orthobenzoate required considerably harsher conditions than the 
corresponding unalkylated orthoesters, due to the combination of the orthobenzoate head group and 
4-C-alkyl substituent causing reduction of the rates, presumably for steric reasons.  The harsh 
conditions required to initiate hydrolysis of the orthobenzoate also caused partial hydrolysis of the 
benzyl ethers.  The corresponding 4-C-benzyl orthoformate was prepared, and was more easily 
removed without evidence of 2 and 6-O-benzyl ether deprotection.  
Using steric bulk on the 4-O in an attempt to influence the direction of DIBAL-H reduction 
for preparation of natural IP3 was unsuccessful.  However, the reduction of 4-C-alkyl 
orthobenzoates with DIBAL-H proceeded regioselectively generating the desired 4-C-alkyl 2,3,6-
O-tribenzyl triols.  DIBAL-H reduction of 4-C-ethyl and larger substituents led to the concurrent 
isolation of the benzylidene acetal.  It was demonstrated that this was labile under mildly acidic 
conditions to easily afford the desired 4-C-alkyl 2,6-O-tetrols for IP4 preparation by an alternative 
route.  The discovery that both IP3 and IP4 precursors can be simultaneously generated using 
DIBAL-H reduction led to this being the primary method for obtaining these compounds for further 
elaboration. 
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Chapter 5: Phosphorylation and deprotection of 4-C-alkyl triols 
and tetrols 
The selectively protected 4-C-alkyl myo-inositol triols and tetrols, the preparation of which 
is described in the previous chapter were now ready for polyphosphorylation.  Unlike in the natural 
systems or published syntheses, the key challenge was to effect phosphorylation of a polyol which 
included a tertiary centre.  As discussed previously (section 2.5), the principle challenge during 
polyphosphorylations of vicinal diols is avoiding cyclisation of the intermediate phosphites with 
the consequent loss of yield.  The reagent of choice would be furnished with benzyl groups to 
permit global deprotection of both the phosphate esters and the 2-, 3- and 6-O-benzyl ethers on the 
ring hydroxyls in one step. 
In the final steps of phosphorylation and deprotection, the 31P-NMR becomes an invaluable 
analytical tool.  Each phosphate introduced gives a single signal in the proton decoupled 31P-NMR.  
Phosphorylation of these derivatives introduces a new dimension into the 1H-NMR; as 31P is also a 
spin ½ nucleus, 1H-31P coupling is observed.  This is useful to identify the regiochemistry of 
phosphorylation although, due to the size of the 3-bond P-H coupling (6-9 Hz) which is roughly the 
same as the anti-periplanar coupling constant, care must be taken not to confuse the two. 
Table 5.1: Additional splitting of protons in 1H-NMR for 4-C-alkyl phosphorylated derivatives due to 31P 
coupling. 
R = alkyl
P = phosphate
112 R1 = H
113 R1 = P
BnO
R1O
OBn
OP
PO
OP
H
HH
H
H
R
 
Proton Orientation Splitting 
31
P-coupling Observed peak 
1-H Axial dd Yes td 
2-H Equatorial t No t 
IP3 No d 
3-H Axial d 
IP4 Yes dd 
4-H - - - - 
5-H Axial d Yes t 
6-H Axial t No t 
The presence of multiple benzyl peaks in the fully protected species, each with doublets in 
the 5 ppm region, would be expected to lead to complex spectra for these intermediates, especially 
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if they are fluxional.  However this intermediate can be characterised using 31P-NMR and the 
removal of side products or phosphorylating reagent should be clear from this spectrum.   
Once the benzyl groups are removed to generate the free 4-C-alkyl inositol tri- or 
tetraphosphate, there should be no peaks above 5 ppm in the 1H-NMR as there will be no remaining 
aromatic groups (except, of course, if they are contained in the 4-C-alkyl substituent), and the 
inositol region of the 1H-NMR spectra will be free of benzylic CH2 peaks.  The distinctive coupling 
of each remaining inositol proton should then be visible. 
The 13C-NMR is also affected by the introduction of 31P nuclei.  31P coupling affects carbon 
centres two and three bonds away, splitting them into doublets with coupling constants of 3-6 Hz, 
with no clear distinction between 2- and 3-bond coupling, Table 5.2. 
Table 5.2: Observed 13C-NMR resonances after phosphorylation and deprotection 
Carbon Peak Type IP3 splitting IP4 splitting 
1-C C-H d d 
2-C C-H d t/dd 
3-C C-H d t/dd 
4-C Quaternary t/dd ~q 
5-C C-H t/dd t/dd 
6-C C-H t/dd t/dd 
5.1 Phosphorylation of a tertiary centre 
As a starting point to test the phosphorylation of the newly introduced tertiary centre N,N-
diisopropyldibenzyl phosphoramidite, 93b, was employed, Figure 5.1.  This commercially 
available reagent is reported by Yu and Reid110 to permit polyphosphitylation under mild 
conditions.  Furthermore the use of a dibenzyl phosphitylating reagent has the advantage of global 
deprotection by catalytic hydrogenation to obtain the final product. 
O
P
O
N
93b  
Figure 5.1: N,N-diisopropyldibenzylphosphoramidite, 93b 
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Phosphitylation of 4-C-methyl, -ethyl and -pentyl tetrols in MeCN with 1-H-tetrazole as 
activator, followed by oxidation with mCPBA furnished the three 1,3,4,5-O-tetrakis 
(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-alkyl-myo-inositols 179a-c, Figure 5.2. 
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179b R = Ethyl, [31 %]
179c R = Pentyl, [28 %]  
Figure 5.2: Phosphorylation of 4-C-methyl, ethyl and pentyl tetrols 
Tetrazole is used as an activator in phosphitylations with phosphoramidies.  The 
mechanism is shown in Figure 5.3. 
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Figure 5.3: Mechanism of phosphitylation using N,N-diisopropyldibenzyl phosphoramidite and 1-H-
tetrazole 
H-Phosphonate, formed by hydrolysis of the phosphoramidite 93b [δP 7.06 ppm, δH 6.99 (d, 
J 710 Hz)] on addition of the hydrous oxidising agent, was difficult to separate from the product 
using column chromatography.  If the P-H bond of the H-phosphonate were oxidised in situ to the 
phospho-diester salt, this by-product would be easy to remove.  However, mildly acidic mCPBA 
does not tautomerise the oxidatively stable P(V) of H-phosphonates to the P(III) phosphite di-ester 
isomer and so cannot oxidise it.  Instead, it was easily removed by oxidation of the crude reaction 
mixture under basic conditions where H-phosphonate 187 tautomerises to the phosphite diester 
188, Figure 5.4. 
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Figure 5.4: By-products in the phosphorylation due to oxidation and hydrolysis of the phosphoramidite, 93b. 
Treatment with 1 M I2 in H2O-THF-Py (1:7:2 v/v), followed by extraction of the crude 
material into CHCl3, leaving the phosphate diester in the aqueous phase.  Following oxidation, the 
remaining debris from the phosphorylating reagent was easily separated using flash 
chromatography, Figure 5.5. 
ppm
-5.00.05.0
ppm
-5.00.05.0
ppm
-5.00.05.0
 
Figure 5.5: Purification 4-C-ethyl IP4 after phosphorylation; a) 
31P-NMR of crude material; b) Removal of 
H-phosphonate by I2 oxidation; c) Pure compound after column chromatography. 
In each case 31P-NMR clearly showed the formation of 4 peaks (for example, 4-C-methyl, 
δP -1.46, -1.65, -1.86 and -6.30 ppm).  For each fully protected 4-C-alkyl IP4, the tertiary centre had 
a characteristic shift in the 31P-NMR around -7 ppm upfield from the three secondary centres.  The 
clean conversion from these reactions is clearly demonstrated by comparison of the crude 31P-NMR 
from reaction mixtures with and without the tetrol, Figure 5.6.  The additional peaks present in the 
crude material are just those from the excess phosphitylating reagent.  
a) b) c) 
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ppm
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Figure 5.6: a) 31P-NMR of the reagent mixture without tetrol 151a; b) 31P-NMR of crude material from 
phosphorylation of 4-C-methyl tetrol 151a 
Phosphitylation of bulkier 4-C-benzyl and -neopentyl tetrols using 93b, followed by 
oxidation with mCPBA, generated a mixture of species, identified by 31P-NMR of the crude 
material, Figure 5.7. 
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 Figure 5.7: Phosphorylation of 4-C-benzyl and -neopentyl tetrols is incomplete 
The highly similar tri- and tetraphosphorylated species were not separable by flash 
chromatography, and were only visible as one spot by TLC.  However, isolation of some 
triphosphate from the 4-C-benzyl reaction mixture confirmed that the two observed species were 4-
C-benzyl-1,3,4,5-tetraphosphate and -1,3,5-triphosphate resulting from incomplete phosphorylation 
at the tertiary 4-OH.  The regiochemistry of phosphorylation of the triphosphate was easily 
ascertained by the absence of a 31P peak in the -6 to -7 ppm region [MS (ES+) m/z (%) found 
triphosphate [M+H]+ 1231 (53), [M+Na]+ 1253 (36), δP -0.34, -1.24, -1.76 ppm and tetraphosphate 
[M+H]+ 1491 (100), [M+Na]+ 1513 (56), δP -1.53, -3.05 (2P), -7.09 ppm].  However, it was 
encouraging to see that limited phosphorylation of the 4-OH had occurred giving hope that a more 
reactive reagent would overcome this problem.  Precipitation during the reaction, presumed to be 
diisopropyl ammonium tetrazolide meant that it was not possible to increase the concentration of 
the reaction while maintaining stirring, to attempt to push the phosphorylation to completion. 
a) b) 
P 3xP 
P = product 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-4-C-alkyl-myo-inositols 179a-c, were globally 
deprotected with Pd(black) under an atmosphere of H2, in BuOOH-H2O to prepare the three 4-C-
alkyl IP4 analogues 191a-c, Figure 5.8. 
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tBuOH-H2O (6:1)
179a R = Methyl
179b R = Ethyl
179c R = Pentyl
OBn
OO
O
R
OBn
O
P
P
P
O
O
O
OBn
OBn
OBnBnO
BnO OBn
PO
BnO OBn
OH
OO
O
R
OH
O
P
P
P
O
O
O
O-
OH
O-HO
-O OH
PO
HO O-
191a R = Methyl, [100 %]
191b R = Ethyl, [100 %]
191c R = Pentyl, [94 %]
4NH4
+
 
Figure 5.8: Global deprotection of ten benzyl groups to generate 4-C-methyl, -ethyl and -pentyl IP4 
The reactions were buffered by the addition of 8 eq. of NaHCO3 in order to neutralise the 
free acids generated during deprotection, preventing any reduction in the pH which might lead to 
cyclisation of the phosphates and subsequent loss of material.  A concentrated aqueous solution of 
the crude material was passed through a short column of DOWEX 50WX8-200 H+ resin to remove 
complexed Pd2+.  Acidic fractions were combined and neutralised with aqueous ammonia before 
lyopholising.  In each case, the 31P-NMR had 4 distinct peaks and a well resolved 1H-NMR 
permitted individual peaks to be identified and assigned by both splitting pattern and COSY cross-
peaks, Table 5.3. 
Table 5.3: Assignment of 4-C-methyl, -ethyl and -pentyl IP4 final compounds compared to natural IP4 
6-H, t 
Entry 4-C-alkyl substituent δP (ppm) 
δH (ppm) J (Hz) 
1 Methyl 1.74, 1.38, 0.83, -2.35 3.6 9.9 
2 Ethyl 1.87, 0.71, 0.27, -4.03 3.77 8.8 
3 Pentyl 1.88, 0.65, 0.18, -4.10 3.83 9.0 
4107 H 1.49, 1.13, 0.59, 0.42 3.77 9.6 
In each case, 1H-NMR confirmed that the 4-H had been substituted; the 3-H all resonate as 
double doublets, rather than the natural double triplet, and the 5-H as triplets, rather than the natural 
triple doublet or quartet.  The stereochemistry of the 4-C-alkyl group in the final product was 
confirmed by observation of an NOESY interaction between the 6-H and the 4-C-CH2 for both 4-
C-methyl and -pentyl IP4.  It is also encouraging to note that these 4-C substituted derivatives 
occupy a naturalistic chair conformation.  This is evident from the coupling constants in which the 
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6-H couples to the pair of adjacent protons with near typical anti-periplanar values (Table 5.3, 6-H 
J values all between 8-10 Hz), Figure 5.9.   
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Figure 5.9: The primary 4-C-alkyl derivatives occupy the natural chair conformation 
If the 4-C-alkyl group was occupying a pseudo equatorial position in a twist-boat 
conformation in order to relieve 1,3-diaxial strain, the dihedral angle between the protons adjacent 
to the 6-H would be reduced, and this would be visible in the size of the coupling constants.  The 
coupling constants with the larger 4-C-alkyl bumps were reduced slightly, suggesting greater 
occupancy of a twist-boat conformer.  The natural chair conformation is essential for binding to the 
modified proteins in RLE.  If the 4-C analogues were locked in another conformation they would 
be unable to fit into the highly conserved binding site. 
The identity of these compounds was confirmed by HRMS in negative ion mode.  The 
fully deprotected polyphosphates bind tightly to any metal ions and successful ionisation was only 
obtained using MeCN-H2O (1:1) with 1 % formic acid.  The presence of TFA due to contamination 
of service instruments caused initial difficulties as TFA clusters completely supressed analyte 
peaks.   
The 4-C-methyl, -ethyl and -pentyl triols 175a-c were phosphitylated in a similar manner 
to the tetrols, using 93b, followed by oxidation using mCPBA to give the corresponding 1,4,5-
triphosphates 194a-c, Figure 5.10. 
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Figure 5.10: Phosphorylation of 4-C-methyl, -ethyl and -pentyl triols 
In each case 31P-NMR confirmed that phosphorylation had occurred on three sites.  For the 
4-C-methyl IP3 194a, the 
1H and 13C-NMR spectra were sharp, but with increasing alkyl chain 
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length the inositol resonances became increasingly broad.  Oxidation of the P(III) phosphite 
triesters has been reported using both mCPBA and tBuOOH.110,125  Yu and Reid110 noted that 
oxidation with mCPBA is cleaner than the corresponding oxidation with tBuOOH.  Oxidation of 
the intermediate 4-C-methyl 1,4,5-triphosphite was attempted with both oxidising agents and the 
crude 31P-NMR compared, Figure 5.11. 
ppm
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Figure 5.11: Comparison of 1H-NMR of the crude material resulting from oxidation with either a) tBuOOH 
or b) mCPBA. 
The 1H-NMR of the crude material resulting from oxidation with tBuOOH clearly shows a 
number of peaks resulting from impurities, compared to the oxidation with mCPBA which only 
shows the three product peaks and reagent debris.  Following the incomplete phosphorylation of 
the branched or benzyl 4-C-alkyl tetrols with 93b, phosphorylation of the corresponding triols was 
not attempted. 
Deprotection of the nine benzyl groups with Pd (black) under an atmosphere of H2 afforded 
4-C-methyl, -ethyl and -pentyl IP3, Figure 5.12.  
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Figure 5.12: Global deprotection of benzyl groups to generate 4-C-methyl, -ethyl and -pentyl IP3 
In each case all the benzyl groups were successfully removed (no signals δH 7-8 ppm).  The 
4-C-methyl IP3 was a single product with sharp 
1H-NMR signals at rt.  Like the corresponding 4-C-
methyl IP4, the 6-H coupling constants were typical of having two adjacent anti-periplanar protons 
a) b) 
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[δH 3.75 (1H, dd, J 9.9, 9.8 Hz) ppm] and there was a clear NOESY between the 4-C-methyl (1.48 
ppm) and the 6-H corroborating the required stereochemistry was present at the 4-C. 
For both the 4-C-ethyl and -pentyl IP3 there was evidence in the 
1H-NMR that another 
inositol phosphate product was present.  Presumably as a result of having one less equatorial 
phosphate, these 4-C-alkyl IP3 were notably more fluxional than the corresponding 4-C-alkyl IP4’s.  
The spectra at rt contained very broad signals corresponding to the 4-C-alkyl IP3 and sharper peaks 
from an unknown inpurity.  Variable temperature NMR was carried out in order to identify the 
impurity and more firmly characterise the final product.  For the 4-C-ethyl IP3, resolution of the 
product peaks was much improved as the temperature reached 328 K.  Unfortunately, as the sample 
was held at this temperature the product decomposed, turning entirely into the impurity.  This 
permitted identification of the impurity as 4-C-ethyl-myo-inositol-1,5-diphosphate, resulting from 
dephosphorylation of the 4-O, Figure 5.13. 
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Figure 5.13: 4-C-ethyl-myo-inositol-1,5-diphosphate 
Although the hydrogenation was buffered using NaHCO3, some initial dephosphorylation 
may have occurred during purification by ion exchange, where the crude material was converted to 
the free acid to remove all the counter ions.  The free acid was neutralised by addition of aqueous 
ammonia, chosen due to its volatility, as excess NH3 could be removed under vacuum.  However, 
upon heating, the weakly acidic NH4
+ counter ions may protonate the tertiary phosphate ester 
resulting in the observed 4-O-dephosphorylation.  Although in isolated phosphate esters this would 
not happen, in inositol polyphosphates neighbouring phosphates effectively raise each others pKa 
due to charge repulsion. 
Further samples of 4-C-ethyl and -pentyl IP3 were prepared and, in order to avoid acidic 
conditions, stored as the sodium salt.  After hydrogenation these compounds were stirred with 
sodiated ion exchange resin to remove any remaining Pd2+ and to avoid preparation of the free acid.  
Unfortunately the sodium salts were difficult to analyse due to excess sodium bicarbonate present 
in the sample (δH 8.36, δC 161.14 ppm).  The 
1H-NMR signals of both compounds were still broad, 
and the 31P-NMR even broader than previously encountered.  Furthermore, it was evident that even 
after multiple hydrogenations, a set of aromatic peaks [δH 7.74 (2H, d), 7.41 (1H, t), 7.35 (2H, t)] 
was present, either from incomplete hydrogenation or an aromatic contaminant.  The MS of these 
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samples also suffered from the presence of excess sodium ions and from multiple sodiated clusters 
as some Na+ ions were ionised with the sample.  Therefore it was not possible to confirm whether 
these peaks were due to only partial hydrogenation of the 2- and 6-O-benzyl groups, or due to 
presence of another species e.g. benzoic acid, from an unknown source. 
4-C-Ethyl IP3 was therefore fractionated by HPLC, eluting with MeCN-H2O (1:49 v/v), to 
isolate the pure product.  Unfortunately, the contaminant was not isolated, and therefore could not 
be identified. 
5.2 More reactive phosphorylating reagents for bulky 4-C-alkyl 
substituents 
Having successfully achieved phosphorylation and deprotection of the straight chain 4-C-
alkyl triols and tetrols, other phosphitylating reagents were considered for use on larger 4-C-alkyl 
substituents, such as the 4-C-benzyl derivative.  Following incomplete phosphitylation of the 4-C-
benzyl 4-OH with phosphoramidite 93b, it was hoped that a more reactive phosphitylating reagent 
would effect complete phosphorylation of the tertiary 4-OH.  Di(2-cyanoethyl) phosphorochloridite 
91 was available in the lab and has been found by the group to be a highly reactive 
polyphosphitylating reagent, Figure 5.14. 
CneO
P
CneO
91 Cne = -CH2CH2CN
Cl
 
Figure 5.14: Dicyanoethyl phosphorochloridite 
Prepared by the reaction of trimethylsilyl(3-propionitrile) with PCl3, this reagent can be 
stored under N2 as a solution in CH2Cl2.
113  Pleasingly, phosphitylation of 4-C-benzyl tetrol 151f 
with 91, in the presence of 3-nitro-1,2,4-1H-triazole, followed by oxidation of the resulting 
tetraphosphite by mCPBA prepared the desired tetraphosphate, with no evidence of triphosphate 
due to incomplete phosphorylation, Figure 5.15.   
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Figure 5.15: Phosphorylation of 4-C-benzyl tetrol with 91 prepares the 1,3,4,5-tetraphosphate 
The phosphorylation was carried out in pyridine to neutralise the HCl evolved during the 
reaction.  Due to the known presence of a small amount of the dichloridite in this reagent,113 
cyanoethanol was added to the reaction 30 min prior to the oxidation.  The low yield of product 
recovered, 24 %, reflects the difficulty in visualising this fully protected species.  Despite using 
many different TLC dips and stains, the most successful method of visualisation was KMnO4 stain, 
but this was still insensitive. 
The cyanoethyl phosphate esters and 2,6-O-benzyl ethers on 197 require two separate steps 
to effect total deprotection.  In order to prevent migration of phosphotriesters, the cyanoethyl 
protected phosphate esters must first be deprotected, followed by the removal of the 2- and 6-O 
benzyl groups.  Treatment of 197 with Barton’s base, in the presence of TmsCl, generated an 
intermediate tetra[bis(trimethylsilyl)phosphate].113  After evaporating the volatile material, 
including acrylonitrile derived from the cyanoethyl esters and excess Bartons’s base, the residue 
was taken up in ether-hexane (1:1 v/v) and filtered under anhydrous conditions to remove excess 
Barton’s base salts.  The filtrate was evaporated and taken up in MeOH containing 4 eq. NaHCO3 
to convert the phosphoric acid groups to their mono-sodium salts as they formed, Figure 5.16. 
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Figure 5.16: Removal of cyanoethyl groups to generate free phosphates and conversion to the sodium salt 
Well resolved 1H-NMR clearly showed the aromatic protons of three phenyl groups; the 2- 
and 6-O-benzyl ethers and 4-C-benzyl substituent, and the mass was confirmed by HRMS.  Despite 
care during the filtration, 13C and 1H-NMR showed evidence of some Barton’s base counter ions.  
However it was anticipated that this could be removed during later cation exchange. 
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol-1,3,4,5-tetraphosphate 198 was treated with Pd 
(black) under an atmosphere of H2.  After 36 h, the crude material was treated with sodiated ion-
exchange resin.  However, 1H-NMR indicated that deprotection was not complete; more than one 
phenyl group was still visible in the aromatic region and at least two sets of 4-C-benzyl peaks were 
visible.  After a further 36 h under the same conditions, and ion exchange in the same manner, it 
was evident that the deprotection was nearer to completion; distinctive peaks of the single 
remaining 4-C-aromatic ring were visible [δH 7.38 (2H, d, J 8.0), 7.18 (2H, t, J 7.6), (1H, t, J 7.2) 
ppm].  However, there were still trace amounts of other aromatic compounds, confirmed by HRMS 
to be the partially deprotected mono-benzyl species [HRMS (ESI+) m/z (%) found [M+H]+ 
590.9850 (17), C13H23O18P4 requires 590.9835 and [M+Bn+H]
+ 681.0322 (33), C20H29O18P4 
requires 681.0304].  Furthermore, new peaks were observed in the 2-0.8 ppm region of the 1H-
NMR, suggesting that not only was deprotection incomplete, but that competing hydrogenation of 
the 4-C-benzyl group to a 4-C-(cyclohexyl)methyl substituent was occurring.   
Unfortunately, the small amounts of material available from this route did not permit 
isolation of the desired compound, hampered as it was by the competing hydrogenation of the 4-C-
benzyl group. 
5.3 Phosphorylation with less hindered N,N-diethylamino-5,6-benzo-
1,3,2-dioxaphosphepane 
Successful phosphorylation of 4-C-benzyl tetrol with di(2-cyanoethyl)phosphorochloridite, 
91, provided evidence that it was possible to effect complete phosphorylation at this tertiary 4-OH.  
Unfortunately, clean deprotection of 1,3,4,5-O-tetrakis(dicyanoethyloxyphosphoryl)-2,6-O-
dibenzyl-4-C-benzyl-myo-inositol 197 was not possible.  Consequently, a reagent was sought that 
was more reactive than dibenzylphosphoramidite 93b, but that would still permit a one step 
deprotection by hydrogenation.  Therefore, N,N-diethylamino-5,6-benzo-1,3,2-dioxaphosphepane 
was prepared, according to the methods of Arbuzov.121  Watanabe et al.111 report that this more 
compact reagent was particularly useful for polyphosphorylation of multiple sterically crowded 
sites.  Arbuzov et al.121 report the preparation of both the N,N-dimethyl- and 
-diethylaminophosphepane, which can be purified by distillation.  The ethyl reagent, 94b, was 
prepared in the hope that this derivative would be somewhat more stable to hydrolysis than the 
corresponding dimethyl reagent, and therefore would be easier to handle and store, Figure 5.17.  
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Figure 5.17: Preparation of N,N-diethylamino-5,6-benzo-1,3,2-dioxaphosphepane 
A test reaction on the already successfully phosphorylated 4-C-methyl tetrol 151a 
demonstrated that the reagent gave very clean 1H- and 31P-NMR spectra of the crude product, with 
reagent peaks at δP 13.16 and 12.51 ppm.  However, purification by column chromatography failed 
to separate the product from the reagent debris.  On initial phosphitylation of 4-C-benzyl 2,3,6-O-
tribenzyl ether 175f with 94b, followed by oxidation by mCPBA, a mixture of bis- and 
trisphosphorylated species 201 and 202 was obtained in the ratio 9:13, visible as one spot by TLC, 
Figure 5.18. 
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 Figure 5.18: Phosphorylation of 4-C-benzyl triol using 94b. 
Separation of a small amount of diphosphate from the mixture confirmed its identity 
[HRMS m/z (%) found [M+H]+ 905.2889 (63), C50H51O12P2 requires 905.2856, [M+Na]
+ 927.2714 
(100), δP 0.64, -1.25 ppm].  By maintaining the temperature of the reaction at 25 ºC using a water 
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bath, and increasing the concentration of the reaction mixture by halving the amount of solvent 
used, it was possible to observe complete phosphorylation on all three hydroxyls, generating the 
desired triphosphate, 202, not contaminated with diphosphate 201.  Unlike with the earlier N,N-
diisopropyl phosphoramidite, the diethyl reagent did not suffer from thick precipitation during the 
reaction, and therefore it was possible to increase the reaction concentration and maintain stirring.  
Purification of the crude material was hampered by difficulty in visualising the product, and the 
substantial amount of phosphorylating reagent debris remaining, which had the same Rf as the 
product.  Even so, use of a slow gradient column successfully isolated triphosphate 202 in 44 % 
yield. 
Following this success, phosphorylation of 4-C-benzyl tetrol 151f and 4-C-neopentyl tetrol 
151e were attempted.  In both cases the crude 1H-NMR was not as clean as that of the 4-C-benzyl 
triol.  Upon purification of the 4-C-neopentyl tetraphosphate, some triphosphate was recovered.  
The absence of a downfield 31P-NMR peak in addition to three 31P-NMR peaks around 0 ppm 
confirmed that this was due to lack of phosphorylation of the tertiary 4-OH.  For the 4-C-benzyl 
tetraphosphate, HRMS of the crude material indicated that there was no triphosphate present and 
that the desired tetraphosphate was present, but this was not isolated from the remaining 
phosphorylating reagent debris. 
1,4,5-O-Tris(5,6-benzo-1,3,2-dioxaphosphoryl)-2,3,6-O-tribenzyl-4-C-benzyl-myo-
inositol, 202, was globally deprotected with Pd(black) under an atmosphere of H2, Figure 5.19.   
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Figure 5.19: Global deprotection of 202 
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After stirring with sodiated ion exchange resin, the 1H-NMR of the crude material clearly 
showed 5 aromatic protons [δH 7.44 (2H, d, J 7.5), 7.22 (2H, t, J 7.4), 7.14 (1H, t, J 7.3) ppm], 
confirming that full 2-, 3- and 6-O-benzyl deprotection had occurred.  However, there was also 
evidence of over-reduction of the 4-C-benzyl group to the 4-C-(cyclohexyl)methyl derivative with 
several peaks, in the 2-0.8 ppm region of the 1H-NMR.  The ratio of the two products was 
estimated to be 4:1 in favour of the desired 4-C-benzyl product.  However separating these very 
similar compounds was not easy.  The desired final product 203 was isolated using HPLC 
(retention time 2.88 min, mobile phase H2O-MeCN gradient (49:1 → 1:1 v/v). However a large 
amount of the injected material was not recovered, possibly due to chelation to the exposed steel 
interior surfaces the HPLC equipment.148 
Due to the highly similar and polar nature of these products, it is not possible to monitor 
the reaction by TLC, and therefore it would be preferable to develop methods which selectively 
reduce only the desired functional groups.  Pearlman’s catalyst149 has been used to selectively 
remove benzyl ethers in the presence of phenyl rings.150,151  Reduction of 202 with Pearlmans 
catalyst under an atmosphere of H2 saw only partial deprotection of the benzyl groups.  There was 
no evidence of over reduction, although the reaction had only gone to ~45 % in 24 h, so it is 
possible that over-reduction would be observed on the timescale required to effect complete 
deprotection. 
For any 4-C-derivatives which are unsaturated, such as the 4-C-benzyl or -(2-
naphthyl)methyl analogues, careful control of the hydrogenation could be used to generate more 
than one 4-C-derivative.  For example, the 4-C-benzyl substituent could be reduced to the 4-C-
(cyclohexyl)methyl group during deprotection of the benzyl ethers, Figure 5.20.  The key challenge 
would be to either develop selective deprotection conditions for the 2- and 6-O benzyl ethers 
without simultaneous hydrogenation of the 4-C-benzyl substituent, or be able to effect complete 
hydrogenation, including the reduction of the benzyl to the cyclohexyl.  The selective removal of 
benzyl ethers in the presence of other sensitive groups such as aryl chlorides and bromides is 
described using triethylsilane catalysed by palladium acetate.151  Theoretically, both species may be 
accessed during this last step of the synthetic route, making this an attractive route to further 4-C-
alkyl substituents. 
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Figure 5.20: The 4-C-benzyl group may be selectively reduced to generate both the 4-C-benzyl and the 4-C-
(cyclohexyl)methyl IP3 products 
Since 4-C-(cyclohexyl)methyl IP3 is a viable 4-C-alkyl target in its own right, complete 
reduction of 202 was attempted using Raney nickel.  Unfortuately this showed no further reaction 
on the mixture of products compared to treatment with Pd(black).  It is postulated that as the benzyl 
groups are removed, the increasingly polar species have a decreasing affinity for the solid phase 
catalyst, compared to the hydrophobic phenyl ring of the C-benzyl group, and this may lead to the 
lack of selectivity observed in this system compared to literature reports which indicate these 
catalysts are selective.152  If this is the case, then a homogeneous catalyst may provide the 
selectivity needed by overcoming the problems associated with restricted access to the benzyl 
ethers for a solid catalyst face. 
5.4 Concluding Remarks 
It has been demonstrated in this chapter that phosphorylation of a 4-C-alkyl tertiary centre 
is possible.  For less sterically demanding straight chain C-alkyl groups this was possible using 
N,N-diisopropyldibenzyl phosphoramidite which generated 4-C-alkyl IP3 and IP4 precursors with 
nine or ten benzyl groups respectively.  These globally protected precursors could be fully 
deprotected with Pd(black) under an atmosphere of H2.  Following the obervation of 4-O-
dephosphorylation of their ammonium salts, these final 4-C-alkyl products were stored as the more 
stable sodium salts.  For larger 4-C-alkyl groups, the less sterically demanding N,N-diethyl cyclic 
phosphoramidite was successfully employed to prepare fully protected 4-C-benzyl IP3.  During 
subsequent total deprotection this derivative proved easier to unblock than attempts to deprotect a 
related cyanethyl protected phosphate, followed by removal of the benzyl ethers.  The use of the 
cyclic phosphoramidite for the phosphorylation of 4-C-benzyl tetrol and 4-C-neopentyl tetrol 
seems promising, although more time is needed to optimise the purification of these fully protected 
derivatives. 
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5.5 Biological Results 
5.5.1 4-C-methyl IP3 as a substrate for IP3Rs 
Inositol triphosphate receptors (IP3R)s undergo a conformational change upon binding of 
IP3,
153 which is thought to result in opening of the ion channel, allowing release of Ca2+.  It was 
hoped that a small 4-C-alkyl group would cause a steric clash which would prevent conformational 
change in the tight binding site, thereby acting as an antagonist.  4-C-Methyl IP3, 195a, was tested 
by Geert Bultynck who performed in vitro assays to compare it to natural IP3 as a ligand for 
IP3Rs,
154 and therefore determine its ability to release Ca2+.  4-C-Methyl IP3 did release Ca
2+ from 
permeablised L15 cells, and a dose-response curve was measured, Figure 5.21. 
 
Figure 5.21: Experiments carried out by Geert Bultynck: A) A typical experiment in permeabilised L15 cells 
showing the fractional loss of 45Ca2+ with time. The black bar indicates the addition of IP3 or 4-C-methyl IP3 
(195a). Cells were treated with A23187 to estimate the maximal releasable 45Ca2+; B) Dose response for 
IP3R-dependent Ca
2+ release provoked by IP3 or 4-C-methyl IP3 (195a) in permeabilised L15 cells. Values 
were normalized to the A23187-releasable Ca2+. Data points were obtained from at least 3 independent 
experiments and are plotted as mean +/- standard error of the mean. EC50 values were obtained by sigmoidal 
curve fitting (Origin® 7.0). 
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The EC50 of 4-C-ethyl IP3 was 13.75 µM, compared to 1.06 µM for IP3.  Only 45 % of the 
available Ca2+ was released (calculated by comparision with the Ca2+ released by ionophore 
A23187).  This result was encouraging:  4-C-methyl IP3 was able to release Ca
2+
, suggesting that it 
bound to the IP3R, and therefore confirming that the natural chair conformation is occupied.  The 
release of a lesser percentage of the available Ca2+ than natural IP3 may also suggest that partial 
inhibition of these receptors is being observed, or that 4-C-methyl IP3 is selective for one of the 
three IP3R subtypes. 
Larger 4-C-alkyl groups will be tested using this assay in the future, and it is hoped that 
they may provide interesting results for probing this pathway. 
5.5.2 4-C-Methyl IP3, 4-C-methyl, -ethyl and -pentyl IP4 as substrates and inhibitors of 
synaptojanin 
The type II phosphatase synaptojanin can hydrolyse PtdIns(4,5)P2, PtdIns(3,4,5)P3, 
Ins(1,4,5)P3 and Ins(1,3,4,5)P4 and has attracted particular interest due to its possession of two 
phosphatase domains in one protein.155  Synaptojanin has both a central inositol 5-phosphatase 
domain and an N-terminal Sac1 homology domain, which hydrolyses the 3, 4 and 5-
monophosphates and PtdIns(3,5)P2.  Therefore it has the potential to generate PtdIns without the 
production of any intermediate monophosphates. 
4-C-Methyl IP3 (195a), 4-C-methyl (191a), -ethyl (191b) and -pentyl IP4 (191c) were tested 
by Jessica Knott as substrates, competitive and uncompetitive/allosteric inhibitors of synaptojanin.  
The four compounds were tested as substrates by direct addition to the synaptojanin construct, 
followed by addition of malachite green to determine the amount of free phosphate generated.  
Unfortunately 4-C-methyl and -pentyl IP4 191a and c appeared to contain too much free phosphate 
in the sample, and therefore were not measurable within the range of the assay.  Of the remaining 
4-C-methyl IP3 and 4-C-ethyl IP4, neither compound was a substrate for the 5-phosphatase domain, 
even at a high concentrations (400 µM), Figure 5.22 
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Figure 5.22: Testing 4-C-methyl IP3 and 4-C-ethyl IP4 as a substrate for synaptojanin 
In the inhibition assay, the hydrolysis of natural IP3 by synaptojanin was reduced by 50 % 
with a substrate concentration of KM, and by 25 % with a substrate concentration of Vmax, by 4-C-
ethyl IP4 191b which appeared to be acting as a competitive inhibitor, Figure 5.23. 
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Figure 5.23: Testing the inhibition of synaptojanin with 4-C-methyl IP3 and 4-C-ethyl IP4 
Therefore a dose response curve for 4-C-ethyl IP4 was measured which demonstrated that 
further increasing its concentration did not increase the inhibition of IP3 hydrolysis, Figure 5.24 
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Figure 5.24:  Dose-response curve for 4-C-ethyl IP4 
The dual-phosphatase domains of Synaptojanin make it complex to decipher its 
mechanisms of action and to study the effects of the individual domains in isolation.  Therefore 
selective inhibitors of one phosphatase domain are valuable.  The 4-C-ethyl IP4 was assayed with 5-
phosphatase dead and Sac dead mutants to establish if it was a specific inhibitor of just one of the 
phosphatase domains.  The 5-phosphatase dead mutant showed slightly higher activity than the 
control, suggesting that this phosphatase domain was not inhibited.  The Sac dead mutant showed 
50 % inhibition in the presence of 4-C-ethyl IP4 inhibitor, Figure 5.25. 
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Figure 5.25: Testing the inhibition of 4-C-ethyl IP4 on 5-phosphatase and Sac dead mutants  
Both experiments were carried out at Vmax concentrations of IP3.  This result suggests that 
4-C-ethyl IP4 may be a selective inhibitor of the synaptojanin 5-phosphatase domain.  This 
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compound may therefore be useful in the elucidation of the function of the Sac domain.  The results 
for the inhibition of the two isolated domains at [IP3] = KM are still pending. 
For the RLE project, it is not desired that the 4-C-alkyl IPn are turned over metabolically or 
act as competitive inhibitors of natural cellular proteins.  It is hoped that they will only interact with 
their complementary modified binding proteins.  The inhibition observed with synaptojanin only 
occurred at relatively high (µL) concentrations of 4-C-ethyl IP4 analogue 191b.  This suggests that 
as the size of the C-alkyl group increases, the modified ligand should become orthogonal to 
synaptojanin, and other natural proteins. 
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Chapter 6: 4-, 5- or 6-C-alkyl substituents from a common 
intermediate 
Chapters three to five of this thesis have focussed on the introduction of a 4-C-alkyl 
substituent and the subsequent protecting group manipulations, phosphorylation and deprotection 
required to generate a 4-C-alkyl inositol phosphate head group.  This position was chosen to allow 
rapid access to an isolated hydroxyl for manipulation.  The inositol head-group binds with the 
inositol ring roughly parallel to the protein surface, suggesting that any one of the 1-, 3-, 4-, 5- or 6-
H may point towards the binding pocket during binding to different types of receptor (see Figure 
1.13).  Ultimately, any one of these protons might need to be substituted by a C-alkyl group for a 
particular application.  Therefore, during the development of the 4-C-alkyl synthesis, it became 
apparent that a more divergent synthesis which permitted access to more than one ring position 
would be of great benefit. 
At first glance, this aim appears to require the sequential isolation of each hydroxyl, in 
order to introduce an alkyl group at that position.  Of the six inositol hydroxyls the 5-OH is the 
most difficult to isolate.  This is substantially due to its distance from the axial 2-OH, which 
directly modulates the reactivities of the neighbouring hydroxyls, but also distinguishes one face of 
the inositol ring from the other.  Therefore it may be anticipated that introducing a 5-C-alkyl would 
be particularly challenging.  It was postulated that by manipulation of the inositol hydroxyls’ 
stereochemistry, a C-alkyl group introduced at one location could effectively be manoeuvred 
around the ring by coordinated hydroxyl inversions to generate multiple C-alkyl groups from a 
common intermediate. 
This chapter is divided into three sections.  First, an introduction to the new strategy for 
generating 4-, 5- and 6-C-alkyl substituents, including a review of the literature which has led to 
this proposal.  Secondly, the results from a test system and initial application of this approach, 
generating a 2-C-alkyl group and further manipulations, are reported.  The final section looks at the 
prospects for this strategy and future work. 
6.1 A general method for the preparation of 4-, 5- and 6-C-alkyl 
substituents 
myo-Inositol has one axial hydroxyl.  If this hydroxyl is converted to an equatorial 
orientation, a scyllo-inositol framework is generated, with all 6 hydroxyls in an equatorial 
orientation.  If this is followed by one further inversion of a different equatorial hydroxyls’ 
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stereochemistry (potentially at any one of the ring carbons) the myo-geometry is regenerated but 
with the reference frame rotated, Figure 6.1. 
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Figure 6.1: Manipulation of the ring geometry via a scyllo-inositol by hydroxyl inversion and subsequent 
reintroduction of myo-geometry. 
Inversion of a hydroxyl could be carried out by oxidation of one ring position to the 
inosose, followed by stereospecific reduction.  The stereoselective conversion of a myo-inositol 
framework to scyllo-derivatives has been reported for inositol orthobenzoates, Figure 6.2.   
O
O
O
H
HO
OR
RO
O
O
O
H
RO
O
O
O
H
OR
RO
Swern NaBH4
HO
O
OR
3938a R = Ts
38b R = Bn
40a R = Ts, [87 %]68
40b R = Bn, [99 %]86
(2 steps)
MeMgI
O
O
O
H
OTs
TsO
HO
205 [74 %]87  
Figure 6.2: Reduction of inos-2-ose orthoester to generate scyllo-geometry products. 
Oxidation of the 2-OH to the inos-2-ose is widely reported70,82,88,89 (see chapter 2.3).  Both 
selective reduction with NaBH4,
70,89 and addition of MeMgI are reported90 to generate protected 
scyllo-inositols.  Both hydride and methyl delivery occurred stereoselectively to the top face of the 
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inosose, via an axial approach to the carbonyl.  The reintroduced hydroxyl is axial (N.B. equatorial 
once the orthoester is removed) corresponding to a scyllo-geometry framework. 
It has been demonstrated in chapter 3 that a wide variety of 4-C-alkyl substituents can be 
introduced by nucleophilic opening of the exo-methylene oxide.  Consequently, preparation of the 
inos-2-ose, conversion to the exo-methylene oxide, followed by ring opening with lithium alkyl 
cuprates, should permit access to the same range of 2-C-alkyl derivatives.  The proposed series of 
2-C-alkyl intermediates would be of scyllo-geometry resulting from delivery of methylene to the 
top face of the inosose, in the preparation of the exo-methylene oxide 207, Figure 6.3. 
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Figure 6.3: Introduction of a 2-C-alkyl and conversion to the 4,5-diol to manipulate ring stereochemistry 
To perform a second inversion of a stereocentre the protecting group regiochemistry of 
scyllo-inositol 207, must be manipulated.  It was anticipated that reduction of the orthoester would 
occur selectively at the 5-O (using DIBAL-H,104,106 see chapter 2.4) to generate the 1,3-O-
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benzylidene acetal due to the greater directing effect of the equatorial alkyl group than the 2-
alkoxyl groups of myo-inositol orthoesters.  Inversion of the resultant 5-hydroxyl would then 
regenerate a myo-inositol framework, but now with the C-alkyl substituent effectively migrated to 
the 5-C.  However, it was further hoped that more than one C-alkyl derivative could be accessed 
from one intermediate.  Removal of the 6-O protecting group R2 would permit the introduction of a 
bridging protective group, R3, such as Markiewicz.156  Removal of the 4-O protecting group R1 
would then generate the 4,5-diol 208 after DIBAL-H reduction.  This intermediate allows inversion 
of both the 4- and 5-hydroxyls.  Didehydroxylation of the 4,5-diol to an olefin simultaneously 
generates two sp2 centres, 209.157  It was expected that from this intermediate, concerted cis-
dihydroxylation could be carried out on either face of the double bond, by osmylation.158  
Furthermore removal of either of the bridging protecting groups would be expected to direct 
approach to the opposite face of the inositol ring preferred for steric reasons.  Concerted cis-
dihydroxylation on either face creates one axial and one equatorial hydroxyl restoring the myo-
geometry.  By removal of R3, it is postulated that concerted cis-dihydroxylation from the bottom 
face introduces diol 212 with the equatorial hydroxyl directly across the ring from the 2-C-alkyl, 
renumbering according to convention (see chapter 1.1), this would give a myo-inositol derivative 
with a 5-C-alkyl substituent.  Further manipulation of protecting groups is then required before 
phosphorylation to produce the 5-C-alkyl tri- and tetraphosphates.  Alternatively if the benzylidene 
is hydrolysed (see chapter 4.6), osmylation from the top face will introduce a 5-O-equatorial 
hydroxyl to generate diol 213.  Again further manipulation of the protecting groups is required at 
this stage to generate the protected intermediates for phosphorylation and global deprotection of the 
required hydroxyls to furnish 4-C-alkyl IP3 and IP4 analogues. 
Unlike the 4-C-alkyl intermediates prepared in chapter 3, this synthesis requires different 
protecting groups on the 4- and 6-O, to allow selective introduction of a bridging group on the 
opposite face to the orthoester.  One of these groups is required to be removed selectively in the 
presence of the other.  The introduction of various protecting groups on the 2-, 4- and 6-O was 
reviewed in chapter 2.2, and it is clear that sequential introduction of ether groups by use of sodium 
hydride or butyl lithium to effect selective axial protections should be possible.   
Since, the introduction of a 2-C-alkyl substituent and selective reduction of the orthoester 
to a benzylidene acetal do not require differential protection of the 4- and 6-O, a test system was 
employed to confirm that selective introduction of methylene to the inos-2-ose generated the exo-
methylene oxide with scyllo-geometry.  The model system was also used to test selective DIBAL-
H reduction of the 2-O-alkyl orthobenzoate.  It was hoped that selective opening at the 5-O would 
be observed to generate the 1,3-O-benzylidene acetal. 
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6.2 A test system for 2-C-alkyl delivery and DIBAL-H reduction 
4,6-O-Dibenzyl myo-inositol orthobenzoate,159 214, was prepared as a test system for 
alkylation and reduction of the orthobenzoate, Figure 6.4. 
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Figure 6.4: Preparation of 4,6-O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoate 
It was hoped that 214 would be easily prepared in two steps from myo-inositol 1.  
Unfortunately, despite the reported preference for symmetrical diaxial 4,6-O-dibenzylation over 
2,6-O-dibenzylation with sodium hydride,159 poor yields of the symmetrical product were obtained 
for direct benzylation of myo-inositol 1,3,5-O-orthobenzoate 22d.  Following addition of 2.3 eq. 
butyl lithium and equilibration at room temperature, desired 214 was obtained in only 13 % yield 
on addition of benzyl bromide, along with unreacted starting material and unwanted 2,4,6-O-
tribenzyl ether (13 %) resulting from further deprotonation of the 2-OH.  As an alternative route, 
mono-benzyl ether 215 was prepared in almost quantitative yield by deprotonation of the 4-OH 
with 1 eq. sodium hydride followed by addition of benzyl bromide.  However, attempts to effect 
benzylation of the second axial 6-OH using butyl lithium and benzyl bromide, only returned 
desired dibenzyl ether 214 in 41 % yield, alongside a small amount of the 2,4,6-O-tribenzyl ether 
(6 %).  The high (89 %) yield reported by Devaraj et al.160 resulting from chelation of lithium in the 
di-axial 4,6-dioxa-pocket was not replicated, although they also report formation of 5-10 % of tri-
O-substituted derivatives.  These yields were not optimised.  Subsequently, 4,6-O-dibenzyl 
orthobenzoate 214 was oxidised using Dess Martin periodinane to generate inos-2-ose 216, Figure 
6.5. 
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Figure 6.5: Oxidation of the 2-OH to the inosose and hydration to the gem-diol 
As reported88,91 the inos-2-ose had a tendency to hydrate, forming the gem-diol 217; this 
had not been observed with the inos-4-ose prepared in chapter 3.  The inos-2-ose was dried over 
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activated molecular sieves and repeatedly evaporated from dry MeCN to dehydrate any gem-diol 
before use in further steps.  Upon addition of methyl Grignard to inosose 216 at -78 ºC, selective 
methyl delivery to the top face of the inosose generated 2-C-methyl-scyllo-inositol 1,3,5-O-
orthobenzoate 218, Figure 6.6. 
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Figure 6.6: Preparation of 2-C-methyl by addition of MeMgBr to the inos-2-ose, or by conversion to the exo-
methylene oxide followed by reduction with LiAlH4 
The stereochemistry of methyl addition was confirmed by NOESY in the later DIBAL-H 
reduction of the orthoester.  In order to verify that methylene insertion also occurred by delivery to 
the top face of the inos-2-ose, exo-methylene oxide 219 was prepared.  Addition of 
dimethylsulfoxonium methylide to inosose 216 generated one exo-methylene oxide product, 219, 
the stereochemistry of which was confirmed by reduction with LiAlH4 to 2-C-methyl 
orthobenzoate 218, Figure 6.6. 
Upon treatment of 218 with 3 eq. DIBAL-H two products were observed, although the 
reaction did not go to completion.  Isolation of the two products by chromatography demonstrated 
that only one benzylidene acetal was present, alongside the 2,3,5-triol 221 resulting from a second 
hydride delivery to the orthobenzoate.  Triol 221 had a clear cross-peak between the 2-CH3 and 
both the 4- and 6-H in the NOESY spectrum, confirming that scyllo-geometry had resulted from 
methyl addition.  The ratio of compounds as judged by 1H-NMR of the crude was 3:2:1 (starting 
material-acetal-triol), Figure 6.7. 
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Figure 6.7: Reduction of 2-C-methyl orthobenzoate with limited DIBAL-H 
Benzylidene acetal 220 was symmetrical, confirming that the expected regioselective 
hydride insertion had occurred to the 5-O-C bond.  This result suggests that the benzylidene acetal 
generated is not significantly more stable than the orthobenzoate towards DIBAL-H reduction.  It 
has been postulated in chapter 4 that the steric effect of the methyl group may not be very large 
(compared to e.g. a benzyl ether or larger C-alkyl group).  Therefore it is hoped that with larger 2-
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C-alkyl substituents, the tendency for over-reduction would be reduced, as was observed for the 
larger 4-C-alkyl compounds in chapter 4.5. 
6.3 Orthogonal protection of the 4- and 6-O 
The test system demonstrated that 2-C-alkyl introduction via an exo-methylene oxide  
selectively generates a scyllo-inositol intermediate and that DIBAL-H reduction could prepare (in 
moderate yield) the desired 1,3-O-benzylidene acetal.  The subsequent manipulations required 
protection of the 4- and 6-OH with two different groups.  Therefore 4-O-allyl-6-O-p-
methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate 222 was prepared in three steps, from myo-
inositol, Figure 6.8. 
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Figure 6.8: Preparation of orthogonally protected 4-O-allyl-6-O-Pmb-myo-inositol 1,3,5-O-orthoformate. 
4-O-Allyl 92 was prepared as described in section 2.6.  Subsequent addition of sodium 
hydride followed by p-methoxybenzyl chloride generated 222 in low (35 %) yield, unoptimised.  
2,6-O-Di(p-methoxybenzyl)-4-O-allyl-myo-inositol 1,3,5-O-orthoformate 224 (10 %) and 
unreacted 92 (11 %) were also isolated upon purification.  None of the possible 2-O-(p-
methoxybenzyl) side product was observed, suggesting that deprotonation with sodium hydride 
occurred preferentially at the 6-OH.  The selective removal of the 4-O-allyl protecting group was 
demonstrated by addition of 4-methyl morpholine N-oxide and OsO4 followed by NaIO4 to 
generate 223.161  Oxidation of 222 with Dess Martin periodinane quantatively generated the inos-2-
ose 225, Figure 6.9. 
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Figure 6.9: Oxidation of 222 to the inos-2-ose followed by stereoselective introduction of a 2-C-methyl 
substituent via exo-methylene oxide 226. 
Inos-2-ose 225 was selectively converted to the scyllo-inositol exo-methylene oxide, 226, 
by addition of dimethylsulfoxonium methylide.  Subsequent reduction with 2 eq. LiAlH4 afforded 
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2-C-methyl scyllo-inositol 227.  Prolonged treatment of 227 with 6 eq. LiAlH4 led to the formation 
of a lower Rf side product, isolated and identified as 228, the product of reductive cleavage of the 
4-O-allyl ether (51 %).  Alternatively, the 4-O-allyl ether could be selectively removed in the 
presence of the 6-O-Pmb ether, by oxidation of the double bond to the diol using OsO4, followed 
by treatment with NaIO4.
161  The majority of the resultant formate ester was cleaved during work 
up to generate 228, and the remaining portion was treated with triethylamine in ethanol to remove 
the formate ester, Figure 6.10. 
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Figure 6.10: Removal of the 4-O-allyl followed by attempted introduction of a 1,3-diaxial bridging group 
The apparent reductive removal of the allyl group with LiAlH4 was unexpected, and it is 
not understood why this group was selectively cleaved in the presence of the Pmb group.  This 
demonstrated that the 4-O-allyl ether could be removed either simultaneously with reduction of the 
exo-methylene oxide, or as a separate step.  For larger 2-C-alkyl groups, where LiAlH4 reduction is 
not required, the 4-O-allyl could be removed by either set of conditions, providing synthetic 
flexibility. 
A bridging protective group was then required for 2,4-diol 228 for which Markiewicz 
reagent (1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane)156 was selected as it is known to react with 
1,3-diols to give an 8-membered ring.  Upon addition of Markiewicz to 2,4-diol 228, a single 
product was observed, 230.  It was confirmed by MS and subsequent acylation of the free 2-OH 
that the cyclisation of the Markiewicz reagent to the tertiary 2-OH to prepare the desired 230 had 
not occurred.  This reaction has not yet been thoroughly explored and it may be possible to force it 
to completion or to employ an alternative bridging protecting group. 
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6.4 Concluding Remarks 
The lessons learnt from the 4-C-alkyl system have been successfully applied to this more 
elaborate synthetic route.  The test system, and subsequent reactions on the orthogonally protected 
inos-2-ose 223 have demonstrated the introduction of a 2-C-methyl in the preparation of 225 both 
directly from the inosose and via key exo-methylene oxide 224.  It is anticipated that this exo-
methylene oxide can be opened with larger alkyl substituents in the same way as amply 
demonstrated for 4-C-exo-methylene oxide 98 in chapter 3, to create a range of 2-C-alkyl 
inositides.  It has also been demonstrated that the 4-O-allyl ether can be selectively cleaved in the 
presence of the 6-O-Pmb ether, orthoester and 2-C-methyl substituent to generate a diol with free 
2- and 4-OH.  Initial unsuccessful attempts to introduce the bridging Markiewicz protecting group 
need further investigation.  However, following the experiments on the test system it is expected 
that the resulting scyllo-inositol intermediate 230 will undergo regiocontrolled DIBAL-H insertion 
at the 5-O-C bond.  The elimination and reintroduction of the 4,5-diol still need to be probed to 
confirm that they occur selectively as predicted.  The subsequent steps after reintroduction of myo-
stereochemistry involve protecting group manipulations, phosphorylation and deprotection.  It is 
expected that these steps will proceed in a similar manner to the 4-C-alkyl system in the preceding 
chapters to prepare the final C-alkyl inositol phosphate analogues. 
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Conclusions 
The aim of this thesis was to prepare 4-C-alkyl inositol phosphates.  This has been 
successfully achieved and a small library of both 4-C-alkyl Ins(1,4,5)P3 and 4-C-alkyl 
Ins(1,3,4,5)P4 analogues have been prepared.  The preparation of C-alkyl analogues for use in RLE 
is therefore certainly feasable.  At each stage of the synthesis, the chemical limitations have been 
explored, and these were evaluated in the concluding remarks at the end of each chapter. 
A wide range of 4-C-alkyl groups were introduced by nucleophilic opening of the exo-
methylene oxide using alkyl lithium cuprates in chapter three to generate a series of 4-C-alkyl-2,6-
O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoates.  It has been proven that it is possible to introduce 
large alkyl and aryl substituents including 4-C-benzyl and -(2-naphthyl)methyl groups.  The 1,3,5-
O-orthobenzoate was manipulated in chapter four using either acidic hydrolysis or reduction with 
DIBAL-H to selectively reveal the hydroxyls required for phosphorylation, generating 4-C-alkyl 
triols and tetrols.  Tri- or tetraphosphorylation was then carried out in chapter five using P(III) 
phosphoramidites with subsequent oxidation using mCPBA.  Global deprotection of benzyl groups 
then furnished the final target compounds.  Time did not permit the phosphorylation of all 4-C-
alkyl derivatives.  However, the successful phosphorylation of 4-C-benzyl IP3 and IP4 
demonstrated that phosphorylation of hindered tertiary centres is possible with a less sterically 
demanding P(III) phosphoramidite.  The limitation of the methods developed here may be 
phosphorylation of β-tertiary centres such as the 4-C-neopentyl substituent.  However, such bulky 
groups may be more amenable to phosphorylation if a larger alkyl spacer was placed between the 
bulky substituent and the inositol ring. 
The initial investigations to introduce a C-alkyl substituent on a wider variety of positions 
in chapter six, demonstrated that preparation of an exo-methylene oxide and subsequent 
nucleophilic opening can be applied to other positions on the inositol ring.  Although further work 
is required to reintroduce the myo-geometry, the generation of multiple C-alkyl derivatives from a 
common intermediate appeared promising. 
A new class of IPn head group has been prepared in this thesis.  These analogues have a 
wide range of potential applications.  An exo-methylene oxide at any position on the ring could be 
opened with a wide range of nucleophiles, to introduce a vast array of functionalities.  Cross-
linkers, fluorescent markers and probes could be introduced on the carbon backbone using this 
method, rather than as has been reported on the inositol hydroxyls.56  Addition of these species to 
the carbon framework will not impact the coulombic and H-bonding interactions as the phosphate 
and hydroxyl groups are left in tact.  If the 3-, 4- and 5-C are most suitable for addition of steric 
Conclusions 
 
 
 
- 124 - 
protrusions, the 2- and 6-C may be suited to introduction of additional functionalities such as 
fluorescent markers without impinging on binding affinity. 
The smaller 4-C-alkyl IP3 and IP4 derivatives which have been prepared in this thesis, are 
not expected to be suitable for RLE applications, as the alkyl groups would be insufficiently large 
to prevent binding to the WT protein.   However, there are alternative uses for these compounds.  
As research into phosphoinositide biology expands, small molecules which differ only slightly 
from the natural ligands are potential selective agonists or antagonists for their WT protein binding 
sites.  The reduced Ca2+ release observed from the interaction of IP3Rs with 4-C-methyl IP3, 
suggests that alternative small 4-C-alkyl IP3s may act as antagonists which could bind to the IP3Rs 
and prevent Ca2+ release.  The experimentally determined selective inhibition of the 5-phosphatase 
domain of synaptojanin with 4-C-ethyl IP4, also suggests that the smaller 4-C-alkyl analogues may 
be useful probles for elucidating the mechanism of action of this double phosphatase.  These are 
only the results from two initial experiments and there may be many more applications in the future 
for this series of compounds.  
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Outlook 
Following the work presented in this thesis, it cannot be denied that the preparation of a C-
substituted IPn is certainly possible.  There are still areas which require further investigation, to 
ensure the successful preparation of any C-alkyl substituent. 
Continued study of the general approach in chapter six towards the preparation of 4-, 5- 
and 6-C alkyl substituents would generate a wide variety of C-alkyl-IPns.  This would provide three 
new sites for the introduction of substituents for biological studies and prove the generalisability of 
C-alkyl introduction, phosphorylation and deprotection. 
Time did not permit a full investigation of the reaction of less sterically demanding cyclic 
phosphoramidite, N,N-diethylamino-5,6-benzo-1,3,2-dioxaphosphepane with larger C-alkyl triols 
or tetrols.  There are alternative reagents which could be employed to effect this transformation, 
such as the phosphorochloridites.  Di(2-cyanoethyl)phosphorochloridite did successfully 
phosphorylate 4-C-benzyl tetrol and this may be a more reactive reagent for phosphitylating 
hindered tertiary hydroxyls.  However, the conditions for the two step deprotection of the 
phosphate cyanoethyl and hydroxyl benzyl ether groups would need to be resolved.  The choice of 
hydrogenation catalyst, and perhaps the use of a homogenious catalyst may improve the 
deprotection of the final 2- and 6-O-benzyl ethers. 
The range of C-substituents is not limited to alkyl and aryl groups.  Other nucleophiles 
could be used to open the exo-methylene oxide to generate for example O- or N-linked alkyl 
groups.  Furthermore, C-alkyl or aryl substituents could be manipulated after they are introduced, 
for example the proposed route to 4-C-alkyl IP4 analogues suitable for ion-pair exchange RLE from 
4-C-[3-phenyl(prop-2-enyl)] at the end of chapter three.  A considerable amount of time could have 
been spent in the introduction of such groups.  However, this was beyond the scope this project.  
Now that the chemistry is in place to reach the final targets, such alternative ‘bumps’ could be 
explored. 
The ultimate targets for RLE protein-ligand binding pairs are the full PIPn lipids, and this 
will require a synthetic strategy which differentiates between the 1-O and remaining positions 
requiring phosphorylation, in order to introduce the phosphatidate group.  They will also require a 
resolution step at some stage in the synthesis, for example by preparation and separation of the 
camphanate esters73 of the 2,6-O-dibenzyl orthoester as the species prepared in this thesis are 
racemic.  Both these challenges have been overcome in the reported chiral syntheses of PIPn
145 and 
therefore should be readily applied to the 4-C-alkyl analogue synthesis reported here. 
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Chapter 7: Experimental 
The experimental details for the compounds prepared in this thesis are divided by chapter 
(three to six), and ordered sequentially by number within each chapter.  Side products are included 
alongside the main reaction from which they were generated.  A number of preparation methods 
were developed and used to effect a series of transformations.  To prevent repetition, these have 
been included in section 7.2, entitled General Methods, before the main experimental sections 7.3-
7.6. 
7.1 General Experimental and spectroscopic methods 
All reactions were conducted at room temperature in dry glassware under an atmosphere of 
nitrogen unless otherwise stated.  All chemicals were used directly from the supplier’s vessel 
unless otherwise stated.  Reagents were purchased from Sigma-Aldrich Ltd or Acros Organics.  All 
evaporation of organic solvents was carried out using a water-cooled Buchi rotary evaporator.  
Solvents were distilled before use, after drying over a suitable reagent, and stored under nitrogen in 
sealed containers over 4 Å molecular sieves. 
1H-NMR spectra were recorded on Bruker AC-270, AV-400 or AV-500 spectrometers. 
Chemical shifts (δ) are quoted in parts per million (ppm) relative to an internal solvent standard.  
The splitting patterns for 1H-NMR spectra are denoted as follows; s (singlet), d (doublet), t (triplet), 
q (quartet), m (multiplet), b (broad) and combinations thereof.  Coupling constants (J) are quoted in 
Hertz (Hz).  13C-NMR spectra were recorded at 100 or 125MHz.  Chemical shifts are again given 
in parts per million.  Peaks are assigned as C (quaternary), CH (tertiary), CH2 (secondary) and CH3 
(primary).  Assignments were made with the aid of DEPT90 and 135, HSQC, COSY and NOESY 
experiments.  13C and 31P-NMR are proton decoupled.  Mass spectra were recorded on a VG 
AutoSpec-Q (CI) or a Micromass LCT Premier (ESI) spectrometer.  Infra-red spectra were 
recorded on KBr disks as solutions in CH2Cl2.  Analytical TLC was carried out on Merck silica gel 
60 F254 glass-backed plates.  Plates were visualised using UV light or developed using potassium 
permanganate (KMnO4).  Flash chromatography was carried out using flash silica from Merck. 
7.2 General Methods 
General method 1: Synthesis of 2,6-O-dibenzyl-4-C-alkyl-myo-inositol 1,3,5-O-orthobenzoates 
using alkyl lithium cuprates. 
CuCN (4.0 mmol) was evaporated from toluene (3 × 2 mL), taken up in ether (5 mL) and 
cooled to -78 ºC.  Alkyl lithium (8.0 mmol) was added dropwise to the stirred suspension which 
turned pale yellow.  In a separate vessel, 2,6-O-dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-
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O-orthobenzoate (1.0 mmol) was azeotroped with toluene (3 × 2 mL), taken up in ether (5 mL) and 
cooled to -78 ºC.  The methylidene solution was added slowly to the alkyl lithium cuprate solution 
and stirred for 4 h, at -78 ºC, or until complete as judged by TLC visualised with KMnO4 stain.  
Excess reagent was quenched with NH4Cl-NH4 (9:1 v/v, 10 mL) and the two-phase solution stirred 
for a further 30 min before addition of brine (5 mL).  The aqueous phase was washed with ether (3 
× 50 mL) and the combined organic layers dried (MgSO4) and evaporated to dryness under reduced 
pressure.   
General method 2: Total reduction of myo-inositol orthobenzoates with DIBAL-H. 
The myo-inositol 1,3,5-O-orthobenzoate (0.50 mmol) was evaporated from toluene (3 × 2 
mL), taken up in CH2Cl2 (5 mL) and cooled to -78 °C.  DIBAL-H (0.7 M in hexanes, 1.75 mmol) 
was added drop-wise, the solution warmed to rt over 3 h and stirred for 24 h. The reaction was 
quenched by drop-wise addition of H2O (25 mL) and extracted with CH2Cl2 (4 × 100 mL).  The 
combined organic layers were washed with H2O (50 mL) and brine (50 mL), dried (MgSO4), 
filtered and evaporated to dryness under reduced pressure.   
General method 3: Reduction of the 4-C-alkyl orthobenzoates using excess DIBAL-H. 
2,6-O-Dibenzyl-4-C-alkyl-myo-inositol 1,3,5-O-orthobenzoate (0.21 mmol) was 
evaporated from MeCN (3 × 1 mL), taken up in CH2Cl2 (1 mL) and cooled to -78 ºC.  DIBAL-H 
(1.0 M solution in hexanes, 0.84 mmol) was added drop-wise at -78 ºC.  The solution was allowed 
to warm to rt over 2 h.  The reaction was monitored by TLC (EtOAc-hexane, 3:7 v/v) and 
quenched by drop-wise addition of H2O (5 mL) when all starting material was consumed.  The 
product was taken up in CH2Cl2 (10 mL), and separated from the aqueous layer, which was 
subsequently washed with CH2Cl2 (3 × 10 mL).  The combined organic layers were washed with 
sat. NaHCO3, and then brine.  The organic layer was dried (MgSO4) and all solvents evaporated 
under reduced pressure. 
General method 4: Acidic hydrolysis of orthobenzoate to mixture of benzoyls 
2,6-O-Dibenzyl-4-C-alkyl-myo-inositol 1,3,5-O-orthobenzoate (0.2 mmol) was taken up in 
conc. HCl-(propan-1-ol) (1:2 v/v, 3 mL) and refluxed for 3 h.  The solution was cooled, neutralised 
with sat. NaHCO3 and the products extracted into EtOAc (× 2).  The combined organic layers were 
washed with H2O then brine, dried (MgSO4) and all solvents evaporated under reduced pressure. 
General method 5: Removal of benzoyls under basic conditions to yield the 4-C-alkyl tetrol 
The crude mixture of benzoyls (0.2 mmol) was evaporated from MeCN (3 × 1 mL) and 
taken up in MeOH (2 mL).  After addition of NaOMe (25% solution in MeOH, 0.15 mL, 0.1 
mmol) the solution was heated to reflux for 3 h.  The resulting solution was cooled, neutralised by 
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drop-wise addition of 4 M HCl and all solvents removed under reduced pressure.  The crude 
material was taken up in dry MeOH and the salts removed by filtration under gravity.  The mother 
liquor was evaporated to dryness under reduced pressure. 
General method 6: Phosphorylation of triols using N,N-diisopropyldibenzyl phosphoramidite 
2,3,6-O-Tribenzyl-4-C-alkyl-myo-inositol (0.1 mmol) and 1-H-tetrazole (1.2 mmol) were 
evaporated from MeCN (3 × 2 mL), taken up in MeCN (5 mL) and N,N-diisopropyldibenzyl 
phosphoramidite (0.6 mmol) added.  After 2 h the solution was cooled to -40 ºC and mCPBA (0.7 
mmol) added.  Stirring was continued at 0 ºC for 2 h.  The solution was diluted with CH2Cl2, 
washed with 10 % aq. Na2S2O3, sat. NaHCO3, H2O and brine.  The organic layer was dried 
(MgSO4) and evaporated to dryness under reduced pressure.  The crude material was stirred with 1 
M I2 in pyridine-H2O-THF (2:1:7 v/v, 3 mL) for 15 mins before dilution with H2O and CHCl3. 
Na2S2O3 was added to the vigourously stirred solution until both layers were clear in colour.  The 
organic layer was washed with sat. NaHCO3, then HCl (0.4 M), dried (MgSO4) and all solvents 
evaporated under reduced pressure. 
General method 7: Phosphorylation of tetrols using N,N-diisopropyldibenzyl 
phosphoramidite 
2,6-O-Dibenzyl-4-C-alkyl-myo-inositol (0.1 mmol) and 1-H-tetrazole (1.4 mmol) were 
evaporated from MeCN (3 × 2 mL), taken up in MeCN (5 mL) and N,N-diisopropyldibenzyl 
phosphoramidite (0.7 mmol) added.  After 2 h the solution was cooled to -40 ºC and mCPBA (1.4 
mmol) added.  Stirring was continued at 0 ºC for 2 h.  The solution was diluted with CH2Cl2, 
washed with 10 % aq. Na2S2O3, sat. NaHCO3, H2O and brine.  The organic layer was dried 
(MgSO4) and evaporated to dryness under reduced pressure.  The crude material was stirred with 1 
M I2 in pyridine-H2O-THF (2:1:7 v/v, 3 mL) for 15 mins before dilution with H2O and CHCl3. 
Na2S2O3 was added to the vigourously stirred solution until both layers were clear in colour.  The 
organic layer was washed with sat. NaHCO3, then HCl (0.4 M), dried (MgSO4) and all solvents 
evaporated under reduced pressure. 
General method 8: Phosphorylation of tetrols using N,N-diethylamino-5,6-benzo-1,3,2-
dioxaphosphepane 
2,6-O-Dibenzyl-4-C-alkyl-myo-inositol (0.1 mmol) and 1-H-tetrazole (1.4 mmol) were 
evaporated from MeCN (3 × 2 mL), taken up in MeCN (1 mL) and placed in a water bath at 25 ºC.  
N,N-diethylamino-5,6-benzo-1,3,2-dioxaphosphepane121 (0.9 mmol) was added in one batch.  After 
2 h the solution was cooled to 0 ºC and mCPBA (1.4 mmol) added.  Stirring was continued at 0 ºC 
for 2 h.  The solution was diluted with CH2Cl2, washed with 10 % aq. Na2S2O3, sat. NaHCO3, H2O 
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and brine.  The organic layer was dried (MgSO4) and evaporated to dryness under reduced 
pressure. 
General method 9: Global deprotection of benzyl groups using H2 and Pd(black): IP3 
precursors  
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-alkyl-myo-inositol (0.05 
mmol) was taken up in tBuOH-H2O (6:1 v/v, 6 mL) to which was added NaHCO3 (0.41 mmol) and 
Pd-black (1.03 mmol).  The solution was stirred under an atmosphere of H2 for 36 h.  The catalyst 
was filtered off, washed with H2O (4 × 10 mL) and the mother liquor concentrated under reduced 
pressure, before being taken up in H2O, washed with CH2Cl2 (× 2) and freeze dried. 
General method 10: Global deprotection of benzyl groups using H2 and Pd(black): IP4 
precursors  
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-alkyl-myo-inositol (0.25 
mmol) was taken up in tBuOH-H2O (6:1 v/v, 54 mL) to which was added NaHCO3 (1.98 mmol) 
and Pd-black (4.95 mmol).  The solution was stirred under an atmosphere of H2 for 36 h.  The 
catalyst was filtered off, washed with H2O (4 × 10 mL) and the filtrate concentrated under reduced 
pressure.  The remaining solution was taken up in H2O, washed with CH2Cl2 (× 2) and freeze dried.  
The powdery solid was redissolved in the minimum volume of H2O and passed through DOWEX 
50WX8-200 H+ resin.  Acidic fractions of eluent were combined, neutralised with aq. NH3 and 
freeze dried. 
7.3 Chapter 3 
2,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (95) 
O
O
O
Ph
BnO
OH
BnO
 
2,6-O-Dibenzyl-inos-4-ose 1,3,5-O-orthobenzoate (96, 100 mg, 0.22 mmol) was 
evaporated from MeCN (1 mL × 3) and taken up in diethyl ether (1 mL).  The solution was cooled 
to -78°C, ethylmagnesium bromide (1.0 M solution in THF, 0.27 mL, 0.27 mmol) was added drop-
wise and the reaction stirred for 30 min before warming to rt.  After 2 h the reaction was quenched 
by drop-wise addition of H2O (2 mL) and the product extracted into CH2Cl2.  The organic layer was 
washed with HCl (0.1 M ×2), sat. NaHCO3, H2O and brine, then dried (MgSO4) and evaporated to 
dryness under reduced pressure.  The title compound (95, 100 mg, 99 %) was obtained as a pale 
yellow oil; Rf (EtOAc-hexane, 1:4 v/v) 0.16; δH
 (400 MHz, CDCl3) 7.66-7.19 (15H, m, 15 × Ar H), 
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4.80 (1H, d, J 12.5), 4.68 (1H, d, J 12.4) (2 × OCHHPh), 4.58-4.53 [4H, m, (2 × Ins H) + 
OCH2Ph], 4.50-4.47 (2H, m), 4.40-4.38 (1H, m), 3.94-3.93 (1H, m) (4 × Ins H), 3.63 (1H, bs, Ins 
4-OH) ppm; δC (125 MHz, CDCl3) 137.81, 136.79, 135.93 (3 × Ar C), 129.46, 128.84 (2C), 
128.75, 128.53 (2C), 128.11 (2C), 127.93 (5C), 125.37 (2C) (15 × Ar CH), 107.32 (PhCO3), 74.46, 
73.41 (2 × Ins CH), 72.96 (OCH2Ph), 71.29 (Ins CH), 70.99 (OCH2Ph), 68.67, 67.94, 65.07 (3 × 
Ins CH) ppm; HRMS (ESI+) m/z (%) found [M+H]+ 447.1793 (100), C27H27O6 requires 447.1808. 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98) 
O
O
O
Ph
BnO
O
BnO
 
To a clear solution of trimethylsulfoxonium iodide (109 mg, 0.49 mmol) in DMSO (1 mL) 
was added NaH (60 % dispersion in mineral oil, 21 mg, 0.54 mmol) and the mixture stirred for 40 
min.  2,6-O-Dibenzyl-inos-4-ose 1,3,5-O-orthobenzoate (96, 200 mg, 0.45 mmol) was evaporated 
from MeCN (1 mL × 3), taken up in THF (1 mL) and added to the reaction mixture, which was 
stirred at rt for 1 h.  The reaction was quenched by drop-wise addition of H2O (2 mL) and the 
product taken up in CH2Cl2.  The organic layer was washed with sat. NaHCO3, H2O, then brine, 
dried (MgSO4) and evaporated to dryness under reduced pressure.  The crude material was 
fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 2:5 v/v) 
afforded the title compound (98, 184 mg, 89 %) as a clear oil; Rf (EtOAc- hexane, 1:1 v/v) 0.70; δH 
(400 MHz, CDCl3) 7.68-7.26 (15H, m, 15 × Ar H), 4.75 (1H, d, J 12.2), 4.70 (1H, d, J 12.1), 4.68 
(1H, d, J 11.8) (3 × OCHHPh), 4.55 (1H, dq, J 4.2, 2.0, Ins 1-H), 4.53 (1H, d, J 11.9, OCHHPh),  
4.42 (1H, t, J 3.8 Ins 6-H), 4.03 (1H, t, J 1.7 Ins 2-H), 3.95-3.94 (2H, m, Ins 3-H + Ins 5-H), 2.95 
(1H, d, J 4.7), 2.93 (1H, d, J 4.7) (2 × Ins 4-CCHH) ppm; δC (100 MHz, CDCl3) 137.76, 137.25, 
136.74 (3 × Ar C), 129.55, 128.56 (2C), 128.46 (2C), 128.10, 127.99 (2C), 127.84 (3C), 127.79 
(2C), 125.41 (2C) (15 × Ar CH), 108.14 (PhCO3), 74.85, 72.50, 72.34, 71.55 (4 × Ins CH), 71.46, 
71.25 (2 × OCH2Ph), 68.29 (Ins CH), 54.92 (Ins C), 51.01 (Ins 4-CCHH) ppm; MS (ESI
+) m/z (%) 
found [M+H]+ 459 (62), [M+Na]+ 481 (100); HRMS (ESI+) found [M+H]+ 459.1800, C28H27O6 
requires 459.1808. 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol-1,3,5-O-orthobenzoate (115)
130 
O
O
O
Ph
BnO
OH
BnO
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By addition of MeMgBr to the inos-4-ose.  2,6-O-Dibenzyl-inos-4-ose 1,3,5-O-
orthobenzoate (96, 100 mg, 0.225 mmol) was evaporated from MeCN (1 mL × 3), taken up in 
diethyl ether (1 mL) and the solution cooled to -78 °C.  Methylmagnesium bromide (3.0 M solution 
in diethyl ether, 90 µL, 0.27 mmol) was added drop-wise and the solution stirred for 20 min before 
warming to rt.  After 2 h the reaction was quenched by drop-wise addition of H2O (2 mL).  The 
crude product was extracted into CH2Cl2, washed with 0.1 M HCl, sat. NaHCO3 and brine, dried 
(MgSO4) and evaporated to dryness under reduced pressure.  The crude material was fractionated 
by chromatography on flash silica. Elution with ether-hexane (0:1 → 3:10 v/v) afforded the title 
compound (115, 66 mg, 64 %) as a clear oil. 
By reduction of the exo-methylene oxide.  2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-
inositol 1,3,5-O-orthobenzoate (98, 150 mg, 0.33 mmol) was evaporated from MeCN (1 mL × 3), 
taken up in ether (2 mL) and added drop-wise to a suspension of LiAlH4 (86 mg, 2.26 mmol) in 
ether (1 mL).  After 45 min the reaction was quenched by drop-wise addition of EtOAc.  The 
resulting solution was diluted with ether and washed with HCl (0.5 M, 10 mL, × 2), sat. NaHCO3, 
H2O and then brine.  The organic layer was dried (MgSO4) and all solvents evaporated under 
reduced pressure to afford the title compound (115, 70 mg, 46 %) as a clear oil:  Rf (hexane-ether, 
3:7 v/v) 0.70; δH (400 MHz, CDCl3) 7.65-7.20 (15H, m, 15 × Ar H), 4.80 (1H, d, J 12.5), 4.66 (1H, 
d, J 12.5), 4.60 (1H, d, J 11.6), 4.55 (1H, d, J 11.6) (4 × OCHHPh), 4.50 (1H, t, J 3.9, Ins 6-H), 
4.44 (1H, dq, J 3.6, 1.7, Ins 1-H), 4.29 (1H, s, Ins 4-OH), 4.17 (1H, q, J 3.7, 1.8, Ins 3-H), 4.02 
(1H, dt, J 3.8, 1.9, Ins 5-H), 3.99 (1H, t, J 1.8, Ins 2-H), 1.64 (3H, s, Ins 4-CH3) ppm; δC (100 
MHz, CDCl3) 137.89, 136.94, 135.87 (3 × Ar C), 129.44, 128.84 (2C), 128.75, 128.51 (2C), 128.10 
(2C), 127.98 (2C), 127.93 (3C), 127.88, 125.35 (15 × Ar CH), 107.31 (PhCO3), 77.29, 74.70 (2 × 
Ins CH), 72.96 (OCH2Ph), 72.89 (Ins CH), 71.04 (OCH2Ph), 70.66 (Ins CH), 69.58 (Ins C), 66.22 
(Ins CH), 24.27 (Ins 4-CH3) ppm; MS (CI
+) m/z (%) found [M+H]+ 461 (100), [M+Na]+ 483 (93); 
HRMS (ESI+) found 461.1959 (100), C28H29O6 requires 461.1964. 
2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 1,3,5-O-orthobenzoate (125) 
O
O
O
Ph
BnO
OH
BnO
 
By addition of benzyl magnesium chloride to the inosose.  2,6-O-Dibenzyl-inos-4-ose 
1,3,5-O-orthobenzoate (96, 105 mg, 0.24 mmol) was evaporated from toluene (3 × 1 mL), taken up 
in ether (1 mL) and cooled to -78 ºC.  In a separate vessel, to magnesium turnings (32 mg, 1.33 
mmol) in ether (1 mL) was added benzyl chloride (153 µL, 1.33 mmol).  The cloudy suspension 
was cooled to -78 ºC and added to the inosose solution.  After 30 mins the solution was warmed to 
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rt for a further 2 h.  The reaction was quenched with H2O, diluted with ether and washed with H2O, 
then brine, dried (MgSO4) and all solvents evaporated under reduced pressure.  The crude material 
was fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 2:3 v/v) 
afforded two products, the title compound (125, 13 mg, 10 %) and 2,6-O-dibenzyl-myo-inositol 
1,3,5-O-orthobenzoate (95, 30 mg, 28 %) both as pale yellow oils. 
By addition of phenyl lithium to the exo-methylene oxide.  2,6-O-Dibenzyl-4,4-O,C-
methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 300 mg, 0.65 mmol) was evaporated from 
toluene (3 × 3 mL) and taken up in ether (3 mL).  Phenyl lithium (1.8 M in dibutyl ether, 724 µL, 
1.30 mmol) was added drop-wise to the stirred solution.  After 6 h the reaction was quenched with 
H2O (1 mL), diluted with ether and washed with H2O (× 2), then brine, dried (MgSO4) and all 
solvents evaporated under reduced pressure.  The crude material (732 mg) was fractionated using 
chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 3:7 v/v) afforded the title 
compound (125, 231 mg, 66 %) as a pale yellow oil. 
By addition of phenyl lithium cuprate to the exo-methylene oxide.  2,6-O-Dibenzyl-4,4-
O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 970 mg, 2.10 mmol) was treated with 
phenyl lithium cuprate according to general method 1.  The crude material was fractionated using 
chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 3:7 v/v) afforded the title 
compound (125, 1.02 g, 90 %) as a clear oil; Rf (EtOAc-hexane, 3:7 v/v) 0.63; δH (400 MHz, 
CDCl3) 7.78-7.75 (2H, m), 7.45-7.29 (16H, m), 7.17-7.14 (2H, m) (20 × Ar H), 4.78 (1H, d, J 
12.2), 4.64 (1H, d, J 12.2), 4.54 (1H, d, J 11.7) (3 × OCHHPh), 4.51 (1H, t, J 3.9, Ins 6-H), 4.49 
(1H, d, J 11.2, OCHHPh), 4.48 (1H, dq, J 3.9, 2.0, Ins 1-H), 4.24 (1H, q, J 2.0, Ins 3-H), 4.23 (1H, 
s, Ins 4-OH), 4.01 (1H, t, J 1.5, Ins 2-H), 3.97 (1H, dt, J 3.4, 1.5, Ins 5-H), 3.42 (1H, d, J 13.7), 
3.27 (1H, d, J 13.7) (2 × CHHPh) ppm; δC (125 MHz, CDCl3) 137.83, 137.02, 135.92, 135.76 (4 × 
Ar C), 131.04 (2C), 129. 49, 128.76 (2C), 128.69, 128.46 (2C), 128.11 (2C), 128.04 (2C), 128.02 
(2C), 127.95 (2C), 127.86, 126.51, 125.41 (2C) (20 × Ar CH), 107.44 (PhCO3), 75.50, 74.58 (2 × 
Ins CH), 73.03, 71.11 (2 × OCH2Ph), 71.09 (Ins C), 70.81, 70.48, 66.36 (3 × Ins CH), 41.62 
(CH2Ph) ppm; HRMS (CI
+) m/z (%) found [M+H]+ 537.2296 (100), C34H33O6 requires 537.2277. 
2,6-O-Dibenzyl-4-C-bromomethyl-myo-inositol 1,3,5-O-orthobenzoate (126) 
O
O
O
Ph
BnO
OH
BnO
Br
 
By treatment of exo-methylene oxide with MeMgBr: 2,6-O-Dibenzyl-4,4-O,C-
methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 100 mg, 0.22 mmol) was evaporated from 
MeCN (1 mL × 3) and taken up in THF (1 mL).  The solution was cooled to -78 °C, MeMgBr (3.0 
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M solution in diethyl ether, 80 µL, 0.24 mmol) was added drop-wise and the reaction stirred for 30 
min before being warmed to rt.  The reaction was quenched by drop-wise addition of H2O (2 mL) 
and taken up in CH2Cl2.  The organic layer was filtered through celite, washed with H2O and then 
brine, dried (MgSO4) and all solvents evaporated under reduced pressure to afford the title 
compound (126, 62 mg, 53 %) as a colourless oil. 
By treatment of exo-methylene oxide with β-styrene lithium cuprate; 2,6-O-Dibenzyl-
4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 100 mg, 0.22 mmol) was treated 
with β-styrene lithium cuprate according to the general method 1, using β-lithium styrene prepared 
according to the following method; β-bromo-styrene was taken up in ether-toluene (1:1 v/v, 2 mL) 
and cooled to -20 ºC.  n-Butyl lithium (1.0 M solution in hexanes, 1.95 mL, 1.95 mmol) was added 
dropwise and the solution maintained at -20 ºC for a further 30 mins, before being cooled to -78 ºC 
for use in general method 1.  The crude material was fractionated using chromatography on flash 
silica.  Elution with EtOAc-hexane (1:0 → 3:7 v/v) afforded the title compound (126, 60 mg, 51 %) 
as a colourless oil; Rf (EtOAc-hexane, 3:7 v/v) 0.56; δH (400 MHz, CDCl3) 7.66-7.23 (15H, m, 15 
× Ar H), 4.82 (1H, d, J 12.0), 4.70 (1H, d, J 12.4), 4.64 (1H, d, J 11.6), 4.58 (1H, d, J 11.6) (4 × 
OCHHPh), 4.55 (1H, t, J 4.0, Ins 6-H), 4.47 (1H, s, Ins 4-OH), 4.45 (2H, m, Ins 1-H + Ins 3-H), 
4.38 (1H, dt, J 3.6, 2.0, Ins 5-H), 4.08 (1H, d, J 10.4, CHHBr), 4.04 (1H, t, J 1.9, Ins 2-H), 3.90 
(1H, d, J 10.4, CHHBr) ppm; MS (ESI+) m/z (%) found [M(79Br)+H]+ 539 (98), [M(81Br)+H]+ 541 
(100), [M(79Br)+Na]+ 561 (89), [M(81Br)+Na]+ 563 (90); HRMS (ESI+) found [M(79Br)+H]+ 
539.1085, C28H28O6
79Br requires 539.1069 and [M(81Br)+H]+ 541.1068, C28H28O6
81Br requires 
541.1049. 
2,6-O-Dibenzyl-4-C-pentyl-myo-inositol 1,3,5-O-orthobenzoate (133) 
O
O
O
Ph
BnO
OH
BnO
 
Alkyl lithium method on epoxide: 2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 
1,3,5-O-orthobenzoate (98, 170 mg, 0.38 mmol) was evaporated from toluene (3 × 2 mL) and taken 
up in ether (2 mL).  n-Butyl lithium (1.6 M in hexanes, 476 µL, 0.76 mmol) was added drop-wise 
to the stirred solution.  After 6 h the reaction was quenched with H2O (1 mL), diluted with ether 
and the organic layer washed with H2O (× 2), then brine, dried (MgSO4) and all solvents 
evaporated under reduced pressure.  The crude material was fractionated by chromatography on 
flash silica.  Elution with EtOAc-hexane (0:1 → 1:4 v/v) afforded the title compound (133, 34 mg, 
18 %) as a pale yellow oil. 
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Alkyl lithium cuprates on epoxide, Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-
orthobenzoate (98, 335 mg, 0.72 mmol) was treated with butyl lithium cuprate according to general 
method 1.  The crude material was fractionated by chromatography on flash silica.  Elution with 
EtOAc-hexane (1:9 → 1:4 v/v) afforded the title compound (133, 338 mg, 90 %) as a pale yellow 
oil: Rf (EtOAc-hexane, 3:7 v/v) 0.61; δH (400 MHz, CDCl3) 7.67-7.64 (2H, m), 7.47-7.44 (2H, m), 
7.41-7.32 (9H, m), 7.24-7.22 (2H, m) (15 × Ar H), 4.82 (1H, d, J 12.7), 4.70 (1H, d, J 12.7), 4.62 
(1H, d, J 11.2), 4.57 (1H, d, J 11.2) (4 × OCHHPh), 4.53 (1H, t, J 4.1, Ins 6-H), 4.48 (1H, dq, J 
3.9, 2.0, Ins 1-H), 4.25 (1H, q, J 2.0, Ins 3-H), 4.23 (1H, bs, Ins 4-OH), 4.10 (1H, dt, J 3.9, 2.0, Ins 
5-H), 4.01 (1H, t, J 2.0, Ins 2-H), 2.08 (1H, dt, J 13.2, 4.4, CHH(CH2)3CH3), 1.95 (1H, dt, J 13.6, 
4.8, CHH(CH2)3CH3), 1.52-1.31 (6H, m, CH2(CH2)3CH3), 0.93 (3H, t, J 6.8, CH2(CH2)CH3) ppm; 
δC (125 MHz, CDCl3) 137.92, 137.01, 135.90 (3 × Ar C), 129.42, 128.83 (2C), 128.73, 128.50 
(2C), 128.13 (2C), 127.97 (4C), 127.87, 125.36 (2C) (15 × Ar CH), 107.28 (PhCO3), 75.82, 74.72 
(2 × Ins CH), 73.01, 71.08 (2 × OCH2Ph), 70.97 (2 × Ins CH), 70.92 (Ins C), 66.37 (Ins CH), 
35.57, 32.17, 22.71, 21.62 (4 × CH2), 14.04 (CH3) ppm; HRMS (ESI
+) m/z (%) found [M+H]+ 
517.2598 (100), C32H37O6 requires 517.2590. 
2,6-O-Dibenzyl-4-C-ethyl-myo-inositol 1,3,5-O-orthobenzoate (136) 
O
O
O
Ph
BnO
OH
BnO
 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 255 mg, 
0.55 mmol) was treated with methyl lithium cuprate according to general method 1.  The crude 
material was fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 
→ 3:7 v/v) afforded the title compound (136, 241 mg, 92 %) as a pale yellow oil; Rf (EtOAc-
hexane, 3:7 v/v) 0.57; δH (400 MHz, CDCl3) 7.69-7.67 (2H, m), 7.48-7.34 (11H, m), 7.25-7.23 (2H, 
m) (15 × Ar H), 4.83 (1H, d, J 12.2), 4.71 (1H, d, J 12.2), 4.62 (1H, d, J 11.7), 4.57 (1H, d, J 11.7) 
(4 × OCHHPh), 4.54 (1H, t, J 3.9, Ins 6-H), 4.49 (1H, dq, J 3.9, 2.0, Ins 1-H), 4.27 (1H, q, J 2.0, 
Ins 3-H), 4.23 (1H, bs, Ins 4-OH), 4.10 (1H, dt, J 3.4, 1.5, Ins 5-H), 4.03 (1H, t, J 1.5, Ins 2-H), 
2.15 (1H, dq, J 14.0, 7.3, CHHCH3), 2.01 (1H, dt, J 21.5, 7.3, CHHCH3), 1.03 (3H, t, J 7.3, 
CH2CH3) ppm; δC (125 MHz, CDCl3) 137.91, 136.98, 135.91 (3 × Ar C), 129.42, 128.84 (2C), 
128.74, 128.50 (2C), 128.14 (2C), 127.97 (4C), 127.88, 125.35 (2C) (15 × Ar CH), 107.27 
(PhCO3), 75.56 (Ins 3-CH), 74.66 (Ins 6-CH), 73.02, 71.09 (2 × OCH2Ph), 70.98 (Ins 1-CH), 70.88 
(Ins 4-C), 70.62 (Ins 5-CH), 66.41 (Ins 2-CH), 28.27 (CH2CH3), 6.35 (CH2CH3) ppm; MS (ESI
+) 
m/z (%) found [M+H]+ 475 (100), [M+Na]+ 497 (82), [2M+Na]+ 971 (53); HRMS (ESI+) found 
[M+H]+ 475.2137, C29H31O6 requires 475.2121. 
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2,6-O-Dibenzyl-4-C-isobutyl-myo-inositol 1,3,5-O-orthobenzoate (137) and 6-benzyloxy-2-
isobutyl-5-isopropyl-cyclohex-4-ene-1,2,3-triol (138) 
O
O
O
Ph
BnO
OH
BnO
OBn
HO
OH
H
HO
 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 170 mg, 
0.37 mmol) was treated with iso-propyl lithium cuprate according to general method 1. The crude 
material was fractionated by chromatography on flash silica to yield two compounds – 2,6-O-
dibenzyl-4-C-iso-butyl-myo-inositol 1,3,5-O-orthobenzoate (137, 48 mg, 26 %) as a pale yellow oil 
and 6-benzyloxy-2-isobutyl-5-isopropyl-cyclohex-4-ene-1,2,3-triol (138, 42 mg, 34 %) as a white 
crystalline solid. 
For 2,6-O-dibenzyl-4-C-isobutyl-myo-inositol 1,3,5-O-orthobenzoate 137; Rf (EtOAc-
hexane, 3:7 v/v) 0.60; δH (400 MHz, CDCl3) 7.68-7.65 (2H, m), 7.48-7.45 (2H, m), 7.42-7.35 (9H, 
m), 7.25-7.23 (2H, m) (15 × Ar H), 4.82 (1H, d, J 12.2), 4.71 (1H, d, J 12.7), 4.63 (1H, d, J 11.7), 
4.58 (1H, d, J 11.2) (4 × OCHHPh), 4.53 (1H, t, J 4.2, Ins 6-H), 4.49 (1H, dq, J 3.9, 1.5, Ins 1-H), 
4.25 (1H, q, J 2.0, Ins 3-H), 4.21 (1H, s, Ins 4-OH), 4.13 (1H, dt, J 3.9, 2.0, Ins 5-H), 4.03 (1H, t, J 
1.5, Ins 2-H), 2.08-1.96 [2H, m, CHHCH(CH3)2 + CH2CH(CH3)2], 1.88 [1H, d, J 13.2, 5.4, 
CHHCH(CH3)2], 1.05 [3H, d, J 6.4, CH2C(CH3)2], 1.04 [3H, d, J 6.4, CH2C(CH3)2] ppm; δC (125 
MHz, CDCl3) 137.89, 137.02, 135.88 (3 × Ar C), 129. 36, 128.80 (2C), 128.70, 128.48 (2C), 
128.11 (2C), 127.95 (4C), 127.85, 125.34 (2C) (15 × Ar CH), 107.23 (PhCO3), 76.09, 74.82 (2 × 
Ins CH), 73.00 (OCH2Ph), 71.44 (Ins C), 71.08 (OCH2Ph), 70.97, 70.81, 66.25 (3 × Ins CH), 43.89 
[CH2CH(CH3)2], 24.58 [2 × CH2CH(CH3)2], 23.04 [CH2CH(CH3)2] ppm; MS (ESI
+) m/z (%) found 
[M+H]+ 503 (93), [M+Na]+ 525 (100); HRMS (ESI+) 503.2440, C31H35O6 requires 503.2434. 
For 6-benzyloxy-2-isobutyl-5-isopropyl-cyclohex-4-ene-1,2,3-triol 138; Rf (EtOAc-
hexane, 3:7 v/v) 0.44; δH (400 MHz, CDCl3) 7.40 -7.31 (5H, m, 5 × Ar H), 5.74 (1H, d, J 5.4, Ins 
6-H), 4.72 (1H, d, J 11.2), 4.62 (1H, d, J 10.8) (2 × OCHHPh), 4.40 (1H, d, J 3.9, Ins 2-H), 4.08 
(1H, dd, J 4.4, 2.0, Ins 3-H), 3.74 (1H, dd, J 11.7, 5.4, ex → d, Ins 5-H), 3.09 (1H, d, J 11.2, ex, Ins 
5-OH), 2.86 (1H, s, ex, Ins 3-OH), 2.68 [1H, septet, J 6.8, 1-CH(CH3)2], 2.10 [1H, m, 4-
CH2CH(CH3)2], 2.03 [1H, dd, J 15.1, 5.4, 4-CHHCH(CH3)2], 1.71 [1H, dd, J 14.7, 7.3, 4-
CHHCH(CH3)2], 1.12 [3H, d, J 6.8, 1-CH2CH(CH3)2], 1.08 [3H, d, J 6.4, 4-CH2CH(CH3)2], 1.06 
[3H, d, J 6.4, 4-CH2CH(CH3)2], 1.02 [3H, d, J 6.8, 1-CH2CH(CH3)2] ppm; δC (125 MHz, CDCl3) 
142.50 (Ins 1-C) 137.49 (Ar C), 128.56 (2C), 127.65, 126.97 (2C) (5 × Ar CH), 121.57 (Ins 6-CH), 
75.65 (Ins CH), 73.86 (Ins C), 72.17 (OCH2Ph), 70.63, 70.60 (2 × Ins CH), 44.50 [4-
CH2CH(CH3)2], 28.58 [1-CH(CH3)2], 25.04, 24.75 [2 × 4-CH(CH3)2], 22.69 [4-CH2CH(CH3)2], 
22.14, 20.56 [2 × 1-CH(CH3)2] ppm; MS (ESI
+) m/z (%) found [M+Na]+ 357 (43), 
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[M+Na+MeCN]+ 398 (58), [2M+Na]+ 691 (100); HRMS (ESI+) found [M+Na]+ 357.2045, 
C20H30O4Na requires 357.2042. 
6-Benzyloxy-2-methyl-5-isopropyl-cyclohex-4-ene-1,2,3-triol (139) 
OBn
HO
OH
H
HO
 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate (115, 135 mg, 0.29 mmol) 
was treated with iso-propyl lithium cuprate according to general method 1. The crude material was 
fractionated by chromatography on flash silica to yield the title compound (139, 25 mg, 30 %) and 
starting material (115, 91 mg, 68 %).  For the title compound; Rf (EtOAc-hexane, 3:7 v/v) 0.49; δH 
(400 MHz, CDCl3) 7.41 -7.35 (5H, m, Ar H), 5.68 (1H, d, J 4.2, Ins 6-H), 4.75 (1H, d, J 11.2), 
4.67 (1H, d, J 11.2) (2 × OCHHPh), 4.35 (1H, d, J 4.1, Ins 2-H), 3.98 (1H, d, J 3.9, Ins 3-H), 3.76 
(1H, bs, Ins 5-H), 2.86 (1H, bs, ex, Ins 5-OH), 2.82 (1H, s, ex, Ins 3-OH), 2.63 [1H, septet, J 6.8, 
1-CH(CH3)2], 1.50 (3H, s, 4-CH3), 1.13 [3H, d, J 6.7, 1-CH(CH3)2], 1.04 [3H, d, J 6.8, 1-
CH(CH3)2] ppm; δC (100 MHz, CDCl3) 142.97 (Ins 1-C), 137.65 (Ar C), 128.63 (2C), 128.12, 
127.82 (2C) (5 × Ar CH), 122.17 (Ins 6-CH), 75.86 (Ins 2-CH), 73.11 (Ins 5-CH), 72.91 
(OCH2Ph),  72.64 (Ins 4-C), 72.15 (Ins 3-CH), 29.02 [1-CH(CH3)2], 22.61 (4-CH3), 22.26, 20.81 [2 
× 1-CH(CH3)2] ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 315.1580 (42), C17H24O4Na requires 
315.1572. 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate, 115, as characterised 
previously. 
2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol 1,3,5-O-orthobenzoate (144) 
O
O
O
Ph
BnO
OH
BnO
 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 400 mg, 
0.87 mmol) was treated with tert-butyl lithium cuprate according to general method 1.  The crude 
material was fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 
1:4 v/v) afforded the title compound (144, 161 mg, 36 %) as a pale yellow oil and the reduction 
product 2,6-O-dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate (115, 121 mg, 30 %) as a 
clear oil. 
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For the title compound 144; Rf (EtOAc-hexane, 3:7 v/v) 0.62; δH (400 MHz, CDCl3) 7.68-
7.65 (2H, m), 7.47-7.45 (2H, m), 7.41-7.34 (9H, m), 7.25-7.23 (2H, m) (15 × Ar H), 4.80 (1H, d, J 
12.7), 4.70 (1H, d, J 12.7), 4.62 (1H, d, J 11.2), 4.58 (1H, d, J 11.2) (4 × OCHHPh), 4.52 (1H, t, J 
4.2, Ins 6-H), 4.46 (1H, dq, J 3.9, 2.0, Ins 1-H), 4.30 (1H, q, J 2.0, Ins 3-H), 4.25 (1H, dt, J 3.9, 
2.0, Ins 5-H), 4.19 (1H, bs, Ins 4-OH), 4.02 (1H, t, J 2.0, Ins 2-H), 2.10 [1H, d, J 14.2, 
CHHC(CH3)3], 1.96 [1H, d, J 14.2, CHHC(CH3)3], 1.11 [9H, s, CH2C(CH3)3] ppm; δC (125 MHz, 
CDCl3) 137.98, 137.11, 135.93 (3 × Ar C), 129. 36, 128.83 (2C), 128.72, 128.48 (2C), 128.14 (2C), 
127.95 (4C), 127.84, 125.40 (2C) (15 × Ar CH), 107.22 (PhCO3), 76.89, 75.10 (2 × Ins CH), 73.08 
(OCH2Ph), 72.30 (Ins C), 71.54 (Ins CH), 71.14 (OCH2Ph), 70.66, 66.29 (2 × Ins CH), 47.32 
[CH2C(CH3)3], 31.62 [CH2C(CH3)3], 31.23 [CH2C(CH3)3] ppm; HRMS (ESI
+) m/z (%) found 
[M+H]+ 517.2590 (100), C32H37O6 requires 517.2590. 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate, 115, as characterised 
previously. 
2,6-O-Dibenzyl-4-C-(2-naphthyl)methyl-myo-inositol 1,3,5-O-orthobenzoate (145) 
O
O
O
Ph
BnO
OH
BnO
 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate (98, 335 mg, 
0.73 mmol) was treated with napthyl lithium cuprate prepared according to general method 1, using 
2-lithium napthalene, prepared from 2-bromo napthalene according to the following method; 2-
bromo napthalene (1.36 mg, 6.55 mmol) was evaporated from toluene (2 × 5 mL) and taken up in 
ether-toluene (1:1 v/v, 8 mL).  To this solution was added drop-wise, n-butyl lithium (1.0 M 
solution in hexanes, 6.50 mL, 6.55 mmol) over 5 min and the resulting solution stirred for 20 min, 
during which time the colour changed from cloudy white to pale orange.   
The crude material after treatment with napthyl lithium cuprate was fractionated using 
chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 3:7 v/v) afforded the title 
compound (145, 283 mg, 66 %) as a pale yellow oil; Rf (EtOAc-hexane, 3:7 v/v) 0.41; δH (400 
MHz, CDCl3) 7.85-7.80 (6H, m), 7.50-7.25 (14H, m), 7.13-7.11 (2H, m) (22 × Ar H), 4.77 (1H, d, 
J 12.2), 4.64 (1H, d, J 12.2), 4.50 (1H, d, J 12.2) (3 × OCHHPh), 4.48-4.47 (2H, m, Ins 1-H + Ins 
6-H), 4.46 (1H, d, J 11.2, OCHHPh), 4.27 (1H, q, J 1.5, Ins 3-H), 4.25 (1H, s, Ins 4-OH), 4.01 
(1H, t, J 2.0, Ins 2-H), 3.96 (1H, dt, J 3.4, 1.4, Ins 5-H), 3.60 (1H, d, J 13.7), 3.40 (1H, d, J 13.7) (2 
× CHHAr) ppm; δC (100 MHz, CDCl3) 137.87, 137.11, 135.75, 133.66, 133.39, 132.42 (6 × Ar C), 
129.70, 129.59 (2C), 128.78 (2C), 128.71, 128.52 (2C), 128.19 (2C), 128.14 (2C), 128.02 (2C), 
127.91, 127.85, 127.58, 127.39, 125.76, 125.52 (2C), 125.43 (22 × Ar CH), 107.54 (PhCO3), 75.75, 
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74.66 (2 × Ins CH), 73.18 (OCH2Ph), 71.35 (Ins C), 71.22 (OCH2Ph), 70.95, 70.48, 66.40 (3 × Ins 
CH), 41.78 (4-CCH2Ar) ppm; MS (CI
+) m/z (%) found [M+H]+ 587 (54), [M+Na]+ 609 (100); 
HRMS (ESI+) m/z found [M+H]+ 587.2428, C38H35O6 requires 587.2434. 
7.4 Chapter 4 
4-O-Allyl-myo-inositol 1,3,5-orthoformate (31)
76 
O
O
O
H
HO
O
HO
 
To myo-inositol (10.80 g, 60.0 mmol) in DMF (150 mL) was added trimethylorthoformate 
(18.0 mL, 175 mmol) and p-toluene sulfonic acid (3.00g, 16 mmol).  The clear solution was stirred 
at 100 ºC for 18 h before addition of triethyl amine (to pH 7) followed by evaporation of all 
solvents under reduced pressure.  The resulting off-white solid was evaporated from MeCN (3 × 15 
mL) and taken up in DMF (100 mL).  After cooling to -15 ºC, NaH (60 % dispersion in mineral oil, 
2.40g, 60 mmol) was added portion-wise and the solution allowed to warm to rt for 30 min.  Allyl 
bromide (5.2 mL, 60 mmol) was added drop-wise and the solution stirred for 12h.  The DMF was 
reduced under high vacuum and the resulting gum taken up in EtOAc, washed with H2O (× 3), then 
brine, dried (MgSO4) and all solvents evaporated.  The crude material was fractionated by 
chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 4:6 v/v) afforded the title 
compound (31, 4.70 g, 34 %) as a pale yellow oil; Rf (EtOAc-hexane 1:1 v/v) 0.19; δH (400 MHz, 
CDCl3) 5.88 (1H, ddt, J 17.0, 10.5, 5.9, OCH2CHCH2), 5.48 (1H, s, O3CH), 5.34 (1H, dq, J 17.1, 
1.0, OCH2CHCHH), 5.31 (1H, dq, J 10.2, 1.0, OCH2CHCHH), 4.48 (1H, bs, Ins 6-H), 4.39 (1H, 
td, J 3.9, 1.5, Ins 4-H), 4.33 (1H, dq, J 3.4, 2.0, Ins 3-H), 4.31 (1H, tt, J 3.9, 2.0, Ins 5-H), 4.23 
(1H, dq, J 3.9, 2.0, Ins 1-H), 4.22-4.14 (2H, m, OCH2CHCH2), 4.08 (1H, bs, Ins 2-H), 3.76 (1H, 
bd, J 8.84, Ins-OH), 3.34 (1H, bs, Ins-OH) ppm; δC (100 MHz, CDCl3) 132.65 (OCH2CHCH2), 
119.54 (OCH2CHCH2), 102.71 (O3CH), 74.74, 74.18, 72.24 (3 × Ins CH), 71.96 (OCH2CHCH2), 
67.83, 67.26, 60.64 (3 × Ins CH) ppm; MS (CI+) m/z (%) found [M+H]+ 231 (47), [M+NH4]
+ 248 
(100); HRMS (CI+) found 248.1139, C10H18NO6 requires 248.1134. 
2,6-O-Dibenzyl-4-O-allyl-myo-inositol 1,3,5-orthoformate (32)
76 
O
O
O
H
BnO
O
BnO
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4-O-Allyl-myo-inositol 1,3,5-orthoformate (4.70 g, 20.4 mmol) was evaporated from 
MeCN (3 × 10 mL), taken up in DMF (50 mL) and cooled to -15 °C.  Sodium hydride (60% 
dispersion in mineral oil, 2.45 g, 61.28 mmol) was added portion-wise, the reaction stirred at -15 
°C for 30 min then warmed to rt and benzyl bromide (7.29 mL, 61.28 mmol) was added drop-wise.  
The reaction was stirred at 60 °C for 12 h then quenched by drop-wise addition of H2O (5 mL) and 
stirred for a further 30 min.  The solvent volume was reduced under high vacuum, the residue 
dissolved in EtOAc and washed with H2O (× 3) then brine.  The organic phase was dried (MgSO4) 
and the solvent evaporated under reduced pressure.  The crude material was fractionated by 
chromatography on flash silica in a large sinter funnel. Elution with EtOAc-hexane (1:9 → 3:7 v/v) 
afforded the title compound (8.03 g, 96 %) as a pale yellow oil; Rf (EtOAc-hexane 1:1 v/v) 0.65, δH 
(400 MHz, CDCl3) 7.42-7.28 (10H, m, 10 × Ar H), 5.83 (1H, ddt, J 17.1, 10.5, 5.5, OCH2CHCH2), 
5.55 (1H, s, O3CH), 5.24 (1H, dq J 17.2, 1.4, OCH2CHCHH), 5.17 (1H, dq J 10.5, 0.8, 
OCH2CHCHH), 4.70 (2H, s, OCH2Ph), 4.64 (1H, d, J 11.8, OCHHPh), 4.50 (1H, d, J 11.8, 
OCHHPh), 4.42 (1H, m, Ins H), 4.34-4.31 (2H, m, 2 × Ins H), 4.30-4.26 (2H, m, 2 × Ins H), 4.09 
(1H, ddt, J 12.4, 5.2, 1.0, OCHHCHCH2), 4.03 (1H, q, J 1.2, Ins 2-H), 3.99 (1H, ddt, J 12.8, 5.6, 
1.2, OCHHCHCH2) ppm; δC (100 MHz, CDCl3) 137.89, 137.73 (2 × Ar C), 134.10 
(OCH2CHCH2), 128.46 (2C), 128.43 (2C), 128.11 (2C), 127.88 (2C), 127.53 (2C) (10 × Ar CH), 
117.54 (OCH2CHCH2), 103.25 (O3CH), 73.93, 73.85 (2 × Ins CH), 71.67, 71.45 (2 × OCH2Ph), 
70.72 (Ins CH), 70.66 (OCH2CHCH2), 70.59, 68.16, 67.47 (3 × Ins CH) ppm; MS (ESI
+) m/z (%) 
found [M+H]+ 411 (62), [M+Na]+ 433 (67); HRMS (ESI+) found 411.1812, C24H27O6 requires 
411.1808. 
2,6-O-Dibenzyl-myo-inositol 1,3,5-orthoformate (41)
90 
O
O
O
H
BnO
OH
BnO
 
2,6-O-Dibenzyl-4-O-(prop-1-enyl)-myo-inositol 1,3,5-O-orthoformate (159, 4.60 g, 11.21 
mmol) was taken up in MeOH (250 mL) and NaOMe (25 mL).  A solution of KMnO4 (1.95 g, 
12.34 mmol) in H2O (250 mL) was added drop-wise over 30 min and the resulting solution stirred 
for a further 30 min during which time a solid brown precipitate formed.  The mixture was filtered 
under gravity and the mother liquor neutralised with HCl (4 M).  The volume was reduced under 
reduced pressure and the crude material extracted into EtOAc (× 2).  The combined organic layers 
were washed with brine, dried (MgSO4) and all solvents evaporated under reduced pressure.  The 
crude material was fractionated by chromatography on flash silica in a large sinter funnel.  Elution 
with hexane-EtOAc (1:0 → 1:1 v/v) afforded the title compound (41, 3.41 g, 82 %) as a colourless 
Chapter 7: Experimental 
 
 
 
- 140 - 
oil; Rf (hexane-EtOAc 4:1 v/v) 0.12; δH (400 MHz, CDCl3) 7.43-7.35 (8H, m), 7.22-7.20 (2H, m) 
(10 × Ar H), 5.54 (1H, s, O3CH), 4.78 (1H, d, J 12.3), 4.69 (1H, d, J 12.3), 4.57 (1H, d, J 11.5), 
4.52 (1H, d, J 11.6) (4 × OCHHPh), 4.50-4.48 (1H, m, Ins 4-H), 4.41-4.37 (2H, m, 2 × Ins H), 
4.30-4.28 (2H, m, 2 × Ins H), 3.91 (1H, q, J 1.0 Ins 2-H), 3.64 (1H, bd, J 10.0, Ins 4-OH) ppm; δC 
(100 MHz, CDCl3) 137.58, 135.92 (2 × Ar C), 128.89 (2C), 128.82, 128.63 (2C), 128.12 (2C), 
128.08 (3C) (10 × Ar CH), 102.66 (O3CH), 74.52 (Ins CH), 72.97 (OCH2Ph), 72.19 (Ins CH), 
71.42 (OCH2Ph), 69.99, 68.03, 67.69, 66.16 (4 × Ins CH) ppm; HRMS (ESI
+) m/z (%) found 
[M+H]+ 371.1499 (46), C21H23O6 requires 371.1495. 
2,6-O-Dibenzyl-inos-4-ose 1,3,5-orthoformate (42)
90 
O
O
O
H
BnO
BnO O  
2,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthoformate (41, 1.21 g, 3.28 mmol) was 
evaporated from MeCN (3 × 5 mL) and taken up in CH2Cl2 (10 mL).  Dess Martin periodinane 
(2.78 g, 6.56 mmol) was added portion-wise and the suspension stirred for 3 h.  Na2S2O3.H2O (10 
% solution in H2O) was added and stirring continued for 10 min.  The product was extracted with 
CH2Cl2 (× 2), and the combined organic layers washed successively with sat. NaHCO3, H2O and 
brine, before drying (MgSO4) and evaporation to dryness under reduced pressure.  The crude inos-
4-ose (1.15 g, 96 %) was used without further purification; Rf (hexane-EtOAc, 1:1 v/v) 0.22; δH 
(400 MHz, CDCl3) 7.42-7.36 (8H, m), 7.23-7.21 (2H, m) (10 × Ar H), 5.71 (1H, s, O3CH), 4.76 
(1H, d, J 12.1), 4.65 (1H, d, J 12.1), 4.59 (1H, d, J 11.8) (3 × OCHHPh), 4.51 (1H, q, J 1.7, Ins 3-
H), 4.44 (1H, d, J 11.7, OCHHPh), 4.46-4.44 (1H, m, Ins H), 4.39-4.36 (2H, m, 2 × Ins H), 3.79 
(1H, q J 1.4, Ins 2-H) ppm;  δC (100 MHz, CDCl3) 199.30 (Ins C=O), 136.96, 136.37 (2 × Ar C), 
128.71 (2C), 128.68 (2C), 128.50, 128.26, 128.04 (2C), 127.94 (2C) (10 × Ar CH), 103.00 (O3CH), 
78.97, 76.81 (2 × Ins CH), 71.86, 71.75 (2 × OCH2Ph), 71.33, 70.61, 70.53 (3 × Ins CH) ppm; MS 
(ESI+) m/z (%) found [M+H]+ 369 (52), [M+H3O]
+ 387 (100); HRMS (ESI+) found [M+H]+ 
369.1347, C21H21O6 requires 369.1338. 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol (151a)  
BnO
OBn
OH
OH
OH
HO
 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate (115, 200 mg, 0.43 mmol) 
was refluxed in conc. HCl-methanol (6 mL, 1:2 v/v).  After 3 h the solution was cooled, diluted 
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with H2O and extracted with EtOAc.  The organic layer was washed with sat. NaHCO3, H2O, and 
then brine, dried (MgSO4) and all solvents evaporated under reduced pressure. 
1H NMR illustrated 
that more than one isomeric product was present, including 150a.  If desired 150a may be isolated 
by chromatography on flash silica, eluting with EtOAc-hexane (1:4 → 3:2 v/v); δH (400 MHz, 
CD3OD) 7.93-7.06 (15H, m, 15 × Ar H), 5.11 (1H, dd, J 10.1, 3.3, Ins 1-H), 4.84 (1H, d, J 11.1), 
4.81 (1H, d, J 11.7), 4.68 (1H, d, J 11.1), 4.59 (1H, d, J 11.7) (4 × PhCHHO), 4.10 (1H, t, J 3.1, Ins 
2-H), 3.90 (1H, t, J 10.0, Ins 6-H), 3.67 (1H, d, J 3.0, Ins 3-H), 3.52 (1H, d, J 9.8, Ins 5-H), 1.41 
(3H, s, Ins 4-CH3) ppm; δC (100 MHz, CD3OD) 167.26 (PhCO2), 140.13, 139.80 (2 × Ar C), 
134.41 (2 × Ar CH), 131.13 (Ar C), 130.80 (3C), 129.57 (2C), 129.17, 129.08 (3C), 128.55 (2C), 
128.47, 128.36 (13 × Ar CH), 80.21, 79.86, 79.12 (3 × Ins CH), 77.70 (Ins 4-CCH3), 76.40, 76.17 
(2 × PhCH2O), 75.56, 75.30 (2 × Ins CH), 16.97 (Ins 4-CCH3); HRMS (CI
+) m/z (%) found 
[M+NH4]
+ 496.2330 (100), C28H34NO7 requires 496.2335.  
The crude mixture of isomeric benzoates 150a-c (180 mg, 0.38 mmol) was evaporated 
from MeCN (3 × 1 mL) and taken up in MeOH (2 mL).  NaOMe (25 % solution in MeOH, 52 µL, 
0.19 mmol) was added and the reaction refluxed for 3 h.  After careful neutralisation with 4 M HCl 
all solvents were evaporated under reduced pressure.  The residue was taken up in methanol, the 
solids removed by filtration, and the mother-liquor evaporated to dryness.  The crude material was 
fractionated by chromatography on flash silica.  Elution with CH2Cl2-hexane (0:1 → 1:0 v/v) then 
EtOH-CH2Cl2 (0:1 → 3:97 v/v) afforded the title compound (151a, 139 mg, 87 %) as a colourless 
glass; δH (400 MHz, CD3OD) 7.46-7.25 (10H, m, 10 × Ar H), 4.89 (1H, d, J 11.3) 4.85-4.80 (3H, 
m) (4 × OCHHPh), 3.90 (1H, t, J 3.1, Ins 2-H), 3.67 (1H, dd, J 9.6, 3.2, Ins 1-H), 3.60-3.55 (2H, 
m, Ins 6-H + Ins 3-H), 3.43 (1H, d, J 9.4, Ins 5-H), 1.36 (3H, s, Ins 4-CH3) ppm; MS (ESI
+) m/z 
(%) found [M+Na]+ 397.1628 (100), C21H26O6Na requires 397.1627. 
2,6-O-Dibenzyl-4-C-ethyl-myo-inositol (151b)  
BnO
OBn
OH
OH
OH
HO
 
2,6-O-Dibenzyl-4-C-ethyl-myo-inositol 1,3,5-O-orthobenzoate (136, 280 mg, 0.60 mmol) 
was refluxed in conc. HCl-(propan-1-ol) according to general method 4 to recover a crude mixture 
of benzoyls (294 mg), HRMS (ESI+) m/z (%) found [M+H] 493.2246 (32), C29H33O7 requires 
493.2226, [M+Na]+ 515.2055 (100), C29H32NaO7 requires 515.2046.  The crude mixture was 
treated with NaOMe in MeOH according to general method 5 to afford the title compound (151b, 
204 mg, 88 % over 2 steps) as a pale yellow oil; Rf (EtOAc-hexane 7:3 v/v) 0.20; δH (500 MHz, 
CDCl3) 7.38-7.32 (8H, m), 7.26-7.24 (2H, m) (10 × Ar H), 4.72 (1H, d, J 11.5), 4.67 (1H, d, J 
11.5), 4.65 (1H, d, J 11.6), 4.59 (1H, d, J 11.6) (4 × OCHHPh), 4.28 (1H, bs, Ins 1-H), 4.13 (1H, t, 
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J 3.0, Ins 2-H), 4.04 (1H, bs, Ins 5-H), 3.98 (1H, t, J 3.4, Ins 6-H), 3.80 (1H, bs, Ins 4-OH), 3.73 
(1H, bd, J 8.1, Ins 3-H), 3.32 (1H, bd, J 10.6, Ins 3-OH), 2.95 (1H, bs, Ins 1-OH), 2.74 (1H, bs, Ins 
5-OH), 2.01 (1H, dq, J 14.4, 7.2), 1.85 (1H, dq, J 14.3, 7.0) (2 × CHHCH3), 1.02 (3H, t, J 7.4, 
CH2CH3) ppm; δC (125 MHz, CDCl3) 137.44, 136.56 (2 × Ar C), 128.70 (2C), 128.66 (2C), 
128.41, 128.25, 128.08 (2C), 127.93 (2C) (10 × Ar CH), 80.12 (Ins CH), 74.99 (Ins C), 74.10 (Ins 
CH), 73.41 (OCHPh), 73.30 (Ins CH), 71.32 (OCHPh), 70.86, 69.71 (2 × Ins CH), 27.68 
(CH2CH3), 6.12 (CH2CH3) ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 411.1799, C22H28O6Na 
requires 411.1784. 
2,6-O-Dibenzyl-4-C-pentyl-myo-inositol (151c)  
BnO
OBn
OH
OH
OH
HO
 
2,6-O-Dibenzyl-4-C-pentyl-myo-inositol 1,3,5-O-orthobenzoate (133, 170 mg, 0.34 mmol) 
was refluxed in conc. HCl-(propan-1-ol) according to general method 4, to recover a crude mixture 
of benzoyls (175 mg); HRMS (ESI+) m/z (%) found [M+Na]+ 557.2525 (100), C32H38O7Na requires 
557.2515.  The crude mixture was treated with NaOMe in MeOH according to general method 5 to 
afford the title compound (151c, 71 mg, 49 %) as a pale yellow oil; Rf (EtOAc) 0.28; δH (400 MHz, 
CDCl3) 7.43-7.33 (8H, m), 7.29-7.26 (2H, m) (10 × Ar H), 4.76 (1H, d, J 11.2), 4.71 (1H, d, J 
11.2), 4.69 (1H, d, J 11.7), 4.62 (1H, d, J 11.2) (4 × OCHHPh), 4.32 (1H, m, Ins 1-H), 4.16 (1H, t, 
J 2.9, Ins 2-H), 4.08 (1H, m, Ins 5-H), 4.02 (1H, t, J 3.4, Ins 6-H), 3.85 (1H, bs, ex, Ins OH), 3.78 
(1H, bd, J 4.9, ex → bs, Ins 3-H), 3.41 (1H, bd, J 8.3, ex, Ins OH), 3.16 (1H, bs, ex, Ins OH), 2.92 
(1H, bs, ex, Ins OH), 1.99-1.92 (1H, m), 1.89-1.81 (1H, m) [2 × CHH(CH2)3CH3], 1.55-1.51 [2H, 
m, CH2(CH2)3CH3], 1.42-1.31 [4H, m, 2 × CH2(CH2)3CH3], 0.94 [3H, t, J 6.8, CH2(CH2)3CH3] 
ppm; δC (100 MHz, CDCl3) 137.43, 136.57 (2 × Ar C), 128.33 (2C), 128.49 (2C), 128.44, 128.27, 
128.12 (2C), 127.96 (2C) (10 × Ar CH), 80.12 (Ins CH), 75.08 (Ins C), 74.36 (Ins CH), 73.44 
(OCH2Ph), 73.29 (Ins CH), 71.36 (OCH2Ph), 71.20, 69.75 (2 × Ins CH), 35.08, 32.42, 22.78, 21.37 
(4 × CH2), 14.13 (CH3) ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 453.2254, C25H34O6Na 
requires 453.2253. 
2,6-O-Dibenzyl-4-C-iso-butyl-myo-inositol (151d)  
BnO
OBn
OH
OH
OH
HO
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2,6-O-Dibenzyl-4-C-iso-butyl-myo-inositol 1,3,5-O-orthobenzoate (137, 171 mg, 0.34 
mmol) was refluxed with conc. HCl-(propan-1-ol) according to general method 4, to recover a 
crude mixture of benzoyls (120 mg); HRMS (ESI+) m/z (%) found [M+Na]+ 543.2387 (100), 
C31H36O7Na requires 543.2359.  The crude mixture was treated with NaOMe in MeOH according 
to general method 5 to afford the title compound (151d, 28 mg, 20 %) as a yellow oil; Rf (EtOAc-
hexane 7:3 v/v) 0.21; δH (400 MHz, CDCl3) 7.41-7.34 (8H, m), 7.27-7.25 (2H, m) (10 × Ar H), 
4.73 (1H, d, J 11.7), 4.69 (1H, d, J 11.7), 4.68 (1H, d, J 11.7), 4.60 (1H, d, J 11.7) (4 × OCHHPh), 
4.30 (1H, bs, Ins 1-H), 4.15 (1H, t, J 2.9, Ins 2-H), 4.08 (1H, bs, Ins 5-H), 4.01 (1H, t, J 3.4, Ins 6-
H), 3.86 (1H, bs, Ins 4-OH), 3.78 (1H, bd, J 7.3, Ins 3-H), 3.40 (1H, bd, J 9.3, Ins 3-OH), 2.99 
(1H, bs, Ins 1-OH), 2.78 (1H, bs, Ins 5-OH), 2.03 [1H, m, CH2CH(CH3)2], 1.89 [1H, dd, J 14.2, 
5.4, CHHCH(CH3)2], 1.76 [1H, dd, J 14.7, 6.4, CHHCH(CH3)2], 1.05 [3H, s, CH2CH(CH3)2], 1.03 
[3H, s, CH2CH(CH3)2] ppm; δC (125 MHz, CDCl3) 137.44, 136.55 (2 × Ar C), 128.71 (2C), 128.69 
(2C), 128.43, 128.28, 128.12 (2C), 127.96 (2C) (10 × Ar CH), 80.27 (Ins CH), 75.72 (Ins C), 74.65 
(Ins CH), 73.41 (OCH2Ph), 73.14 (Ins CH), 71.28 (OCH2Ph), 71.19, 69.56 (2 × Ins CH), 43.25 
[CH2CH(CH3)2], 24.90 [CH2CH(CH3)2], 22.75 [2 × CH2CH(CH3)2] ppm; HRMS (ESI
+) m/z (%) 
found [M+Na]+ 439.2112 (100), C24H32O6Na requires 439.2097. 
2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol (151e)  
BnO
OBn
OH
OH
OH
HO
 
By acidic hydrolysis of the orthoester: 2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol 
1,3,5-O-orthobenzoate (144, 98 mg, 0.19 mmol) was refluxed with conc. HCl-(propan-1-ol) 
according to general method 4, to recover a crude mixture of benzoyls (90 mg); HRMS (ESI+) m/z 
(%) found [M+Na]+ 557.2520 (100), C32H38O7Na requires 557.2515.  The crude mixture was 
treated with NaOMe in MeOH according to general method 5 to afford the title compound (151e, 
40 mg, 49 %) as a clear oil. 
By acidic hydrolysis of the benzylidene acetal: 2,6-O-Dibenzyl-4-C-neopentyl-myo-
inositol 3,5-O-benzylidene acetal (176e, 138 mg, 0.27 mmol) was taken up in CH2Cl2-EtOH-H2O 
(5:1:1 v/v, 1.4 mL) and p-TsOH (10 mg, 0.05 mmol) added.  After 24 h, all solvents were 
evaporated and the crude material purified by chromatography on flash silica.  Elution with EtOAc-
hexane (1:9 → 4:1 v/v) afforded the title compound (151e, 115 mg, 56 %) as a clear glass; Rf 
(EtOAc-hexane 7:3) 0.23; δH (400 MHz, CDCl3) 7.41-7.35 (8H, m), 7.29-7.26 (2H, m) (10 × Ar 
H), 4.72 (1H, d, J 11.7), 4.69 (1H, d, J 11.7), 4.67 (1H, d, J 11.7), 4.60 (1H, d, J 11.7) (4 × 
OCHHPh), 4.29 (1H, bs, Ins 1-H), 4.16 (1H, t, J 2.9, Ins 2-H), 4.13 (1H, bs, Ins 5-H), 4.01 (1H, t, 
J 3.4, Ins 6-H), 3.89 (1H, bd, J 5.4, Ins 3-H), 3.87 (1H, bs, Ins 4-OH), 3.48 (1H, bd, J 6.8, Ins 3-
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OH), 3.07 (1H, bs, Ins 1-OH), 2.85 (1H, bs, Ins 5-OH), 1.98 [1H, d, J 14.7, CHHC(CH3)3], 1.85 
[1H, d, J 15.2, CHHC(CH3)3], 1.11 [9H, s, CH2C(CH3)3] ppm; δC (125 MHz, CDCl3) 137.45, 
136.51 (2 × Ar C), 128.69 (2C), 128.64 (2C), 128.40, 128.22, 128.07 (2C), 127.94 (2C) (10 × Ar 
CH), 80.48 (Ins 2-CH), 76.60 (Ins 4-C), 75.66 (Ins 5-CH), 73.40 (OCH2Ph), 72.99, 71.74 (Ins 6-
CH + Ins 3-CH), 71.19 (OCH2Ph), 69.19 (Ins 1-CH), 46.23 [CH2C(CH3)3], 31.87 [CH2C(CH3)3], 
31.32 [CH2C(CH3)3] ppm; HRMS (ESI
+) found [M+Na]+ 453.2234, C25H34O6Na requires 
453.2253. 
2,6-O-Dibenzyl-4-C-benzyl-myo-inositol (151f)  
BnO
OBn
OH
OH
OH
HO
 
By acidic hydrolysis of the orthobenzoate: 2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 
1,3,5-O-orthobenzoate (125, 561 mg, 1.05 mmol) was refluxed in conc. HCl-(propan-1-ol) 
according to general method 4, to recover a crude mixture of benzoyls (580 mg); HRMS (ESI+) m/z 
(%) found [M+H]+ 555.2408, [M+Na]+ 577.2216 (100), C34H35O7 requires 555.2383.  The crude 
mixture was treated with NaOMe in MeOH according to general method 5 to afford the title 
compound (151f, 195 mg, 41 % over two steps) as a pale yellow oil.  
By acidic hydrolysis of the benzylidene acetal: 2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 
3,5-O-benzylidene acetal (176f, 160 mg, 0.30 mmol) was taken up in CH2Cl2-EtOH-H2O (5:1:1 
v/v, 4 mL) and p-TsOH (11 mg, 0.06 mmol) added.  After 24 h, all solvents were evaporated and 
the crude material purified by chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 
4:1 v/v) afforded the title compound (151f, 101 mg, 75 %) as a clear glass; Rf (EtOAc-hexane 7:3 
v/v) 0.23; δH (400 MHz, CDCl3) 7.43-7.26 (13H, m), 7.20-7.18 (2H, m) (15 × Ar H), 4.67 (1H, d, J 
11.2), 4.63 (1H, d, J 10.3), 4.60 (1H, d, J 11.2), 4.52 (1H, d, J 11.7) (4 × OCHHPh), 4.27 (1H, bs, 
Ins 1-H), 4.15 (1H, t, J 2.9, Ins 2-H), 3.98-3.96 (2H, m, Ins 5-H + Ins 6-H), 3.83 (1H, bs, Ins OH), 
3.64 (1H, bs, Ins 3-H), 3.58 (1H, bs, Ins OH), 3.25 (1H, d, J 14.2), 3.21 (1H, d, J 14.2) (2 × 4-
CHHPh), 2.96 (1H, bs, Ins OH), 2.87 (1H, bs, Ins OH) ppm; δC (125 MHz, CDCl3) 137.35, 136.48, 
136.42 (3 × Ar C), 131.20 (2C), 128.63 (2C), 128.61 (2C), 128.32, 128.24, 128.09 (2C), 127.87 
(2C), 127.83 (2C), 126.23 (15 × Ar CH), 80.14 (Ins CH), 75.17 (Ins C), 73.80, 73.35 (2 × Ins CH), 
73.34, 71.39 (2 × OCHPh), 71.21, 69.53 (2 × Ins CH), 41.05 (4-CHPh) ppm; MS (CI+) m/z (%) 
found [M+NH4]
+ 468 (100); HRMS (CI+) found [M+NH4]
+ 468.2393, C27H34NO6 requires 
468.2386. 
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2,6-O-Dibenzyl-4-C-napthyl-myo-inositol (151g)  
BnO
OBn
OH
OH
OH
HO
 
2,6-O-Dibenzyl-4-C-naphthyl-myo-inositol 3,5-O-benzylidene acetal (176g, 105 mg, 0.18 
mmol) was taken up in CH2Cl2-EtOH-H2O (5:1:1 v/v, 1.4 mL) and p-TsOH (7 mg, 0.04 mmol) 
added.  After 24 h, all solvents were evaporated and the crude material purified by chromatography 
on flash silica.  Elution with EtOAc-hexane (1:9 → 4:1 v/v) afforded the title compound (151g, 38 
mg, 43 %) as a clear glass; Rf (EtOAc-hexane 7:3 v/v) 0.26; δH (400 MHz, CDCl3) 7.87-7.79 (4H, 
m), 7.61 (1H, d, J 8.4), 7.48-7.46 (2H, m), 7.36-7.28 (8H, m), 7.19-7.17 (2H, m) (17 × Ar H), 4.67 
(1H, d, J 11.6), 4.63 (1H, d, J 11.6), 4.59 (1H, d, J 11.6), 4.52 (1H, d, J 11.6) (4 × OCHHPh), 4.30-
4.27 (1H, bs, Ins H), 4.15-4.13 (1H, m, Ins H), 4.00-3.96 (2H, m, 2 × Ins H), 3.67-3.65 (1H, bs, Ins 
H), 3.42 (1H, d, J 13.6), 3.37 (1H, d, J 13.6) (2 × 4-CHHNaphthyl) ppm; δC (125 MHz, CDCl3) 
137.37, 136.47, 134.20, 133.39, 132.33 (5 × Ar C), 129.93, 129.69, 128.69 (2C), 128.61 (2C), 
128.38, 128.29, 128.14 (2C), 127.95 (2C), 127.82, 127.55, 127.12, 125.61, 125.25 (17 × Ar CH), 
80.17 (2 × Ins CH), 75.48 (Ins C), 74.00 (Ins CH), 73.45, 71.48 (2 × OCH2Ph), 71.14, 69.63 (2 × 
Ins CH), 41.37 (4-CH2Ph) ppm; HRMS (ESI
+) found [M+Na]+ 523.2110 (100), C31H32O6Na 
requires 523.2097. 
1,3,4,5-O-Tetraacetyl-2,6-O-dibenzyl-4-C-methyl-myo-inositol (152) 
BnO
OBn
OAc
OAc
OAc
AcO
 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol (151a, 60 mg, 0.16 mmol) and DMAP (2 mg, 
0.02 mmol) were evaporated from pyridine (3 × 1 mL) and taken up in CH2Cl2 (1 mL).  Acetic 
anhydride (127 µL, 1.28 mmol) and triethylamine (267 µL, 1.92 mmol) were added and the 
reaction mixture stirred for 2 h.  The reaction was quenched by drop-wise addition of H2O (0.5 mL) 
and stirred for a further 30 min before the product was taken up in CH2Cl2, washed with H2O, then 
brine, dried (MgSO4) and all solvents evaporated under reduced pressure.  The crude material was 
fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 7:10 v/v) 
afforded the title compound (152, 45 mg, 52 %) as a colourless oil; Rf (EtOAc) 0.9; δH (400 MHz, 
CDCl3) 7.41-7.25 (10H, m, 10 × Ar H), 6.14 (1H, d, J 3.6  Ins 3-H), 6.03 (1H, d, J 9.6, Ins 5-H), 
5.09 (1H, dd, J 11.2, 2.8, Ins 1-H), 4.72-4.61 (4H, m, 2 × OCH2Ph), 4.18 (1H, t, J 3.2, Ins 2-H), 
3.99 (1H, t, J 10.0, Ins 6-H), 2.08 (3H, s), 2.02 (3H, s), 1.96 (3H, s), 1.91 (3H, s) (4 × OCOCH3), 
1.59 (3H, s, Ins 4-CH3) ppm; δC (100 MHz, CDCl3) 170.31, 169.70, 169.58, 169.35 (4 × 
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OCOCH3), 138.24, 137.99 (2 × Ar C), 128.39 (2C), 128.33 (2C), 127.83, 127.64 (2C), 127.56, 
127.25 (2C) (10 × Ar CH), 84.52 (Ins 4-C), 76.77, 76.21 (2 × Ins CH), 75.55, 74.97 (2 × OCH2Ph), 
72.86, 72.48, 70.32 (3 × Ins CH), 22.33, 20.78, 20.74, 20.71 (4 × OCOCH3), 17.42 (Ins 4-CH3) 
ppm. 
2,6-O-Dibenzyl-4-O-(prop-1-enyl)-myo-inositol 1,3,5-orthoformate (159) 
O
O
O
H
BnO
O
BnO
 
2,6-O-Dibenzyl-4-O-allyl-myo-inositol 1,3,5-O-orthobenzoate (3.85 g, 9.39 mmol) was 
evaporated from MeCN (3 × 5 mL), dissolved in DMSO (10 mL) and potassium t-butoxide (2.11 g, 
18.75 mmol) added.  The solution was stirred at 100 °C for 3 h.  The reaction was cooled, diluted 
with H2O (5 mL) and extracted with EtOAc.  The organic layer was washed with H2O (× 4), then 
brine, dried (MgSO4) and the solvent evaporated under reduced pressure.  The title compound (3.85 
g, 100 %) was isolated as a yellow oil and used without further purification; Rf (EtOAc-hexane 1:1 
v/v) 0.65, δH (400 MHz, CDCl3) 7.43-7.26 (10H, m, 10 × Ar H), 6.00 (1H, dq J 6.0, 1.6, 
OCHCHCH3), 5.57 (1H, d, J 1.0, O3CH), 4.73 (1H, d, J 12.3, OCHHPh), 4.70 (1H, d, J 12.2, 
OCHHPh), 4.64 (1H, d, J 11.8, OCHHPh), 4.55-4.43 [3H, m, OCHCHCH3 + (2 × Ins H)], 4.48 
(1H, d, J 12.1, OCHHPh), 4.37-4.29 (3H, m, 3 × Ins H). 4.03 (1H, q, J 1.4, Ins 2-H), 1.38 (3H, dd, 
J 6.8, 1.3, OCHCHCH3) ppm; MS (ESI
+) m/z (%) found [M+H]+ 411 (62), [M+Na]+ 433 (67); 
HRMS (ESI+) found 411.1812, C24H27O6 requires 411.1808. 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthoformate (160) 
O
O
O
H
BnO
O
BnO
 
To a clear solution of trimethylsulfoxonium iodide (759 mg, 3.45 mmol) in DMSO (6 mL) 
was added NaH (60 % dispersion in mineral oil, 150 mg, 3.76 mmol) and the mixture stirred for 40 
min.  2,6-O-Dibenzyl-inos-4-ose 1,3,5-O-orthoformate (42, 1.15 g, 3.13 mmol) was evaporated 
from MeCN (3 × 5 mL ), taken up in THF (6 mL) and added to the reaction mixture, which was 
stirred at rt for 1 h.  The reaction was quenched by drop-wise addition of H2O (2 mL) and the 
product taken up in EtOAc.  The organic layer was washed with sat. NaHCO3, H2O, then brine, 
dried (MgSO4) and evaporated to dryness under reduced pressure.  The crude material was 
fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 2:5 v/v) 
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afforded the title compound (160, 440 mg, 37 %) as a clear oil; Rf (EtOAc- hexane, 1:1 v/v) 0.47; 
δH (400 MHz, CDCl3) 7.42-7.29 (10H, m, 10 × Ar H), 5.67 (1H, d, J 1.0, O3CH), 4.70 (1H, d, J 
12.0), 4.64 (1H, d, J 12.0), 4.62 (1H, d, J 11.8) 4.46 (1H, d, J 11.8) (4 × OCHHPh), 4.34-4.32 (1H, 
m, Ins 1-H), 4.32 (1H, t, J 4.4 Ins 6-H), 4.00 (1H, q, J 1.2, Ins 2-H), 3.84 (1H, td, J 3.9, 2.0, Ins 5-
H), 3.78 (1H, q, J 2.0, Ins 3-H), 2.91 (1H, d, J 4.4), 2.88 (1H, d, J 4.4) (2 × Ins 4-CCHH) ppm; δC 
(100 MHz, CDCl3) 137.58, 137.30 (2 × Ar C), 128.57 (2C), 128.52 (2C), 128.11, 127.97 (3C), 
127.76 (2C) (10 × Ar CH), 103.42 (HCO3), 73.62, 72.48 (2 × Ins CH), 71.60 (OCH2Ph), 71.58 (Ins 
CH), 71.39 (OCH2Ph), 70.19, 69.34 (2 × Ins CH), 60.37 (Ins 4-CCHH), 54.91 (Ins C) ppm; HRMS 
(ESI+) m/z (%) found [M+H]+ 383.1483 (72), C22H23O6 requires 383.1495. 
2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 1,3,5-O-orthobenzoate (161) 
O
O
O
H
BnO
OH
BnO
 
2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthoformate (160, 440 mg, 
1.15 mmol) was treated with phenyl lithium cuprate according to general method 1.  The crude 
material was fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 
→ 3:7 v/v) afforded the title compound (161, 464 mg, 87 %) as a clear oil; Rf (EtOAc-hexane, 3:7 
v/v) 0.61; δH (400 MHz, CDCl3) 7.43-7.28 (13H, m), 7.15-7.12 (2H, m) (15 × Ar H), 5.64 (1H, d, J 
0.7, O3CH) 4.75 (1H, d, J 12.3), 4.62 (1H, d, J 12.3), 4.51 (1H, d, J 11.5), 4.44 (1H, d, J 11.5) (4 × 
OCHHPh), 4.38 (1H, t, J 3.9, Ins 6-H), 4.27 (1H, dq, J 3.9, 2.0, Ins 1-H), 4.23 (1H, bs, Ins 4-OH), 
4.04 (1H, q, J 2.0, Ins 3-H), 3.96 (1H, q, J 1.5, Ins 2-H), 3.85 (1H, dt, J 3.9, 2.0, Ins 5-H), 3.34 
(1H, d, J 13.6), 3.18 (1H, d, J 13.6) (2 × CHHPh) ppm; δC (125 MHz, CDCl3) 137.68, 135.99, 
135.81 (3 × Ar C), 131.05 (2C), 128.83 (2C), 128.76, 128.57 (2C), 128.12 (3C), 128.08 (3C), 
128.00, 126.57 (2C) (15 × Ar CH), 102.89 (HCO3), 74.74, 74.28 (2 × Ins CH), 73.05, 71.55 (2 × 
OCH2Ph), 71.40 (Ins C), 69.61, 69.52, 67.52 (3 × Ins CH), 41.56 (CCH2Ph) ppm; HRMS (CI
+) m/z 
(%) found [M+H]+ 461.1951 (50), C28H29O6 requires 461.1964. 
1,2,4,6-O-Tetrabenzyl-myo-inositol (164) 
OBnBnO
OBn
OHBnO
OH  
2,4,6-O-Tribenzyl-myo-inositol 1,3,5-O-orthobenzoate (162, 100 mg, 0.19 mmol) was 
reduced with DIBAL-H using general method 2, affording 164 (102 mg, 100 %); Rf (EtOAc-
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hexane, 1:1 v/v) 0.48; δH (400 MHz, CDCl3) 7.41-7.29 (20H, m, 20 × Ar H), 5.03 (1H, d, J 11.6), 
5.02 (1H, d, J 11.2), 4.93 (1H, d, J 11.3), 4.82 (1H, d, J 11.4), 4.80 (1H, d, J 11.2), 4.77 (1H, d, J 
11.6), 4.71 (2H, s) (8 × OCH2Ph), 4.09 (1H, t, J 2.5, Ins 2-H), 3.95 (1H, t, J 9.4, Ins 4-H), 3.74 
(1H, t, J 9.3, Ins 6-H), 3.58 (1H, t, J 9.1, Ins 5-H), 3.52 (1H, bd, J 10.1, Ins 1-H), 3.48 (1H, dd, J 
9.7, 2.4, Ins 3-H), 2.57 (1H, bs, Ins 5-OH), 2.38 (1H, bs, Ins 1-OH) ppm; δC (100 MHz, CDCl3) 
138.66, 138.62 (2C), 138.05 (4 × Ar C), 128.50 (4C), 128.45 (2C), 128.37 (2C), 128.03 (2C), 
128.00 (2C), 127.77 (4C), 127.75, 127.65, 127.60 (2C) (20 × Ar CH), 81.66 (Ins 6-CH), 81.25 (Ins 
4-CH), 80.87 (Ins 3-CH), 77.05 (Ins 2-CH), 75.48 (OCH2Ph), 74.98 (Ins 5-CH), 74.98, 74.94, 
72.70 (3 × OCH2Ph), 72.18 (Ins 1-CH) ppm; MS (CI
+) m/z (%) [M+H]+ 540 (100). 
1,2,6-O-Tribenzyl-myo-inositol (165) and 2,3,6-O-tribenzyl-myo-inositol (166) 
OBnHO
OBn
OHBnO
OH
OBnHO
OBn
OBnHO
OH  
2,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (95, 225 mg, 0.50 mmol) was reduced 
with DIBAL-H using general method 2.  The crude residue was fractionated by chromatography on 
flash silica.  Elution with hexane-EtOAc (9:1 → 2:8 v/v) afforded 165 (40 mg, 18 %) and 166 (60 
mg, 26 %) both as off-white solids; for 165 Rf (EtOAc-hexane, 7:3 v/v) 0.18; δH (500 MHz, d6-
DMSO) 7.31-7.21 (15H, m, 15 × Ar CH), 4.88 (1H, d, J 5.2, ex, Ins 5-OH), 4.81-4.70 [6H, m, Ins 
3-OH (ex) + Ins 4-OH (ex) + (2 × OCH2Ph)], 4.62 (1H, d, J 11.9), 4.54 (1H, d, J 11.9) (2 × 
OCHHPh), 3.98 (1H, t, J 2.4, Ins 2-H), 3.58 (1H, t, J 9.5, Ins 6-H), 3.47 (1H, td, J 9.5, 4.6, ex → t, 
Ins 4-H), 3.45 (1H, dd, J 9.9, 2.5, Ins 1-H), 3.27 (1H, ddd, J 9.8, 4.6, 2.4, ex → dd, Ins 3-H), 3.16 
(1H, td, J 9.0, 5.2, ex → t, Ins 5-H) ppm; δC (125 MHz, CDCl3) 138.64 (2C), 138.10 (3 × Ar C), 
128.48 (4C), 128.43 (2C), 128.07 (2C), 127.81 (2C), 127.78 (2C), 127.73, 127.64 (2C) (15 × Ar 
CH), 81.11, 80.92, 77.34 (3 × Ins CH), 75.48, 74.89 (2 × OCH2Ph), 74.51, 73.60 (2 × Ins CH), 
72.85 (OCH2Ph), 72.10 (Ins CH) ppm; HRMS (CI
+) m/z (%) found [M+Na]+ 473.1947 (100), 
C27H30O6Na requires 473.1940; for 166 Rf (EtOAc-hexane, 7:3 v/v) 0.46; δH (400 MHz, d6-DMSO) 
7.42-7.24 (15H, m, 15 × Ar CH), 4.96 (1H, d, J 5.1, ex, Ins 1-OH), 4.93 (1H, d, J 4.9, ex, Ins 4-
OH), 4.91 (1H, d, J 5.2, ex, Ins 6-OH), 4.83 (1H, d, J 11.9), 4.81 (1H, d, J 11.5), 4.76 (1H, d, J 
11.5), 4.73 (1H, d, J 11.9), 4.64 (2H, s) (6 × OCHHPh), 3.96 (1H, bs, Ins 2-H), 3.64 (1H, td, J 9.4, 
4.9, ex → t, Ins 4-H), 3.51-3.44 (2H, m, Ins 5-H + Ins 1-H), 3.25 (1H, dd, J 9.9, 2.3, Ins 3-H), 3.18 
(1H, td, J 8.8, 5.2, ex → t, Ins 6-H) ppm; δC (100 MHz, d6-DMSO) 140.23, 140.06, 139.59 (3 × Ar 
C), 128.57 (2C), 128.45 (2C), 128.33 (2C), 128.03, 127.84 (2C), 127.67 (4C), 127.53, 127.43 (15 × 
Ar CH), 82.45, 80.56, 79.42, 75.60 (4 × Ins CH), 74.51, 74.10 (2 × OCH2Ph), 73.17, 71.97 (2 × Ins 
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CH), 71.91 (OCH2Ph) ppm; HRMS (CI
+) m/z (%) found [M+Na]+ 473.1947 (100), C27H30O6Na 
requires 473.1940. 
1,2,6-O-Tribenzyl-4-O-tert-butyldimethylsilyl-myo-inositol (169) and 2,3,6-O-tribenzyl-4-O-
tert-butyldimethylsilyl-myo-inositol (170) 
OBnTbdmsO
OBn
OHBnO
OH
OBnTbdmsO
OBn
OBnHO
OH  
2,6-O-Dibenzyl-4-O-tert-butyldimethylsilyl-myo-inositol 1,3,5-O-orthobenzoate (167, 100 
mg, 0.15 mmol) was reduced by DIBAL-H using general method 2.  The residue (86 mg) was 
fractionated by chromatography on flash silica. Elution with hexane-EtOAc (9:1 → 3:7 v/v) 
afforded 169 (40 mg, 40 %) and 170 (42 mg, 42 %); for 169 Rf (EtOAc-hexane, 1:1 v/v) 0.72; δH 
(400 MHz, CDCl3) 7.41-7.31 (15H, m, 15 × Ar H), 5.02 (1H, d, J 12.1, 2-OCHHPh), 4.99 (1H, d, J 
11.9), 4.78 (1H, d, J 11.4) (2 × 6-OCHHPh), 4.75 (1H, d, J 12.1, 2-OCHHPh), 4.70 (2H, s, 1-
OCH2Ph), 4.06 (1H, t, J 2.6, Ins 2-H), 3.90 (1H, t, J 9.5, Ins 6-H), 3.80 (1H, t, J 9.1, Ins 4-H), 3.48 
(1H, dd, J 9.7, 2.4, Ins 1-H), 3.37 (1H, t, J 9.0, Ins 5-H), 3.34 (1H, dd, J 9.4, 2.6, Ins 3-H), 2.43 
(1H, bs, Ins OH), 2.17 (1H, bs, Ins OH), 0.93 (9H, s, SiCMe3), 0.14 (3H, s), 0.13 (3H, s) (2 × 
SiMe) ppm; δC (100 MHz, CDCl3) 128.72 (2C), 138.7 (3 × Ar C), 128.41 (2C), 128.38 (3C), 
127.89 (2C), 127.70, 127.66 (2C), 127.64 (3C), 127.61 (2C) (15 × Ar CH), 81.14, 80.82, 77.09, 
75.47 (4 × Ins CH), 75.47 (OCH2Ph), 75.23 (Ins CH), 74.66 (OCH2Ph), 72.95 (Ins CH), 72.70 
(OCH2Ph), 25.93 (SiCMe3), 18.30 (SiCMe3), -4.28, -4.44 (2 × SiMe) ppm; HRMS (ESI
+) m/z (%) 
found [M+H]+ 565.2992 (100), C33H45O6Si requires 565.2985; for 170 Rf (EtOAc-hexane, 1:1 v/v) 
0.63; δH (400 MHz, CDCl3) 7.41-7.30 (15H, m, 15 × Ar H), 4.94 (1H, d, J 11.6, 6-OCHHPh), 4.91 
(1H, d,  J 11.5), 4.83 (1H, d,  J 11.2) (2 × 2-OCHHPh), 4.69 (1H, d,  J 11.5, 6-OCHHPh), 4.66 
(2H, s, 3-OCH2Ph), 4.04 (1H, t, J 9.1, Ins 4-H), 4.02 (1H, t, J 2.8, Ins 2-H), 3.68 (1H, t, J 9.3, Ins 
6-H), 3.53 (1H, ddd, J 9.2, 6.4, 2.6, ex → dd, Ins 1-H), 3.45 (1H, td, J 8.9, 2.1, ex → t, Ins 5-H), 
3.27 (1H, dd, J 9.5, 2.2, Ins 3-H), 2.44 (1H, d, J 2.2, Ins 5-OH), 2.33 (1H, d, J 6.6, Ins 1-OH), 0.92 
(9H, s, SiCMe3), 0.17 (3H, s), 0.09 (3H, s) (2 × SiMe) ppm; δC (125 MHz, CDCl3) 138.79, 138.70, 
137.99 (3 × Ar C), 128.47 (2C), 128.35 (3C), 127.98 (2C), 127.73, 127.62 (7C) (15 × Ar CH), 
81.77, 80.91, 77.11, 76.09 (4 × Ins CH), 74.96, 74.79 (2 × OCH2Ph), 74.07 (Ins CH), 72.73 
(OCH2Ph), 72.32 (Ins CH), 25.99 (SiCMe3), 18.31 (SiCMe3), -4.06, -4.55 (2 × SiMe) ppm; HRMS 
(ESI+) m/z (%) found [M+H]+ 565.2972 (100), C33H45O6Si requires 565.2985. 
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1,2,6-O-Tribenzyl-4-O-tert-butyldiphenylsilyl-myo-inositol (171) and 2,3,6-O-tribenzyl-4-O-
tert-butyldiphenylsilyl-myo-inositol (172) 
OBnTbdpsO
OBn
OHBnO
OH
OBnTbdpsO
OBn
OBnHO
OH  
2,6-O-Dibenzyl-4-O-tert-butyldiphenylsilyl-myo-inositol 1,3,5-O-orthobenzoate (168, 460 
mg, 1.07 mmol) was reduced with DIBAL-H using general method 2.  The residue (430 mg) was 
fractionated by chromatography on flash silica. Elution with hexane-EtOAc (9:1 → 7:3 v/v) 
afforded 171 (193 mg, 42 %) and 172 (153 mg, 33 %); for 171 Rf (EtOAc-hexane, 3:7 v/v) 0.62; δH 
(400 MHz, CDCl3) 7.75-7.72 (4H, m), 7.44-7.26 (19H, m), 7.07-7.05 (2H, m) (25 × Ar H), 4.88 
(2H, d, J 11.3, 2-OCHHPh + 6-OCHHPh), 4.75 (1H, d, J 10.9, 6-OCHHPh), 4.69 (1H, d, J 11.9), 
4.66 (1H, d, J 11.8) (2 × 1-OCHHPh), 4.49 (1H, d, J 11.8, 2-OCHHPh), 3.90 (1H, t, J 2.6, Ins 2-
H), 3.89 (1H, t, J 8.9, Ins 4-H), 3.77 (1H, t, J 9.3, Ins 6-H), 3.59 (1H, td, J 8.9, 2.3, Ins 5-H), 3.46 
(1H, dd, J 9.5, 2.6, Ins 1-H), 3.45 (1H, td, J 8.8, 2.7, Ins 3-H), 2.44 (1H, d, J 2.4, Ins 5-OH), 1.68 
(1H, d, J 8.4, Ins 3-OH), 1.21 (9H, s, SiCMe3) ppm; δC (100 MHz, CDCl3) 138.81, 138.61, 138.13 
(3 × Ar C), 135.85 (2C), 135.82 (2C) (4 × Ar CH), 133.85 (2 × Ar C), 129.66, 129.61, 128.40 (2C), 
128.32 (2C), 128.21 (2C), 127.86 (2C), 127.71 (2C), 127.69, 127.61 (2C), 127.59 (2C), 125.53, 
127.31, 127.12 (2C) (21 × Ar CH), 81.12, 80.66, 77.59, 76.47, 75.53 (5 × Ins CH), 75.51, 74.39 (2 
× OCH2Ph), 72.82 (Ins CH), 72.73 (OCH2Ph), 27.09 (SiCMe3), 19.71 (SiCMe3) ppm; HRMS 
(ESI+) m/z (%) found [M+Na]+ 711.3106 (100), C43H48O6SiNa requires 711.3118; for 172 Rf 
(EtOAc-hexane, 3:7 v/v) 0.34; δH (400 MHz, CDCl3) 7.76-7.68 (4H, m), 7.45-7.18 (17H, m), 7.14-
7.12 (2H, m), 6.96-6.94 (2H, m) (25 × Ar H), 4.88 (1H, d, J 11.2), 4.71 (1H, d, J 11.2) (2 × 6-
OCHHPh), 4.59 (1H, d, J 11.5), 4.53 (1H, d, J 11.4) (2 × 2-OCHHPh), 4.41 (1H, d, J 11.3, 3-
OCHHPh), 4.27 (1H, t, J 8.7, Ins 4-H), 4.19 (1H, d, J 11.3, 3-OCHHPh), 4.04 (1H, t, J 2.1, Ins 2-
H), 3.70 (1H, td, J 8.0, 2.7, Ins 5-H), 3.67-3.60 (2H, m, Ins 1-H + Ins 6-H), 3.41 (1H, dd, J 9.0, 
2.1, Ins 3-H), 2.41 (1H, d, J 3.0, Ins 5-OH), 2.35 (1H, d, J 4.3, Ins 1-OH), 1.04 (9H, s, SiCMe3) 
ppm; δC (100 MHz, CDCl3) 138.69, 138.65, 137.62 (3 × Ar C), 135.94 (2C), 135.87 (2C) (4 × Ar 
CH), 133.88, 133.77 (2 × Ar C), 129.48, 129.44,. 128.42 (2C), 128.18 (2C), 128.02 (2C), 127.93 
(2C), 127.70 (2C), 127.56 (2C), 127.45 (2C), 127.36 (5C) (21 × Ar CH), 81.60, 80.95, 76.29, 
75.83, 75.03 (5 × Ins CH), 74.88, 74.11 (2 × OCH2Ph), 72.23 (Ins CH), 71.77 (OCH2Ph), 27.06 
(SiCMe3), 19.65 (SiCMe3) ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 711.3102 (100), 
C43H48O6SiNa requires 711.3118. 
Stirring 171 or 172 (155 mg, 0.225 mmol) with TBAF (1 M solution in THF, 1.125 mmol) 
in THF (1 mL) for 16 h, followed by purification by chromatography on flash silica (elution with 
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EtOAc-hexane 1:9 → 7:3 v/v) isolated 165 from 171 (70 mg, 69 %) and 166 from 172 (93 mg, 92 
%), as characterized previously. 
2,3,6-O-Tribenzyl-4-C-methyl-myo-inositol (175a) 
BnO
OBn
OH
OH
OH
BnO
 
2,6-O-Dibenzyl-4-C-methyl-myo-inositol 1,3,5-O-orthobenzoate (115, 100 mg, 0.21 mmol) 
was treated with DIBAL-H according to general method 3.  The crude material was fractionated 
using chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 2:5 v/v) afforded the 
title compound (175a, 55 mg, 55 %) as a clear glass; Rf (EtOAc-hexane, 3:7 v/v) 0.09; δH (500 
MHz, CD3OD) 7.44-7.21 (15H, m, 15 × Ar H), 4.84-4.81 (3H, m, 6-OCH2Ph, 2-OCHHPh), 4.73  
(1H, d, J 11.7, 3-OCHHPh), 4.72 (1H, d, J 11.4, 2-OCHHPh), 4.66 (1H, d, J 11.7, 3-OCHHPh), 
3.99 (1H, t, J 2.8, Ins 2-H), 3.86 (1H, bs, Ins OH), 3.74 (1H, bs, Ins OH), 3.55-3.50 (2H, m, Ins 1-
H + Ins 6-H), 3.39 (1H, d, J 8.9, Ins 5-H), 3.37 (1H, d, J 2.8, Ins 3-H), 2.79 (1H, bs, Ins OH), 1.41 
(3H, s, Ins 4-CH3) ppm; δC (125 MHz, CD3OD) 140.50, 140.40, 140.22 (3 × Ar C), 129.29 (2C), 
129.45 (2C), 128.14 (2C), 129.10 (2C), 128.93 (2C), 128.83 (2C), 128.53, 128.46, 128.32 (15 × Ar 
CH), 84.04, 82.55, 79.23, 78.89 (4 × Ins CH), 78.24 (Ins C), 76.09, 75.88, 74.35 (3 × OCH2Ph), 
73.31 (Ins CH), 17.70 (Ins 4-CH3) ppm; HRMS (CI
+) m/z (%) found [M+NH4]
+ 482.2545 (100), 
C28H36NO6 requires 482.2542. 
2,6-O-Dibenzyl-4-C-ethyl-myo-inositol 3,5-O-benzylidene acetal (176b) and 2,3,6-O-tribenzyl-
4-C-ethyl-myo-inositol (175b) 
BnO
OBn
OH
OH
OH
BnO
OO
OH
OBn
OBn
Ph
H
OH  
2,6-O-Dibenzyl-4-C-ethyl-myo-inositol 1,3,5-O-orthobenzoate (136, 220 mg, 0.46 mmol) 
was treated with DIBAL-H for 12 h, according to general method 3.  The crude material was 
fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 1:1 v/v) 
afforded the benzylidene acetal (176b, 42 mg, 19 %) and tribenzyl (175b, 72 mg, 32 %). 
Treatment of 2,6-O-dibenzyl-4-C-ethyl-myo-inositol 1,3,5-O-orthobenzoate (136, 350 mg, 
0.74 mmol) with. DIBAL-H according to general method 3 for 48 h afforded only the tribenzyl 
(175b, 216 mg, 61 %) after purification by chromatography on flash silica as detailed above. 
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For 2,6-O-dibenzyl-4-C-ethyl-myo-inositol 3,5-O-benzylidene acetal, 176b: Rf (EtOAc-
hexane, 3:7 v/v) 0.23; δH (500 MHz, d6-DMSO) 7.40-7.25 (15H, m, 15 × Ar H), 5.98 (1H, s, 
PhCHO2), 4.93 (1H, s, ex, Ins 4-OH), 4.74 (1H, d, J 12.1, 2-OCHHPh), 4.70 (2H, s, 6-OCH2Ph), 
4.67 (1H, d, J 7.4, ex, Ins 1-OH), 4.64 (1H, d, J 12.1, 2-OCHHPh), 4.46 (1H, q, J 7.7, ex → t, Ins 
1-H), 4.20 (1H, dd, J 6.6, 1.9, Ins 3-H), 4.13 (1H, dd, J 8.2, 6.8, Ins 2-H), 3.94 (1H, d, J 6.3, Ins 6-
H), 3.83 (1H, d, J 1.7, Ins 5-H), 2.01 (1H, dq, J 14.3, 6.9), 1.90 (1H, dq, J 14.3, 7.7) (2 × 
CHHCH3), 0.90 (3H, t, J 7.4, CH2CH3) ppm; δC (100 MHz, d6-DMSO) 139.20 (2C), 139.16 (3 × 
Ar C), 129.12 , 128.60 (2C), 128.57 (2C), 128.50 (2C), 128.09 (2C), 127.98 (2C), 127.79, 127.78, 
126.73 (2C) (15 × Ar CH), 92.57 (PhCHO2), 84.95, 77.48, 72.92, 72.46 (4 × Ins CH), 72.00, 71.60 
(2 × OCH2Ph), 69.36 (Ins CH), 69.02 (Ins C), 28.75 (CH2CH3), 7.06 (CH2CH3) ppm; HRMS (ESI
+) 
m/z (%) found [M+Na]+ 499.2093 (100), C29H32O6Na requires 499.2097. 
For 2,3,6-O-tribenzyl-4-C-ethyl-myo-inositol, 175b: Rf (EtOAc-hexane, 3:7 v/v) 0.32; δH 
(400 MHz, CDCl3) 7.42-7.27 (15H, m, 15 × Ar H), 4.91 (1H, d, J 10.8), 4.77 (1H, d, J 11.2), 4.70 
(1H, d, J 11.7), 4.69 (1H, d, J 11.2), 4.67 (1H, d, J 10.8), 4.63 (1H, d, J 11.7) (6 × OCHHPh), 4.37 
(1H, m, Ins H), 4.16 (1H, t, J 3.2, Ins 2-H), 4.16-4.13 (1H, m), 3.92 (1H, m), 3.74 (1H, m) (3 × Ins 
H), 2.11 (1H, dq, J 13.7, 6.8), 1.77 (1H, dq, J 13.7, 7.3) (2 × CHHCH3), 1.03 (3H, t, J 7.3, 
CH2CH3) ppm; δC (100 MHz, CDCl3) 137.89, 137.74, 136.80 (3 × Ar C), 128.70 (2C), 128.56 
(4C), 128.36, 127.99, 127.93 (5C), 127.73 (2C) (15 × Ar CH), 83.94, 80.51 (2 × Ins CH), 76.63 
(OCH2Ph), 75.90 (Ins C), 73.56 (Ins CH), 73.47, 71.06 (2 × OCH2Ph), 70.70, 69.48 (2 × Ins CH), 
27.77 (CH2CH3), 6.42 (CH2CH3) ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 501.2251 (100), 
C29H34O6Na requires 501.2253. 
2,6-O-Dibenzyl-4-C-pentyl-myo-inositol 3,5-O-benzylidene acetal (176c) and 2,3,6-O-
tribenzyl-4-C-pentyl-myo-inositol (175c) 
BnO
OBn
OH
OH
OH
BnO
OO
OH
OBn
OBn
Ph
H
OH  
2,6-O-Dibenzyl-4-C-pentyl-myo-inositol 1,3,5-O-orthobenzoate (133, 510 mg, 0.99 mmol) 
was treated with DIBAL-H according to general method 3.  The crude material was fractionated 
using chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 3:2 v/v) afforded the 
benzylidene acetal (176c, 68 mg, 13 %) and tribenzyl (175c, 276 mg, 54 %).  
For 2,6-O-dibenzyl-4-C-pentyl-myo-inositol 3,5-O-benzylidene acetal, 176c: Rf (EtOAc-
hexane, 3:7 v/v) 0.39; δH (500 MHz, d6-DMSO) 7.40-7.25 (15H, m, 15 × Ar H), 5.99 (1H, s, 
PhCHO2), 4.94 (1H, s, ex, Ins 4-OH), 4.73 (1H, d, J 11.8, 2-OCHHPh), 4.70 (2H, s, 6-OCH2Ph), 
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4.66 (1H, d, J 7.4, ex, Ins 1-OH), 4.64 (1H, d, J 12.1, 2-OCHHPh), 4.45 (1H, q, J 7.3, ex → t, Ins 
1-H), 4.20 (1H, dd, J 6.6, 1.7, Ins 3-H), 4.13 (1H, t, J 6.6, Ins 2-H), 3.93 (1H, d, J 6.3, Ins 6-H), 
3.82 (1H, d, J 1.4, Ins 5-H), 2.01-1.95 (1H, m), 1.92-1.87 (1H, m) [2 × CHH(CH2)3CH3], 1.43-1.39 
[2H, m, CH2CH2(CH2)2CH3], 1.33-1.25 [4H, m, 2 × (CH2)2(CH2)2CH3], 0.87 [3H, t, J 6.9, 
(CH2)4CH3] ppm; δC (100 MHz, d6-DMSO) 139.24, 139.22, 139.16 (3 × Ar C), 129.12 , 128.59 
(2C), 128.55 (2C), 128.52 (2C), 128.07 (2C), 127.98 (2C), 127.78, 127.74, 126.71 (2C) (15 × Ar 
CH), 92.59 (PhCHO2), 84.99, 77.75, 72.92, 72.85 (4 × Ins CH), 72.00, 71.59 (2 × OCH2Ph), 69.33 
(Ins CH), 68.99 (Ins C), 36.30, 32.42, 22.67, 21.77 (4 × CH2), 14.43 (CH3) ppm; HRMS (ESI
+) m/z 
(%) found [M+Na]+ 541.2556 (100), C32H38O6Na requires 541.2566. 
For 2,3,6-O-tribenzyl-4-C-pentyl-myo-inositol, 175c: Rf (EtOAc-hexane, 3:7 v/v) 0.26; δH 
(400 MHz, CDCl3) 7.42-7.26 (15H, m, 15 × Ar H), 4.91 (1H, d, J 10.8), 4.77 (1H, d, J 11.7), 4.72-
4.61 (4H, m) (6 × OCHHPh), 4.39-4.36 (1H, m), 4.18-4.13 (2H, m), 3.93-3.92 (1H, m), 3.73-3.72 
(1H, m) (5 × Ins H), 2.02 (1H, td, J 13.2, 4.9), 1.75-1.67 (1H, m) [2 × CHH(CH2)3CH3], 1.55-1.46 
[2H, m, CH2CH2(CH2)2CH3], 1.39-1.29 [4H, m, 2 × (CH2)2(CH2)2CH3], 0.93 [3H, t, J 6.8 
(CH2)4CH3] ppm; δC (100 MHz, CDCl3) 137.90 (2C), 137.75 (3 × Ar C), 128.69 (2C), 128.54 (4C), 
128.34, 127.97 (4C), 127.90 (2C), 127.73 (2C) (15 × Ar CH), 83.97, 80.58, 76.38 (3 × Ins CH), 
75.89 (2 × OCH2Ph), 73.62 (Ins CH), 73.46 (OCH2Ph), 71.17 (Ins C), 69.48 (Ins CH), 35.22, 
32.47, 22.78, 21.64 (4 × CH2), 14.14 (CH3) ppm; HRMS (ESI
+) m/z (%) found [M+Na]+ 543.2723 
(100), C32H40O6Na requires 543.2723. 
2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol 3,5-O-benzylidene acetal (176e) and 2,3,6-O-
tribenzyl-4-C-neopentyl-myo-inositol (175e) 
BnO
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2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol 1,3,5-O-orthobenzoate (144, 290 mg, 0.51 
mmol) was treated with DIBAL-H according to general method 3.  The crude material was 
fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 3:2 v/v) 
afforded the benzylidene acetal (176e, 170 mg, 58 %) and tribenzyl (175e, 36 mg, 12 %). 
For 2,6-O-dibenzyl-4-C-neopentyl-myo-inositol 3,5-O-benzylidene acetal, 176e: Rf 
(EtOAc-hexane, 3:7 v/v) 0.47; δH (400 MHz, d6-DMSO) 7.42-7.27 (15H, m, 15 × Ar H), 6.02 (1H, 
s, PhCHO2), 4.73 (1H, s, ex, Ins 4-OH), 4.73 (1H, d, J 12.2, OCHHPh), 4.70 (2H, s, OCH2Ph), 
4.69 (1H, d, J 7.3, ex, Ins 1-OH), 4.66 (1H, d, J 11.7, OCHHPh), 4.44 (1H, q, J 7.3, ex → t, Ins 1-
H), 4.32 (1H, dd, J 6.4, 1.5, Ins 3-H), 4.17 (1H, dd, J 8.3, 6.4, Ins 2-H), 3.93 (1H, s, Ins 5-H), 3.92 
Chapter 7: Experimental 
 
 
 
- 154 - 
(1H, d, J 5.4, Ins 6-H), 2.03 (1H, d, J 15.2), 1.95 (1H, d, J 14.7) [2 × CHHC(CH3)3], 1.05 [9H, s, 
CH2C(CH3)3] ppm; δC (100 MHz, d6-DMSO) 139.36, 139.19 (2C) (3 × Ar C), 129.13, 128.62 (2C), 
128.55 (4C), 128.04 (2C), 127.96 (2C), 127.79 (2C), 126.83 (2C) (15 × Ar CH), 92.72 (PhCHO2), 
85.43, 77.97, 73.68, 72.74 (4 × Ins CH), 71.99, 71.59 (2 × OCH2Ph), 70.43 (Ins C), 69.07 (Ins CH), 
47.92 [CH2C(CH3)3] 32.15 [CH2C(CH3)3], 31.24 [CH2C(CH3)3] ppm; HRMS (ESI
+) m/z (%) found 
[M+Na]+ 541.2563 (82), C32H38O6Na requires 541.2566. 
For 2,3,6-O-tribenzyl-4-C-neopentyl-myo-inositol, 175e: Rf (EtOAc-hexane, 3:7 v/v) 0.29; 
δH (400 MHz, CDCl3) 7.42-7.27 (15H, m, 15 × Ar H), 4.94 (1H, d, J 10.8), 4.77 (1H, d, J 11.2), 
4.70 (1H, d, J 11.2), 4.67 (2H, d, J 10.3), 4.62 (1H, d, J 11.7) (6 × OCHHPh), 4.37-4.35 (1H, m), 
4.17-4.14 (2H, m), 3.94-3.93 (2H, m) (5 × Ins H), 2.14 (1H, d, J 15.1), 1.55 (1H, d, J 14.7) [2 × 
CHHC(CH3)3], 1.10 [9H, s, CH2C(CH3)3] ppm; δC (100 MHz, CDCl3) 137.91, 137.71, 136.79 (3 × 
Ar C), 128.71 (2C), 128.55 (4C), 128.37, 128.06 (2C), 128.01, 127.93 (3C), 127.72 (2C) (15 × Ar 
CH), 86.11, 81.07 (2 × Ins CH), 76.72, 73.48 (2 × OCH2Ph), 73.33, 71.35 (2 × Ins CH), 70.94 
(OCH2Ph), 68.98 (Ins CH), 46.15 [CH2C(CH3)3], 31.95 [CH2C(CH3)3], 31.46 [CH2C(CH3)3] ppm; 
HRMS (ESI+) m/z (%) found [M+Na]+ 543.2726 (100), C32H40O6Na requires 543.2723. 
* No quaternary carbon was visible in the 13C-NMR due to the fluxional nature of the compound. 
2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 3,5-O-benzylidene acetal (176f) and 2,3,6-O-
tribenzyl-4-C-benzyl-myo-inositol (175f) 
BnO
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 1,3,5-O-orthobenzoate (125, 294 mg, 0.55 mmol) 
was treated with DIBAL-H according to general method 3.  The crude material was fractionated 
using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 1:1 v/v) afforded the 
benzylidene acetal (176f, 83 mg, 28 %) and tribenzyl (175f, 115 mg, 39 %).  
For 2,6-O-dibenzyl-4-C-benzyl-myo-inositol 3,5-O-benzylidene acetal, 176f: Rf (EtOAc-
hexane, 3:7 v/v) 0.38; δH (400 MHz, d6-DMSO) 7.50-7.44 (2H, m), 7.43-7.22 (18H, m) (20 × Ar 
H), 6.09 (1H, s, PhCHO2), 5.23 (1H, s, ex, Ins 4-OH), 4.72 (1H, d, J 7.3, ex, Ins 1-OH), 4.69 (1H, 
d, J 11.7), 4.65 (1H, d, J 11.7), 4.64 (1H, d, J 12.2), 4.60 (1H, d, J 12.2) (4 × OCHHPh), 4.43 (1H, 
q, J 7.3, ex → t, Ins 1-H), 4.06-3.97 (2H, m, Ins 2-H + Ins 3-H), 3.98 (1H, d, J 6.4, Ins 6-H), 3.80 
(1H, s, Ins 5-H), 3.41 (1H, d, J 13.2), 3.14 (1H, d, J 13.7) (2 × 4-CCHHPh) ppm; δC (100 MHz, d6-
DMSO) 139.23, 139.12 (2C), 137.41 (4 × Ar C), 131.30 (2C), 128.67 (2C), 128.60 (2C), 128.52 
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(2C), 128.23 (2C), 128.14 (3C), 127.90 (3C), 127.79, 127.76, 126.84 (2C) (20 × Ar CH), 92.96 
(PhCHO2), 85.07, 77.72, 72.92, 72.14 (4 × Ins CH), 72.12, 71.68 (2 × OCH2Ph), 69.52 (Ins C), 
69.40 (Ins CH), 41.94 (4-CCH2Ph) ppm; HRMS (ESI
+) m/z (%) found [M+H]+ 539.2434 (26), 
C34H35O6 requires 539.2434, [M+Na]
+ 561.2250 (70). 
For 2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol, 175f: Rf (EtOAc-hexane, 3:7 v/v) 0.22; δH 
(400 MHz, d6-DMSO) 7.44-7.41 (4H, m), 7.36-7.23 (12H, m), 7.12-7.10 (4H, m) (20 × Ar H), 4.87 
(1H, d, J 5.9, ex, Ins OH), 4.82 (2H, d, J 11.7), 4.75 (2H, d, J 11.7), 4.73-4.62 (1H, m), 4.45 (1H, 
d, J 11.7) (6 × OCHHPh), 4.02 (1H, t, J 2.9, Ins 2-H), 3.97 (1H, s, ex, Ins OH), 3.76-3.65 (2H, m), 
3.52-3.50 (1H, m) (3 × Ins H), 3.41 (1H, s, ex, Ins OH), 3.36 (1H, d, J 9.6, Ins H), 3.20 (1H, d, J 
13.7, 4-CCHHPh), 3.08 (1H, d, J 13.7, 4-CCHHPh) ppm; HRMS (ESI+) m/z (%) found [M+Na]+ 
563.2404 (100), C34H36O6Na requires 563.2410. 
* 13C-NMR too fluxional to interpret 
2,6-O-Dibenzyl-4-C-(2-naphthyl)methyl-myo-inositol 3,5-O-benzylidene acetal (176g) and 
2,3,6-O-tribenzyl-4-C-(2-naphthyl)methyl-myo-inositol (175g) 
BnO
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2,6-O-Dibenzyl-4-C-(2-naphthyl)methyl-myo-inositol 1,3,5-O-orthobenzoate (145, 280 
mg, 0.48 mmol) was treated with DIBAL-H according to general method 3.  The crude material 
was fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 3:2 
v/v) afforded the benzylidene acetal (176g, 118 mg, 42 %) and tribenzyl (175g, 82 mg, 29 %). 
For 2,6-O-dibenzyl-4-C-(2-naphthyl)methyl-myo-inositol 3,5-O-benzylidene acetal, 176g: 
Rf (EtOAc-hexane, 3:7 v/v) 0.42; δH (400 MHz, d6-DMSO) 7.89-7.82 (3H, m), 7.77 (1H, s), 7.55-
7.39 (8H, m), 7.36-7.23 (10H, m) (22 × Ar H), 6.12 (1H, s, PhCHO2), 5.31 (1H, s, ex, Ins 4-OH), 
4.71 (1H, d, J 7.3, ex, Ins 1-OH), 4.68 (1H, d, J 11.7), 4.64 (2H, bd, J 9.8), 4.59 (1H, d, J 11.7) (4 
× OCHHPh), 4.42 (1H, q, J 6.8, ex → t, Ins 1-H), 4.09-4.03 (2H, m, Ins 2-H + Ins 3-H), 3.99 (1H, 
d, J 5.9, Ins 6-H), 3.86 (1H, s, Ins 5-H), 3.58 (1H, d, J 13.2), 3.32 (1H, d, J 12.7) (2 × CHHAr) 
ppm; δC (100 MHz, d6-DMSO) 139.03, 138.92, 138.81, 135.10, 133.27, 132.21 (6 × Ar C), 129.96, 
129.47, 129.31, 128.77 (2C), 128.60 (2C), 128.55 (2C), 128.14 (2C), 127.90 (4C), 127.85 (2C), 
127.46, 126.91 (2C), 126.39, 125.84 (22 × Ar CH), 93.10 (PhCHO2), 84.78, 77.30, 72.78, 72.43 (4 
× Ins CH), 72.13, 71.56 (2 × OCH2Ph), 69.62 (Ins CH), 69.18 (Ins C), 42.56 (CH2Ar) ppm; HRMS 
(ESI+) m/z (%) found [M+H]+ 589.2597 (11), C38H37O6 requires 589.2590, [M+Na]
+ 611.2384 (54). 
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For 2,3,6-O-tribenzyl-4-C-CH2naphthyl-myo-inositol, 175g: Rf (EtOAc-hexane, 3:7 v/v) 
0.25; δH (400 MHz, CDCl3) 7.86-7.78 (4H, m), 7.60-7.57 (1H, dd, J 8.3, 1.0), 7.48-7.45 (2H, m), 
7.40-7.34 (10H, m), 7.28-7.27 (3H, m) (22 × Ar H), 5.01 (1H, d, J 10.8), 4.74 (1H, d, J 11.7), 4.68 
(1H, d, J 11.7), 4.66 (1H, d, J 10.8), 4.57 (1H, d, J 11.7), 4.51 (1H, d, J 11.2) (6 × OCHHPh), 4.36-
4.33 (1H, m, Ins H), 4.20 (1H, t, J 3.4, Ins 2-H), 4.14-4.12 (1H, m), 3.94-3.93 (1H, m) (2 × Ins H), 
3.62 (1H, d, J 13.7, CHHAr), 3.56 (1H, m, Ins H), 3.12 (1H, d, J 12.2, CHHAr) ppm; HRMS 
(ESI+) m/z (%) found [M+Na]+ 613.2577 (100), C38H38O6Na requires 613.2566. 
* 13C-NMR spectrum too fluxional to interpret 
1,5-O-Diacetyl-2,3,6-O-tribenzyl-4-C-pentyl-myo-inositol (177c) 
BnO
OBn
OAc
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BnO
 
To 2,3,6-O-tribenzyl-4-C-pentyl-myo-inositol (175c, 35 mg, 0.07 mmol) in pyridine (0.3 
mL) was added DMAP (4 mg, 0.03 mmol), triethylamine (61 µL, 0.44 mmol) and acetic anhydride 
(35 µL, 0.37 mmol).  After 18 h, H2O (1 mL) was added and the crude material extracted into 
CH2Cl2.  The organic layer was washed with brine, dried (MgSO4) and all solvents evaporated 
under reduced pressure.  The crude material was fractionated by chromatography on flash silica.  
Elution with EtOAc-hexane (1:9 → 1:1, v/v) afforded the title compound (177c, 37 mg, 98 %); Rf 
(EtOAc-hexane, 3:7 v/v) 0.45; δH (400 MHz, CDCl3) 7.37-7.26 (15H, m, 15 × Ar H), 5.01 (1H, d, J 
9.6, Ins 5-H), 4.92 (1H, bd, J 6.0, Ins 1-H), 4.75 (1H, d, J 11.6), 4.70-4.63 (5H, m) (6 × OCHHPh), 
4.24 (1H, t, J 3.2, Ins 2-H), 3.99 (1H, t, J 9.6, Ins 6-H), 3.55 (1H, m, Ins 3-H), 2.06 (3H, s), 1.98 
(3H, s) (2 × OCOCH3), 1.71-1.66 (1H, m) [2 × CHH(CH2)3CH3], 1.51-1.46 [2H, m, 
CH2CH2(CH2)2CH3], 1.33-1.22 [4H, m, 2 × (CH2)2(CH2)2CH3], 0.90 [3H, t, J 6.8 (CH2)4CH3] ppm; 
HRMS (ESI+) m/z (%) found [M+Na]+ 627.2928 (100), C36H44O8Na requires 627.2934. 
1,5-O-Diacetyl-2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol (177f) 
BnO
OBn
OAc
OH
OAc
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To 2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol (175f, 19 mg, 0.04 mmol) in pyridine (0.25 
mL) was added DMAP (2 mg, 0.01 mmol), triethylamine (29 µL, 0.21 mmol) and acetic anhydride 
(17 µL, 0.18 mmol).  After 18 h, H2O (1 mL) was added and the crude material extracted into 
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CH2Cl2.  The organic layer was washed with brine, dried (MgSO4) and all solvents evaporated 
under reduced pressure.  The crude material was fractionated by chromatography on flash silica.  
Elution with EtOAc-hexane (1:9 → 1:1, v/v) afforded the title compound (177f, 22 mg, 100 %); Rf 
(EtOAc-hexane, 3:7 v/v) 0.47; δH (400 MHz, CDCl3) 7.39-7.22 (20H, m, 20 × Ar H), 5.01 (1H, d, J 
9.8, Ins 5-H), 4.95 (1H, bd, J 7.8, Ins 1-H), 4.84 (1H, d, J 12.2), 4.78-4.74 (3H, m), 4.71 (1H, d, J 
11.7), 4.70 (1H, d, J 11.7) (6 × OCHHPh), 4.26 (1H, t, J 2.9, Ins 2-H), 4.18 (1H, t, J 9.3, Ins 6-H), 
3.64 (1H, d, J 2.4, Ins 3-H), 3.57 (1H, d, J 14.2), 3.25 (1H, d, J 14.2) (2 × 4-CCHHPh), 2.72 (1H, 
bs, Ins 4-OH), 2.00 (3H, s), 1.76 (3H, s) (2 × OCOCH3) ppm; δC (100 MHz, CDCl3) 170.74, 
170.19 (2 × OCOCH3), 138.38, 138.29, 138.14, 137.55 (4 × Ar C), 131.68 (2C), 128.44 (2C), 
128.38 (4C), 127.87 (2C), 127.82 (3C), 127.75 (2C), 127.63 (2C), 127.33 (2C), 126.20 (20 × Ar 
CH), 82.69, 77.76, 76.35, 75.06 (2C) (5 × Ins CH), 74.99 (2C), 73.94 (3 × OCH2Ph), 38.12 
(CCH2Ph), 20.95, 20.57 (2 × OCOCH3) ppm; HRMS (ESI
+) m/z (%) found [M+H]+ 625.2830 (7), 
C38H41O8 requires 625.2801, [M+Na]
+ 647.2647 (100). 
7.5 Chapter 5 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-methyl-myo-inositol (179a)   
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2,6-O-Dibenzyl-4-C-methyl-myo-inositol (151a, 75 mg, 0.20 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
general method 7.  The residue was fractionated by chromatography on flash silica. Elution with 
hexane-EtOAc (3:1 → 0:1: v/v) afforded the title compound (179a, 178 mg, 63 %); Rf (EtOAc-
CH2Cl2, 1:4 v/v) 0.52; δH (400 MHz, CDCl3) 7.41-7.01 (50H, m, 50 × Ar H), 5.12-4.67 [25H, m, 
(20 × Ph-CHHO) + (5 × Ins H)], 1.31 (3H, s, Ins 4-CH3) ppm; δP (162 MHz, CDCl3) -1.46, -1.65, -
1.86, -6.30 ppm; MS (MALDI-TOF) m/z (%) found [M+Na]+ 1438 (40). 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-ethyl-myo-inositol (179b) 
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2,6-O-Dibenzyl-4-C-ethyl-myo-inositol (151b, 72 mg, 0.19 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
general method 7.  The residue was fractionated by chromatography on flash silica. Elution with 
EtOAc-hexane (1:9 → 1:0: v/v) afforded the title compound (179b, 82 mg, 31 %); Rf (EtOAc-
hexane, 2:3 v/v) 0.05; δH (400 MHz, CDCl3) 7.38-7.35 (2H, m), 7.27-7.23 (10H, m), 7.22-7.10 
(33H, m), 7.08-7.04 (5H, m) (50 × Ar H), 5.41 (1H, dd, J 10.5, 2.7, Ins 3-H), 5.12-5.04 (2H, m, Ins 
5-H + OCHHPh), 4.99-4.72 [13H, m, (12 × OCHHPh) + Ins 1-H], 4.65 (1H, d, J 11.8, OCHHPh), 
4.61 (1H, d, J 11.3, OCHHPh), 4.52 (1H, t, J 2.8, Ins 6-H), 4.50 (1H, d, J 11.8, OCHHPh), 4.33-
4.30 (1H, m, Ins 2-H), 2.34 (2H, q, J 7.4, CH2CH3), 1.13 (3H, t, J 7.4, CH2CH3) ppm; δC (100 
MHz, CDCl3) 137.90, 137.69 (2 × Ar C), 136.47 (d, J 7.8), 136.16-135.86 (7C, m) (8 × 
ArCCH2OP), 128.45 (3C), 128.44 (5C), 128.34 (12C), 128.29 (5C), 128.24 (2C), 128.13 (3C), 
128.12 (2C), 128.01 (2C), 127.95 (2C), 127.93 (2C), 127.87, 127.84 (2C), 127.79 (4C), 127.73 
(2C), 127.68 (2C), 127.62 (50 × Ar CH), 86.84 (m, Ins 4-C), 78.79, 77.20 (2 × Ins CH), 75.13 (t, J 
5.2), 74.14 (d, J 4.3) (2 × Ins CH), 73.44, 72.09 (2 × OCH2Ph), 71.45-71.28 (m, Ins CH), 69.68 (d, 
J 6.1), 69.62 (d, J 6.1), 69.52 (d, J 6.1), 69.39 (d, J 5.2), 69.37 (d, J 5.2), 69.31 (d, J 5.2), 69.23 (d, 
J 5.2), 69.20 (d, J 5.2) (8 × POCH2Ph), 26.43 (CH2CH3), 6.50 (CH2CH3) ppm; δP (162 MHz, 
CDCl3) -0.94, -1.76, -1.96, -7.07 ppm; MS (ES
+) m/z (%) found [M+H]+ 1429 (100), [M+Na]+ 
1451 (57). 
*Inositol peaks assigned using NOESY and COSY spectroscopy. 
1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-pentyl-myo-inositol (179c) 
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2,6-O-Dibenzyl-4-C-pentyl-myo-inositol (151c, 71 mg, 0.17 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
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general method 7.  The residue was fractionated by chromatography on flash silica. Elution with 
EtOAc-hexane (1:4 → 1:0: v/v) afforded the title compound (179c, 69 mg, 28 %); Rf  (EtOAc-
hexane, 7:3 v/v) 0.52; δH (400 MHz, CDCl3) 7.39-7.36 (2H, m), 7.32-7.11 (43H, m), 7.09-7.06 
(5H, m) (50 × Ar H), 5.43 (1H, dd, J 10.8, 2.8, Ins H), 5.10-5.05 (2H, m, Ins H + OCHHPh), 4.97-
4.79 [13H, m, (12 × OCHHPh) + Ins H], 4.67 (1H, d, J 11.9), 4.64 (1H, d, J 11.5) (2 × OCHHPh), 
4.54-4.52 (1H, m, Ins H), 4.52 (1H, d, J 11.9, OCHHPh), 4.36-4.33 (1H, m, Ins H), 2.27-2.22 (2H, 
m), 1.71-1.62 (2H, m), 1.14-0.85 (4H, m) (4 × CH2), 0.72 (3H, t, J 7.0, CH3) ppm; δC (100 MHz, 
CDCl3) 137.89, 137.65 (2 × Ar C), 136.44 (d, J 7.8), 136.04 (3C, d, J 7.8), 135.87 (3C, d, J 6.9), 
135.82 (d, J 6.9) (8 × Ar CCH2OP), 128.37 (5C), 128.34 (4C), 128.29 (12C), 128.25 (5C), 128.19 
(5C), 128.05 (3C), 127.95 (2C), 127.90 (2C), 127.84 (3C), 127.78 (2C), 127.74 (2C), 127.65 (2C), 
127.61 (2C), 127.54 (50 × Ar CH), 86.76-86.58 (m, Ins C), 78.69, 77.16, 75.38 (br), 74.20 (br) (4 × 
Ins CH), 73.40, 72.13 (2 × OCH2Ph), 71.39-71.28 (m, Ins CH), 69.58 (d, J 6.9), 69.52 (d, J 6.9), 
69.45 (d, J 6.1), 69.33 (d, J 5.2), 69.30 (d, J 6.1), 69.23 (d, J 6.1), 69.18 (d, J 5.2), 69.08 (d, J 5.2) 
(8 × POCH2Ph), 33.74, 32.09, 22.51, 21.33 (4 × CH2), 14.03 (CH3) ppm; δP (162 MHz, CDCl3) -
0.96, -1.73, -2.05, -7.06 ppm; MS (ES+) m/z (%) found [M+H]+ 1471 (100), [M+Na]+ 1493 (49). 
1,3,4,5-O-Tetrakis (dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-benzyl-myo-inositol (179f) 
and 1,3,5-O-Tris(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-benzyl-myo-inositol (190f) 
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol (151f, 195 mg, 0.43 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
general method 7.  The residue was fractionated by chromatography on flash silica. Elution with 
EtOAc-hexane (1:9 → 7:3: v/v) afforded an inseperable mixture of the title compounds (420 mg); 
Rf  (EtOAc-hexane, 3:7 v/v) 0.21; MS (ES
+) m/z (%) found triphosphate [M+H]+ 1231 (53), 
[M+Na]+ 1253 (36); δP (162 MHz, CDCl3) -0.34, -1.24, -1.76 ppm and tetraphosphate 179f [M+H]+ 
1491 (100), [M+Na]+ 1513 (56); δP (162 MHz, CDCl3) -1.53, -3.05 (2P), -7.09 ppm. 
Chapter 7: Experimental 
 
 
 
- 160 - 
4-C-Methyl-myo-inositol 1,3,4,5-O-tetraphosphate (191a)   
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-methyl-myo-inositol 
(179a, 350 mg, 0.25 mmol) was hydrogenated according to general method 10 to yield the title 
compound (191a, 69 mg, 100 %); δH (500 MHz, D2O) 4.23 (1H, t, J 3.4, Ins 2-H), 4.14 (1H, dd, J 
10.1, 3.4, Ins 3-H), 4.02 (1H, t, J 9.5, Ins 5-H), 3.87 (1H, ddd J 10.1, 8.5, 3.3, Ins 1-H), 3.66 (1H, t, 
J 9.9, Ins 6-H), 1.44 (3H, s, Ins 4-CH3) ppm; δC (125 MHz, D2O) 84.05 (dt, J 6.8, 4.9, Ins 4-
CCH3), 81.28 (bm), 76.69 (d, J 5.7), 73.92 (d, J 5.2), 70.48 (s), 70.21 (bm) (5 × Ins CH), 15.21 (s, 
Ins 4-CH3) ppm; δP (162 MHz, D2O) 1.74, 1.38, 0.83, -2.35 ppm; HRMS (ESI-) m/z (%) found [M-
H]- 512.9350 (77), C7H17O18P4 requires 512.9365. 
4-C-Ethyl-myo-inositol 1,3,4,5-O-tetraphosphate (191b) 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-ethyl-myo-inositol (179b, 
160 mg, 0.11 mmol) was hydrogenated according to general method 6 to yield the title compound 
(191b, 59 mg, 100 %); δH (500 MHz, D2O) 4.51 (1H, dd, J 9.3, 2.9, Ins 3-H), 4.37 (1H, t, J 9.3, Ins 
5-H), 4.36 (1H, t, J 3.4, Ins 2-H), 3.89 (1H, td, J 9.3, 3.4, Ins 1-H), 3.77 (1H, t, J 8.8, Ins 6-H), 
1.94-1.83 (2H, m, CH2CH3), 0.93 (3H, t, J 7.3, CH2CH3) ppm; δC (125 MHz, D2O) 84.68 (quintet, 
J 4.8, Ins C), 79.16-78.86 (m), 75.48 (d, J 6.4), 74.64 (d, J 4.8), 70.80 (d, J 6.4), 69.86-69.61 (m) (5 
× Ins CH), 24.95 (d, J 6.4, CH2CH3), 8.94 (CH2CH3) ppm; δP (162 MHz, D2O) 1.87, 0.71, 0.27, -
4.03 ppm; HRMS (ES-) m/z (%) found [M-H]- 526.9519 (100), C8H19O18P4 requires 526.9522. 
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4-C-Pentyl-myo-inositol 1,3,4,5-O-tetraphosphate (191c) 
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1,3,4,5-O-Tetrakis(dibenzyloxyphosphoryl)-2,6-O-dibenzyl-4-C-pentyl-myo-inositol 
(179c, 95 mg, 0.06 mmol) was hydrogenated according to general method 10 to yield the title 
compound (191c, 40 mg, 94 %); δH (500 MHz, D2O, 298 K) 4.59 (1H, dd J 9.5, 3.0, Ins 3-H), 4.45 
(1H, t, J 9.3, Ins 5-H), 4.44 (1H, t, J 3.0, Ins 2-H), 3.97 (1H, dt, J 9.2, 3.6, Ins 1-H), 3.83 (1H, t, J 
9.0, Ins 6-H), 1.96-1.91 (1H, m), 1.87-1.81 (1H, m), 1.61 (2H, quintet, J 7.8), 1.23 (2H, sextet, J 
7.3), 1.18-1.13 (2H, m) (4 × CH2), 0.79 (3H, t, J 7.4, CH3) ppm; δC (125 MHz, D2O, 298 K) 84.97 
(q, J 4.9, Ins 4-C), 79.19-79.13 (m, Ins 5-CH), 75.61 (d, J 6.0, Ins 3-CH), 74.71 (d, J 5.4, Ins 1-
CH), 70.97 (d, J 5.2, Ins 6-CH), 70.08-70.02 (m, Ins 2-CH) 32.56, 32.36 (d, J 7.1), 23.43, 21.94 (4 
× CH2), 13.58 (CH3) ppm; δP (162 MHz, D2O, 298 K) 1.88, 0.65, 0.18, -4.10 ppm; HRMS (ES-) 
m/z (%) found [M-H]- 568.9976 (100), C11H25O18P4 requires 568.9991. 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-methyl-myo-inositol (194a)   
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2,3,6-O-Tribenzyl-4-C-methyl-myo-inositol (175a, 64 mg, 0.14 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
general method 6.  The crude material was fractionated by chromatography on flash silica. Elution 
with hexane-EtOAc (3:1 → 0:1 v/v) afforded the title compound (194a, 97 mg, 57 %); Rf (hexane-
EtOAc, 7:3 v/v) 0.15; δH (400 MHz, CDCl3) 7.42-7.02 (45H, m, 45 × Ar H), 5.12-4.68 [18H, m, 
(17 × Ph-CHHO) + Ins 5-H], 4.58-4.50 (3 H, m, OCHHPh + Ins 1-H + Ins 2-H), 4.16 (1H, d, J 
2.3, Ins 3-H), 4.00 (1H, t, J 9.6, Ins 6-H), 1.02 (3H, s, Ins 4-CH3) ppm; δC (100 MHz, CDCl3) 
138.38, 138.21, 137.97 (3 × Ar C), 136.26 (d, J 7.8), 136.10 (d, J 7.8), 136.03 (d, J 6.0), 135.81 (d,  
J 7.1), 135.60 (d, J 6.5), 135.57 (d, J 6.6) (6 × Ar CCH2OP), 128.56 (5C), 128.35 (5C), 128.29 
(4C), 128.23 (5C), 128.13 (4C), 127.99 (3C), 127.92 (2C), 127.83 (2C), 127.76 (2C), 127.61 (2C), 
127.58 (2C), 127.49, 127.44 (2C), 127.34, 127.27 (2C), 127.16 (3C) (45 × Ar CH), 89.35 (dd, Ins 
4-CCH3, J 8.2, 2.6), 82.73 (bs, Ins 5-CH), 78.40 (Ins 3-CH), 77.54 (d, J 5.6, Ins 1-CH), 77.09 (d, J 
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6.1, Ins 6-CH), 75.29 (2-OCH2Ph), 74.59 (6-OCH2Ph), 74.15 (Ins 2-CH), 70.84 (3-OCH2Ph), 69.63 
(d, J 5.2), 69.39 (d, J 5.2), 69.22 (2C, d, J 5.2), 69.03 (2C, d, J 5.1) (6 × POCH2Ph), 17.65 (d, J 2.1, 
Ins 4-CH3) ppm; δP (162 MHz, CDCl3) -1.88, -2.06, -7.23 ppm; HRMS (ES+) m/z (%) found 
[M+H]+ 1245.4048 (100), C70H72O15P3 requires 1245.4084. 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-ethyl-myo-inositol (194b)   
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2,3,6-O-Tribenzyl-4-C-ethyl-myo-inositol (175b, 67 mg, 0.14 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
general method 6.  The crude material was fractionated by chromatography on flash silica. Elution 
with EtOAc-hexane (1:9 → 1:0 v/v) afforded the title compound (194b, 143 mg, 81 %); Rf (EtOAc-
hexane, 3:7 v/v) 0.11; δH (400 MHz, CDCl3) 7.41-7.00 (45H, m, 45 × Ar H), 5.09-4.67 [18H, m, 
(17 × OCHHPh) + Ins 5-H], 4.61-4.52 (3H, m, OCHHPh + Ins 1-H + Ins 2-H), 4.43 (1H, d, J 2.3, 
Ins 3-H), 4.08-4.02 (1H, m, Ins 6-H), 2.48 (1H, dqd, J 14.9, 7.4, 3.0, CHHCH3), 2.18 (1H, dq, J 
14.1, 7.4, CHHCH3), 1.19 (3H, t, J 7.4, CH2CH3) ppm; δC (100 MHz, CDCl3) 138.33, 138.26, 
138.92 (3 × Ar C), 136.27 (d, J 8.0), 136.11 (d, J 7.8), 136.03 (d, J 8.1), 135.88 (d, J 7.4), 135.70 
(d, J 5.8), 135.64 (d, J 6.4) (6 × Ar CCH2OP), 128.53 (2C), 128.51  (2C), 128.42, 128.34 (3C), 
128.29 (3C), 128.25 (2C), 128.17 (2C), 128.13 (4C), 128.08 (2C), 127.98, 127.91 (3C), 127.83 
(2C), 127.78 (3C), 127.59 (2C), 127.50 (4C), 127.45 (2C), 127.32 (2C), 127.23, 127.16, 126.91 
(3C) (45 × Ar CH), 89.87-89.68 (m, Ins 4-C), 78.68, 77.63, 77.25 (2C) (4 × Ins CH), 74.39 (2 × 
OCH2Ph), 73.83 (Ins CH), 69.50 (d, J 5.2), 69.34-69.10 (5C, m), 68.83 (d, J 5.9) [OCH2Ph + (6 × 
POCH2Ph)], 25.82 (d, J 4.3, CH2CH3), 9.36 (CH2CH3) ppm; δP (162 MHz, CDCl3) -1.82, -2.15, -
7.07 ppm; MS (ES+) m/z (%) found [M+H]+ 1259 (55), [M+Na]+ 1281 (100). 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-pentyl-myo-inositol (194c)   
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2,3,6-O-Tribenzyl-4-C-pentyl-myo-inositol (175c, 60 mg, 0.12 mmol) was phosphitylated 
using  N,N-diisopropyldibenzyl phosphoramidite and then oxidised with mCPBA as described in 
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general method 6.  The crude material was fractionated by chromatography on flash silica. Elution 
with hexane-EtOAc (3:1 → 0:1 v/v) afforded the title compound (194c, 74 mg, 49 %); Rf (EtOAc-
hexane, 3:7 v/v) 0.12; δH (400 MHz, CDCl3) 7.44-6.99 (45H, m, 45 × Ar H), 5.11 (2H, d, J 6.7), 
5.01-4.55 (19H, m) (18 × OCHHPh, Ins 1-H, Ins 2-H, Ins 5-H), 4.47 (1H, d, J 2.2, Ins 3-H), 4.10-
4.02 (1H, m, Ins 6-H), 2.37 (1H, bt, J 12.4), 2.10 (1H, bt, J 13.1) [CH2(CH2)3CH3], 1.85-1.80 (1H, 
m), 1.75-1.66 (1H, m) [CH2CH2(CH2)2CH3], 1.21-1.07 [4H, m, (CH2)2(CH2)2CH3], 0.80 [3H, t, J 
7.0, (CH2)4CH3] ppm;  δC (100 MHz, CDCl3) 138.28 (2C), 138.23 (3 × Ar C), 136.34 (d, J 6.9), 
136.14 (d, J 8.7), 136.05 (d, J 8.7), 135.89 (d, J 8.7), 135.69 (d, J 6.9), 135.63 (d, J 5.2) (6 × 
CCH2OP), 128.52 (3C), 128.43, 128.31 (3C), 128.28 (3C), 128.23 (2C), 128.17 (3C), 128.12 (5C), 
128.09 (4C), 128.03, 127.93 (3C), 127.79 (5C), 127.57 (2C), 127.50 (2C), 127.42 (2C), 127.28 
(2C), 127.21, 127.12, 126.88 (2C) (45 × Ar CH), 89.89-89.83 (m, Ins 4-C), 78.87, 77.64, 77.25 (3 
× Ins CH), 74.43 (2 × OCH2Ph), 73.82 (2 × Ins CH), 69.51 (d, J 5.2), 69.30 (d, J 5.2), 69.19-69.04 
(3C, m), 68.74 (d, J 5.2) (6 × POCH2Ph), 33.18 (d, J 5.2), 32.76, 24.28-24.08 (m), 22.62 (4 × CH2), 
14.05 (CH3) ppm; δP (162 MHz, CDCl3) -1.83, -2.19, -7.12 ppm; MS (ES+) m/z (%) found [M+H]+ 
1301 (58), [M+Na]+ 1323 (100). 
* Third benzyl peak not visible 
** Ins-CH assigned using 1H-13C correlation spectroscopy   
4-C-Methyl-myo-inositol 1,4,5-O-triphosphate (195a)   
OH
OHO
O
OH
O
P
P
P
O
O
O
O-
OH
OH-O
-O OH
3NH4
+
 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-methyl-myo-inositol (194a, 
64 mg, 0.05 mmol) was hydrogenated according to general method 9. The powdery solid was re-
dissolved in the minimum volume of H2O and passed through DOWEX 50WX8-200 H
+ resin. 
Acidic fractions of eluent were combined, neutralised with aq. ammonium and freeze dried to yield 
the title compound (195a, 30 mg, 100 %) as a pale brown powdery salt; δH (400 MHz, D2O) 4.20 
(1H, t, J 3.1, Ins 2-H), 4.05 (1H, dd, J 9.5, 8.9, Ins 5-H), 3.98 (1H, ddd, J 9.6, 9.1, 3.0, Ins 1-H), 
3.89 (1H, d, J 3.2, Ins 3-H), 3.75 (1H, dd, J 9.9, 9.8, Ins 6-H), 1.48 (3H, s, Ins 4-CH3) ppm; δC 
(125 MHz, D2O) 87.76 (d, Ins 4-CCH3, J 7.0), 83.82 (t, J 6.8), 77.65 (d, J 5.3), 75.59 (s), 72.59 (s), 
72.33 (s) (5 × Ins CH), 17.81 (s, Ins 4-CH3) ppm; δP (162 MHz, D2O) 2.55, 2.31, 0.30 ppm; HRMS 
(ES-) m/z (%) found [M-H]- 432.9716 (100), C7H16O15P3 requires 432.9702. 
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4-C-Ethyl-myo-inositol 1,4,5-O-triphosphate (195b) 
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As the ammonium salt: 1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-
ethyl-myo-inositol (194b, 138 mg, 0.11 mmol) was hydrogenated according to general method 9. 
The powdery solid was re-dissolved in the minimum volume of H2O and passed through DOWEX 
50WX8-200 H+ resin. Acidic fractions of eluent were combined, neutralised with aq. ammonium 
and freeze dried to yield the title compound (49 mg, 100 %) as a pale brown powdery salt; δH (500 
MHz, D2O) ~4.48-4.70 (under HOD, Ins 2-H + Ins 5-H), 4.55 (1H, d, J 2.7, Ins 3-H), 4.50 (1H, dt, 
J 8.4, 2.7, Ins 1-H), 4.41 (1H, t, J 7.8, Ins 6-H), 2.44 (1H, dt, J 22.0, 7.3), 2.34 (1H, dt, J 21.8, 7.3) 
(2 × CHHCH3), 1.44 (3H, t, J 7.3, CH2CH3) ppm; δP (162 MHz, D2O) 1.34, 0.58, -3.25 ppm; 
HRMS (ES-) m/z (%) found [M-H]- 446.9842 (100), C8H18O15P3 requires 446.9859. 
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As the sodium salt: 4-C-Ethyl-myo-inositol 1,4,5-O-triphosphate ammonium salt (45 mg, 
0.09 mmol) was stirred with DOWEX 50WX8-200 H+ resin which had been treated with NaOH.  
After filtration, the mother liquor was freeze dried to yield the title compound (47 mg, 100 %); δH 
(500 MHz, D2O) 4.61 (1H, t, J 3.4, Ins 2-H), 4.48 (1H, t, J 8.2, Ins 5-H), 4.40-4.37 (1H, m, Ins 3-
H), 4.34-4.29 (1H, m, Ins 1-H), 4.27-4.23 (1H, m, Ins 6-H), 2.34 (1H, dt, J 21.9, 7.3), 2.22 (1H, dt, 
J 21.9, 7.2) (2 × CHHCH3), 1.31 (3H, t, J 7.3, CH2CH3) ppm; δC (125 MHz, D2O) 83.86-83.76 (m, 
Ins 4-C), 78.61-78.10 (br m, Ins 5-CH), 75.45 (d, J 4.4, Ins 1-CH), 73.13 (d, J 5.5, Ins 3-CH), 
72.22 (d, J 5.5, Ins 6-CH), 69.31-69.06 (m, Ins 2-CH), 24.96 (CH2CH3), 9.07 (CH2CH3) ppm; δP 
(162 MHz, D2O) 4.45, 4.08, 0.52 ppm: HRMS (ES
-) m/z (%) found [M-H]- 446.9842 (100), 
C8H18O15P3 requires 446.9859. 
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4-C-Pentyl-myo-inositol 1,4,5-O-triphosphate (195c) 
OH
OHO
O
OH
O
P
P
P
O
O
O
O-
OH
OH-O
-O OH
3NH4
+
 
1,4,5-O-Tris(dibenzyloxyphosphoryl)-2,3,6-O-tribenzyl-4-C-pentyl-myo-inositol (194c, 80 
mg, 0.06 mmol) was hydrogenated according to general method 9.  The powdery solid was re-
dissolved in the minimum volume of H2O and passed through DOWEX 50WX8-200 H
+ resin. 
Acidic fractions of eluent were combined, neutralised with aq. ammonium and freeze dried to yield 
the title compound (195c, 30 mg, 100 %) as a pale brown powdery salt; δH (500 MHz, D2O, 318 K) 
4.56-4.52 (2H, m), 4.39-4.36 (1H, m), 4.24-4.17 (1H, m), 4.15-4.08 (1H, m) (5 × Ins H), 2.15-1.98 
(2H, m), 1.86-1.77 (2H, m), 1.50-1.39 (4H, m) (4 × CH2), 1.04 (3H, t, J 7.3, CH3) ppm; δC (125 
MHz, D2O, 318 K) 84.82-84.66 (m, Ins C), 78.24-78.06 (m), 75.24 (d, J 5.0), 72.42, 71.66, 70.33-
69.93 (m) (5 × Ins CH), 32.70, 32.66, 23.38, 22.25 (4 × CH2), 13.78 (CH3) ppm; δP (162 MHz, 
D2O, 318 K) 3.11, 2.61, -2.38 ppm; HRMS (ES
-) m/z (%) found [M-H]- 489.0315 (100), 
C11H24O15P3 requires 489.0328. 
4-C-Ethyl-myo-inositol 1,5-O-diphosphate (196b)  
OH
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O
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From decomposition of 4-C-ethyl-myo-inositol 1,4,5-O-triphosphate (195b): δH (500 MHz, 
D2O) 4.61 (1H, t, J 3.4, Ins 2-H), 4.53 (1H, dt, J 8.1, 3.4, Ins 1-H), 4.46-4.41 (1H, m, Ins 6-H), 
4.31 (1H, t, J 8.7, Ins 5-H), 4.03 (1H, d, J 3.4, Ins 3-H), 2.28 (1H, dt, J 22.4, 7.6), 2.17 (1H, dt, J 
22.4, 7.6) (2 × CHHCH3), 1.37 (3H, t, J 7.6, CH2CH3) ppm; δC (125 MHz, D2O) 80.77-80.54 (m, 
Ins 5-CH), 77.20 (d, J 3.3, Ins 4-C), 76.20 (d, J 5.5, Ins 1-CH), 74.68 (Ins 3-CH), 70.72 (t, J 3.3, 
Ins 6-CH), 69.66-69.43 (m, Ins 2-CH), 25.37 (CH2CH3), 8.02 (CH2CH3) ppm; δP (162 MHz, D2O) 
1.09, 0.77 ppm; HRMS (ESI-) m/z (%) found [M-H]- 367.0184 (100), C8H17O12P2 requires 
367.0195. 
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1,3,4,5-O-Tetrakis(dicyanoethylphosphoryl)-2,6-O-dibenzyl-4-C-benzyl-myo-inositol (197) 
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol (151f, 200 mg, 0.44 mmol) and 3-nitro-1,2,4-1H-
triazole (709 mg, 6.22 mmol) were evaporated from MeCN (3 × 2 mL) and taken up in pyridine (2 
mL).  Dicyanoethyl phosphorochloridite (0.5 mmol/mL solution in CH2Cl2, 6.22 mL, 3.11 mmol) 
was added and the solution stirred for 2 h.  After addition of cyanoethyl (88 µL, 1.33 mmol) the 
reaction was stirred for a further 1 h, before cooling to 0 ºC.  mCPBA (75 %, 1.07 g, 6.22 mmol) 
was added portion-wise and the resulting solution allowed to warm to rt and stirred for a further 2 
h.  The reaction was quenched with Na2S2O3 (10 % solution in H2O) and stirred for 30 min before 
extracting with CH2Cl2 (4 × 50 mL).  The combined organic layers were washed with brine, dried 
(MgSO4) and all solvents evaporated under reduced pressure.  The crude residue (1.60 g) was 
separated from phosphorylating reagent by chromatography on reverse phase silica.  Elution with 
MeCN-H2O (1:19 → 1:1 v/v) afforded the crude product which was then fractionated by 
chromatography on flash silica.  Elution with MeOH-CH2Cl2 (0:1 → 3:50 v/v) afforded the title 
compound (197, 127 mg, 24 %) as a clear oil; Rf (MeOH-CH2Cl2, 1:25 v/v) 0.37; δH (400 MHz, 
CDCl3) 7.51-7.46 (4H, m), 7.42-7.36 (5H, m), 7.35-7.25 (5H, m), 7.23-7.19 (1H, m) (15 × Ar H), 
5.37-5.34 (1H, m, Ins H), 5.06-5.04 (1H, m, Ins H), 5.04 (1H, d, J 12.7), 5.00 (1H, d, J 11.4), 4.97 
(1H, d, J 11.0), 4.89 (1H, d, J 11.0) (4 × OCHHPh), 4.78-4.72 (2H, m, 2 × Ins H), 4.27-3.95 [17H, 
m, (8 × OCH2CH2CN) + Ins H], 3.65 (1H, dd, J 15.0, 3.5), 3.47 (1H, d, J 15.4) (2 × CCHHPh), 
2.76-2.54 (16H, m, 8 × OCH2CH2CN) ppm; δC (100 MHz, CDCl3) 137.79, 137.57 (2 × Ar C)*, 
131.82, 128.66 (3C), 128.56 (3C), 128.16 (2C), 128.04, 127.90 (2C), 127.84, 127.54, 126.63 (15 × 
Ar CH), 117.12, 117.00, 116.80, 116.69, 116.64, 116.51 (2C), 116.43 (8 × OCH2CH2CN), 88.06-
87.94 (m, Ins C), 77.21, 77.15, 77.10, 77.00, 76.91 (5 × Ins CH), 76.21, 74.89 (2 × OCH2Ph), 
63.06-62.96 (4C, m), 62.87 (d, J 5.5), 62.83 (d, J 4.9), 62.74 (d, J 4.9), 62.70 (d, J 4.9) (8 × 
OCH2CH2CN), 19.63 (d, J 7.6), 19.60 (d, J 8.2), 19.57 (d, J 6.5), 19.54 (2C, d, J 8.2), 19.52 (2C, d, 
J 7.6), 19.31 (d, J 7.6) (8 × OCH2CH2CN) ppm; δP (162 MHz, CDCl3) -3.17, -3.99, -4.17, -8.61 
ppm; MS (ES+) m/z (%) found 338 (100), [M+H]+ 1195 (61), [M+Na]+ 1217 (92). 
* Third Ar C peak not visible in 13C-NMR spectra. 
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 1,3,4,5-O-tetraphosphate (198) 
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1,3,4,5-O-Tetrakis(dicyanoethylphosphoryl)-2,6-O-dibenzyl-4-C-benzyl-myo-inositol (197, 
77 mg, 0.06 mmol) was evaporated from MeCN (3 × 1 mL) and then taken up in MeCN (1 mL).  
Barton’s base (155 µL, 0.77 mmol) and TmsCl (82 µL, 0.65 mmol) were added and the solution 
stirred for 16 h.  All solvents were evaporated under reduced pressure and the residue was 
evaporated from toluene (2 × 2 mL).  The residue was washed with ether-hexane (1:1 v/v) and 
filtered under N2 using the Gaffney filtration apparatus.  The filtrate was evaporated to dryness and 
then stirred with NaHCO3 (20 mg, 0.24 mmol) in MeOH (2 mL) .  After 10 mins, all solvents were 
evaporated and the residue evaporated from MeCN (2 × 5 mL), to afford the title compound (198, 
47 mg, 85 %) as a white residue; δH (500 MHz, MeOD) 7.68 (2H, d, J 7.3), 7.53 (2H, d, J 7.3), 
7.34 (6H, t, J 7.3), 7.26 (2H, t, J 6.8), 7.09 (2H, t, J 6.8), 7.03 (1H, t, J 6.8) (15 × Ar H), 5.04 (1H, 
t, J 8.3, Ins 3-H), 5.01 (2H, s, OCH2Ph), 4.98 (1H, d, J 10.5), 4.95 (1H, d, J 10.5) (2 × OCHHPh), 
~4.94 (under HOD, Ins 5-H), 4.72 (1H, t, J 3.4, Ins 2-H), 4.37 (1H, t, J 8.3, Ins 1-H), 4.06 (1H, t, J 
9.8, Ins 6-H), 3.55 (1H, d, J 14.2), 3.31 (1H, d, J 14.2) (2 × CCHHPh) ppm; δC (100 MHz, MeOD) 
139.50, 138.39, 138.06 (3 × Ar C), 131.77 (2C), 129.45 (2C), 127.66 (4C), 127.57 (2C), 127.13, 
126.77, 126.40 (2C), 124.58 (15 × Ar CH), 79.32 (Ins 5-CH), 78.71 (Ins 2-CH), 77.27 (Ins 6-CH), 
76.08 (OCH2Ph), 75.57 (Ins 1-CH), 75.33 (Ins 3-CH), 74.87 (OCH2Ph), 36.79 (CCH2Ph) ppm; δP 
(162 MHz, D2O) 0.13, -0.17, -0.23, -2.99 ppm; HRMS (ESI
-) m/z (%) found [M-H]- 769.0649 (65), 
C27H33O18P4 requires 769.0617. 
*Contaminated with Bartons Base. 
**Quatenary 4-C not visible in 13C-NMR spectrum. 
4-C-Benzyl-myo-inositol 1,3,4,5-O-tetraphosphate. 
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2,6-O-dibenzyl-4-C-benzyl-myo-inositol 1,3,4,5-O-tetraphosphate (198, 23 mg, 0.03 
mmol) was taken up in tBuOH-H2O (6:1 v/v, 3 mL) to which was added Pd-black (18 mg, 0.16 
mmol).  The solution was stirred under an atmosphere of H2 for 36 h.  The catalyst was filtered off, 
washed with H2O (4 × 10 mL) and the filtrate concentrated under reduced pressure.  The remaining 
solution was taken up in H2O, washed with CH2Cl2 (× 2) and freeze dried.  The powdery solid was 
re-dissolved in the minimum volume of H2O and passed through DOWEX 50WX8-200 H
+ resin.  
Acidic fractions of eluent were combined, neutralised with aq. NH3 and freeze dried to afford the 
title compound (13 mg, 72 %) as a brown powdery salt; HRMS (ESI+) m/z (%) found [M+H]+ 
590.9850, C13H23O18P4 requires 590.9835 and [M+Bn+H]
+ 681.0322, C20H29O18P4 requires 
681.0304. 
1,4,5-O-Tris(5,6-benzo-1,3,2-dioxaphosphoryl)-2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol 
(202) 
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2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol (175f, 79 mg, 0.15 mmol) and 1-H tetrazole 
(102 mg, 1.46 mmol) were evaporated from MeCN (3 × 1 mL) and taken up in MeCN (1 mL).  The 
resulting suspension was placed in a water bath at 25 ºC, and N,N-diethylamino-5,6-benzo-1,3,2-
dioxaphosphepane (158 µL, 1.02 mmol) added, upon which all solids dissolved immediately.  After 
2 h the solution was cooled to 0 ºC and mCPBA (336 mg, 1.46 mmol) added.  The solution was 
then allowed to warm to rt and stirred for a further 1 h 30 min, before addition of Na2S3O3 (10 % 
solution in H2O).  After 30 min the organic layer was separated and the aqueous layer extracted 
with CH2Cl2 (× 3).  The combined organic layers were washed with brine, dried (MgSO4) and all 
solvents evaporated under reduced pressure.  The crude material was fractionated by 
chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 1:0 v/v) afforded the title 
compound (202, 69 mg, 44 %) as a clear oil; Rf (EtOAc-hexane, 3:7 v/v) 0.19; δH (400 MHz, 
CDCl3) 7.52-7.47 (4H, m), 7.35-6.95 (28H, m) (32 × Ar H), 5.30-4.74 (17H, m, 3 × Ins H, 3 × 
OCH2Ph, 8 × OCHHAr), 4.65-4.60 (3H, m, Ins H, OCH2Ar), 4.39 (1H, dd, J 13.7, 9.8, OCHHAr), 
4.27-4.21 (Ins H), 4.09-4.06 (1H, m, OCHHAr), 4.00 (1H, d, J 13.7), 3.61 (1H, d, J 11.7) (2 × 
CCHHPh) ppm; δC (100 MHz, CDCl3) 138.22, 137.80, 137.68, 135.71, 135.58 (2C), 135.45, 
135.19, 135.09, 132.57 (10 × Ar C), 129.17, 129.08 (2C), 129.02 (2C), 128.98 (2C), 128.77 (3C), 
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128.66 (2C), 128.60 (2C), 128.49 (2C), 128.40 (3C), 128.06 (4C), 127.74 (2C), 127.69, 127.53 
(2C), 127.43 (2C), 127.29, 127.26 (32 × Ar C), 88.19-88.15 (m, Ins C), 82.84-82.74 (m), 78.93, 
77.25, 76.52-76.46 (m) (4 × Ins CH), 76.26, 75.68 (2 × OCH2Ph), 74.72-74.67 (m, Ins CH), 71.91 
(OCH2Ph), 68.89 (d, J 6.4), 68.57 (d, J 11.2), 68.52 (d, J 11.2), 68.34 (d, J 6.4), 68.18 (d, J 6.4), 
68.10 (d, J 9.6) (6 × OCH2Ar), 36.51 (CCH2Ph) ppm; δP (162 MHz, D2O) -0.48, -2.27, -9.11 ppm; 
MS (ES+) m/z (%) found [M+H]+ 1087 (40), [M+Na]+ 1109 (100). 
*Inositol region assigned using 1H-13C correlation spectra. 
1,3,4,5-O-Tetrakis(5,6-benzo-1,3,2-dioxaphosphoryl)-2,6-O-dibenzyl-4-C-benzyl-myo-inositol. 
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2,6-O-Dibenzyl-4-C-benzyl-myo-inositol (160 mg, 0.36 mmol) was phosphorylated 
according to general method 8.  The crude material was not separated from reagent debris during 
purification using chromatography on flash silica.  HRMS (ESI+) m/z (%) found [M+H]+ 
1179.2699 (61), C59H59O18P4 requires 1179.2652, [M+Na]
+ 1201.2593 (100). 
1,3,4,5-O-Tetrakis(5,6-benzo-1,3,2-dioxaphosphoryl)-2,6-O-dibenzyl-4-C-neopentyl-myo-
inositol and 1,3,5-O-Tris(5,6-benzo-1,3,2-dioxaphosphoryl)-2,6-O-dibenzyl-4-C-neopentyl-
myo-inositol. 
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2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol (65 mg, 0.15 mmol) was phosphorylated 
according to general method 8.  On attempted fractionation of the crude material only a small 
fraction of triphosphate was isolated from phosphorylating reagent debris using chromatography on 
flash silica.  For the triphosphate: δP (162 MHz, D2O) 0.99, -0.76, -1.98 ppm; HRMS (ESI+) m/z 
(%) found [M+H]+977.2829 (83), C49H56O15P3 requires 977.2832, [M+Na]
+ 999.2631 (100) 
4-C-Benzyl-myo-inositol 1,4,5-O-triphosphate (203)   
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1,4,5-O-Tris(5,6-benzo-1,3,2-dioxaphosphoryl)-2,3,6-O-tribenzyl-4-C-benzyl-myo-inositol 
(202, 64 mg, 0.06 mmol) was hydrogenated according to general method 9. The crude material (30 
mg) was purified by HPLC.  Elution with a gradient of H2O-MeCN (49:1 → 1:1 v/v) yielded the 
title compound (203, 8 mg, 27 %) as a pale brown powdery salt; δH (500 MHz, D2O) 7.44 (2H, d, J 
7.5), 7.22 (2H, t, J 7.4), 7.14 (1H, t, J 7.3) (5 × Ar H), 4.41-4.33 (1H, m), 4.30-4.27 (1H, m), 4.20-
4.15 (1H, m), 4.08-3.99 (2H, m) (5 × Ins H), 3.21 (2H, s, CCHPh) ppm; δP (162 MHz, D2O) 0.91, 
0.11, -4.33 ppm; HRMS (ES-) m/z (%) found [M-H]- 508.9998 (100), C13H20O15P3 requires 
509.0015. 
7.6 Chapter 6 
4,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (214) and 2,4,6-O-tribenzyl-myo-inositol 
1,3,5-O-orthobenzoate (162) 
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Direct from orthobenzoate: myo-Inositol 1,3,5-O-orthobenzoate (22d, 550 mg, 2.04 
mmol) was evaporated from MeCN (3 × 10 mL) and then toluene (3 × 5 mL).  The residue was 
taken up in THF (15 mL) and cooled to 0 °C.  n-BuLi (2.5 M in hexanes, 1.7 mL, 4.28 mmol) was 
added drop-wise and the solution allowed to warm to rt.  BnBr (540 µL, 4.49 mmol) was taken up 
in DMF (4 mL) and added drop-wise to the reaction mixture.  When complete by TLC, H2O was 
added drop-wise and the volume reduced under reduced pressure. The product was taken up in 
EtOAc, washed with H2O (×4) and then brine, dried (MgSO4) and all solvents removed under 
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reduced pressure.  The crude product was purified by chromatography on flash silica.  Elution with 
EtOAc-hexane (0:1 → 2:5 v/v) afforded 4,6-O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoate 214 
(120 mg, 13 %) as a clear oil and 2,4,6-O-tribenzyl-myo-inositol 1,3,5-O-orthobenzoate 162 (169 
mg, 13 %) as a pale yellow oil. 
From monobenzyl 215: 4-O-Benzyl-myo-inositol 1,3,5-O-orthobenzoate (215, 1.38 g, 
3.87 mmol) was evaporated from MeCN (3 × 10mL) and then toluene (3 × 5mL).  The residue was 
taken up in THF (40 mL) and cooled to 0 °C.  n-BuLi (2.5 M in hexanes, 1.54 mL, 3.87 mmol) was 
added drop-wise and the solution warmed slowly to 30 °C.  BnBr (506µL, 3.87 mmol) was taken 
up in DMF (10 mL) and added drop-wise to the reaction mixture which was stirred at rt.  When 
complete by TLC, the reaction was quenched by drop-wise addition of H2O and the volume 
reduced under reduced pressure. The crude material was taken up in EtOAc, washed with H2O (×4) 
and then brine, dried (MgSO4) and all solvents removed under reduced pressure.  The crude 
material was purified by chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 1:1 
v/v) afforded 4,6-O-dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (214, 716 mg, 41 %) and 2,4,6-
O-tribenzyl-myo-inositol 1,3,5-O-orthobenzoate (162, 103 mg, 6 %) both as yellow oils. 
4,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate 214: Rf (EtOAc-hexane, 1:1 v/v) 0.71; 
δH (400 MHz, CDCl3) 7.66-7.36 (15H, m, Ar H), 4.71 (2H, d, J 11.5, 2 × OCHHPh), 4.64 (2H, d, J 
11.5, 2 × OCHHPh), 4.59 (1H, tt, J 3.4, 1.7, Ins 5-H), 4.51 (2H, t, J 4.0, Ins 4-H + Ins 6-H), 4.45 
(2H, dt, J 3.6, 1.8, Ins 1-H + Ins 3-H), 4.29 (1H, m, Ins 2-H) ppm; δC (100 MHz, CDCl3) 137.45 
(2C), 136.82 (3 × Ar C), 129.61, 128.42 (4C), 128.05 (2C), 127.86 (2C), 127.63 (4C), 125.15 (2C) 
(15 × Ar CH), 107.91 (PhCO3), 74.24 (2C), 73.57 (2C) (4 × Ins CH), 71.70 (2 × OCH2Ph), 68.58, 
60.62 (2 × Ins CH) ppm; MS (CI+) m/z (%) found [M+H]+ 447 (56), [M+NH4]
+ 461(9); HRMS 
(CI+) found 447.1813, C27H27O6 requires 447.1808. 
2,4,6-O-Tribenzyl-myo-inositol 1,3,5-O-orthobenzoate 162: Rf (EtOAc-hexane, 1:1 v/v) 
0.76; δH (270 MHz, CDCl3) 7.67-7.63 (2H, m), 7.35-7.24 (18H, m) (20 × Ar H), 4.68 (2H, s, 
OCH2Ph), 4.64 (2H, d, J 11.6, 2 × OCHHPh), 4.56-4.44 (5H, m, 5 × Ins H), 4.51 (2H, d, J 11.6, 2 
× OCHHPh), 4.14-4.12 (1H, m, Ins H) ppm; δC (100 MHz, CDCl3) 138.10, 137.70 (2C), 137.21 (4 
× Ar C), 129.47, 128.48 (5C), 128.13 (3C), 128.01 (3C), 127.88 (2C), 127.69 (4C), 125.45 (2C) 
(20 × Ar CH), 107.93 (PhCO3), 74.07 (2C), 71.98 (2C) (4 × Ins CH), 71.68 (2C), 71.28 (3 × 
OCH2Ph), 69.11, 66.20 (2 × Ins CH) ppm; MS (CI
+) m/z (%) found [M+H]+ 537 (100), [M+NH4]
+ 
551 (8). 
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4-O-Benzyl-myo-inositol 1,3,5-O-orthobenzoate (215) 
O
O
O
Ph
HO
OH
BnO
 
myo-Inositol 1,3,5-O-orthobenzoate (22d, 1.0 g, 3.76 mmol) was evaporated from MeCN 
(3 × 5 mL) and taken up in DMF (20 mL).  The solution was cooled to -15 °C.  NaH (60 % in oil, 
150 mg, 3.76 mmol) was added portion-wise and the solution stirred for 15 min before being 
allowed to warm to rt and stirred for a further 30 min.  BnBr (434 mL, 3.76 mmol) was added drop-
wise and the reaction mixture stirred for 4 h.  The reaction was quenched at 0 °C by drop-wise 
addition of H2O and the product taken up in EtOAc.  The organic layer was washed with H2O then 
brine, dried (MgSO4) and all solvents evaporated under reduced pressure.  The crude product was 
fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 1:1 v/v) 
afforded the title compound (215, 1.32 g, 99 %) as a colourless oil: Rf (EtOAc-hexane, 3:1 v/v) 
0.72; δH (270 MHz, CDCl3) 7.66-7.34 (10H, m, 10 × Ar H), 4.73 (1H, d, J 14.2, OCHHPh), 4.67 
(1H, d, J 14.2, OCHHPh), 4.60-4.52 (2H, m, 2 × Ins H), 4.46-4.39 (3H, m, 3 × Ins H), 4.18-4.11 
(1H, m, Ins H), 3.75 (1H, d, J 10.1, Ins OH), 3.16 (1H, d, J 11.8, Ins OH) ppm; HRMS (ESI+) 
found 357.1324 (100), C20H21O6 requires 357.1338. 
4,6-O-Dibenzyl-inos-2-ose 1,3,5-O-orthobenzoate (216) and 4,6-O-dibenzyl-2,2-dihydroxy-
inositol 1,3,5-O-orthobenzoate (217) 
O
O
O
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4,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (214, 100 mg, 0.22 mmol) was 
evaporated from MeCN (3 × 1 mL) and taken up in CH2Cl2 (1 mL).  DMP (180 mg, 0.44 mmol) 
was added portion-wise and the reaction stirred at rt for 3 h.  The reaction was quenched by stirring 
with sat. NaHCO3 and Na2O3S2.H2O for 30 min.  The product was taken up in CH2Cl2 and the 
organic layer washed with sat. NaHCO3, H2O and then brine, dried (MgSO4), and all solvents 
removed under reduced pressure.  The crude material was dried over molecular sieves in CHCl3 for 
24 h to afford 4,6-O-dibenzyl-inos-2-ose 1,3,5-O-orthobenzoate (216, 98 mg, 98 %) as a pale 
yellow oil and used without further purification: Rf (EtOAc-hexane, 3:7) 0.59; δH (400 MHz, 
CDCl3) 7.67-7.65 (2H, m), 7.46-7.25 (13H, m) (15 × Ar H), 4.77-4.74 (3H, m, 3 × Ins H), 4.71 
(2H, d, J 11.6), 4.67 (2H, d, J 11.6) (2 × OCH2Ph), 4.61-4.59 (2H, m, 2 × Ins H) ppm; δC (100 
MHz, CDCl3) 199.98 (Ins C=O), 136.94 (2C), 135.24 (3 × Ar C), 129.97, 128.54 (4C), 128.21 
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(2C), 128.08 (2C), 127.88 (4C), 125.5 (2C) (15 × Ar CH), 108.18 (PhCO3), 78.44 (2C), 76.68 (2C) 
(4 × Ins CH), 71.67 (2 × OCH2Ph), 69.72 (Ins CH) ppm; MS (CI
+) m/z (%) found [M+H]+ 445 
(42), [M+NH4]
+ 462 (16); HRMS (ESI+) found 445.1644 (58), C27H25O6 requires 445.1651. 
4,6-O-dibenzyl-2,2-dihydroxy-myo-inositol 1,3,5-O-orthobenzoate (217) was observed in 
the crude material and could be generated on addition of water to the inos-2ose 216: Rf (EtOAc-
hexane, 3:7) 0.85; δH (400 MHz, DMSO + D2O) 7.59-7.24 (15H, m, 15 × Ar H), 5.02 (1H, m, Ins 
H), 4.75-4.73 (2H, m, 2 × Ins H), 4.69-4.68 (2H, m, 2 × Ins H), 4.64-4.63 (4H, m, 2 × OCH2Ph) 
ppm. 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol 1,3,5-O-orthobenzoate (218) 
O
O
O
Ph
OBn
BnO
HO  
Directly from the inos-2ose: 4,6-O-Dibenzyl-inos-2-ose 1,3,5-O-orthobenzoate (216, 150 
mg, 0.34 mmol) was evaporated from MeCN (3 × 1 mL) and taken up in ether (1 mL).  The 
solution was cooled to -78 ºC and methylmagnesium bromide (135 µL, 0.41 mmol) added drop-
wise.  After 30 min at -78 ºC the solution was allowed to warm to rt and stirred 3 h.  The reaction 
was quenched by drop-wise addition of H2O and taken up in CH2Cl2.  The organic layer was 
washed with 0.1 M HCl, sat. NaHCO3, H2O and then brine, dried (MgSO4) and all solvents 
evaporated under reduced pressure.  The crude material was purified by chromatography on flash 
silica.  Elution with EtOAc-hexane (0:1 → 3:7 v/v) afforded the title compound (218, 58 mg, 37 %) 
and unreacted starting material (216, 74 mg, 49 %). 
From the exo-methylene oxide: 4,6-O-Dibenzyl-2,2-O,C-methylidene-myo-inositol 1,3,5-
O-orthobenzoate (219, 170 mg, 0.38 mmol) was evaporated from MeCN (3 × 1 mL) and taken up 
in THF (0.5 mL).  LiAlH4 (87 mg, 2.29 mmol) was taken up in THF (0.5 mL) and added to the 
methylidene solution, which was stirred for a further 3 h.  The reaction was quenched by drop-wise 
addition of EtOAc and the crude material was taken up in ether.  The organic layer was washed 
with sat. NaHCO3, H2O then brine, dried (MgSO4) and all solvents removed under reduced 
pressure.  The crude material (117 mg) was purified by chromatography on flash silica.  Elution 
with EtOAc-hexane (0:1 → 1:5 v/v) afforded the title compound (218, 115 mg, 67 %) as a glass. 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol 1,3,5-O-orthobenzoate (218): Rf (EtOAc-
hexane, 3:7 v/v) 0.74; δH (400 MHz, CDCl3) 7.66-7.63 (2H, m), 7.40-4.37 (3H, m), 7.32-7.28 (10H, 
m) (15 × Ar H), 4.77-4.74 (1H, m, Ins 5-H), 4.75 (2H, d, J 11.2), 4.70 (2H, d, J 11.2) (4 × 
OCHHPh), 4.60 (2H, t, J 3.4, Ins 4-H + Ins 6-H), 4.28 (2H, dt, J 3.9, 1.9, Ins 3-H + Ins 1-H), 1.67 
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(Ins 4-CCH3) ppm; δC (100 MHz, CDCl3) 136.89 (2C), 136.59 (3 × Ar C), 129.57, 128.54 (4C), 
128.12 (2C), 128.04 (2C), 127.92 (4C), 125.32 (2C) (15 × Ar CH), 107.5 (PhCO3), 74.19 (2C), 
74.15 (2C) (4 × Ins CH), 71.83 (2 × OCH2Ph), 68.46 (Ins CH), 67.83 (Ins C), 24.99 (Ins 4-CCH3) 
ppm; MS (CI+) m/z (%) found [M+H]+ 461 (100), [M+NH4]
+ 478 (26); HRMS (ESI+) found 
[M+H]+ 461.1946 (63), C28H29O6 requires 461.1964 
4,6-O-Dibenzyl-2,2-O,C-methylidene-scyllo-inositol 1,3,5-O-orthobenzoate (219) 
O
O
O
Ph
OBn
BnO
O  
To a clear solution of trimethylsulfoxonium iodide (130 mg, 0.59 mmol) in DMSO (2 mL) 
was added NaH (60% dispersion in mineral oil, 26 mg, 0.65 mmol) and the mixture stirred for 40 
min.  4,6-O-Dibenzyl-inos-2-ose 1,3,5-O-orthobenzoate (216, 240 mg, 0.54 mmol) was evaporated 
from MeCN (2 mL × 3), taken up in THF (2 mL) and added to the reaction mixture, which was 
stirred at rt for 1 h.  The reaction was quenched by drop-wise addition of H2O (2 mL) and taken up 
in CH2Cl2.  The organic layer was washed with sat. NaHCO3, H2O, then brine, dried (MgSO4) and 
evaporated to dryness under reduced pressure.  The crude material was fractionated using 
chromatography on flash silica.  Elution with ether-hexane (0:1 → 3:5 v/v) afforded the title 
compound (219, 169 mg, 68 %) as a clear oil; Rf (ether- hexane, 7:3 v/v) 0.69; δH (400 MHz, 
CDCl3) 7.67-7.65 (2H, m), 7.43-7.39 (7H, m), 7.36-7.28 (5H, m) (15 × Ar H), 4.74-4.72 [5H, m, (2 
× OCHHPh) + Ins 5-H], 4.50 (2H, t, J 3.6, Ins 4-H + Ins 6-H), 4.53 (2H, dt, J 3.4, 1.5, Ins 1-H + 
Ins 3-H), 2.89 (2H, s, Ins 4-CCH2) ppm; δC (100 MHz, CDCl3) 129.79 (2C), 129.69 (3 × Ar C), 
128.62, 128.43 (4C), 128.14 (2C), 127.98 (4C), 127.87 (2C), 125.40 (2C) (15 × Ar CH), 108.40 
(PhCO3), 73.47 (2C), 72.53 (2C) (4 × Ins CH), 71.32 (2 × OCH2Ph), 69.16 (Ins CH), 53.09 (Ins C), 
49.23 (Ins 4-CCH2) ppm; HRMS (ESI
+) found [M+H]+ 459.1808 (17), C28H27O6 requires 459.1808. 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol-1,3-O-benzylidine-acetal (220) and 2-C-methyl-
1,4,6-O-tribenzyl-scyllo-inositol (221) 
O
O
OH
Ph
OBn
OBn
HO
HO
BnO
OBn
OBn
OH
OH
 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol 1,3,5-O-orthobenzoate (218, 115 mg, 0.25 
mmol) was evaporated from MeCN (3 × 1mL) and taken up in CH2Cl2 (0.6 mL).  DIBAL-H (0.8 M 
solution in hexanes, 0.9mL, 0.75mmol) was added and the reaction stirred at rt for 3h.  Excess 
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DIBAL-H was quenched by drop-wise addition of H2O (5 mL) and the product taken up in ether, 
washed with 0.1% HCl, sat. NaHCO3, H2O and then brine, dried (MgSO4) and all solvents removed 
under reduced pressure.  The crude material was purified by chromatography on flash silica.  
Elution with EtOAc-hexane (1:9 → 7:3 v/v) afforded 2-C-methyl-4,6-O-dibenzyl-scyllo-inositol 
1,3-O-benzylidine-acetal (220, 25 mg, 22 %), 2-C-methyl-1,4,6-O-tribenzyl-scyllo-inositol (221, 
15 mg, 13 %) and starting material (218, 49 mg, 43 %). 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol-1,3-O-benzylidene-acetal, 220: Rf (EtOAc-
hexane, 3:7 v/v) 0.52; δH (400 MHz, CDCl3) 7.49-7.47 (2H, m), 7.45-7.31 (13H, m) (15 × Ar-CH), 
5.51 (1H, s, PhCHO2), 4.83 (2H, d, J 11.6), 4.68 (2H, d, J 11.6) (2 × OCH2Ph), 4.58 (1H, t, J 6.8, 
Ins 5-H), 4.05 (2H, s, 2 × Ins H), 3.93 (2H, d, J 7.2, 2 × Ins H), 1.72 (3H, s, Ins 4-CCH3) ppm; δC 
(100 MHz, CDCl3) 137.84 (2C), 137.30 (3 × Ar C), 129.40, 128.57 (4C), 128.52 (2C), 128.09 (4C), 
127.98 (2C), 126.36 (2C) (15 × Ar CH), 92.52 (PhCHO2), 83.13 (2C), 79.49 (2C), 75.31 (5 × Ins 
CH), 72.00 (2 × OCH2Ph), 69.02 (Ins C), 25.06 (2-CCH3) ppm; HRMS (ESI
+) found [M+H]+ 
463.2113 (27), C28H31O6 requires 463.2121. 
2-C-Methyl-1,4,6-O-Tribenzyl-scyllo-inositol, 221: Rf (EtOAc-hexane, 3:7 v/v) 0.24; δH 
(400 MHz, CDCl3) 7.39-7.31 (15H, m, 15 × Ar H), 4.93 (1H, d, J 11.2), 4.92 (1H, d, J 11.2), 4.91 
(1H, d, J 11.2), 4.87 (1H, d, J 11.2), 4.83 (1H, d, J 11.2), 4.77 (1H, d, J 11.2) (6 × OCHHPh), 3.67 
(1H, t, J 8.8, Ins H), 3.52 (1H, d, J10.3, Ins H), 3.46 (1H, d, J 9.8, Ins H), 3.40 (1H, t, J 8.8, Ins H), 
3.30 (1H, t, J 3.30, Ins H), 2.19 (3H, s, CCH3) ppm; δC (100 MHz, CDCl3) 138.75, 138.54, 138.49 
(3 × Ar C), 128.57 (3C), 128.48 (2C), 127.98 (2C), 127.95 (3C), 127.91, 127.86, 127.78 (2C), 
127.73 (15 × Ar CH), 84.59, 82.69, 81.46, 75.87 (4 × Ins CH), 75.55 (2 × OCH2Ph), 75.41 (Ins C), 
75.31 (Ins CH), 74.95 (OCH2Ph), 21.06 (2-CCH3) ppm. 
2-C-Methyl-4,6-O-dibenzyl-scyllo-inositol 1,3,5-O-orthobenzoate, 218 as characterised 
previously. 
4-O-Allyl-6-O-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate (222) and 4-O-allyl-
2,6-O-di(para-methoxybenzyl)-myo-inositol 1,3,5-O-orthobenzoate (224)  
O
O
O
Ph
HO
O
PmbO
O
O
O
Ph
PmbO
O
PmbO
 
4-O-Allyl-myo-inositol 1,3,5-O-orthobenzoate (92, 1.0 g, 3.26 mmol) was evaporated from 
MeCN (3 × 10 mL) and taken up in DMF (10 mL).  The solution was cooled to 0 ºC and NaH (60 
% dispersion in mineral oil, 125 mg, 3.26 mmol) added portion-wise.  After 30 min the solution 
was warmed to rt and para-methoxybenzylchloride (442 µL, 3.26 mmol) in DMF (5 mL) added 
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dropwise.  After 6 h the reaction was quenched with H2O and then taken up in EtOAc.  The organic 
layer was washed with H2O (×4) and then brine, dried (MgSO4) and all solvents evaporated.  The 
crude material was fractionated by chromatography on flash silica.  Elution with EtOAc-hexane 
(0:1 → 1:5 v/v) afforded 4-O-allyl-6-O-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate 
(222, 467 mg, 35 %) and 4-O-allyl-2,6-O-di-para-methoxybenzyl-myo-inositol 1,3,5-O-
orthobenzoate (224, 171 mg, 10 %) and starting material (92, 110 mg, 11 %).  
4-O-Allyl-6-O-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate 222: Rf (EtOAc-
hexane, 1:1 v/v) 0.61; δH (400 MHz, CDCl3) 7.66-7.64 (2H, m), 7.40-7.36 (3H, m), 7.30 (2H, d, J 
8.8), 6.91 (2H, d, J 8.8) (9 × Ar H), 5.93 (1H, ddt, J 15.7, 10.3, 5.4, OCH2CCH2), 5.33 (1H, dq, J 
17.1, 1.5), 5.24 (1H, dq, J 10.7, 1.5) (2 × OCH2HCHH), 4.67 (1H, d, J 11.2), 4.58 (1H, d, J 11.2) 
(2 × OCHHPh), 4.54-4.52 (1H, m, Ins H), 4.47-4.43 (3H, m, 3 × Ins H), 4.40-4.38 (1H, m, Ins H), 
4.23 (1H, bs, Ins OH), 4.21-4.12 (3H, m, Ins H + OCH2CHCH2), 3.84 (OCH3) ppm; δH (400 MHz, 
d6-DMSO) 7.55-7.53 (2H, m), 7.37-7.34 (3H, m), 7.29 (2H, d, J 8.3), 6.90 (2H, d, J 8.8) (9 × Ar 
H), 5.89 (1H, ddt, J 17.1, 10.3, 5.4, OCH2CHCH2), 5.40 (1H, d, J 6.4, Ins OH), 5.28 (1H, dq, J 
17.1, 2.0), 5.16 (1H, dq, J 10.3, 1.5) (2 × OCH2HCHH), 4.66-4.64 (1H, m, Ins H), 4.61 (1H, d, J 
11.2), 4.52 (1H, d, J 11.2) (2 × OCHHPh), 4.30-4.26 (3H, m, 3 × Ins H), 4.22-4.20 (1H, m, Ins H), 
4.19-4.13 (1H, ddt, J 13.2, 5.4, 1.5), 4.14-4.09 (1H, ddt, J 12.7, 5.4, 1.5) (2 × OCHHCHCH2), 4.00 
(1H, dt, J 6.4, 2.4, Ins 2-H), 3.75 (3H, s, OCH3) ppm; δC (100 MHz, CDCl3) 159.42, 136.94 (2 × 
Ar C), 134.12 (OCH2CHCH2), 129.71 (Ar C), 129.65, 129.29 (2C), 128.11 (2C), 125.21 (2C) (7 × 
Ar CH), 117.74 (OCH2CHCH2), 113.89 (2 × Ar CH), 107.95 (PhCO3), 74.43, 74.36, 73.55, 73.14 
(4 × Ins CH), 71.31, 70.89 (2 × OCH2PG), 68.69, 60.68 (2 × Ins CH), 55.31 (OCH3) ppm; MS 
(CI+) m/z (%) found [M+H]+ 427 (100); HRMS (ESI+) m/z (%) found [M+H]+ 427.1759, C24H27O7 
requires 427.1757. 
4-O-Allyl-2,6-O-di-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate 224: Rf 
(EtOAc-hexane, 1:1 v/v) 0.53; δH (400 MHz, CDCl3) 7.68-7.66 (2H, m), 7.37-7.34 (5H, m), 7.23 
(2H, d, J 8.3), 6.89 (2H, d, J 8.8), 6.88 (2H, d, J 8.8) (13 × Ar H), 5.87 (1H, ddt, J 16.1, 10.7, 5.9, 
OCH2CHCH2), 5.26 (1H, dq, J 17.1, 1.5), 5.20 (1H, dq, J 10.3, 1.5) (2 × OCH2HCHH), 4.67 (2H, 
s, OCH2Ph), 4.60 (1H, d, J 11.7, OCHHPh), 4.52-4.49 (2H, m, 2 × Ins H), 4.46 (1H, d, J 11.2, 
OCHHPh), 4.43-4.39 (3H, m, 3 × Ins H), 4.12 (1H, ddt, J 12.7, 5.4, 1.5, OCHHCHCH2), 4.05 (1H, 
m, Ins H), 4.03 (1H, ddt, J 13.2, 5.9, 1.5, OCHHCHCH2) 3.84 (3H, s, OCH3), 3.81 (3H, m, OCH3) 
ppm; δC (100 MHz, CDCl3) 159.35, 159.06 (2 × Ar C), 134.22 (OCH2CHCH2), 130.27, 130.23, 
129.89 (3 × Ar C), 129.62 (2C), 129.37, 129.19 (2C), 127.93 (2C), 125.41 (2C) (9 × Ar CH), 
117.49 (OCH2CHCH2), 113.82 (4 × Ar CH), 106.66 (PhCO3), 73.87, 73.62, 72.07 (2C) (4 × Ins 
CH), 71.19, 70.93, 70.68 (3 × OCH2PG), 69.12, 65.95 (2 × Ins CH), 55.31, 55.27 (2 × OCH3) ppm; 
MS (CI+) m/z (%) found [M+NH4]
+ 547 (7).  
4-O-Allyl-myo-inositol 1,3,5-O-orthobenzoate 92: Data as previously reported. 
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6-O-para-Methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate (223) 
O
O
O
Ph
HO
OH
PmbO
 
To a solution of 4-O-allyl-6-O-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate 
(222, 120 mg, 0.29 mmol) in dioxane (1 mL) and H2O (0.1 mL) was added a mixture of 4-methyl 
morpholine N-oxide (118 mg, 0.88 mmol) and OsO4 (4 % solution, 3 drops).  After 1 h, NaIO4 (188 
mg, 0.88 mmol) was added and the solution stirred for a further 12 h.  The solution was diluted 
with brine and the product extracted into CH2Cl2.  The organic layer was washed with H2O and 
then brine, dried (MgSO4) and all solvents evaporated under reduced pressure.  The crude material 
was fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (0:1 → 3:2 v/v) 
afforded the title compound (223, 50 mg, 44 %) as a pale brown residue; Rf (EtOAc-hexane, 3:2 
v/v) 0.43; δH (400 MHz, CDCl3) 7.64-7.62 (2H, m), 7.39-7.36 (3H, m), 7.27 (2H, d, J 8.8), 6.93 
(2H, d, J 8.8) (9 × Ar H), 4.66 (1H, d, J 11.7), 4.62 (1H, d, J 11.2) (2 × OCHHPh), 4.61-4.56 (1H, 
m, Ins H), 4.53 (1H, td, J 3.4, 1.5, Ins H), 4.43-4.39 (2H, m, 2 × Ins H), 4.37 (1H, td, J 3.4, 1.5, Ins 
H), 4.17-4.13 (1H, m, Ins H), 3.83 (3H, s, OCH3), 2.94 (1H, s, Ins OH), 2.88 (1H, s, Ins OH) ppm; 
δC (100 MHz, CDCl3) 160.04, 136.64 (2 × Ar C), 129.93 (2C), 129.72, 128.10 (2C) (5 × Ar CH), 
127.97 (Ar C), 125.25 (2C), 114.30 (2C) (4 × Ar CH), 107.41 (PhCO3), 76.09, 73.67, 73.64 (3 × 
Ins CH), 72.81 (OCH2Ph), 68.23, 67.79, 59.98 (3 × Ins CH), 55.34 (OCH3) ppm; HRMS (ESI
+) 
found [M+H]+ 387.1438 (5), C21H23O7 requires 387.1444. 
4-O-Allyl-6-O-para-methoxybenzyl-inos-2-ose 1,3,5-O-orthobenzoate (225) 
O
O
O
Ph
OAllyl
OO
Pmb  
4-O-Allyl-6-O-para-methoxybenzyl-myo-inositol 1,3,5-O-orthobenzoate (222, 1.00 g, 2.44 
mmol) was evaporated from MeCN (3 × 5 mL) and taken up in CH2Cl2 (10 mL).  DMP (2.07 g, 
4.88 mmol) was added portion-wise and the reaction stirred at rt for 3 h.  The reaction was 
quenched by stirring with sat. NaHCO3 and Na2O3S2.H2O for 30 min.  The product was taken up in 
CH2Cl2 and the organic layer washed with sat. NaHCO3, H2O and then brine, dried (MgSO4), and 
all solvents removed under reduced pressure.  4-O-Allyl-6-O-para-methoxybenzyl-inos-2-ose 
1,3,5-O-orthobenzoate (225, 9.95 g, 100 %) was recovered as a pale yellow oil and used without 
further purification: Rf (EtOAc-hexane, 2:3 v/v) 0.39; δH (400 MHz, CDCl3) 7.67-7.64 (2H, m), 
7.41-7.38 (3H, m), 7.28 (2H, d, J 8.8), 6.90 (2H, d, J 8.3) (9 × Ar H), 5.89 (1H, ddt, 17.1, 10.3, 5.9, 
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OCH2CHCH2), 5.30 (1H, dq, J 17.6, 1.5), 5.24 (1H, dq, J 10.3, 1.5) (2 × OCH2HCHH), 4.70-4.67 
(3H, m, 3 × Ins H), 4.61 (2H, s, OCH2Ph), 4.58-4.55 (1H, m, Ins H), 4.52-4.50 (1H, m, Ins H), 
4.15 (2H, dt, J 5.9, 1.5, OCH2CHCH2), 3.83 (3H, s, OCH3) ppm; δC (100 MHz, CDCl3) 200.09 
(C=O), 159.52, 135.27 (2 × Ar C), 133.69 (OCH2CHCH2), 129.66, 129.50 (2C) (3 × Ar CH), 
129.03 (Ar C), 128.16 (2C), 125.50 (2C) (4 × Ar CH), 118.28 (OCH2CHCH2), 113.93 (2 × Ar CH), 
108.12 (PhCO3), 78.51, 76.70, 76.12, 74.27 (4 × Ins CH), 71.23, 70.88 (2 × OCH2PG), 69.77 (Ins 
CH), 55.31 (OCH3) ppm; MS (CI
+) m/z (%) found [M+H]+ 425 (100 %); HRMS (CI+) m/z (%) 
found [M+H]+ 425.1599 (100), C24H25O7 requires 425.1600. 
4-O-Allyl-6-O-para-methoxybenzyl-2,2-O,C-methylidene-scyllo-inositol 1,3,5-O-orthobenzoate 
(226) 
O
O
O
Ph
OAllyl
O
O
Pmb  
To a clear solution of trimethylsulfoxonium iodide (1.18 g, 5.36 mmol) in DMSO (10 mL) 
was added NaH (60% dispersion in mineral oil, 224 mg, 5.85 mmol) and the mixture stirred for 40 
min.  4-O-Allyl-6-O-para-methoxybenzyl-inos-2-ose 1,3,5-O-orthobenzoate (225, 2.07 g, 4.88 
mmol) was evaporated from MeCN (3 × 10 mL), taken up in THF (10 mL) and added to the 
reaction mixture, which was stirred at rt for 1 h.  The reaction was quenched by drop-wise addition 
of H2O (10 mL) and taken up in CH2Cl2.  The organic layer was washed with sat. NaHCO3, H2O, 
then brine, dried (MgSO4) and evaporated to dryness under reduced pressure.  The crude material 
was fractionated using chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 2:3 
v/v) afforded the title compound (226, 1.45 g, 68 %) as a clear oil; Rf (EtOAc-hexane, 2:3 v/v) 
0.48; δH (400 MHz, CDCl3) 7.66-7.64 (2H, m), 7.39-7.35 (5H, m), 6.89 (2H, d, J 8.8) (9 × Ar H), 
5.96 (1H, ddt, J 17.1, 10.3, 5.4, OCH2CHCH2), 5.33 (1H, dq, J 17.1, 1.5), 5.23 (1H, dq, J 10.3, 1.5) 
(2 × OCH2HCHH), 4.68 (1H, tt, J 3.4, 2.0, Ins 5-H), 4.66 (2H, s, OCH2Ph), 4.46-4.43 (2H, m, Ins 
4-H + Ins 6-H), 4.18 (2H, ddt, J 6.9, 1.5, 1.0, OCH2CHCH2), 3.99 (1H, dt, J 3.4, 1.5, Ins 1/3-H), 
3.95 (1H, dt, J 3.4, 2.0, Ins 1/3-H), 3.83 (3H, s, OCH3) ppm; HRMS (ESI
+) m/z (%) found [M+H]+ 
439.1748 (7), C25H27O7 requires 439.1757. 
4-O-Allyl-6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate (227) 
O
O
O
Ph
OAllyl
O
HO
Pmb  
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4-O-Allyl-6-O-para-methoxybenzyl-2,2-O,C-methylidene-scyllo-inositol 1,3,5-O-ortho 
benzoate (226, 1.45 g, 3.31 mmol) was evaporated from MeCN (3 × 5 mL) and taken up in THF 
(15 mL).  LiAlH4 (251 mg, 6.62 mmol) was added and the resulting suspension was stirred for 3 h.  
The reaction was quenched by drop-wise addition of EtOAc and the crude material was taken up in 
ether.  The organic layer was washed with sat. NaHCO3, H2O then brine, dried (MgSO4) and all 
solvents removed under reduced pressure.  The crude material was purified by chromatography on 
flash silica.  Elution with EtOAc-hexane (0:1 → 3:7 v/v) afforded the title compound (227, 1.28 g, 
88 %) as a yellow oil: Rf (EtOAc-hexane, 7:13 v/v) 0.66; δH (400 MHz, CDCl3) 7.65-7.62 (2H, m), 
7.40-7.38 (3H, m), 7.30 (2H, d, J 8.8), 6.91 (2H, d, J 8.3) (9 × Ar H), 5.92 (1H, ddt, J 16.1, 10.6, 
5.9, OCH2CHCH2), 5.29 (1H, dq, J 17.1, 1.5), 5.23 (1H, dq, J 10.8, 1.5) (2 × OCH2HCHH), 4.72 
(1H, bs, Ins 2-OH), 4.69 (1H, d, J 11.2, OCHHPh), 4.69-4.67 (1H, m, Ins H), 4.66 (1H, d, J 11.2, 
OCHHPh), 4.55-4.53 (2H, m, 2 × Ins H), 4.25-4.21 [3H, m, (2 × Ins H) + OCHHCHCH2], 4.18 
(1H, ddt, J 12.2, 5.9, 1.5, OCHHCHCH2) 3.84 (3H, s, OCH3), 1.66 (3H, s, 2-CCH3) ppm; δC (100 
MHz, CDCl3) 159.43, 136.55 (2 × Ar C), 133.52 (OCH2CHCH2), 129.45 (3 × Ar CH), 129.01 (Ar 
C), 128.03 (2C), 125.23 (2C) (4 × Ar CH), 117.81 (OCH2CHCH2), 113.83 (2 × Ar C), 107.39 
(PhCO3), 74.11, 74.08, 73.87, 73.47 (4 × Ins CH), 71.25, 70.54 (2 × OCH2PG), 68.41 (Ins CH), 
67.66 (Ins C), 55.23 (OCH3), 24.89 (2-CCH3) ppm; HRMS (ESI
+) m/z (%) found [M+H]+ 441.1893 
(100), C25H29O7 requires 441.1913. 
6-O-para-Methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate (228) and 4-O-
formyl-6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate (229) 
O
O
O
Ph
OH
O
HO
Pmb
O
O
O
Ph
O
O
HO
Pmb
O
H  
To a solution of 4-O-allyl-6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-
orthobenzoate (227, 360 mg, 0.85 mmol) in dioxane (3 mL) and H2O (0.3 mL) was added a 
mixture of 4-methyl morpholine N-oxide (344 mg, 2.55 mmol) and OsO4 (4 % solution, 10 drops).  
After 1 h, NaIO4 (545 mg, 2.55 mmol) was added and the solution stirred for a further 12 h.  The 
solution was diluted with brine and the product extracted into CH2Cl2.  The organic layer was 
washed with H2O and then brine, dried (MgSO4) and all solvents evaporated under reduced 
pressure.  The crude material was fractionated by chromatography on flash silica.  Elution with 
EtOAc-hexane (0:1 → 3:2 v/v) afforded 6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 
1,3,5-O-orthobenzoate (228, 220 mg, 65 %) as a glass and 4-O-formyl-6-O-para-methoxybenzyl-2-
C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate (229, 74 mg, 20 %) as a pale yellow oil. 
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6-O-para-Methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate 228; Rf 
(EtOAc-hexane, 3:7 v/v) 0.29; δH (500 MHz, CDCl3) 7.61-7.59 (2H, m), 7.37-7.34 (3H, m), 7.29 
(2H, d, J 8.3), 6.89 (2H, d, J 8.3) (9 × Ar H), 4.71 (1H, d, J 11.2, OCHHPh), 4.69-4.67 (1H, m, Ins 
H), 4.66 (1H, d, J 11.2, OCHHPh), 4.56-4.54 (2H, m, 2 × Ins H), 4.18 (1H, td, J 2.9, 2.5, Ins 1/3-
H), 4.12 (1H, dt, J 2.0, 3.9, Ins 4/6-H), 4.11 (1H, bs, Ins OH), 3.54 (1H, bs, Ins OH), 3.80 (3H, s, 
OCH3), 1.64 (3H, s, 2-CCH3) ppm; δC (125 MHz, CDCl3) 159.73, 136.39 (2 × Ar C), 129.83 (2C), 
129.54 (3 × Ar CH), 128.54 (Ar C), 128.17 (2C), 125.28 (2C), 114.09 (2C) (6 × Ar C), 107.12 
(PhCO3), 75.40, 73.89 (2C) (3 × Ins CH), 71.88 (OCH2Ar), 69.74 (Ins CH), 68.68 (Ins C), 68.22 
(Ins CH), 55.27 (OCH3), 25.91 (2-CCH3) ppm; MS (CI
+) m/z (%) found [M+H]+ 401 (100 %); 
HRMS (CI+) m/z (%) found [M+H]+ 401.1604 (100), C22H25O7 requires 401.1604. 
 4-O-Formyl-6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate 
229: Rf (EtOAc-hexane, 3:7 v/v) 0.48; δH (500 MHz, CDCl3) 8.04 (1H, d, J 1.0, 4-OCOH), 7.62-
7.59 (2H, m), 7.39-7.35 (3H, m), 7.26 (2H, d, J 8.8), 6.90 (2H, d, J 8.8) (9 × Ar H), 5.81 (1H, t, J 
3.4, Ins 4-H), 4.69 (1H, tt, J 3.4, 1.5, Ins 5-H), 4.67 (1H, d, J 11.2), 4.64 (1H, d, J 11.2) (2 × 
OCHHPh), 4.55 (1H, td, J 3.4, 1.5, Ins 6-H), 4.49 (1H, d, J 1.5, Ins 2-OH), 4.24 (1H, dt, J 3.9, 2.0, 
Ins 1/3-H), 4.19 (1H, dt, J 3.4, 1.5, Ins 1/3-H), 3.84 (3H, s, OCH3), 1.65 (3H, s, 2-CCH3) ppm; δC 
(125 MHz, CDCl3) 159.77 (Ar C), 159.39 (4-OCOH), 136.01 (Ar C), 129.65, 129.60 (2C) (3 × Ar 
CH), 128.15 (Ar C), 128.06 (2C), 125.27 (2C), 114.08 (2C) (6 × Ar CH), 107.47 (PhCO3), 74.03, 
73.41, 73.01 (3 × Ins CH), 72.02 (OCH2Ar), 68.13 (Ins CH), 67.54 (Ins C), 67.38 (Ins CH), 55.25 
(OCH3), 24.84 (2-CCH3) ppm. 
4-O-Formyl-6-O-para-methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate 
(229, 74 mg, 0.17 mmol) was converted to 6-O-para-Methoxybenzyl-2-C-methyl-scyllo-inositol 
1,3,5-O-orthobenzoate (228, 67 mg, 97 %) by stirring with Et3N-EtOH (1:2) for 1 h. 
4-O-(1,1,3,3-Tetra-iso-propyl-1,3-disiloxane)-6-O-para-methoxybenzyl-2-C-methyl-scyllo-
inositol 1,3,5-O-orthobenzoate, 230 
O
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O
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6-O-para-Methoxybenzyl-2-C-methyl-scyllo-inositol 1,3,5-O-orthobenzoate (228, 430 mg, 
1.07 mmol) and imidazole (440 mg, 6.45 mmol) were evaporated from MeCN (3 × 3 mL) and 
taken up in DMF (10 mL).  1,3-dichloro-1,1,3,3-tetra-iso-propyl-1,3-disiloxane (506 mg, 1.60 
mmol) was added drop-wise and the solution stirred for 18 h.  The reaction was quenched with H2O 
(0.5 mL) and triethylamine (1 mL).  After 30 min the volume was reduced under vacuum and the 
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residue taken up in EtOAc.  The organic layer was washed with sat. NaHCO3, H2O and then brine, 
dried (MgSO4) and all solvents removed under reduced pressure.  The crude material (722 mg) was 
fractionated by chromatography on flash silica.  Elution with EtOAc-hexane (1:9 → 3:7 v/v) 
afforded the title compound (230, 322 mg, 65 %) as a pale yellow oil; Rf (EtOAc-hexane, 3:7 v/v) 
0.62; δH (400 MHz, CDCl3) 7.64-7.62 (2H, m), 7.39-7.37 (3H, m), 7.31 (2H, d, J 8.3), 6.90 (2H, d, 
J 8.8) (9 × Ar H), 4.93 (1H, td, J 3.4, 2.0, Ins 4-H), 4.90 (1H, bs, SiOH), 4.71 (1H, d, J 11.2, 
OCHHPh), 4.63 (1H, d, J 11.2, OCHHPh), 4.55-4.54 (2H, m, 2 × Ins H), 4.24-4.21 (2H, m, 2 × Ins 
H), 3.83 (3H, s, OCH3), 3.76 (1H, bs, Ins 2-OH), 1.68 (3H, s, 2-CCH3), 1.34-1.28 [4H, m, 4 × 
SiCH(CH3)2], 1.10-1.01 [24H, m, 4 × SiCH(CH3)2] ppm; δC (100 MHz, CDCl3) 159.68, 136.58 (2 
× Ar C), 129.99 (2C), 129.53 (3 × Ar CH), 128.54 (Ar C), 128.09 (2C), 125.35 (2C), 113.94 (2C) 
(6 × Ins CH), 107.23 (PhCO3), 75.94, 73.51, 73.48 (3 × Ins CH), 71.57 (OCH2Ar), 70.68, 68.47 (2 
× Ins CH), 68.27 (Ins C), 55.29 (OCH3), 24.92 (2-CCH3), 17.36 (2C), 17.27 (2C), 17.19, 17.08, 
17.03, 14.14, 13.58, 13.55, 12.90, 12.33 [4 × SiCH(CH3) + 6 × SiCH(CH3)] ppm; MS (CI
+) m/z 
(%) found [M+H]+ 661 (44 %); HRMS (CI+) m/z (%) found [M+H]+ 661.3211 (100), C34H53O9Si2 
requires 661.3228. 
4-O-(1,1,3,3-Tetra-iso-propyl-1,3-disiloxane)-6-O-para-methoxybenzyl-2-C-methyl-2-O-acetyl-
scyllo-inositol 1,3,5-O-orthobenzoate (231) 
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4-O-(1,1,3,3-Tetra-iso-propyl-1,3-disiloxane)-6-O-para-methoxybenzyl-2-C-methyl-
scyllo-inositol 1,3,5-O-orthobenzoate (230, 33 mg, 0.05 mmol) was taken up in CH2Cl2 (0.5 mL).  
DMAP (1 mg, 0.01 mmol), acetic anhydride (29 µL, 0.31 mmol) and triethylamine (72 µL, 0.51 
mmol) were added and the solution stirred for 2 h.  The reaction was quenched by addition of H2O, 
and taken up in CH2Cl2.  The organic layer was washed with H2O, then brine, dried (MgSO4) and 
all solvents evaporated under reduced pressure to afford the title compound (231, 35 mg, 100 %) as 
a clear oil; Rf (EtOAc-hexane, 3:7 v/v) 0.73; δH (400 MHz, CDCl3) 7.61-7.59 (2H, m), 7.37-7.35 
(3H, m), 7.29 (2H, d, J 8.8), 6.88 (2H, d, J 8.8) (9 × Ar H), 4.98 (1H, td, J 3.4, 1.5, Ins 4-H), 4.70 
(1H, d, J 10.7, OCHHPh), 4.65 (1H, d, J 1.5, SiOH), 4.59 (1H, d, J 11.2, OCHHPh), 4.54-4.52 
(2H, m, 2 × Ins H), 4.24 (1H, td, J 4.9, 2.0, Ins 6-H), 4.13-4.11 (1H, m, Ins H), 3.83 (3H, s, OCH3), 
2.10 (3H, s, OCOCH3), 1.64 (3H, s, 2-CCH3), 1.29-1.23 [4H, m, 4 × SiCH(CH3)2], 1.12-1.00 [24H, 
m, 6 × SiCH(CH3)2] ppm; δC (100 MHz, CDCl3) 170.65 (OCOCH3), 159.52, 136.08 (2 × Ar C), 
129.84 (2C), 129.43 (3 × Ar CH), 129.07 (Ar C), 128.05 (2C), 125.32 (2C), 113.83 (2C) (6 × Ar 
CH), 107.21 (PhCO3), 76.11, 73.84, 73.54 (3 × Ins CH), 71.38 (OCH2Ar), 70.81, 68.07 (2 × Ins 
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CH), 67.88 (Ins C), 55.32 (OCH3), 25.17 (2-CCH3), 22.55 (OCOCH3), 17.05, 17.02 (2C), 16.95 
(5C), 13.06 (2C), 12.93, 12.86 [4 × SiCH(CH3) + 6 × SiCH(CH3)] ppm; MS (CI
+) m/z (%) found 
[M+H]+ 703 (15), [M+Na]+ 725 (100); HRMS (CI+) m/z (%) found [M+Na]+ 703.3334, 
C36H55O10Si2 requires 703.3334. 
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Appendix A: Preparation of 2,6-O-dibenzyl-inos-4-ose 1,3,5-O-
orthobenzoate 
The development and optimisation of these experimental proceedures was carried out 
during my MChem project, October 2004-June 2005. 
4-O-Allyl-myo-inositol 1,3,5-O-orthobenzoate (92).  
O
O
O
Ph
HO
O
HO
 
myo-Inositol (1, 5.00 g, 27 mmol) was taken up in DMSO (23 mL).  To the suspension was 
added trimethylorthobenzoate (6.01 mL, 33.3 mmol) and p-toluene sulfonic acid (56 mg, 0.29 
mmol).  The suspension was stirred at 100 ºC for 5 h.  The reaction was quenched with 
methylamine (0.9 mL) and the solvent removed under high vacuum.  Crude myo-inositol 1,3,5-O-
orthobenzoate (22d, 7.6 g) was taken up in DMF (50 mL).  The reaction mixture was cooled to -15 
ºC and sodium hydride (60 % dispersion in mineral oil, 1.08 g, 27 mmol) added portion wise.  The 
mixture was stirred at -15 ºC for 15 min, allowed to warm to rt and stirred for a further 30 min.  
Allyl bromide (2.34 mL, 27 mmol) was then added drop-wise and the reaction stirred for 24 h.  The 
reaction was quenched by drop-wise addition of H2O (5 mL) and the volume reduced under high 
vacuum.  The residue was taken up in EtOAc and washed with H2O (× 3) and then brine.  The 
combined aqueous layers were back-extracted with EtOAc, and this solution was washed with H2O 
(× 3) and brine.  The organic layers were combined, dried (MgSO4) and the solvent evaporated 
under reduced pressure.  The crude material was fractionated by chromatography on flash silica.  
Elution with hexane-EtOAc (7:3 → 0:1 v/v) yielded the title compound (92, 6.03 g, 73 % over 2 
steps); Rf (EtOAc) 0.72; δH (400 MHz, CDCl3) 7.66-7.60 (2H, m, Ar H), 7.42-7.26 (3H, m, Ar H), 
5.90 (1H, ddt, J 16.3, 10.3, 5.9, OCH2CHCH2), 5.36 (1H, dq, J 15.7, 1.2, OCH2CHCHaH), 5.32 
(1H, dq, J 10.3, 1.2, OCH2CHCHbH), 4.61 (1H, dtd, J 10.0, 4.1, 1.2, Ins 6-H), 4.52-4.47 (2H, m, 2 
× Ins H), 4.45-4.39 (2H, m, 2 × Ins H), 4.21-4.16 (3H, m, Ins H + OCH2CHCH2), 3.73 (1H, bd, J 
10.3, Ins OH), 3.19 (1H, bd, J 11.8, Ins OH) ppm;  δC (100 MHz, CDCl3) 136.52 (Ar C), 132.64 
(OCH2CHCH2), 129.70, 128.07 (2C), 125.17 (2C) (5 × Ar CH), 119.56 (OCH2CHCH2), 107.37 
(PhCO3), 76.02, 74.04, 73.53 (3 × Ins CH), 71.99 (OCH2CHCH2), 68.16, 67.69, 59.93 (3 × Ins CH) 
ppm; HRMS (CI+) m/z (%) found [M+H]+ 307.1189 (100), C16H19O6 requires 307.1182. 
Appendix A: Preparation of 2,6-O-dibenzyl-inos-4-ose 1,3,5-O-orthobenzoate 
 
 
 
- 184 - 
2,6-O-Dibenzyl-4-O-allyl-myo-inositol 1,3,5-O-orthobenzoate (93).  
O
O
O
Ph
BnO
O
BnO
 
4-O-Allyl-myo-inositol 1,3,5-O-orthobenzoate (92, 11.30 g, 36.9 mmol) was evaporated 
from MeCN (3 × 10 mL), taken up in DMF (100 mL) and cooled to -15 °C.  Sodium hydride (60 % 
dispersion in mineral oil, 4.25 g, 111 mmol) was added portion-wise, the reaction stirred at -15 °C 
for 30 min then warmed to rt and benzyl bromide (13.2 mL, 111 mmol) was added drop-wise.  The 
reaction was stirred at 60 °C overnight then quenched by drop-wise addition of H2O (5 mL) and 
stirred for 30 min.  The solvent volume was reduced under high vacuum, the residue dissolved in 
EtOAc and washed with H2O (× 3) then brine.  The organic phase was dried (MgSO4) and the 
solvent evaporated under reduced pressure.  The crude material was fractionated by 
chromatography on flash silica in a large sinter funnel. Elution with hexane-EtOAc (9:1 → 7:3 v/v) 
afforded the title compound (93, 17.30 g, 97 %) as a yellow oil; Rf (hexane-EtOAc 1:1 v/v) 0.76; δH 
(400 MHz, CDCl3) 7.66-7.22 (15H, m, Ar H), 5.82 (1H, ddt, J 17.1, 10.7, 5.6, OCH2CHCH2), 5.24 
(1H, dq, J 17.2, 1.5, OCH2CHCHH), 5.18 (1H, dq, J 10.5, 1.2, OCH2CHCHH), 4.70 (2H, s, 
OCH2Ph), 4.67 (1H, d, J 11.8 OCHHPh), 4.51 (1H, d, J 11.8, OCHHPh), 4.55-4.52 (2H, m, 2 × Ins 
H), 4.50 (1H, dq, J 3.8, 1.7, Ins H), 4.47 (1H, dt, J 3.5, 1.6, Ins H), 4.43 (1H, dt, J 3.7, 1.6, Ins H), 
4.13 (1H, ddt, J 12.7, 5.7, 1.7, OCHHCHCH2), 4.10 (1H, t, J 1.4, Ins 2-H), 4.04 (1H, ddt, J 12.7, 
5.7, 1.7, OCHHCHCH2) ppm;  δC (100 MHz, CDCl3) 138.13, 137.77, 137.18 (3 × Ar C), 134.13 
(OCH2CHCH2), 129.39, 128.42 (4C), 128.00 (2C), 127.94 (2C), 127.84, 127.75, 127.54 (2C), 
125.39 (2C) (15 × Ar CH), 117.56 (OCH2CHCH2), 107.85 (PhCO3), 73.83, 72.06, 71.92 (3 × Ins 
CH), 71.49, 71.29, 70.71 [(2 × OCH2Ph) + OCH2CHCH2], 69.05, 66.34, 60.41 (3 ×  Ins CH) ppm; 
HRMS (CI+) m/z (%) found [M+H]+ 487.2130 (100), C30H31O6 requires 487.2121. 
2,6-O-Dibenzyl-4-O-(prop-1-enyl)-myo-inositol 1,3,5-O-orthobenzoate (94).  
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2,6-O-Dibenzyl-4-O-allyl-myo-inositol 1,3,5-O-orthobenzoate (93, 5.40 g, 11.1 mmol) was 
evaporated from MeCN (3 × 5 mL), dissolved in DMSO (11 mL) and potassium t-butoxide (2.50 g, 
22.2 mmol) added.  The solution was stirred at 100 °C for 3 h.  The reaction was cooled, diluted 
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with H2O (5 mL) and extracted with EtOAc.  The organic layer was washed with H2O (× 4), then 
brine, dried (MgSO4) and the solvent evaporated under reduced pressure.  The title compound (94, 
5.40 g, 100 %) was isolated as a yellow oil and used without further purification; Rf (hexane-EtOAc 
1:1 v/v) 0.76; δH (400 MHz, CDCl3) 7.61-7.68 (2H, m, Ar H), 7.22-7.46 (13H, m,  Ar H), 6.03 
(1H, dq, J 6.1, 1.7, OCHCHCH3), 4.72 (2H, s, OCH2Ph), 4.67-4.62 (1H, m, Ins H), 4.66 (1H, d, J 
11.8, OCHHPh), 4.50 (1H, d, J 12.2, OCHHPh), 4.57-4.42 [5H, m, (4 × Ins H) + OCHCHCH3], 
4.10 (1H, t, J 1.6, Ins 2-H), 1.39 (3H, dd, J 6.8, 1.5, OCHCHCH3) ppm; δC (100 MHz, CDCl3) 
143.26 (OCHCHCH3), 137.83, 137.56, 136.93 (3 × Ar C), 129.44, 128.42 (2C), 128.34 (2C), 
128.04 (2C), 127.93 (2C), 127.80 (2C), 127.54 (2C), 125.36 (2C) (15 × Ar CH), 107.83 (PhCO3), 
103.96 (OCHCHCH3), 75.17, 73.51, 71.94, 71.73 (4 × Ins CH), 71.45, 71.10 (2 × OCH2Ph), 69.06, 
65.59 (2 × Ins CH), 14.17 (OCHCHCH3) ppm; HRMS (CI
+) m/z (%) found [M+H]+ 487.2130 
(100) C30H31O6 requires 487.2121. 
2,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (95).  
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2,6-O-Dibenzyl-4-O-(prop-1-enyl)-myo-inositol 1,3,5-O-orthobenzoate (94, 17.41 g, 35.78 
mmol) was taken up in MeCN (50 mL) and H2O (5 mL).  To the vigorously stirred solution was 
added p-toluene sulfonic acid (680 mg, 3.58 mmol).  After 48 h the reaction was quenched with 
triethylamine (1.5 mL) and concentrated under vacuum.  The residue was taken up in EtOAc, then 
washed with sat. NaHCO3, H2O (× 2) and brine.  The organic layer was dried (MgSO4) and the 
solvent evaporated under reduced pressure.  The crude material was fractionated by 
chromatography on flash silica in a large sinter funnel.  Elution with hexane-EtOAc (1:0 → 1:1 
v/v) afforded the title compound (95, 12.61 g, 79 %) as a colourless oil; Rf (hexane-EtOAc 4:1 v/v) 
0.16; δH (400 MHz, CDCl3) 7.66-7.19 (15H, m, 15 × Ar H), 4.82 (1H, d, J 12.5, PhCHHO), 4.68 
(1H, d, J 12.5, PhCHHO), 4.58-4.53 [4H, m, (2 × Ins CH) + PhCH2O], 4.50-4.47 (2H, m, 2 × Ins 
CH), 4.40-4.38 (1H, m, Ins CH), 3.94-3.93 (1H, m, Ins CH), 3.63 (1H, bs, Ins OH) ppm; δC (100 
MHz, CDCl3) 137.81, 136.79, 135.93 (3 × Ar C), 129.46, 128.84 (2C), 128.75, 128.53 (2C), 128.11 
(2C), 127.93 (5C), 125.37 (2C) (15 × Ar CH), 107.32 (PhCO3), 74.46, 73.41 (2 × Ins CH), 72.96 
(OCH2Ph), 71.29 (Ins CH), 70.99 (OCH2Ph), 68.67, 67.94, 65.07 (3 × Ins CH) ppm; HRMS (ESI
+) 
m/z (%) found [M+H]+ 447.1793 (100), C27H27O6 requires 447.1808. 
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2,6-O-Dibenzyl-inos-4-ose 1,3,5-O-orthobenzoate (96).  
O
O
O
Ph
BnO
BnO
O  
2,6-O-Dibenzyl-myo-inositol 1,3,5-O-orthobenzoate (95, 2.00 g, 4.47 mmol) was 
evaporated from MeCN (3 × 5 mL) and taken up in CH2Cl2 (20 mL).  Dess Martin periodinane 
(3.80 g, 4.94 mmol) was added portion-wise and the suspension stirred for 3 h.  Na2S2O3.H2O (10 
% solution in H2O) was added and stirring continued for 10 min.  The product was extracted with 
CH2Cl2 (× 2), and the combined organic layers washed successively with sat. NaHCO3, H2O and 
brine, before drying (MgSO4) and evaporation to dryness under reduced pressure.  The crude inos-
4-ose (96, 1.98 g, 100 %) was used without further purification; Rf (hexane-acetone, 7:3 v/v) 0.21; 
IR υ(C=O) 1766.5 cm-1;  δH (400 MHz, CDCl3) 7.68-7.63 (3H, m, Ar H), 7.43-7.20 (12H, m, Ar 
H), 4.81-4.45 [8H, m, (4 × Ins H) + (2 × OCH2Ph)], 3.82-3.81 (1H, m, Ins H) ppm;  δC (100 MHz, 
CDCl3) 200.01 (Ins C=O), 137.14, 136.33, 135.66 (3 × Ar C), 129.80, 128.67 (2C), 128.58 (2C), 
128.45, 128.11, 128.05 (2C), 127.94 (2C), 127.89 (2C), 125.49 (2C) (15 × Ar CH), 108.04 
(O3CPh), 79.77, 77.40, 71.95 (3 × Ins CH), 71.76, 71.49 (2 × OCH2Ph), 70.46, 70.38 (2 × Ins CH) 
ppm; HRMS (CI+) m/z (%) found [M+H]+ 445.1666 (100), C27H25O6 requires 445.1651. 
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Appendix B: Crystal Structure Data 
For conduritol derivative 6-benzyloxy-2-isobutyl-2-isopropyl-cyclohex-4-ene-1,2,3-triol, 138 
. 
 
 
 
 
 
Table 1. Crystal data and structure refinement for 138. 
Table 1. Crystal data and structure refinement for 138. 
Identification code PG0801 
Empirical formula C20 H30 O4 
Formula weight 334.44 
Temperature 173(2) K 
Diffractometer, wavelength OD Xcalibur PX Ultra, 1.54184 Å 
Crystal system, space group Monoclinic, P2(1)/c 
Unit cell dimensions a = 14.5758(3) Å α = 90° 
 b = 9.37699(17) Å β = 101.251(3)° 
 c = 28.4197(9) Å γ = 90° 
Volume, Z 3809.67(16) Å3, 8 
Density (calculated) 1.166 Mg/m3 
Absorption coefficient 0.637 mm-1 
F(000) 1456 
Crystal colour / morphology Colourless platy needles 
Crystal size 0.31 x 0.24 x 0.01 mm3 
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θ range for data collection 3.09 to 73.27° 
Index ranges -16<=h<=17, -11<=k<=11, -35<=l<=35 
Reflns collected / unique 51329 / 51329 [R(int) = 0.0000] 
Reflns observed [F>4σ(F)] 22052 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 51329 / 0 / 448 
Goodness-of-fit on F2 1.022 
Final R indices [F>4σ(F)] R1 = 0.1157, wR2 = 0.3357 
R indices (all data) R1 = 0.1869, wR2 = 0.3561 
Largest diff. peak, hole 0.738, -0.694 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
 
Table 2. Bond lengths [Å] and angles [°] for 138. 
C(1)-O(7) 1.448(3) 
C(1)-C(6) 1.496(4) 
C(1)-C(2) 1.518(4) 
C(2)-O(15) 1.435(3) 
C(2)-C(3) 1.558(3) 
C(3)-O(16) 1.452(3) 
C(3)-C(17) 1.500(4) 
C(3)-C(4) 1.552(3) 
C(4)-O(21) 1.453(3) 
C(4)-C(5) 1.481(4) 
C(5)-C(6) 1.380(4) 
C(6)-C(22) 1.510(4) 
O(7)-C(8) 1.424(3) 
C(8)-C(9) 1.497(4) 
C(9)-C(10) 1.381(4) 
C(9)-C(14) 1.404(4) 
C(10)-C(11) 1.400(5) 
C(11)-C(12) 1.382(5) 
C(12)-C(13) 1.342(5) 
C(13)-C(14) 1.387(4) 
C(17)-C(18) 1.512(4) 
C(18)-C(20) 1.542(4) 
C(18)-C(19) 1.545(4) 
C(22)-C(24) 1.530(4) 
C(22)-C(23) 1.531(4) 
C(1')-O(7') 1.432(3) 
C(1')-C(2') 1.493(4) 
C(1')-C(6') 1.520(4) 
C(2')-O(15') 1.451(3) 
C(2')-C(3') 1.530(4) 
C(3')-O(16') 1.460(3) 
C(3')-C(17') 1.514(4) 
C(3')-C(4') 1.555(4) 
C(4')-O(21') 1.462(3) 
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C(4')-C(5') 1.506(4) 
C(5')-C(6') 1.319(4) 
C(6')-C(22') 1.506(4) 
O(7')-C(8') 1.447(3) 
C(8')-C(9') 1.503(4) 
C(9')-C(10') 1.370(4) 
C(9')-C(14') 1.374(4) 
C(10')-C(11') 1.391(5) 
C(11')-C(12') 1.392(6) 
C(12')-C(13') 1.353(5) 
C(13')-C(14') 1.390(5) 
C(17')-C(18') 1.542(4) 
C(18')-C(19') 1.498(5) 
C(18')-C(20') 1.523(4) 
C(22')-C(23') 1.523(4) 
C(22')-C(24') 1.544(4) 
O(7)-C(1)-C(6) 107.0(2) 
O(7)-C(1)-C(2) 109.6(2) 
C(6)-C(1)-C(2) 114.9(2) 
O(15)-C(2)-C(1)111.4(2) 
O(15)-C(2)-C(3)104.9(2) 
C(1)-C(2)-C(3) 111.8(2) 
O(16)-C(3)-C(17)110.6(2) 
O(16)-C(3)-C(4)105.7(2) 
C(17)-C(3)-C(4)113.5(2) 
O(16)-C(3)-C(2)104.2(2) 
C(17)-C(3)-C(2)115.0(2) 
C(4)-C(3)-C(2) 107.0(2) 
O(21)-C(4)-C(5)110.2(2) 
O(21)-C(4)-C(3)110.2(2) 
C(5)-C(4)-C(3) 115.2(2) 
C(6)-C(5)-C(4) 124.0(3) 
C(5)-C(6)-C(1) 119.2(3) 
C(5)-C(6)-C(22)122.6(3) 
C(1)-C(6)-C(22) 118.0(2) 
C(8)-O(7)-C(1)  113.83(19) 
O(7)-C(8)-C(9)  108.9(2) 
C(10)-C(9)-C(14) 118.9(3) 
C(10)-C(9)-C(8) 122.2(3) 
C(14)-C(9)-C(8) 118.9(3) 
C(9)-C(10)-C(11) 119.9(3) 
C(12)-C(11)-C(10) 120.2(4) 
C(13)-C(12)-C(11) 119.8(3) 
C(12)-C(13)-C(14) 121.7(3) 
C(13)-C(14)-C(9) 119.5(3) 
C(3)-C(17)-C(18) 118.1(2) 
C(17)-C(18)-C(20) 110.1(3) 
C(17)-C(18)-C(19) 113.5(2) 
C(20)-C(18)-C(19) 108.2(3) 
C(6)-C(22)-C(24) 110.9(2) 
C(6)-C(22)-C(23) 115.1(3) 
C(24)-C(22)-C(23) 110.5(3) 
O(7')-C(1')-C(2') 110.8(2) 
O(7')-C(1')-C(6') 107.3(2) 
C(2')-C(1')-C(6') 113.8(2) 
O(15')-C(2')-C(1') 110.0(2) 
O(15')-C(2')-C(3') 104.9(2) 
C(1')-C(2')-C(3') 113.5(2) 
O(16')-C(3')-C(17') 111.9(2) 
O(16')-C(3')-C(2') 103.8(2) 
C(17')-C(3')-C(2') 115.8(2) 
O(16')-C(3')-C(4') 105.7(2) 
C(17')-C(3')-C(4') 111.8(2) 
C(2')-C(3')-C(4') 107.0(2) 
O(21')-C(4')-C(5') 109.1(2) 
O(21')-C(4')-C(3') 110.6(2) 
C(5')-C(4')-C(3') 114.9(2) 
C(6')-C(5')-C(4') 124.9(3) 
C(5')-C(6')-C(22') 123.7(3) 
C(5')-C(6')-C(1') 119.4(3) 
C(22')-C(6')-C(1') 116.9(2) 
C(1')-O(7')-C(8') 113.28(19) 
O(7')-C(8')-C(9') 109.0(2) 
C(10')-C(9')-C(14') 120.6(3) 
C(10')-C(9')-C(8') 118.4(3) 
C(14')-C(9')-C(8') 121.0(3) 
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C(9')-C(10')-C(11') 119.3(3) 
C(10')-C(11')-C(12') 119.6(4) 
C(13')-C(12')-C(11') 120.7(3) 
C(12')-C(13')-C(14') 119.6(3) 
C(9')-C(14')-C(13') 120.2(3) 
C(3')-C(17')-C(18') 116.8(2) 
C(19')-C(18')-C(20') 108.5(3) 
C(19')-C(18')-C(17') 113.1(3) 
C(20')-C(18')-C(17') 109.4(3) 
C(6')-C(22')-C(23') 114.4(3) 
C(6')-C(22')-C(24') 111.9(3) 
C(23')-C(22')-C(24') 110.2(3) 
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Appendix C:  Experimental for Biological Assays 
45
Ca
2+
 Flux Assay (Geert Bultnyck) 
L15 cells were obtained by stable exogenous expression of IP3R1 in L fibroblasts.  The 
cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% foetal calf 
serum, 3.8 mM L-glutamine, 0.9% (v/v) non-essential amino acids, 85 IU/mL penicillin, 85 µg/mL 
streptomycin, and 20 mM HEPES, pH 7.4. 45Ca2+ fluxes were performed on saponin-permeabilized 
cells.  The cells were seeded in 12-well clusters (Costar, Cambridge, MA) at a density of 
approximately 4 x 104 cm2. Experiments were carried out on confluent monolayers of cells at the 
seventh day after plating. The cells were permeabilized by incubating them for 10 min with a 
solution containing 120 mM KCl, 30 mM imidazole hydrochloride, pH 6.8, 2 mM MgCl2, 1 mM 
ATP, 1 mM EGTA, and 40 µg/mL saponin at 30 °C. The non-mitochondrial Ca2+ stores were 
loaded for 45 min at 30 °C in 120 mM KCl, 30 mM imidazole hydrochloride, pH 6.8, 5 mM 
MgCl2, 5 mM ATP, 0.44 mM EGTA, 10 mM NaN3, and 150 nM free 
45Ca2+ (28 µCi/mL). The 
cells were then washed twice with 1 mL of efflux medium containing 120 mM KCl, 30 mM 
imidazole hydrochloride, pH 6.8, 1 mM EGTA, and 10 µM thapsigargin. The efflux medium was 
replaced every 2 min, and the efflux was performed at 30 °C. At the end of the experiment, the 
45Ca2+ remaining in the stores was released by incubation with 1 mL of a 2 % sodium dodecyl 
sulfate solution for 30 min. Ca2+ release is plotted as the fractional loss (i.e., the amount of Ca2+ 
released in 2 min divided by the total store Ca2+ content at that time). The latter value was 
calculated by summing in retrograde order the amount of tracer remaining in the cells at the end of 
the efflux and the amounts of tracer collected during the successive time intervals. The Ca2+ release 
provoked by IP3 and 4-C-methyl IP3 was normalized to the maximal releasable Ca
2+, measured by 
the addition of 10 µM A23187. 
Synaptojanin Assays (Jessica Knott) 
Malachite Green Assay: 
Compounds, enzyme (SAL) and Tris (50mM) were incubated at room temperature for 15 min.  
MgCl2 was then added to make a final concentration of 4mM.  
Boiled enzyme was used as a negative control.  
The final volume of the assay was 80 uL 
IP3 was used to start the reaction and samples were incubated for 25 min at 37 
oC. 
To stop the enzyme reaction, equi-volume of the acidic malachite green dye was added 
The mixture was allowed to develop for 10 min 
An elisa reader was used to read the absorption of the dye at a wavelength of 625 nm 
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OMFP assay  
The total volume of the assay was 160uL 
Inhibitor (100uM), Tris (50mM) and enzyme were incubated in a 96 well plate for 15 minutes. 
MgCl2 (4mM) was then added 
OMFP (300uM) was added to start the reaction 
The well plate was incubated at 37degC 
The control consisted of the same as above but without enzyme 
The formation of o-methylfluorescein from OMFP was detected by fluorescence at excitation = 
485nm and emission 525nm at 5 minute intervals up to 40 minutes 
The activites in the graph (Figure 5.25) were taken at 35 minutes 
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Appendix D: NMR spectra 
The spectra in this thesis were measured on 270 MHz, 400 MHz and 500 MHz machines, 
depending on availability.  There is a noticeable difference in quality of spectra and therefore 
possible interpretation, depending on the machine used. 
Ten spectra are included here to illustrate the characteristic inositol signals at each stage of 
the synthesis 
1.  2,6-O-Dibenzyl-4,4-O,C-methylidene-myo-inositol 1,3,5-O-orthobenzoate, 98 
2.  2,6-O-Dibenzyl-4-C-neopentyl-myo-inositol 1,3,5-O-orthobenzoate, 144 
3.  2,6-O-Dibenzyl-4-C-benzyl-myo-inositol 1,3,5-O-orthobenzoate, 125 
4.  2,6-O-Dibenzyl-4-C-bromomethyl-myo-inositol 1,3,5-O-orthobenzoate, 126 
5.  2,6-O-Dibenzyl-4-C-ethyl-myo-inositol 3,5-O-benzylidene acetal, 176b 
6.  2,6-O-Dibenzyl-4-C-ethyl-myo-inositol, 151f 
7.  1,5-O-Diacetyl-2,6-O-dibenzyl-4-C-benzyl-myo-inositol, 177f 
8.  4-C-Methyl IP4, 191a 
9.  4-C-Ethyl IP4, 191b 
10.  4-C-Benzyl IP3, 203 
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